<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Prezista PI EN</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
@font-face
	{font-family:Goudy;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Garamond-Italic;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:DIN-Bold;}
@font-face
	{font-family:"CG Times \(W1\)";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"HelveticaNeue Condensed";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HGMaruGothicMPRO";}
@font-face
	{font-family:CourierStd;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EFPPNA+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@TimesNewRoman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRomanPSMT\,Times New Rom";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Times New Roman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"CG Times";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Minion;}
@font-face
	{font-family:CourierNew;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Noto Sans Symbols";}
@font-face
	{font-family:LZLLQG+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPS;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:HelveticaNeueLTStd-Cn;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HelveticaNeueLTStd-Cn";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Wingdings-Regular";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Geneva;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,BoldItalic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:ArialMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-name:"Heading 1\,D70AR";
	mso-style-link:"Heading 1 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:17.85pt;
	text-indent:-17.85pt;
	font-size:13.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;}
h2
	{mso-style-name:"Heading 2\,D70AR2";
	mso-style-link:"Heading 2 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Helvetica",sans-serif;
	font-style:italic;}
h3
	{mso-style-name:"Heading 3\,D70AR3\,OLD Heading 3\,titel 3";
	mso-style-link:"Heading 3 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
h4
	{mso-style-name:"Heading 4\,D70AR4\,titel 4";
	mso-style-link:"Heading 4 Char";
	margin:0in;
	text-align:justify;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h5
	{mso-style-name:"Heading 5\,D70AR5\,titel 5";
	mso-style-link:"Heading 5 Char";
	margin:0in;
	text-align:justify;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;}
h6
	{mso-style-link:"Heading 6 Char";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin:0in;
	text-align:justify;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin:0in;
	text-align:justify;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\,Annotationtext";
	mso-style-link:"Comment Text Char\,Annotationtext Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:.8in;
	text-indent:-.8in;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.MsoFootnoteReference
	{vertical-align:super;}
span.MsoEndnoteReference
	{vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin:0in;
	text-align:justify;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;
	text-decoration:underline;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin:0in;
	text-align:justify;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Body Text Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-align:justify;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:31.65pt;
	text-align:justify;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.AHeader1, li.AHeader1, div.AHeader1
	{mso-style-name:"AHeader 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.2pt;
	text-indent:-14.2pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2, li.AHeader2, div.AHeader2
	{mso-style-name:"AHeader 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:35.45pt;
	text-indent:-21.25pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader3, li.AHeader3, div.AHeader3
	{mso-style-name:"AHeader 3";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2abc, li.AHeader2abc, div.AHeader2abc
	{mso-style-name:"AHeader 2 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-align:justify;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.AHeader3abc, li.AHeader3abc, div.AHeader3abc
	{mso-style-name:"AHeader 3 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:85.05pt;
	text-align:justify;
	text-indent:-21.25pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.Noparagraphstyle, li.Noparagraphstyle, div.Noparagraphstyle
	{mso-style-name:"\[No paragraph style\]";
	margin:0in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times",serif;
	color:black;}
p.Body, li.Body, div.Body
	{mso-style-name:Body;
	margin:0in;
	text-align:justify;
	text-indent:.2in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.SubSectionHeadings, li.SubSectionHeadings, div.SubSectionHeadings
	{mso-style-name:"Sub Section Headings";
	margin:0in;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;
	font-style:italic;}
p.TableBodyText, li.TableBodyText, div.TableBodyText
	{mso-style-name:"Table Body Text";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.CcList, li.CcList, div.CcList
	{mso-style-name:"Cc List";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.CM27, li.CM27, div.CM27
	{mso-style-name:CM27;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	text-autospace:none;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.Footnote, li.Footnote, div.Footnote
	{mso-style-name:Footnote;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:17.3pt;
	text-indent:-17.3pt;
	font-size:7.0pt;
	font-family:"Times New Roman",serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1\,D70AR";
	color:black;
	text-transform:uppercase;
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2\,D70AR2";
	font-family:"Helvetica",sans-serif;
	color:black;
	font-weight:bold;
	font-style:italic;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3\,D70AR3\,OLD Heading 3\,titel 3";
	color:black;
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4\,D70AR4\,titel 4";
	color:black;
	font-weight:bold;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5\,D70AR5\,titel 5";
	color:black;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	color:black;
	font-style:italic;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	color:black;
	font-style:italic;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	color:black;
	font-weight:bold;
	font-style:italic;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	color:black;
	font-weight:bold;
	font-style:italic;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Helvetica",sans-serif;
	color:black;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	color:black;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";
	color:black;}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";
	color:blue;}
span.BodyTextIndent2Char
	{mso-style-name:"Body Text Indent 2 Char";
	mso-style-link:"Body Text Indent 2";
	color:blue;
	font-weight:bold;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	color:green;
	font-style:italic;}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";
	color:blue;
	font-weight:bold;
	text-decoration:underline;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char\,Annotationtext Char";
	mso-style-link:"Comment Text\,Annotationtext";
	color:black;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Tahoma",sans-serif;
	color:black;
	background:navy;}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";
	color:black;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";
	color:black;}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";
	color:black;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	color:black;
	font-weight:bold;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Tahoma",sans-serif;
	color:black;}
p.Reference, li.Reference, div.Reference
	{mso-style-name:Reference;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.3in;
	text-indent:-.3in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.TableText, li.TableText, div.TableText
	{mso-style-name:"Table Text";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.TableFootnote, li.TableFootnote, div.TableFootnote
	{mso-style-name:"Table Footnote";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	text-indent:-.2in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.Normal1, li.Normal1, div.Normal1
	{mso-style-name:Normal1;
	margin:0in;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
I</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>SUMMARY
OF PRODUCT CHARACTERISTICS</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA 100&nbsp;mg/ml oral suspension</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each ml of oral suspension contains 100&nbsp;mg
of darunavir (as ethanolate).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipient with known effect:</span></u><span
lang=EN-GB> sodium methyl parahydroxybenzoate (E219) 3.43&nbsp;mg/ml.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For the full list of excipients, see
section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral suspension</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>White to off&#8209;white opaque suspension</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CLINICAL
PARTICULARS</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic
indications</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA, co&#8209;administered with low
dose ritonavir is indicated in combination with other antiretroviral medicinal
products for the treatment of human immunodeficiency virus (HIV&#8209;1)
infection in adult and paediatric patients from the age of 3&nbsp;years and at
least 15&nbsp;kg body weight (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA, co&#8209;administered with cobicistat
is indicated in combination with other antiretroviral medicinal products for
the treatment of human immunodeficiency virus (HIV&#8209;1) infection in adults
and adolescents (aged 12&nbsp;years and older, weighing at least 40&nbsp;kg) (see
section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In deciding to initiate treatment with
PREZISTA co&#8209;administered with cobicistat or low dose ritonavir, careful
consideration should be given to the treatment history of the individual
patient and the patterns of mutations associated with different agents.
Genotypic or phenotypic testing (when available) and treatment history should
guide the use of PREZISTA (see sections 4.2, 4.4 and 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="_Hlk515272599"><b><span
lang=EN-GB>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology and method of administration</span></b></a></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Therapy should be initiated by a healthcare
provider experienced in the management of HIV infection. After therapy with
PREZISTA has been initiated, patients should be advised not to alter the
dosage, dose form or discontinue therapy without discussing with their
healthcare provider.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The interaction profile of darunavir
depends on whether ritonavir or cobicistat is used as pharmacokinetic enhancer.
Darunavir may therefore have different contraindications and recommendations
for concomitant medications depending on whether the compound is boosted with
ritonavir or cobicistat (see sections 4.3, 4.4 and 4.5).</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA must always be given orally with cobicistat
or low dose ritonavir as a pharmacokinetic enhancer and in combination with
other antiretroviral medicinal products. The Summary of Product Characteristics
of cobicistat or ritonavir as appropriate, must therefore be consulted prior to
initiation of therapy with PREZISTA. Cobicistat is not indicated for use in twice
daily regimens or for use in the paediatric population less than 12&nbsp;years
of age and weighing less than 40&nbsp;kg.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>ART&#8209;na&iuml;ve
adult patients</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The recommended
dose regimen is 800&nbsp;mg once daily with cobicistat 150&nbsp;mg once daily
or ritonavir 100&nbsp;mg once daily taken with food.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB>ART&#8209;experienced adult patients</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dose regimen is 600&nbsp;mg
twice daily taken with ritonavir 100&nbsp;mg twice daily taken with food.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A dose regimen of 800&nbsp;mg once daily
with cobicistat 150&nbsp;mg once daily or ritonavir 100&nbsp;mg once daily
taken with food may be used in patients with prior exposure to antiretroviral
medicinal products but without darunavir resistance associated mutations (DRV&#8209;RAMs)*
and who have plasma HIV&#8209;1 RNA &lt;&nbsp;100,000&nbsp;copies/ml and CD4+
cell count &#8805;&nbsp;100&nbsp;cells&nbsp;x&nbsp;10<sup>6</sup>/L.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=NO-NYN>*&nbsp;&nbsp; </span><span lang=NO-NYN style='font-size:9.0pt'>DRV&#8209;RAMs:
V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=NO-NYN>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>If HIV&#8209;1
genotype testing is not available, the recommended dose regimen is PREZISTA 600&nbsp;mg
twice daily taken with ritonavir 100 mg twice daily taken with food.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB>ART&#8209;na&iuml;ve paediatric patients (3 to 17&nbsp;years of age
and weighing at least 15&nbsp;kg)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The weight&#8209;based dose of PREZISTA taken
with ritonavir or cobicistat taken with food in paediatric patients is provided
in the table below. The dose of cobicistat to be used with PREZISTA in children
less than 12&nbsp;years of age has not been established.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=2 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Recommended dose for treatment&#8209;na&iuml;ve
  paediatric patients</span></b><b><span lang=EN-GB> (3 to </span><span
  lang=EN-GB>17&nbsp;years) with PREZISTA and ritonavir<sup>a</sup> or
  cobicistat<sup>b</sup></span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=168 valign=top style='width:125.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Body weight (kg)</span></b></p>
  </td>
  <td width=437 valign=top style='width:327.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Dose (once daily with food)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=168 valign=top style='width:125.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;15&nbsp;kg to
  &lt;&nbsp;30&nbsp;kg</span></p>
  </td>
  <td width=437 valign=top style='width:327.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>600&nbsp;mg (6&nbsp;ml)
  PREZISTA/100&nbsp;mg (1.2&nbsp;ml) ritonavir once daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=168 valign=top style='width:125.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;30&nbsp;kg to
  &lt;&nbsp;40&nbsp;kg</span></p>
  </td>
  <td width=437 valign=top style='width:327.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>675&nbsp;mg (6.8&nbsp;ml)<sup>c</sup> PREZISTA/100&nbsp;mg
  (1.2&nbsp;ml) ritonavir once daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=168 valign=top style='width:125.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;40&nbsp;kg</span></p>
  </td>
  <td width=437 valign=top style='width:327.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>800&nbsp;mg (8&nbsp;ml)
  PREZISTA/100&nbsp;mg (1.2&nbsp;ml) ritonavir once daily or</span></p>
  <p class=MsoNormal><span lang=EN-GB>800&nbsp;mg (8&nbsp;ml) PREZISTA/150&nbsp;mg
  (tablet) cobicistat<sup>b</sup> once daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=2 valign=top style='width:6.3in;border:none;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>ritonavir oral solution: 80&nbsp;mg/ml</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; adolescents
  12&nbsp;years and older</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>c</span></sup><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>rounded up for suspension dosing
  convenience</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><i><span lang=EN-GB>ART&#8209;experienced paediatric patients (3 to
17&nbsp;years of age and weighing at least 15&nbsp;kg)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA twice daily taken with ritonavir
taken with food is usually recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A once daily dose regimen of PREZISTA taken
with ritonavir or cobicistat taken with food may be used in patients with prior
exposure to antiretroviral medicinal products but without darunavir resistance
associated mutations (DRV&#8209;RAMs)* and who have plasma HIV&#8209;1 RNA
&lt;&nbsp;100,000&nbsp;copies/ml and CD4+ cell count &#8805;&nbsp;100&nbsp;cells&nbsp;x&nbsp;10<sup>6</sup>/L.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=NO-NYN>*&nbsp;&nbsp; </span><span lang=NO-NYN style='font-size:9.0pt'>DRV&#8209;RAMs:
V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V</span></p>

<p class=MsoNormal><span lang=NO-NYN>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The weight&#8209;based dose of PREZISTA taken
with ritonavir or cobicistat in paediatric patients is provided in the table
below. The recommended dose of PREZISTA with low dose ritonavir should not
exceed the recommended adult dose (600/100&nbsp;mg twice daily or
800/100&nbsp;mg once daily). <a name="_Hlk31613696">The dose of PREZISTA with cobicistat
in adolescent patients 12&nbsp;years of age and older weighing at least 40&nbsp;kg
is 800/150&nbsp;mg once daily taken with food.</a> The dose of cobicistat to be
used with PREZISTA in children less than 12&nbsp;years of age has not been
established.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=3 valign=top style='width:462.1pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Recommended dose for treatment&#8209;experienced
  paediatric patients</span></b><b><span lang=EN-GB> (3 to </span><span
  lang=EN-GB>17&nbsp;years) with PREZISTA and ritonavir<sup>a</sup> or
  cobicistat<sup>b</sup></span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=127 valign=top style='width:95.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Body weight (kg)</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Dose (once daily with food)</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Dose (twice daily with food)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=127 valign=top style='width:95.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;15&nbsp;kg to
  &lt;&nbsp;30&nbsp;kg</span></p>
  </td>
  <td width=245 valign=top style='width:183.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>600&nbsp;mg (6&nbsp;ml)
  PREZISTA/100&nbsp;mg (1.2&nbsp;ml) ritonavir once daily</span></p>
  </td>
  <td width=245 valign=top style='width:183.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>380&nbsp;mg (3.8&nbsp;ml)
  PREZISTA/50&nbsp;mg (0.6&nbsp;ml) ritonavir twice daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=127 valign=top style='width:95.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;30&nbsp;kg to
  &lt;&nbsp;40&nbsp;kg</span></p>
  </td>
  <td width=245 valign=top style='width:183.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>675&nbsp;mg (6.8&nbsp;ml)<sup>c</sup> PREZISTA/100&nbsp;mg
  (1.2&nbsp;ml) ritonavir once daily</span></p>
  </td>
  <td width=245 valign=top style='width:183.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>460&nbsp;mg (4.6&nbsp;ml)
  PREZISTA/60&nbsp;mg (0.8&nbsp;ml) ritonavir twice daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=127 valign=top style='width:95.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;40&nbsp;kg</span></p>
  </td>
  <td width=245 valign=top style='width:183.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>800&nbsp;mg (8&nbsp;ml)
  PREZISTA/100&nbsp;mg (1.2&nbsp;ml) ritonavir once daily or</span></p>
  <p class=MsoNormal><span lang=EN-GB>800&nbsp;mg (8&nbsp;ml) PREZISTA/150&nbsp;mg
  (tablet) cobicistat<sup>b</sup> once daily</span></p>
  </td>
  <td width=245 valign=top style='width:183.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>600&nbsp;mg (6&nbsp;ml)
  PREZISTA/100&nbsp;mg (1.2&nbsp;ml) ritonavir twice daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=3 valign=top style='width:462.1pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>ritonavir oral solution: 80&nbsp;mg/ml</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; adolescents
  12 years and older</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>c</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; rounded
  up for suspension dosing convenience</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>For ART&#8209;experienced
paediatric patients HIV genotypic testing is recommended. However, when HIV
genotypic testing is not feasible, the PREZISTA (taken with ritonavir or
cobicistat) once daily dosing regimen is recommended in HIV protease inhibitor&#8209;na&iuml;ve
paediatric patients and the PREZISTA taken with ritonavir twice daily dosing
regimen is recommended in HIV protease inhibitor&#8209;experienced patients.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA oral suspension can be used in
patients unable to swallow PREZISTA tablets. PREZISTA is also available as
75&nbsp;mg, 150&nbsp;mg, 400&nbsp;mg, 600&nbsp;mg and 800&nbsp;mg film&#8209;coated
tablets.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Advice on
missed doses</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The following guidance is based on the half&#8209;life
of darunavir in the presence of cobicistat or ritonavir and the recommended
dosing interval of approximately 12&nbsp;hours (twice daily regimen) or
approximately 24&nbsp;hours (once daily regimen).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If using the twice daily regimen: in case a dose
of PREZISTA and/or ritonavir is missed within 6&nbsp;hours of the time it is
usually taken, patients should be instructed to take the prescribed dose of
PREZISTA and ritonavir with food as soon as possible. If this is noticed later
than 6&nbsp;hours after the time it is usually taken, the missed dose should
not be taken and the patient should resume the usual dosing schedule.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If using the once daily regimen: in case a dose
of PREZISTA and/or cobicistat or ritonavir is missed within 12&nbsp;hours of
the time it is usually taken, patients should be instructed to take the
prescribed dose of PREZISTA and cobicistat or ritonavir with food as soon as
possible. If this is noticed later than 12&nbsp;hours after the time it is
usually taken, the missed dose should not be taken and the patient should
resume the usual dosing schedule.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="_Hlk36030380"></a><a name="_Hlk36030222"><span
lang=EN-GB>If a patient vomits within 4&nbsp;hours of taking the medicine,
another dose of PREZISTA with cobicistat or ritonavir should be taken with food
as soon as possible. </span></a><span lang=EN-GB>If a patient vomits more than
4&nbsp;hours after taking the medicine, the patient does not need to take
another dose of PREZISTA with cobicistat or ritonavir until the next regularly
scheduled time.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Special
populations</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Limited information is available in this
population, and therefore, PREZISTA should be used with caution in this age
group (see sections 4.4 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Hepatic
impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir is metabolised by the hepatic
system. No dose adjustment is recommended in patients with mild (Child&#8209;Pugh
Class&nbsp;A) or moderate (Child&#8209;Pugh Class&nbsp;B) hepatic impairment,
however, PREZISTA should be used with caution in these patients. No
pharmacokinetic data are available in patients with severe hepatic impairment.
Severe hepatic impairment could result in an increase of darunavir exposure and
a worsening of its safety profile. Therefore, PREZISTA must not be used in
patients with severe hepatic impairment (Child&#8209;Pugh Class&nbsp;C) (see
sections 4.3, 4.4 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Renal
impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>No dose adjustment is required for darunavir/ritonavir
in patients with renal impairment (see sections 4.4 and 5.2). Cobicistat has
not been studied in patients receiving dialysis, and, therefore, no
recommendation can be made for the use of darunavir/cobicistat in these
patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Cobicistat inhibits the tubular secretion
of creatinine and may cause modest increases in serum creatinine and modest
declines in creatinine clearance. Hence, the use of creatinine clearance as an
estimate of renal elimination capacity may be misleading. Cobicistat as a
pharmacokinetic enhancer of darunavir should, therefore, not be initiated in
patients with creatine clearance less than 70&nbsp;ml/min if any co&#8209;administered
agent requires dose adjustment based on creatinine clearance: e.g. emtricitabine,
lamivudine, tenofovir disoproxil (as fumarate, phosphate or succinate) or
adefovir dipovoxil.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For information on cobicistat, consult the
cobicistat Summary of Product Characteristics.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>PREZISTA should
not be used in children</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>below 3&nbsp;years of age, because of safety
concerns (see sections&nbsp;4.4 and 5.3), or,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>less than 15&nbsp;kg body weight, as the dose
for this population has not been established in a sufficient number of patients
(see section&nbsp;5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="_Hlk510196957"><span lang=EN-GB style='color:black'>PREZISTA
taken with cobicistat should not be used in children aged 3 to 11&nbsp;years of
age weighing &lt;&nbsp;40&nbsp;kg as the dose of cobicistat to be used in these
children has not been established (see sections&nbsp;4.4 and 5.3).</span></a></p>

<p class=MsoNormal><span lang=NO-NYN>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Pregnancy
and postpartum</span></i></p>

<p class=MsoNormal><span lang=EN-GB>No dose adjustment is required for
darunavir/ritonavir during pregnancy and postpartum. PREZISTA/ritonavir</span>
should be used during pregnancy only if the potential benefit justifies the potential
risk <span lang=EN-GB>(see sections 4.4, 4.6 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Treatment with darunavir/cobicistat
800/150&nbsp;mg during pregnancy results in low darunavir exposure (see
sections&nbsp;4.4 and 5.2). Therefore, therapy with PREZISTA/cobicistat should
not be initiated during pregnancy, and women who become pregnant during therapy
with PREZISTA/cobicistat should be switched to an alternative regimen, (see
sections&nbsp;4.4 and 4.6). PREZISTA/ritonavir may be considered as an alternative.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Patients should
be instructed to take PREZISTA with cobicistat or low dose ritonavir within
30&nbsp;minutes after completion of a meal. The type of food does not affect
the exposure to darunavir (see sections 4.4, 4.5 and 5.2).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA suspension is administered orally.
Shake the bottle vigorously prior to each dose. The supplied oral dosing
pipette should not be used for any other medicinal products.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hypersensitivity to the active substance or
to any of the excipients listed in section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients with severe (Child&#8209;Pugh
Class&nbsp;C) hepatic impairment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Concomitant treatment with any of the
following medicinal products given the expected decrease in plasma
concentrations of darunavir, ritonavir and cobicistat and the potential for
loss of therapeutic effect (see sections 4.4 and 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Applicable
to darunavir boosted with either ritonavir or cobicistat:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The combination product lopinavir/ritonavir (see
section 4.5).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The strong CYP3A inducers rifampicin and herbal
preparations containing St&nbsp;John&#8217;s&nbsp;wort (<i>Hypericum perforatum</i>).
Co&#8209;administration is expected to reduce plasma concentrations of
darunavir, ritonavir and cobicistat, which could lead to loss of therapeutic
effect and possible development of resistance (see sections 4.4 and 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Applicable
to darunavir boosted with cobicistat, not when boosted with ritonavir:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Darunavir boosted with cobicistat is more
sensitive for CYP3A induction than darunavir boosted with ritonavir.
Concomitant use with strong CYP3A inducers is contraindicated, since these may
reduce the exposure to cobicistat and darunavir leading to loss of therapeutic
effect. Strong CYP3A inducers include e.g. carbamazepine, phenobarbital and
phenytoin (see sections 4.4 and 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir boosted with either ritonavir or
cobicistat inhibits the elimination of active substances that are highly dependent
on CYP3A for clearance, which results in increased exposure to the co&#8209;administered
medicinal product. Therefore, concomitant treatment with such medicinal
products for which elevated plasma concentrations are associated with serious
and/or life&#8209;threatening events is contraindicated (applies to darunavir
boosted with either ritonavir or cobicistat). These active substances include
e.g.:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>alfuzosin</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>amiodarone, bepridil, dronedarone, ivabradine, quinidine,
ranolazine</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>astemizole, terfenadine</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>colchicine when used in patients with renal
and/or hepatic impairment (see section 4.5)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ergot derivatives (e.g. dihydroergotamine,
ergometrine, ergotamine, methylergonovine)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>elbasvir/grazoprevir</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cisapride</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dapoxetine</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>domperidone</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>naloxegol</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lurasidone, pimozide, quetiapine, sertindole
(see section 4.5)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>triazolam, midazolam administered orally (for
caution on parenterally administered midazolam, see section 4.5)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sildenafil - when used for the treatment of
pulmonary arterial hypertension, avanafil</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>simvastatin, lovastatin, <a name="_Hlk498286397">lomitapide</a>
(see section 4.5)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dabigatran, ticagrelor (see section 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="_Hlk515272767"><b><span
lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special warnings and precautions for use</span></b></a></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>While effective viral suppression with
antiretroviral therapy has been proven to substantially reduce the risk of
sexual transmission, a residual risk cannot be excluded. Precautions to prevent
transmission should be taken in accordance with national guidelines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Regular assessment of virological response
is advised. In the setting of lack or loss of virological response, resistance
testing should be performed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA must always be given orally with
cobicistat or low dose ritonavir as a pharmacokinetic enhancer and in
combination with other antiretroviral medicinal products (see section 5.2). The
Summary of Product Characteristics of cobicistat or ritonavir as appropriate,
must therefore be consulted prior to initiation of therapy with PREZISTA.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Increasing the dose of ritonavir from that
recommended in section 4.2 did not significantly affect darunavir
concentrations. It is not recommended to alter the dose of cobicistat or
ritonavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir binds predominantly to </span><span
lang=EN-GB style='font-family:Symbol'>a</span><sub><span lang=EN-GB>1</span></sub><span
lang=EN-GB>&#8209;acid glycoprotein. This protein binding is concentration&#8209;dependent
indicative for saturation of binding. Therefore, protein displacement of
medicinal products highly bound to </span><span lang=EN-GB style='font-family:
Symbol'>a</span><sub><span lang=EN-GB>1</span></sub><span lang=EN-GB>&#8209;acid
glycoprotein cannot be ruled out (see section 4.5).</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>ART&#8209;experienced
patients &#8211; once daily dosing</span></u></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA used in combination with
cobicistat or low dose ritonavir once daily in ART&#8209;experienced patients
should not be used in patients with one or more darunavir resistance associated
mutations (DRV&#8209;RAMs) or HIV&#8209;1 RNA
&#8805;&nbsp;100,000&nbsp;copies/ml or CD4+ cell count &lt;&nbsp;100&nbsp;cells&nbsp;x&nbsp;10<sup>6</sup>/L
(see section 4.2). Combinations with optimised background regimen (OBRs) other
than &#8805;&nbsp;2&nbsp;NRTIs have not been studied in this population.
Limited data are available in patients with HIV&#8209;1 clades other than B
(see section 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is not recommended for use in paediatric
patients below 3&nbsp;years of age or less than 15&nbsp;kg body weight (see
sections 4.2 and 5.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal>PREZISTA/ritonavir should be used during pregnancy only if
the potential benefit justifies the potential risk. <span lang=EN-GB>Caution
should be used in pregnant women with concomitant medications which may further
decrease</span> darunavir exposure (see sections 4.5 and 5.2).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Treatment with darunavir/cobicistat 800/150&nbsp;mg once
daily during the second and third trimester has been shown to result in low
darunavir exposure, with a reduction of around 90% in C<sub>min</sub> levels
(see section&nbsp;5.2). Cobicistat levels decrease and may not provide
sufficient boosting. The substantial reduction in darunavir exposure may result
in virological failure and an increased risk of mother to child transmission of
HIV infection. Therefore, therapy with PREZISTA/cobicistat should not be
initiated during pregnancy, and women who become pregnant during therapy with
PREZISTA/cobicistat should be switched to an alternative regimen (see sections&nbsp;4.2
and 4.6). PREZISTA given with low dose ritonavir may be considered as an alternative.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Elderly</span></u></p>

<p class=MsoNormal><span lang=EN-GB>As limited information is available on the
use of PREZISTA in patients aged&nbsp;65 and over, caution should be exercised
in the administration of PREZISTA in elderly patients, reflecting the greater
frequency of decreased hepatic function and of concomitant disease or other
therapy (see sections 4.2 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Severe
skin reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>During the darunavir/ritonavir clinical
development program (N=3,063), severe skin reactions, which may be accompanied
with fever and/or elevations of transaminases, have been reported in 0.4% of
patients. DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) and Stevens&#8209;Johnson
Syndrome has been rarely (&lt;&nbsp;0.1%) reported, and during post&#8209;marketing
experience toxic epidermal necrolysis and acute generalised exanthematous
pustulosis have been reported. PREZISTA should be discontinued immediately if
signs or symptoms of severe skin reactions develop. These can include, but are
not limited to, severe rash or rash accompanied by fever, general malaise,
fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis,
hepatitis and/or eosinophilia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Rash occurred more commonly in treatment&#8209;experienced
patients receiving regimens containing PREZISTA/ritonavir + raltegravir
compared to patients receiving PREZISTA/ritonavir without raltegravir or
raltegravir without PREZISTA (see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir contains a sulphonamide moiety.
PREZISTA should be used with caution in patients with a known sulphonamide
allergy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Hepatotoxicity</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Drug&#8209;induced hepatitis (e.g. acute
hepatitis, cytolytic hepatitis) has been reported with PREZISTA. During the darunavir/ritonavir
clinical development program (N=3,063), hepatitis was reported in 0.5% of
patients receiving combination antiretroviral therapy with PREZISTA/ritonavir.
Patients with pre&#8209;existing liver dysfunction, including chronic active hepatitis
B or C, have an increased risk for liver function abnormalities including
severe and potentially fatal hepatic adverse reactions. In case of concomitant
antiviral therapy for hepatitis&nbsp;B or C, please refer to the relevant
product information for these medicinal products.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Appropriate laboratory testing should be
conducted prior to initiating therapy with PREZISTA used in combination with
cobicistat or low dose ritonavir and patients should be monitored during
treatment. Increased AST/ALT monitoring should be considered in patients with
underlying chronic hepatitis, cirrhosis, or in patients who have pre&#8209;treatment
elevations of transaminases, especially during the first several months of
PREZISTA used in combination with cobicistat or low dose ritonavir treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If there is evidence of new or worsening
liver dysfunction (including clinically significant elevation of liver enzymes
and/or symptoms such as fatigue, anorexia, nausea, jaundice, dark urine, liver
tenderness, hepatomegaly) in patients using PREZISTA used in combination with
cobicistat or low dose ritonavir, interruption or discontinuation of treatment
should be considered promptly.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Patients
with coexisting conditions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Hepatic
impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of PREZISTA have
not been established in patients with severe underlying liver disorders and
PREZISTA is therefore contraindicated in patients with severe hepatic
impairment. Due to an increase in the unbound darunavir plasma concentrations,
PREZISTA should be used with caution in patients with mild or moderate hepatic
impairment (see sections 4.2, 4.3 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Renal
impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>No special precautions or dose adjustments for
darunavir/ritonavir are required in patients with renal impairment. As
darunavir and ritonavir are highly bound to plasma proteins, it is unlikely
that they will be significantly removed by haemodialysis or peritoneal
dialysis. Therefore, no special precautions or dose adjustments are required in
these patients (see sections 4.2 and 5.2). Cobicistat has not been studied in
patients receiving dialysis, therefore, no recommendation can be made for the
use of darunavir/cobicistat in these patients (see section 4.2).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Cobicistat decreases the estimated
creatinine clearance due to inhibition of tubular secretion of creatinine. This
should be taken into consideration if darunavir with cobicistat is administered
to patients in whom the estimated creatinine clearance is used to adjust doses
of co&#8209;administered medicinal products (see section 4.2 and cobicistat
SmPC).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There are currently inadequate data to
determine whether co&#8209;administration of tenofovir disoproxil and
cobicistat is associated with a greater risk of renal adverse reactions
compared with regimens that include tenofovir disoproxil without cobicistat.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Haemophiliac
patients</span></i></p>

<p class=MsoNormal><span lang=EN-GB>There have been reports of increased
bleeding, including spontaneous skin haematomas and haemarthrosis in patients
with haemophilia type A and B treated with PIs. In some patients additional
factor VIII was given. In more than half of the reported cases, treatment with
PIs was continued or reintroduced if treatment had been discontinued. A causal
relationship has been suggested, although the mechanism of action has not been
elucidated. Haemophiliac patients should, therefore, be made aware of the
possibility of increased bleeding.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Weight
and metabolic parameters</span></i></p>

<p class=MsoNormal><span lang=EN-GB>An increase in weight and in levels of
blood lipids and glucose may occur during antiretroviral therapy. Such changes
may in part be linked to disease control and life style. For lipids, there is
in some cases evidence for a treatment effect, while for weight gain there is
no strong evidence relating this to any particular treatment. For monitoring of
blood lipids and glucose reference is made to established HIV treatment
guidelines. Lipid disorders should be managed as clinically appropriate.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Osteonecrosis</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Although the aetiology is considered to be
multifactorial (including corticosteroid use, alcohol consumption, severe
immunosuppression, higher body mass index), cases of osteonecrosis have been
reported particularly in patients with advanced HIV disease and/or long&#8209;term
exposure to combination antiretroviral therapy (CART). Patients should be
advised to seek medical advice if they experience joint aches and pain, joint
stiffness or difficulty in movement.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Immune reconstitution
inflammatory syndrome</span></u></p>

<p class=MsoNormal><span lang=EN-GB>In HIV infected patients with severe immune
deficiency at the time of initiation of combination antiretroviral therapy
(CART), an inflammatory reaction to asymptomatic or residual opportunistic
pathogens may arise and cause serious clinical conditions, or aggravation of
symptoms. Typically, such reactions have been observed within the first weeks
or months of initiation of CART. Relevant examples are cytomegalovirus
retinitis, generalised and/or focal mycobacterial infections and pneumonia
caused by <i>Pneumocystis jirovecii</i> (formerly known as <i>Pneumocystis
carinii</i>). Any inflammatory symptoms should be evaluated and treatment
instituted when necessary. In addition, reactivation of herpes simplex and
herpes zoster has been observed in clinical studies with PREZISTA co&#8209;administered
with low dose ritonavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Autoimmune disorders (such as Graves'
disease and autoimmune hepatitis) have also been reported to occur in the
setting of immune reactivation; however, the reported time to onset is more
variable and these events can occur many months after initiation of treatment
(see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Interactions
with medicinal products</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Several of the interaction studies have
been performed with darunavir at lower than recommended doses. The effects on
co&#8209;administered medicinal products may thus be underestimated and
clinical monitoring of safety may be indicated. For full information on
interactions with other medicinal products see section 4.5.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Pharmacokinetic
enhancer and concomitant medications</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Darunavir
has different interaction profiles depending on whether the compound is boosted
with ritonavir or cobicistat:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Darunavir boosted with cobicistat is more
sensitive for CYP3A induction: concomitant use of darunavir/cobicistat and
strong CYP3A inducers is therefore contraindicated (see section 4.3), and
concomitant use with weak to moderate CYP3A inducers is not recommended (see
section 4.5). Concomitant use of darunavir/ritonavir and darunavir/cobicistat
with lopinavir/ritonavir, rifampicin and herbal products containing St&nbsp;John&#8217;s&nbsp;wort,
<i>Hypericum perforatum</i>, is contraindicated (see section 4.5).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Unlike ritonavir, cobicistat does not have
inducing effects on enzymes or transport proteins (see section 4.5). If
switching the pharmacoenhancer from ritonavir to cobicistat, caution is
required during the first two weeks of treatment with darunavir/cobicistat,
particularly if doses of any concomitantly administered medicinal products have
been titrated or adjusted during use of ritonavir as a pharmacoenhancer. A dose
reduction of the co&#8209;administered drug may be needed in these cases.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Efavirenz in combination with boosted
PREZISTA may result in sub&#8209;optimal darunavir C<sub>min</sub>. If
efavirenz is to be used in combination with PREZISTA, the PREZISTA/ritonavir 600/100&nbsp;mg
twice daily regimen should be used. See the Summary of Product Characteristics
for PREZISTA 75&nbsp;mg, 150&nbsp;mg and 600&nbsp;mg tablets (see section 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Life&#8209;threatening and fatal drug
interactions have been reported in patients treated with colchicine and strong
inhibitors of CYP3A and P&#8209;glycoprotein (P&#8209;gp; see sections 4.3 and
4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA oral suspension contains sodium
methyl parahydroxybenzoate (E219) which may cause allergic reactions (possibly
delayed).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA oral suspension contains less than
1&nbsp;mmol sodium (23&nbsp;mg) per ml, that is to say essentially
&#8216;sodium&#8209;free&#8217;.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction
with other medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The interaction profile of darunavir may
differ depending on whether ritonavir or cobicistat is used as
pharmacoenhancer. The recommendations given for concomitant use of darunavir
and other medicinal products may therefore differ depending on whether darunavir
is boosted with ritonavir or cobicistat (see sections 4.3 and 4.4), and caution
is also required during the first time of treatment if switching the
pharmacoenhancer from ritonavir to cobicistat (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><u><span
lang=EN-GB>Medicinal products that affect darunavir exposure (ritonavir as
pharmacoenhancer)</span></u></b></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir and ritonavir are metabolised by
CYP3A. Medicinal products that induce CYP3A activity would be expected to
increase the clearance of darunavir and ritonavir, resulting in lowered plasma
concentrations of these compounds and consequently that of darunavir, leading
to loss of therapeutic effect and possible development of resistance (see
sections 4.3 and 4.4). CYP3A inducers that are contraindicated include rifampicin,
St&nbsp;John&#8217;s&nbsp;wort and lopinavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Co&#8209;administration of darunavir and
ritonavir with other medicinal products that inhibit CYP3A may decrease the
clearance of darunavir and ritonavir, which may result in increased plasma
concentrations of darunavir and ritonavir. Co&#8209;administration with strong
CYP3A4 inhibitors is not recommended and caution is warranted, these interactions
are described in the interaction table below (e.g. indinavir, azole <a
name="_Hlk497683349">antifungals such as </a>clotrimazole).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><u><span
lang=EN-GB>Medicinal products that affect darunavir exposure (cobicistat as
pharmacoenhancer)</span></u></b></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir and cobicistat are metabolised by
CYP3A, and co&#8209;administration with CYP3A inducers may therefore result in
subtherapeutic plasma exposure to darunavir. Darunavir boosted with cobicistat
is more sensitive to CYP3A induction than ritonavir&#8209;boosted darunavir: co&#8209;administration
of darunavir/cobicistat with medicinal products that are strong inducers of
CYP3A (e.g. St&nbsp;John&#8217;s&nbsp;wort, rifampicin, carbamazepine,
phenobarbital, and phenytoin) is contraindicated (see section 4.3). Co&#8209;administration
of darunavir/cobicistat with weak to moderate CYP3A inducers (e.g. efavirenz,
etravirine, nevirapine, fluticasone, and bosentan) is not recommended (see
interaction table below).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For co&#8209;administration with strong
CYP3A4 inhibitors, the same recommendations apply independent of whether
darunavir is boosted with ritonavir or with cobicistat (see section above).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><u><span
lang=EN-GB>Medicinal products that may be affected by darunavir boosted with
ritonavir</span></u></b></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir and ritonavir are inhibitors of
CYP3A, </span><span lang=EN-GB>CYP2D6 and P&#8209;gp</span><span lang=EN-GB>.
Co&#8209;administration of darunavir/ritonavir with medicinal products
primarily metabolised by CYP3A and/or CYP2D6 or transported by P&#8209;gp may
result in increased systemic exposure to such medicinal products, which could
increase or prolong their therapeutic effect and adverse reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Co&#8209;administration of boosted
darunavir with drugs that have active metabolite(s) formed by CYP3A may result
in reduced plasma concentrations of these active metabolite(s), potentially
leading to loss of their therapeutic effect (see the Interaction table below).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir co&#8209;administered with low
dose ritonavir must not be combined with medicinal products that are highly
dependent on CYP3A for clearance and for which increased systemic exposure is
associated with serious and/or life&#8209;threatening events (narrow
therapeutic index) (see section 4.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The overall pharmacokinetic enhancement
effect by ritonavir was an approximate 14&#8209;fold increase in the systemic
exposure of darunavir when a single dose of 600&nbsp;mg darunavir was given
orally in combination with ritonavir at 100&nbsp;mg twice daily. Therefore, darunavir
must only be used in combination with a pharmacokinetic enhancer (see sections
4.4 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A clinical study utilising a cocktail of
medicinal products that are metabolised by cytochromes CYP2C9, CYP2C19 and
CYP2D6 demonstrated an increase in CYP2C9 and CYP2C19 activity and inhibition
of CYP2D6 activity in the presence of darunavir/ritonavir, which may be
attributed to the presence of low dose ritonavir. Co&#8209;administration of
darunavir and ritonavir with medicinal products which are primarily metabolised
by CYP2D6 (such as flecainide, propafenone, metoprolol) may result in increased
plasma concentrations of these medicinal products, which could increase or
prolong their therapeutic effect and adverse reactions. Co&#8209;administration
of darunavir and ritonavir with medicinal products primarily metabolised by
CYP2C9 (such as warfarin) and CYP2C19 (such as methadone) may result in
decreased systemic exposure to such medicinal products, which could decrease or
shorten their therapeutic effect.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Although the effect on CYP2C8 has only been
studied <i>in vitro</i>, co&#8209;administration of darunavir and ritonavir and
medicinal products primarily metabolised by CYP2C8 (such as paclitaxel,
rosiglitazone, repaglinide) may result in decreased systemic exposure to such
medicinal products, which could decrease or shorten their therapeutic effect.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Ritonavir inhibits the transporters P&#8209;glycoprotein,
OATP1B1 and OATP1B3, and co&#8209;administration with substrates of these
transporters can result in increased plasma concentrations of these compounds
(e.g. dabigatran etexilate, digoxin, statins and bosentan; see the Interaction
table below).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><u><span lang=EN-GB>Medicinal
products that may be affected by darunavir boosted with cobicistat</span></u></b></p>

<p class=MsoNormal><span lang=EN-GB>The recommendations for darunavir boosted
with ritonavir are adequate also for darunavir boosted with cobicistat with
regard to substrates of CYP3A4, CYP2D6, P&#8209;glycoprotein, OATP1B1 and
OATP1B3 (see contraindications and recommendations presented in the section
above). Cobicistat 150&nbsp;mg given with darunavir 800&nbsp;mg once daily
enhances darunavir pharmacokinetic parameters in a comparable way to ritonavir
(see section 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Unlike ritonavir, cobicistat does not
induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or UGT1A1. For further
information on cobicistat, consult the cobicistat Summary of Product
Characteristics.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><u><span
lang=EN-GB>Interaction table</span></u></b></p>

<p class=MsoNormal><span lang=EN-GB>Interaction studies have only been
performed in adults.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Several of the interaction studies
(indicated by </span><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB> in
the table below) have been performed at lower than recommended doses of
darunavir or with a different dosing regimen (see section 4.2 Posology). The
effects on co&#8209;administered medicinal products may thus be underestimated
and clinical monitoring of safety may be indicated.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The interaction profile of darunavir
depends on whether ritonavir or cobicistat is used as pharmacokinetic enhancer.
Darunavir may therefore have different recommendations for concomitant
medications depending on whether the compound is boosted with ritonavir or
cobicistat. The same recommendations apply, unless specifically indicated. For
further information on cobicistat, consult the cobicistat Summary of Product
Characteristics.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Interactions between darunavir/ritonavir
and antiretroviral and non&#8209;antiretroviral medicinal products are listed
in the table below. The direction of the arrow for each pharmacokinetic
parameter is based on the 90% confidence interval of the geometric mean ratio
being within (&#8596;), below (&#8595;) or above (&#8593;) the 80&#8209;125%
range (not determined as &#8220;ND&#8221;).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the table below the specific pharmacokinetic
enhancer is specified when recommendations differ. When the recommendation is
the same for PREZISTA when co&#8209;administered with a low dose ritonavir or
cobicistat, the term &#8220;boosted PREZISTA&#8221; is used.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The below list of examples of drug-drug
interactions is not comprehensive and therefore the label of each drug that is
co-administered with PREZISTA should be consulted for information related to
the route of metabolism, interaction pathways, potential risks, and specific
actions to be taken with regards to co&#8209;administration.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>INTERACTIONS AND DOSE
  RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>Medicinal products by therapeutic areas</span></b></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>Interaction</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>Geometric mean change (%)</span></b></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>Recommendations concerning co&#8209;administration</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>HIV ANTIRETROVIRALS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>Integrase strand transfer
  inhibitors</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>Dolutegravir</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>dolutegravir AUC
  &#8595; 22%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>dolutegravir C<sub>24h</sub>
  &#8595; 38%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>dolutegravir</span><span
  lang=EN-GB style='font-size:10.0pt'> C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 11%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir
  &#8596;*</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>*</span><span
  lang=EN-GB style='font-size:9.0pt'> Using cross&#8209;study comparisons to
  historical pharmacokinetic data</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>Boosted PREZISTA and dolutegravir can be used without dose adjustment.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Raltegravir</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Some clinical
  studies suggest raltegravir may cause a modest decrease in darunavir plasma
  concentrations.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>At present the effect of raltegravir on darunavir plasma concentrations
  does not appear to be clinically relevant.</span><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'> Boosted PREZISTA and
  raltegravir can be used without dose adjustments.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>Nucleo(s/t)ide reverse
  transcriptase inhibitors (NRTIs)</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Didanosine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>400&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>didanosine AUC
  &#8595; 9%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>didanosine C<sub>min</sub>
  ND</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>didanosine</span><span
  lang=EN-GB style='font-size:10.0pt'> C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 16%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir C<sub>max</sub>
  &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>Boosted PREZISTA and didanosine can be used without dose adjustments.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>Didanosine is to be administered on an empty stomach, thus it should be
  administered 1&nbsp;hour before or 2&nbsp;hours after boosted PREZISTA given
  with food.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><a name="_Hlk497072576"><span
  lang=EN-GB style='font-size:10.0pt'>Tenofovir </span></a><span lang=EN-GB
  style='font-size:10.0pt'>disoproxil</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>245&nbsp;mg once daily</span><sup><span lang=EN-GB>&#8225;</span></sup></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>tenofovir AUC
  &#8593; 22%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>tenofovir C<sub>min</sub>
  &#8593; 37%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>tenofovir C</span><sub><span
  lang=EN-GB style='font-size:10.0pt'>max</span></sub><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 24%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir AUC &#8593; 21%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>min</sub> &#8593; 24%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>max</sub> &#8593; 16%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(&#8593;
  tenofovir from effect on MDR&#8209;1 transport in the renal tubules)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Monitoring of
  renal function may be indicated when boosted PREZISTA is given in combination
  with tenofovir disoproxil, particularly in patients with underlying systemic
  or renal disease, or in patients taking nephrotoxic agents.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>PREZISTA co&#8209;administered
  with cobicistat lowers the creatinine clearance. Refer to section 4.4 if
  creatinine clearance is used for dose adjustment of tenofovir disoproxil.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><a name="_Hlk497072702"><span
  lang=EN-GB style='font-size:10.0pt'>Emtricitabine/tenofovir alafenamide</span></a></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Tenofovir
  alafenamide</span><span lang=EN-GB style='font-size:10.0pt'> </span><span
  lang=PT style='font-size:10.0pt'>&#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Tenofovir
  &#8593;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The recommended
  dose of emtricitabine/tenofovir alafenamide is 200/10 mg once daily when used
  with boosted PREZISTA.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Abacavir</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Emtricitabine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Lamivudine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Stavudine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Zidovudine</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. </span><span
  lang=EN-GB style='font-size:10.0pt;layout-grid-mode:line'>Based on the
  different elimination pathways </span><span lang=EN-GB style='font-size:10.0pt'>of
  the other NRTIs zidovudine, emtricitabine, stavudine, lamivudine, that are
  primarily renally excreted, and abacavir for which metabolism is not mediated
  by CYP450, no interactions are expected for these medicinal compounds and boosted
  PREZISTA.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Boosted PREZISTA
  can be used with these NRTIs without dose adjustment.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>PREZISTA co&#8209;administered
  with cobicistat lowers the creatinine clearance. Refer to section 4.4 if
  creatinine clearance is used for dose adjustment of emtricitabine or
  lamivudine.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><i><span
  lang=EN-GB style='font-size:10.0pt'>Non-nucleo(s/t)ide reverse transcriptase
  inhibitors (NNRTIs)</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Efavirenz</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>600&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>efavirenz AUC
  &#8593; 21%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>efavirenz C<sub>min</sub>
  &#8593; 17%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>efavirenz C<sub>max</sub>
  &#8593; 15%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir AUC &#8595; 13%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>min</sub> &#8595; 31%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>max </sub>&#8595; 15%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(&#8593;
  efavirenz from CYP3A inhibition)</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(&#8595;
  darunavir from CYP3A induction)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Clinical
  monitoring for central nervous system toxicity associated with increased
  exposure to efavirenz may be indicated when PREZISTA co&#8209;administered
  with low dose ritonavir is given in combination with efavirenz.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Efavirenz in
  combination with PREZISTA/ritonavir 800/100&nbsp;mg once daily may result in
  sub&#8209;optimal darunavir C<sub>min</sub>. If efavirenz is to be used in
  combination with PREZISTA/ritonavir, the PREZISTA/ritonavir 600/100&nbsp;mg
  twice daily regimen should be used (see section 4.4).</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration
  with PREZISTA co&#8209;administered with cobicistat is not recommended (see
  section 4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Etravirine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>100&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>etravirine AUC
  &#8595; 37%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>etravirine C<sub>min</sub>
  &#8595; 49%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>etravirine C<sub>max
  </sub>&#8595; 32%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8593; 15%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir C<sub>min</sub>
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir C<sub>max</sub>
  &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>PREZISTA co&#8209;administered with low dose ritonavir and etravirine 200&nbsp;mg
  twice daily<b> </b>can be used<b> </b>without dose adjustments.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration
  with PREZISTA co&#8209;administered with cobicistat is not recommended (see
  section 4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Nevirapine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>200&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>nevirapine AUC
  &#8593; 27%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>nevirapine C<sub>min</sub>
  &#8593; 47%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>nevirapine C</span><sub><span
  lang=EN-GB style='font-size:10.0pt'>max</span></sub><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 18%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir: concentrations were consistent with
  historical data</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(&#8593;
  nevirapine from CYP3A inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>PREZISTA co&#8209;administered with low dose ritonavir and nevirapine
  can be used without dose adjustments.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration
  with PREZISTA co&#8209;administered with cobicistat is not recommended (see
  section 4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Rilpivirine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>150&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rilpivirine AUC &#8593;
  130%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rilpivirine C<sub>min</sub>
  &#8593; 178%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rilpivirine C<sub>max</sub>
  &#8593; 79%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir C<sub>min</sub>
  &#8595; 11%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir C<sub>max</sub>
  &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>Boosted PREZISTA and rilpivirine can be used without dose adjustments.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
  style='font-size:10.0pt'>HIV Protease inhibitors (PIs) &#8209; without
  additional co&#8209;administration of low dose ritonavir</span></i></b><sup><span
  lang=EN-GB>&#8224;</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Atazanavir</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>300&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>atazanavir AUC
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>atazanavir C<sub>min</sub>
  &#8593; 52%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>atazanavir C</span><sub><span
  lang=EN-GB style='font-size:10.0pt'>max</span></sub><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 11%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir AUC &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>min</sub> &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>max</sub> &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Atazanavir:
  comparison of atazanavir/ritonavir 300/100&nbsp;mg once daily vs. atazanavir
  300&nbsp;mg once daily in combination with darunavir/ritonavir
  400/100&nbsp;mg twice daily.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Darunavir:
  comparison of darunavir/ritonavir 400/100&nbsp;mg twice daily vs.
  darunavir/ritonavir 400/100&nbsp;mg twice daily in combination with
  atazanavir 300&nbsp;mg once daily.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>PREZISTA co&#8209;administered with low dose ritonavir and atazanavir
  can be used without dose adjustments.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>PREZISTA</span><span lang=EN-GB style='font-size:10.0pt'> co&#8209;administered
  with </span><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:line'>cobicistat
  should not be used in combination with another antiretroviral agent that
  requires pharmacoenhancement by means of co&#8209;administration with an
  inhibitor of CYP3A4 (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Indinavir</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>800&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=FR style='font-size:10.0pt'>indinavir AUC
  &#8593; 23%</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:10.0pt'>indinavir C<sub>min</sub>
  &#8593; 125%</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:10.0pt'>indinavir C<sub>max</sub>
  &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=FR>#</span></sup><span lang=FR
  style='font-size:10.0pt'>darunavir AUC &#8593; 24%</span></p>
  <p class=MsoNormal><sup><span lang=FR>#</span></sup><span lang=FR
  style='font-size:10.0pt'>darunavir C<sub>min</sub> &#8593; 44%</span></p>
  <p class=MsoNormal><sup><span lang=FR>#</span></sup><span lang=FR
  style='font-size:10.0pt'>darunavir C<sub>max</sub> &#8593; 11%</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:10.0pt'>Indinavir:
  comparison of indinavir/ritonavir 800/100&nbsp;mg twice daily vs.
  indinavir/darunavir/ritonavir 800/400/100&nbsp;mg twice daily.</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:10.0pt'>Darunavir:
  comparison of darunavir/ritonavir 400/100&nbsp;mg twice daily vs.
  darunavir/ritonavir 400/100&nbsp;mg in combination with indinavir 800&nbsp;mg
  twice daily.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>When used in
  combination with PREZISTA co&#8209;administered with low dose ritonavir, dose
  adjustment of indinavir from 800&nbsp;mg twice daily to 600&nbsp;mg twice
  daily may be warranted in case of intolerance.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>PREZISTA co&#8209;administered
  with cobicistat should not be used in combination with another antiretroviral
  agent that requires pharmacoenhancement by means of co&#8209;administration
  with an inhibitor of CYP3A4 (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Saquinavir</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>1,000&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir AUC &#8595; 26%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>min</sub> &#8595; 42%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>max</sub> &#8595; 17%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>saquinavir AUC
  &#8595; 6%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>saquinavir C<sub>min</sub>
  &#8595; 18%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>saquinavir C<sub>max</sub>
  &#8595; 6%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Saquinavir:
  comparison of saquinavir/ritonavir 1,000/100&nbsp;mg twice daily vs.
  saquinavir/darunavir/ritonavir 1,000/400/100&nbsp;mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Darunavir:
  comparison of darunavir/ritonavir 400/100&nbsp;mg twice daily vs. darunavir/ritonavir
  400/100&nbsp;mg in combination with saquinavir 1,000&nbsp;mg twice daily.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>It is not
  recommended to combine PREZISTA co&#8209;administered with low dose ritonavir
  with saquinavir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>PREZISTA co&#8209;administered
  with cobicistat should not be used in combination with another antiretroviral
  agent that requires pharmacoenhancement by means of co&#8209;administration
  with an inhibitor of CYP3A4 (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
  style='font-size:10.0pt'>HIV Protease inhibitors (PIs) &#8209; with co&#8209;administration
  of low dose ritonavir</span></i></b><b><sup><span lang=EN-GB>&#8224;</span></sup></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Lopinavir/ritonavir</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>400/100&nbsp;mg twice daily</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Lopinavir/ritonavir</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>533/133.3&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lopinavir AUC
  &#8593; 9%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lopinavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 23%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lopinavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 2%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8595; 38%</span><sup><span lang=EN-GB>&#8225;</span></sup></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 51%</span><sup><span lang=EN-GB>&#8225;</span></sup></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 21%</span><sup><span lang=EN-GB>&#8225;</span></sup></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lopinavir AUC
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lopinavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 13%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lopinavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 11%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8595; 41%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 55%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 21%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>&#8225;</span></sup><span
  lang=EN-GB> </span><span lang=EN-GB style='font-size:9.0pt'>based upon non
  dose normalised values</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Due to a
  decrease in the exposure (AUC) of darunavir by 40%, appropriate doses of the
  combination have not been established. Hence, concomitant use of boosted PREZISTA
  and the combination product lopinavir/ritonavir is contraindicated (see
  section 4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>CCR5 ANTAGONIST</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Maraviroc</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>150&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>maraviroc AUC
  &#8593; 305%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>maraviroc </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub> ND</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>maraviroc </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 129%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir,
  ritonavir concentrations were consistent with historical data</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>The maraviroc dose should be 150&nbsp;mg twice daily when co&#8209;administered
  with boosted PREZISTA.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span style='font-size:
  10.0pt'>&#945;1-ADRENORECEPTOR ANTAGONIST</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span style='font-size:10.0pt'>Alfuzosin</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Based on
  theoretical considerations PREZISTA is expected to increase </span><span
  style='font-size:10.0pt'>alfuzosin </span><span lang=EN-GB style='font-size:
  10.0pt'>plasma concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:10.0pt'>Co-administration
  of </span><span lang=EN-GB style='font-size:10.0pt'>boosted PREZISTA</span><span
  lang=EN-GB style='font-size:10.0pt'> </span><span style='font-size:10.0pt'>and
  alfuzosin is contraindicated </span><span lang=EN-GB style='font-size:10.0pt'>(see
  section&nbsp;4.3)</span><span style='font-size:10.0pt'>.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANAESTHETIC</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Alfentanil</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. The
  metabolism of alfentanil is mediated via CYP3A, and may as such be inhibited
  by boosted PREZISTA.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>The concomitant use with boosted PREZISTA may
  require to lower the dose of alfentanil and requires monitoring for risks of
  prolonged or delayed respiratory depression.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIANGINA/</span></b><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIARRHYTHMIC</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Disopyramide</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Flecainide</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Lidocaine (systemic)</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Mexiletine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Propafenone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Amiodarone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Bepridil</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Dronedarone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Ivabradine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Quinidine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Ranolazine</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Boosted PREZISTA is expected to increase these antiarrhythmic plasma
  concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A and/or
  CYP2D6 inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Caution is
  warranted and therapeutic concentration monitoring, if available, is
  recommended for these antiarrhythmics when co&#8209;administered with boosted
  PREZISTA.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co-administration
  of boosted PREZISTA and amiodarone, bepridil, dronedarone, ivabradine, quinidine,
  or ranolazine is contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Digoxin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>0.4&nbsp;mg single dose</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>digoxin AUC
  &#8593; 61%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>digoxin </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> ND</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>digoxin </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 29%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(&#8593; digoxin
  from probable inhibition of P&#8209;gp)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Given that
  digoxin has a narrow therapeutic index, it is recommended that the lowest
  possible dose of digoxin should initially be prescribed in case digoxin is
  given to patients on boosted PREZISTA therapy. The digoxin dose should be
  carefully titrated to obtain the desired clinical effect while assessing the
  overall clinical state of the subject.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIBIOTIC</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Clarithromycin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>500&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>clarithromycin
  AUC &#8593; 57%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>clarithromycin </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 174%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>clarithromycin </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 26%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir AUC &#8595; 13%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir </span><span lang=EN-GB style='font-size:
  10.0pt'>C<sub>min</sub></span><span lang=EN-GB style='font-size:10.0pt'>
  &#8593; 1%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir </span><span lang=EN-GB style='font-size:
  10.0pt'>C<sub>max</sub></span><span lang=EN-GB style='font-size:10.0pt'>
  &#8595; 17%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>14&#8209;OH&#8209;clarithromycin
  concentrations were not detectable when combined with PREZISTA/ritonavir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(&#8593;
  clarithromycin from CYP3A inhibition and possible P&#8209;gp inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Caution should
  be exercised when clarithromycin is combined with boosted PREZISTA.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>For patients
  with renal impairment the Summary of Product Characteristics for
  clarithromycin should be consulted for the recommended dose.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTICOAGULANT/</span></b><b><span lang=EN-GB
  style='font-size:10.0pt'>PLATELET AGGREGATION INHIBITOR</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Apixaban</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Edoxaban</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Rivaroxaban</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. Co&#8209;administration
  of boosted PREZISTA with these anticoagulants may increase concentrations of
  the anticoagulant, which may lead to an increased bleeding risk.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A and/or P&#8209;gp
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The use of
  boosted PREZISTA and these anticoagulants is not recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Dabigatran</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Ticagrelor</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Clopidogrel</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. Co&#8209;administration
  with boosted PREZISTA may lead to a substantial increase in exposure to dabigatran
  or ticagrelor.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. Co&#8209;administration
  of clopidogrel with boosted PREZISTA is expected to decrease clopidogrel
  active metabolite plasma concentration, which may reduce the antiplatelet
  activity of clopidogrel.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant
  administration of boosted PREZISTA with dabigatran or ticagrelor is
  contraindicated (see section&nbsp;4.3).</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration
  of clopidogrel with boosted PREZISTA is not recommended.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Use of other
  antiplatelets not affected by CYP inhibition or induction (e.g. prasugrel) is
  recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Warfarin</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Warfarin concentrations may be affected when co&#8209;administered with boosted
  PREZISTA.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>It is
  recommended that the international normalised ratio (INR) be monitored when
  warfarin is combined with boosted PREZISTA.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTICONVULSANTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Phenobarbital</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Phenytoin</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Phenobarbital and phenytoin are expected to decrease plasma concentrations of
  darunavir and its pharmacoenhancer.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(induction of
  CYP450 enzymes)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>PREZISTA co&#8209;administered
  with low dose ritonavir should not be used in combination with these
  medicines.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The use of these
  medicines with PREZISTA/cobicistat is contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Carbamazepine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>200&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>carbamazepine
  AUC &#8593; 45%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>carbamazepine </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 54%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>carbamazepine </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 43%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 15%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>No dose
  adjustment for PREZISTA/ritonavir is recommended. If there is a need to
  combine PREZISTA/ritonavir and carbamazepine, patients should be monitored
  for potential carbamazepine&#8209;related adverse events. Carbamazepine
  concentrations should be monitored and its dose should be titrated for
  adequate response. Based upon the findings, the carbamazepine dose may need
  to be reduced by 25% to 50% in the presence of PREZISTA/ritonavir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The use of
  carbamazepine with PREZISTA co&#8209;administered with cobicistat is
  contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Clonazepam</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. </span><span
  lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration of boosted </span><span
  lang=EN-GB style='font-size:10.0pt'>PREZISTA with clonazepam may increase
  concentrations of clonazepam. (CYP3A inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Clinical
  monitoring is recommended when co&#8209;administering boosted PREZISTA with clonazepam.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIDEPRESSANTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Paroxetine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>20&nbsp;mg once daily</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Sertraline</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>50&nbsp;mg once daily</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Amitriptyline</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Desipramine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Imipramine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Nortriptyline</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Trazodone</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>paroxetine</span><span
  lang=IT style='font-size:10.0pt'> AUC &#8595; 39%</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>paroxetine</span><span
  lang=IT style='font-size:10.0pt'> </span><span lang=IT style='font-size:10.0pt'>C<sub>min</sub></span><span
  lang=IT style='font-size:10.0pt'> &#8595;</span><span lang=IT
  style='font-size:10.0pt'> 37%</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>paroxetine</span><span
  lang=IT style='font-size:10.0pt'> </span><span lang=IT style='font-size:10.0pt'>C<sub>max</sub></span><span
  lang=IT style='font-size:10.0pt'> &#8595; 36%</span></p>
  <p class=MsoNormal><sup><span lang=IT>#</span></sup><span lang=IT
  style='font-size:10.0pt'>darunavir AUC &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=IT>#</span></sup><span lang=IT
  style='font-size:10.0pt'>darunavir </span><span lang=IT style='font-size:
  10.0pt'>C<sub>min</sub></span><span lang=IT style='font-size:10.0pt'> &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=IT>#</span></sup><span lang=IT
  style='font-size:10.0pt'>darunavir </span><span lang=IT style='font-size:
  10.0pt'>C<sub>max</sub></span><span lang=IT style='font-size:10.0pt'> &#8596;</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>sertraline AUC
  &#8595; 49%</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>sertraline </span><span
  lang=IT style='font-size:10.0pt'>C<sub>min</sub></span><span lang=IT
  style='font-size:10.0pt'> &#8595;</span><span lang=IT style='font-size:10.0pt'>
  49%</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>sertraline </span><span
  lang=IT style='font-size:10.0pt'>C<sub>max</sub></span><span lang=IT
  style='font-size:10.0pt'> &#8595; 44%</span></p>
  <p class=MsoNormal><sup><span lang=IT>#</span></sup><span lang=IT
  style='font-size:10.0pt'>darunavir AUC &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=IT>#</span></sup><span lang=IT
  style='font-size:10.0pt'>darunavir </span><span lang=IT style='font-size:
  10.0pt'>C<sub>min</sub></span><span lang=IT style='font-size:10.0pt'> &#8595;
  6%</span></p>
  <p class=MsoNormal><sup><span lang=IT>#</span></sup><span lang=IT
  style='font-size:10.0pt'>darunavir </span><span lang=IT style='font-size:
  10.0pt'>C<sub>max</sub></span><span lang=IT style='font-size:10.0pt'> &#8596;</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>In contrast to
  these data with PREZISTA/ritonavir, PREZISTA/cobicistat may increase these
  antidepressant plasma concentrations (CYP2D6 and/or CYP3A inhibition).</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant use
  of boosted PREZISTA and these antidepressants may increase concentrations of
  the antidepressant.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP2D6 and/or
  CYP3A inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>If
  antidepressants are co&#8209;administered with boosted PREZISTA, the
  recommended approach is a dose titration of the antidepressant based on a
  clinical assessment of antidepressant response. In addition, patients on a
  stable dose of these antidepressants who start treatment with boosted
  PREZISTA should be monitored for antidepressant response.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Clinical
  monitoring is recommended when co&#8209;administering boosted PREZISTA with
  these antidepressants and a dose adjustment of the antidepressant may be
  needed.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTI&#8209;DIABETICS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Metformin</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Based on theoretical considerations PREZISTA co&#8209;administered with
  cobicistat is expected to increase metformin plasma concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(MATE1
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Careful patient
  monitoring and dose adjustment of metformin is recommended in patients who
  are taking </span><span lang=EN-GB style='font-size:10.0pt'>PREZISTA co&#8209;administered
  with cobicistat.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(not applicable
  for </span><span lang=EN-GB style='font-size:10.0pt'>PREZISTA co&#8209;administered
  with ritonavir)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIEMETICS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Domperidone</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co-administration
  of domperidone with boosted PREZISTA is contraindicated.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIFUNGALS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Voriconazole</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Ritonavir may decrease plasma concentrations of voriconazole.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(induction of
  CYP450 enzymes)</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concentrations
  of voriconazole may increase or decrease when co&#8209;administered with
  PREZISTA co&#8209;administered with cobicistat.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(inhibition of
  CYP450 enzymes)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Voriconazole
  should not be combined with boosted PREZISTA unless an assessment of the
  benefit/risk ratio justifies the use of voriconazole.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Fluconazole</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Isavuconazole</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Itraconazole</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Posaconazole</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Clotrimazole</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Boosted PREZISTA may increase antifungal plasma concentrations and
  posaconazole, isavuconazole, itraconazole or fluconazole may increase
  darunavir concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A</span><span
  lang=EN-GB style='font-size:10.0pt'> and/or P&#8209;gp</span><span
  lang=EN-GB style='font-size:10.0pt'> inhibition)</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not Studied. Concomitant
  systemic use of clotrimazole and boosted PREZISTA may increase plasma
  concentrations of darunavir and/or clotrimazole.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC<sub>24h</sub>
  &#8593; 33% (based on population pharmacokinetic model)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Caution is
  warranted and clinical monitoring is recommended. When co&#8209;administration
  is required the daily dose of itraconazole should not exceed 200&nbsp;mg.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIGOUT MEDICINES</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Colchicine</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Concomitant use of colchicine and boosted PREZISTA may increase the exposure
  to colchicine.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A and/ or P&#8209;gp
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>A reduction in
  colchicine dosage or an interruption of colchicine treatment is recommended
  in patients with normal renal or hepatic function if treatment with boosted
  PREZISTA is required. For patients with renal or hepatic impairment
  colchicine with boosted PREZISTA is contraindicated (see sections 4.3 and 4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIMALARIALS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Artemether/Lumefantrine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>80/480&nbsp;mg, 6&nbsp;doses at 0, 8, 24, 36, 48,
  and 60&nbsp;hours</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>artemether AUC
  &#8595; 16%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>artemether C<sub>min</sub>
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>artemether C<sub>max</sub>
  &#8595; 18%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>dihydroartemisinin
  AUC &#8595; 18%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>dihydroartemisinin
  C<sub>min</sub> &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>dihydroartemisinin
  C<sub>max</sub> &#8595; 18%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lumefantrine AUC
  &#8593; 175%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lumefantrine C<sub>min</sub>
  &#8593; 126%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lumefantrine C<sub>max</sub>
  &#8593; 65%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir C<sub>min</sub>
  &#8595; 13%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir C<sub>max</sub>
  &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The combination
  of boosted PREZISTA and artemether/lumefantrine can be used without dose
  adjustments; however, due to the increase in lumefantrine exposure, the
  combination should be used with caution.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIMYCOBACTERIALS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Rifampicin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Rifapentine</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Rifapentine and rifampicin are strong CYP3A inducers and have been shown to
  cause profound decreases in concentrations of other protease inhibitors,
  which can result in virological failure and resistance development (CYP450
  enzyme induction). During attempts to overcome the decreased exposure by
  increasing the dose of other protease inhibitors with low dose ritonavir, a
  high frequency of liver reactions was seen with rifampicin.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The combination
  of rifapentine and boosted PREZISTA is not recommended.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The combination
  of rifampicin and boosted PREZISTA is contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Rifabutin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>150&nbsp;mg once every other day</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rifabutin AUC</span><sup><span
  lang=EN-GB>**</span></sup><span lang=EN-GB style='font-size:10.0pt'> &#8593;
  55%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rifabutin C<sub>min</sub></span><sup><span
  lang=EN-GB>**</span></sup><span lang=EN-GB style='font-size:10.0pt'> &#8593;
  ND</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rifabutin C<sub>max</sub></span><sup><span
  lang=EN-GB>**</span></sup><span lang=EN-GB style='font-size:10.0pt'> &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8593; 53%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 68</span><span lang=EN-GB style='font-size:
  10.0pt'>%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 39%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>**</span></sup><span lang=EN-GB
  style='font-size:10.0pt'> </span><span lang=EN-GB style='font-size:9.0pt'>sum
  of active moieties of rifabutin (parent drug +&nbsp;25&#8209;<i>O&#8209;</i>desacetyl
  metabolite)</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The interaction
  trial showed a comparable daily systemic exposure for rifabutin between
  treatment at 300&nbsp;mg once daily alone and 150&nbsp;mg once every other
  day in combination with PREZISTA/ritonavir (600/100&nbsp;mg twice daily) with
  an about 10&#8209;fold increase in the daily exposure to the active
  metabolite 25&#8209;<i>O&#8209;</i>desacetylrifabutin. Furthermore, AUC of
  the sum of active moieties of rifabutin (parent drug +&nbsp;25&#8209;<i>O&#8209;</i>desacetyl
  metabolite) was increased 1.6&#8209;fold, while C<sub>max</sub> remained
  comparable.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Data on
  comparison with a 150&nbsp;mg once daily reference dose is lacking.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(Rifabutin is an
  inducer and substrate of CYP3A.) An increase of systemic exposure to
  darunavir was observed when PREZISTA co&#8209;administered with 100&nbsp;mg
  ritonavir was co&#8209;administered with rifabutin (150&nbsp;mg once every
  other day).</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>A dosage
  reduction of rifabutin by 75% of the usual dose of 300&nbsp;mg/day (i.e.
  rifabutin 150&nbsp;mg once every other day) and increased monitoring for
  rifabutin related adverse events is warranted in patients receiving the
  combination with PREZISTA co&#8209;administered with ritonavir. In case of
  safety issues, a further increase of the dosing interval for rifabutin and/or
  monitoring of rifabutin levels should be considered.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Consideration
  should be given to official guidance on the appropriate treatment of
  tuberculosis in HIV infected patients.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Based upon the
  safety profile of PREZISTA/ritonavir, the increase in darunavir exposure in
  the presence of rifabutin does not warrant a dose adjustment for
  PREZISTA/ritonavir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Based on
  pharmacokinetic modeling, this dosage reduction of 75% is also applicable if
  patients receive rifabutin at doses other than 300&nbsp;mg/day.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration
  of PREZISTA co&#8209;administered with cobicistat and rifabutin is not
  recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTINEOPLASTICS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Dasatinib</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Nilotinib</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Vinblastine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Vincristine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Everolimus</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Irinotecan</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Boosted PREZISTA is expected to increase these antineoplastic plasma
  concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>Concentrations of these medicinal products may be
  increased when co&#8209;administered with boosted PREZISTA resulting in the
  potential for increased adverse events usually associated with these agents.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Caution should
  be exercised when combining one of these antineoplastic agents with boosted
  PREZISTA.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant use
  of everolimus or irinotecan and boosted PREZISTA is not recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIPSYCHOTICS</span></b><b><span lang=EN-GB
  style='font-size:10.0pt'>/NEUROLEPTICS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Quetiapine</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Boosted PREZISTA is expected to increase these antipsychotic plasma
  concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant
  administration of boosted PREZISTA and quetiapine is contraindicated as it
  may increase quetiapine&#8209;related toxicity. Increased concentrations of
  quetiapine may lead to coma (see section&nbsp;4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Perphenazine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Risperidone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Thioridazine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Lurasidone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Pimozide</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Sertindole</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Boosted PREZISTA is expected to increase these antipsychotic plasma
  concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A, CYP2D6
  and/or P&#8209;gp inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>A dose decrease
  may be needed for these drugs when co&#8209;administered with boosted
  PREZISTA.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant administration
  of boosted PREZISTA and lurasidone, pimozide or sertindole is contraindicated
  (see section&nbsp;4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>&#946;-BLOCKERS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Carvedilol</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Metoprolol</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Timolol</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Boosted PREZISTA is expected to increase these &#946;&#8209;blocker plasma
  concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP2D6
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Clinical
  monitoring is recommended when co&#8209;administering boosted PREZISTA with
  &#946;&#8209;blockers. A lower dose of the &#946;&#8209;blocker should be considered.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>CALCIUM CHANNEL BLOCKERS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Amlodipine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Diltiazem</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Felodipine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Nicardipine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Nifedipine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Verapamil</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Boosted PREZISTA can be expected to increase the plasma concentrations of
  calcium channel blockers.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A and/or
  CYP2D6 inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Clinical
  monitoring of therapeutic and adverse effects is recommended when these
  medicines are concomitantly administered with boosted PREZISTA.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB style='font-size:10.0pt'>CORTICOSTEROIDS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Corticosteroids primarily metabolised by CYP3A
  (including betamethasone, budesonide, fluticasone, mometasone, prednisone,
  triamcinolone)</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Fluticasone: in
  a clinical study where ritonavir 100&nbsp;mg capsules twice daily were co&#8209;administered
  with 50&nbsp;</span><span lang=EN-GB style='font-size:10.0pt;font-family:
  Symbol'>m</span><span lang=EN-GB style='font-size:10.0pt'>g intranasal
  fluticasone propionate (4&nbsp;times daily) for 7&nbsp;days in healthy
  subjects, fluticasone propionate plasma concentrations increased
  significantly, whereas the intrinsic cortisol levels decreased by
  approximately 86% (90% CI 82&#8209;89%). Greater effects may be expected when
  fluticasone is inhaled. Systemic corticosteroid effects including
  Cushing&#8217;s syndrome and adrenal suppression have been reported in
  patients receiving ritonavir and inhaled or intranasally administered
  fluticasone. The effects of high fluticasone systemic exposure on ritonavir
  plasma levels are unknown.</span></p>
  <p class=MsoNormal><span style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span style='font-size:10.0pt'>Other corticosteroids: interaction
  not studied. Plasma concentrations of these medicinal products may be
  increased when co-administered with boosted PREZISTA, resulting in reduced
  serum cortisol concentrations.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:10.0pt'>Concomitant use of boosted
  PREZISTA and corticosteroids that are metabolised by CYP3A (e.g. fluticasone
  propionate or other inhaled or nasal corticosteroids) may increase the risk
  of development of systemic corticosteroid effects, including Cushing&#8217;s
  syndrome and adrenal suppression.</span></p>
  <p class=MsoNormal><span style='font-size:10.0pt'>Co-administration with
  CYP3A-metabolised corticosteroids is not recommended unless the potential
  benefit to the patient outweighs the risk, in which case patients should be
  monitored for systemic corticosteroid effects.</span></p>
  <p class=MsoNormal><span style='font-size:10.0pt'>Alternative corticosteroids
  which are less dependent on CYP3A metabolism e.g. beclomethasone for
  intranasal or inhalational use should be considered, particularly for long
  term use.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Dexamethasone</span><span lang=EN-GB
  style='font-size:10.0pt'> (systemic)</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Dexamethasone may decrease plasma concentrations of darunavir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  induction)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Systemic
  dexamethasone should be used with caution when combined with boosted
  PREZISTA.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ENDOTHELIN RECEPTOR ANTAGONISTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><a name="_Hlk497073043"><span
  lang=EN-GB style='font-size:10.0pt'>Bosentan</span></a></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Concomitant use of bosentan and boosted PREZISTA may increase plasma
  concentrations of bosentan.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Bosentan is
  expected to decrease plasma concentrations of darunavir and/or its
  pharmacoenhancer.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  induction)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>When
  administered concomitantly with PREZISTA and low dose ritonavir, the
  patient&#8217;s tolerability of bosentan should be monitored.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co-administration
  of PREZISTA co-administered with cobicistat and bosentan is not recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>HEPATITIS C VIRUS (HCV) DIRECT&#8209;ACTING
  ANTIVIRALS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
  style='font-size:10.0pt'>NS3&#8209;4A protease inhibitors</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span style='font-size:10.0pt'>Elbasvir/grazoprevir</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Boosted PREZISTA
  m</span><span style='font-size:10.0pt'>ay increase the exposure to
  grazoprevir.</span></p>
  <p class=MsoNormal><span style='font-size:10.0pt'>(CYP3A and OATP1B inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:10.0pt'>Concomitant use of boosted PREZISTA
  and elbasvir/grazoprevir is contraindicated </span><span lang=EN-GB
  style='font-size:10.0pt'>(see section&nbsp;4.3)</span><span style='font-size:
  10.0pt'>.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Glecaprevir/pibrentasvir</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Based on
  theoretical considerations boosted PREZISTA may increase the exposure to glecaprevir
  and pibrentasvir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(P&#8209;gp,
  BCRP and/or OATP1B1/3 inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>It is not
  recommended to co&#8209;administer boosted PREZISTA with
  glecaprevir/pibrentasvir.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB style='font-size:10.0pt'>HERBAL PRODUCTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>St&nbsp;John's&nbsp;wort</span><span lang=EN-GB
  style='font-size:10.0pt'> <i>(Hypericum perforatum)</i></span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. </span><span
  lang=EN-GB style='font-size:10.0pt'>St&nbsp;John&#8217;s&nbsp;wort is
  expected to decrease the plasma concentrations of darunavir or its
  pharmacoenhancers.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP450
  induction)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Boosted PREZISTA
  must not be used concomitantly with products containing
  St&nbsp;John&#8217;s&nbsp;wort (<i>Hypericum perforatum</i>) (see section
  4.3). If a patient is already taking St&nbsp;John&#8217;s&nbsp;wort, stop
  St&nbsp;John&#8217;s&nbsp;wort and if possible check viral levels. Darunavir
  exposure (and also ritonavir exposure) may increase on stopping
  St&nbsp;John&#8217;s&nbsp;wort. The inducing effect may persist for at least
  2&nbsp;weeks after cessation of treatment with
  St&nbsp;John&#8217;s&nbsp;wort.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB style='font-size:10.0pt'>HMG&nbsp;CO&#8209;A REDUCTASE INHIBITORS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Lovastatin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Simvastatin</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Lovastatin and simvastatin are expected to have markedly increased plasma
  concentrations when co&#8209;administered with boosted PREZISTA.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Increased plasma
  concentrations of lovastatin or simvastatin may cause myopathy, including
  rhabdomyolysis. Concomitant use of </span><span lang=EN-GB style='font-size:
  10.0pt'>boosted </span><span lang=EN-GB style='font-size:10.0pt'>PREZISTA
  with lovastatin and simvastatin is therefore contraindicated (see section
  4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Atorvastatin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>10&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>atorvastatin</span><span
  lang=EN-GB style='font-size:10.0pt'> AUC &#8593; 3&#8209;4 fold</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>atorvastatin</span><span
  lang=EN-GB style='font-size:10.0pt'> </span><span lang=EN-GB
  style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; </span><span lang=EN-GB style='font-size:
  9.0pt'>&#8776;</span><span lang=EN-GB style='font-size:10.0pt'>5.5&#8209;10
  fold</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>atorvastatin</span><span
  lang=EN-GB style='font-size:10.0pt'> </span><span lang=EN-GB
  style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; &#8776;2 fold</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB># </span></sup><span lang=EN-GB
  style='font-size:9.0pt'>darunavir/ritonavir</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  style='font-size:10.0pt'>atorvastatin AUC &#8593; 290%</span><sup><span
  lang=EN-GB> &#937;</span></sup></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  style='font-size:10.0pt'>atorvastatin C<sub>max</sub> &#8593; 319%</span><sup><span
  lang=EN-GB> &#937;</span></sup></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  style='font-size:10.0pt'>atorvastatin C<sub>min</sub> ND</span><sup><span
  lang=EN-GB> &#937;</span></sup></p>
  <p class=MsoNormal style='text-autospace:none'><sup><span lang=EN-GB>&#937;</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> with darunavir/cobicistat 800/150&nbsp;mg</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>When
  administration of atorvastatin and boosted PREZISTA is desired, it is
  recommended to start with an atorvastatin dose of 10&nbsp;mg once daily. A
  gradual dose increase of atorvastatin may be tailored to the clinical
  response.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Pravastatin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>40&nbsp;mg single dose</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>pravastatin AUC
  &#8593; 81%</span><sup><span lang=EN-GB>&para;</span></sup></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>pravastatin </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> ND</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>pravastatin </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 63%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>&para;</span></sup><span lang=EN-GB
  style='font-size:9.0pt'> an up to five-fold increase was seen in a limited
  subset of subjects</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>When administration
  of pravastatin and boosted PREZISTA is required, it is recommended to start
  with the lowest possible dose of pravastatin and titrate up to the desired
  clinical effect while monitoring for safety.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Rosuvastatin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>10&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rosuvastatin AUC
  &#8593; 48%</span><sup><span lang=EN-GB>&#9553;</span></sup></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rosuvastatin C<sub>max</sub>
  &#8593; 144%</span><sup><span lang=EN-GB>&#9553;</span></sup></p>
  <p class=MsoNormal><sup><span lang=EN-GB>&#9553;</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> based on published data with darunavir/ritonavir</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:10.0pt'>rosuvastatin
  AUC &#8593; 93%</span><sup><span lang=EN-GB>&sect;</span></sup></p>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:10.0pt'>rosuvastatin
  C<sub>max</sub> &#8593; 277%</span><sup><span lang=EN-GB>&sect;</span></sup></p>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:10.0pt'>rosuvastatin
  C<sub>min</sub> ND</span><sup><span lang=EN-GB>&sect;</span></sup></p>
  <p class=MsoNormal style='text-autospace:none'><sup><span lang=EN-GB>&sect;</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> with darunavir/cobicistat 800/150&nbsp;mg</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>When
  administration of rosuvastatin and boosted PREZISTA is required, it is
  recommended to start with the lowest possible dose of rosuvastatin and
  titrate up to the desired clinical effect while monitoring for safety.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><a name="_Hlk498286563"><b><span
  lang=EN-GB style='font-size:10.0pt'>OTHER LIPID MODIFYING AGENTS</span></b></a></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Lomitapide</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Based on
  theoretical considerations boosted PREZISTA is expected to increase the
  exposure of lomitapide when co-administered.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co-administration
  is </span><span lang=EN-GB style='font-size:10.0pt'>contraindicated (see
  section 4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>H</span></b><b><sub><span lang=EN-GB>2</span></sub></b><b><span
  lang=EN-GB style='font-size:10.0pt'>&#8209;RECEPTOR ANTAGONISTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Ranitidine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>150&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir AUC &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir </span><span lang=EN-GB style='font-size:
  10.0pt'>C<sub>min</sub></span><span lang=EN-GB style='font-size:10.0pt'>
  &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir </span><span lang=EN-GB style='font-size:
  10.0pt'>C<sub>max</sub></span><span lang=EN-GB style='font-size:10.0pt'>
  &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Boosted PREZISTA
  can be co&#8209;administered with H<sub>2</sub>&#8209;receptor antagonists
  without dose adjustments.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>IMMUNOSUPPRESSANTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Ciclosporin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Sirolimus</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Tacrolimus</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Everolimus</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Exposure to these immunosuppressants will be increased when co&#8209;administered
  with boosted PREZISTA.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Therapeutic drug
  monitoring of the immunosuppressive agent must be done when co&#8209;administration
  occurs.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant use
  of everolimus and boosted PREZISTA is not recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB style='font-size:10.0pt'>INHALED BETA AGONISTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Salmeterol</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Concomitant use of salmeterol and boosted darunavir may increase plasma
  concentrations of salmeterol.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant use
  of salmeterol and boosted PREZISTA is not recommended. The combination may
  result in increased risk of cardiovascular adverse event with salmeterol,
  including QT prolongation, palpitations and sinus tachycardia.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB style='font-size:10.0pt'>NARCOTIC ANALGESICS / TREATMENT OF OPIOID
  DEPENDENCE</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Methadone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>individual dose ranging from 55&nbsp;mg to
  150&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT-BR style='font-size:10.0pt'>R(&#8209;)&nbsp;methadone</span><span
  lang=PT-BR style='font-size:10.0pt'> AUC &#8595; 16%</span></p>
  <p class=MsoNormal><span lang=PT-BR style='font-size:10.0pt'>R(&#8209;)&nbsp;methadone</span><span
  lang=PT-BR style='font-size:10.0pt'> </span><span lang=PT-BR
  style='font-size:10.0pt'>C<sub>min</sub></span><span lang=PT-BR
  style='font-size:10.0pt'> &#8595; 15%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>R(&#8209;)&nbsp;methadone</span><span
  lang=EN-GB style='font-size:10.0pt'> </span><span lang=EN-GB
  style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 24%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>PREZISTA/cobicistat
  may, in contrast, increase methadone plasma concentrations (see cobicistat
  SmPC).</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>No adjustment of
  methadone dosage is required when initiating co&#8209;administration with boosted
  PREZISTA. However, adjustment of the methadone dose may be necessary when
  concomitantly administered for a longer period of time. Therefore, clinical
  monitoring is recommended, as maintenance therapy may need to be adjusted in
  some patients.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Buprenorphine/naloxone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>8/2&nbsp;mg&#8211;16/4&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>buprenorphine AUC
  &#8595; 11%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>buprenorphine </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>buprenorphine </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 8%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>norbuprenorphine
  AUC &#8593; 46%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>norbuprenorphine
  </span><span lang=EN-GB style='font-size:10.0pt'>C<sub>min </sub></span><span
  lang=EN-GB style='font-size:10.0pt'>&#8593; </span><span lang=EN-GB
  style='font-size:10.0pt'>71%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>norbuprenorphine
  </span><span lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub> </span><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;</span><span lang=EN-GB
  style='font-size:10.0pt'> 36%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>naloxone AUC
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>naloxone C<sub>min</sub>
  ND</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>naloxone C<sub>max</sub>
  &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The clinical
  relevance of the increase in norbuprenorphine pharmacokinetic parameters has
  not been established. Dose adjustment for buprenorphine may not be necessary
  when co&#8209;administered with </span><span lang=EN-GB style='font-size:
  10.0pt'>boosted </span><span lang=EN-GB style='font-size:10.0pt'>PREZISTA but
  a careful clinical monitoring for signs of opiate toxicity is recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Fentanyl</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Oxycodone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Tramadol</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Based on
  theoretical considerations boosted PREZISTA may increase plasma
  concentrations of these analgesics.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP2D6 and/or
  CYP3A inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Clinical
  monitoring is recommended when co&#8209;administering </span><span
  lang=EN-GB style='font-size:10.0pt'>boosted PREZISTA</span><span lang=EN-GB
  style='font-size:10.0pt'> with these analgesics.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>OESTROGEN&#8209;BASED</span></b><b><span lang=EN-GB
  style='font-size:10.0pt'> CONTRACEPTIVES</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Drospirenone Ethinylestradiol
  (3&nbsp;mg/0.02&nbsp;mg once daily)</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Ethinylestradiol</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Norethindrone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>35&nbsp;</span><span lang=EN-GB style='font-size:
  10.0pt;font-family:Symbol'>m</span><span lang=EN-GB style='font-size:10.0pt'>g/1&nbsp;mg
  once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=IT
  style='font-size:10.0pt'>drospirenone AUC &#8593; 58%</span><sup><span
  lang=IT>&#8364;</span></sup></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=IT
  style='font-size:10.0pt'>drospirenone C<sub>min</sub> ND</span><sup><span
  lang=IT>&#8364;</span></sup></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=IT
  style='font-size:10.0pt'>drospirenone C<sub>max</sub> &#8593; 15%</span><sup><span
  lang=IT>&#8364;</span></sup></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=IT
  style='font-size:10.0pt'>ethinylestradiol AUC </span><span style='font-size:
  10.0pt;font-family:Symbol'>&macr;</span><span lang=IT style='font-size:10.0pt'>
  30%</span><sup><span lang=IT>&#8364;</span></sup></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>ethinylestradiol C<sub>min</sub>
  ND</span><sup><span lang=IT>&#8364;</span></sup></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=IT
  style='font-size:10.0pt'>ethinylestradiol C<sub>max</sub> </span><span
  style='font-size:10.0pt;font-family:Symbol'>&macr;</span><span lang=IT
  style='font-size:10.0pt'> 14%</span><sup><span lang=IT>&#8364;</span></sup></p>
  <p class=MsoNormal><sup><span lang=IT>&#8364;</span></sup><span lang=IT
  style='font-size:9.0pt'> </span><span lang=IT style='font-size:9.0pt'>with darunavir/cobicistat</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>ethinylestradiol
  AUC &#8595; 44%</span><sup><span lang=EN-GB>&#946;</span></sup></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>ethinylestradiol </span><span
  lang=IT style='font-size:10.0pt'>C<sub>min</sub></span><span lang=IT
  style='font-size:10.0pt'> &#8595; 62%</span><sup><span lang=EN-GB>&#946;</span></sup></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>ethinylestradiol </span><span
  lang=IT style='font-size:10.0pt'>C<sub>max</sub></span><span lang=IT
  style='font-size:10.0pt'> &#8595; 32%</span><sup><span lang=EN-GB>&#946;</span></sup></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>norethindrone</span><span
  lang=IT style='font-size:10.0pt'> AUC &#8595; 14%</span><sup><span
  lang=EN-GB>&#946;</span></sup></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>norethindrone</span><span
  lang=IT style='font-size:10.0pt'> </span><span lang=IT style='font-size:10.0pt'>C<sub>min</sub></span><span
  lang=IT style='font-size:10.0pt'> &#8595;</span><span lang=IT
  style='font-size:10.0pt'> 30%</span><sup><span lang=EN-GB>&#946;</span></sup></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>norethindrone</span><span
  lang=IT style='font-size:10.0pt'> </span><span lang=IT style='font-size:10.0pt'>C<sub>max</sub></span><span
  lang=IT style='font-size:10.0pt'> &#8596;</span><sup><span lang=EN-GB>&#946;</span></sup></p>
  <p class=MsoNormal><sup><span lang=EN-GB>&#946;</span></sup><span lang=IT
  style='font-size:9.0pt'> with darunavir/ritonavir</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>When PREZISTA is co&#8209;administered with a
  drospirenone&#8209;containing product, clinical monitoring is recommended due
  to the potential for hyperkalaemia.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>Alternative or additional contraceptive measures are
  recommended when oestrogen&#8209;based contraceptives are co&#8209;administered
  with boosted PREZISTA. Patients using oestrogens as hormone replacement
  therapy should be clinically monitored for signs of oestrogen deficiency.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB style='font-size:10.0pt'>OPIOID ANTAGONIST</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Naloxegol</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT-BR style='font-size:10.0pt'>Not studied.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration
  of boosted PREZISTA and naloxegol is contraindicated.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>PHOSPHODIESTERASE, TYPE 5 (PDE&#8209;5) INHIBITORS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>For the
  treatment of erectile dysfunction</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Avanafil</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Sildenafil</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Tadalafil</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Vardenafil</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>In an
  interaction study </span><sup><span lang=EN-GB>#</span></sup><span
  lang=EN-GB style='font-size:10.0pt'>, a comparable systemic exposure to
  sildenafil was observed for a single intake of 100&nbsp;mg sildenafil alone
  and a single intake of 25&nbsp;mg sildenafil co&#8209;administered with</span><span
  lang=EN-GB style='font-size:10.0pt'> PREZISTA and low dose ritonavir.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The combination
  of avanafil and boosted PREZISTA is contraindicated (see section 4.3).</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant use
  of other PDE&#8209;5 inhibitors for the treatment of erectile dysfunction
  with </span><span lang=EN-GB style='font-size:10.0pt'>boosted </span><span
  lang=EN-GB style='font-size:10.0pt'>PREZISTA should be done with caution. If
  concomitant use of </span><span lang=EN-GB style='font-size:10.0pt'>boosted </span><span
  lang=EN-GB style='font-size:10.0pt'>PREZISTA with sildenafil, vardenafil or
  tadalafil is indicated, sildenafil at a single dose not exceeding 25&nbsp;mg
  in 48&nbsp;hours, vardenafil at a single dose not exceeding 2.5&nbsp;mg in
  72&nbsp;hours or tadalafil at a single dose not exceeding 10&nbsp;mg in
  72&nbsp;hours is recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>For the
  treatment of pulmonary arterial hypertension</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Sildenafil</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Tadalafil</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Concomitant use of sildenafil or tadalafil for the treatment of pulmonary
  arterial hypertension and boosted PREZISTA may increase plasma concentrations
  of sildenafil or tadalafil.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>A safe and
  effective dose of sildenafil for the treatment of pulmonary arterial
  hypertension co&#8209;administered with boosted PREZISTA has not been
  established. There is an increased potential for sildenafil&#8209;associated
  adverse events (including visual disturbances, hypotension, prolonged
  erection and syncope). Therefore, co&#8209;administration of boosted PREZISTA
  and sildenafil when used for the treatment of pulmonary arterial hypertension
  is contraindicated (see section 4.3).</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration
  of tadalafil for the treatment of pulmonary arterial hypertension with
  boosted PREZISTA is not recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>PROTON PUMP INHIBITORS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Omeprazole</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>20&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir AUC &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir </span><span lang=EN-GB style='font-size:
  10.0pt'>C<sub>min</sub></span><span lang=EN-GB style='font-size:10.0pt'>
  &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir </span><span lang=EN-GB style='font-size:
  10.0pt'>C<sub>max</sub></span><span lang=EN-GB style='font-size:10.0pt'>
  &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Boosted PREZISTA
  can be co&#8209;administered with proton pump inhibitors without dose
  adjustments.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>SEDATIVES/HYPNOTICS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Buspirone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Clorazepate</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Diazepam</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Estazolam</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Flurazepam</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Midazolam (parenteral)</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Zolpidem</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Midazolam (oral)</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Triazolam</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Sedative/hypnotics are extensively metabolised by CYP3A. Co&#8209;administration
  with boosted PREZISTA may cause a large increase in the concentration of
  these medicines.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>If parenteral
  midazolam is co&#8209;administered with boosted PREZISTA it may cause a large
  increase in the concentration of this benzodiazepine. Data from concomitant
  use of parenteral midazolam with other protease inhibitors suggest a possible
  3&#8209;4 fold increase in midazolam plasma levels.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Clinical
  monitoring is recommended when co&#8209;administering boosted PREZISTA with
  these sedatives/hypnotics and a lower dose of the sedatives/hypnotics should
  be considered.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>If parenteral
  midazolam is co&#8209;administered with boosted PREZISTA, it should be done
  in an intensive care unit (ICU) or similar setting, which ensures close
  clinical monitoring and appropriate medical management in case of respiratory
  depression and/or prolonged sedation. Dose adjustment for midazolam should be
  considered, especially if more than a single dose of midazolam is
  administered.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Boosted PREZISTA
  with triazolam or oral midazolam is contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>TREATMENT FOR PREMATURE EJACULATION</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Dapoxetine</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co-administration
  of boosted PREZISTA with dapoxetine is contraindicated.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>UROLOGICAL DRUGS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt;page-break-after:avoid'><span
  lang=PT style='font-size:10.0pt'>Fesoterodine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt;page-break-after:avoid'><span
  lang=PT style='font-size:10.0pt'>Solifenacin</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Not studied.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Use with caution. Monitor for fesoterodine or
  solifenacin adverse reactions, dose reduction of fesoterodine or solifenacin
  may be necessary.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:none;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><b><sup><span
  lang=EN-GB>#</span></sup></b><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Studies have been performed at lower than
  recommended doses of darunavir or with a different dosing regimen (see
  section 4.2 Posology).</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><b><sup><span
  lang=EN-GB>&#8224;</span></sup></b><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>The efficacy and safety of the use of
  PREZISTA with 100&nbsp;mg ritonavir and any other HIV PI (e.g.
  (fos)amprenavir and tipranavir) has not been established in HIV patients.
  According to current treatment guidelines, dual therapy with protease
  inhibitors is generally not recommended.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>&#8225;</span></sup><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Study was conducted with tenofovir
  disoproxil fumarate 300&nbsp;mg once daily.</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="_Hlk515272801"><b><span
lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility, pregnancy and lactation</span></b></a></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="_Hlk515272795"><u><span
lang=EN-GB>Pregnancy</span></u></a></p>

<p class=MsoNormal><span lang=EN-GB>As a general rule, when deciding to use
antiretroviral agents for the treatment of HIV infection in pregnant women and
consequently for reducing the risk of HIV vertical transmission to the newborn,
the animal data as well as the clinical experience in pregnant women should be
taken into account.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There are no adequate and well controlled
studies on pregnancy outcome with darunavir in pregnant women. Studies in
animals do not indicate direct harmful effects with respect to pregnancy,
embryonal/foetal development, parturition or postnatal development (see section
5.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA co&#8209;administered with low
dose ritonavir should be used during pregnancy only if the potential benefit
justifies the potential risk.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Treatment with darunavir/cobicistat 800/150&nbsp;mg
during pregnancy results in low darunavir exposure (see section&nbsp;5.2),
which may be associated with an increased risk of treatment failure and an
increased risk of HIV transmission to the child. Therapy with PREZISTA/cobicistat
should not be initiated during pregnancy, and women who become pregnant during
therapy with PREZISTA/cobicistat should be switched to an alternative regimen (see
sections&nbsp;4.2 and 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Breast&#8209;feeding</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>It is not known
whether darunavir is excreted in human milk. Studies in rats have demonstrated
that darunavir is excreted in milk and at high levels (1,000&nbsp;mg/kg/day)
resulted in toxicity. Because of both the potential for HIV transmission and
the potential for adverse reactions in breast&#8209;fed infants, mothers should
be instructed not to breast&#8209;feed under any circumstances if they are
receiving PREZISTA.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal><span lang=EN-GB>No human data on the effect of darunavir on
fertility are available. There was no effect on mating or fertility with
darunavir treatment in rats (see section 5.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects
on ability to drive and use machines</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA in combination with cobicistat or ritonavir
has no or negligible influence on the ability to drive and use machines.
However, dizziness has been reported in some patients during treatment with
regimens containing PREZISTA co&#8209;administered with cobicistat or low dose
ritonavir and should be borne in mind when considering a patient&#8217;s
ability to drive or operate machinery (see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable
effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Summary
of the safety profile</span></u></p>

<p class=MsoNormal><span lang=EN-GB>During the clinical development program
(N=2,613 treatment&#8209;experienced subjects who initiated therapy with
PREZISTA/ritonavir 600/100&nbsp;mg twice daily), 51.3% of subjects experienced
at least one adverse reaction. The total mean treatment duration for subjects
was 95.3&nbsp;weeks. The most frequent adverse reactions reported in clinical
trials and as spontaneous reports are diarrhoea, nausea, rash, headache and
vomiting. The most frequent serious reactions are acute renal failure,
myocardial infarction, immune reconstitution inflammatory syndrome,
thrombocytopenia, osteonecrosis, diarrhoea, hepatitis and pyrexia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the 96&nbsp;week analysis, the safety
profile of PREZISTA/ritonavir 800/100&nbsp;mg once daily in treatment&#8209;na&iuml;ve
subjects was similar to that seen with PREZISTA/ritonavir 600/100&nbsp;mg twice
daily in treatment&#8209;experienced subjects except for nausea which was
observed more frequently in treatment&#8209;na&iuml;ve subjects. This was
driven by mild intensity nausea. No new safety findings were identified in the
192&nbsp;week analysis of the treatment&#8209;na&iuml;ve subjects in which the
mean treatment duration of PREZISTA/ritonavir 800/100&nbsp;mg once daily was
162.5&nbsp;weeks.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>During the Phase&nbsp;III clinical trial GS&#8209;US&#8209;216&#8209;130
with darunavir/cobicistat (N=313&nbsp;treatment&#8209;na&iuml;ve and treatment&#8209;experienced
subjects), 66.5% of subjects experienced at least one adverse reaction. The
mean treatment duration was 58.4&nbsp;weeks. The most frequent adverse
reactions reported were diarrhoea (28%), nausea (23%), and rash (16%). Serious
adverse reactions are diabetes mellitus, (drug) hypersensitivity, immune
reconstitution inflammatory syndrome, rash and vomiting.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>For information on cobicistat, consult the
cobicistat Summary of Product Characteristics.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Adverse reactions are listed by system organ
class (SOC) and frequency category. Within each frequency category, adverse
reactions are presented in order of decreasing seriousness. Frequency
categories are defined as follows: very common (&#8805;&nbsp;1/10), common
(&#8805;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&#8805;&nbsp;1/1,000 to &lt;&nbsp;1/100),
rare (&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000) and not known (frequency
cannot be estimated from the available data).</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Adverse
reactions observed with darunavir/ritonavir in clinical trials and post&#8209;marketing</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>MedDRA system
  organ class</span></p>
  <p class=MsoNormal><span lang=EN-GB>Frequency category</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Adverse reaction</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Infections
  and infestations</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>herpes simplex</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Blood
  and lymphatic system disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>thrombocytopenia, neutropenia, anaemia,
  leukopenia</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>increased eosinophil count</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Immune
  system disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>immune reconstitution inflammatory syndrome,
  (drug) hypersensitivity</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Endocrine
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>hypothyroidism, increased blood thyroid
  stimulating hormone</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
  lang=EN-GB>Metabolism and nutrition disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>diabetes mellitus, hypertriglyceridaemia,
  hypercholesterolaemia, hyperlipidaemia</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>gout, anorexia, decreased appetite,
  decreased weight, increased weight, hyperglycaemia, insulin resistance,
  decreased high density lipoprotein, increased appetite, polydipsia, increased
  blood lactate dehydrogenase</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Psychiatric
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>insomnia</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>depression, disorientation, anxiety,
  sleep disorder, abnormal dreams, nightmare, decreased libido</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>confusional state, altered mood,
  restlessness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Nervous
  system disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>headache, peripheral neuropathy,
  dizziness</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>lethargy, paraesthesia, hypoaesthesia,
  dysgeusia, disturbance in attention, memory impairment, somnolence</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>syncope, convulsion, ageusia, sleep phase
  rhythm disturbance</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Eye
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>conjunctival hyperaemia, dry eye</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>visual disturbance</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Ear and
  labyrinth disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>vertigo</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Cardiac
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>myocardial infarction, angina pectoris,
  prolonged electrocardiogram QT, tachycardia</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>acute myocardial infarction, sinus
  bradycardia, palpitations</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Vascular
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>hypertension, flushing</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Respiratory,
  thoracic and mediastinal disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>dyspnoea, cough, epistaxis, throat
  irritation</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rhinorrhoea</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Gastrointestinal
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>very common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>diarrhoea</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>vomiting, nausea, abdominal pain, increased
  blood amylase, dyspepsia, abdominal distension, flatulence</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>pancreatitis, gastritis,
  gastrooesophageal reflux disease, aphthous stomatitis, retching, dry mouth,
  abdominal discomfort, constipation, increased lipase, eructation, oral
  dysaesthesia</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>stomatitis, haematemesis, cheilitis, dry
  lip, coated tongue</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Hepatobiliary
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>increased
  alanine aminotransferase</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>hepatitis, cytolytic hepatitis, hepatic
  steatosis, hepatomegaly, increased transaminase, increased aspartate
  aminotransferase, increased blood bilirubin, increased blood alkaline
  phosphatase, increased gamma&#8209;glutamyltransferase</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
  lang=EN-GB>Skin and subcutaneous tissue disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rash (including macular, maculopapular,
  papular, erythematous and pruritic rash), pruritus</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>angioedema, generalised rash, allergic
  dermatitis, urticaria, eczema, erythema, hyperhidrosis, night sweats,
  alopecia, acne, dry skin, nail pigmentation</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>DRESS, Stevens&#8209;Johnson syndrome,
  erythema multiforme, dermatitis, seborrhoeic dermatitis, skin lesion,
  xeroderma</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>not known</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>toxic epidermal necrolysis, acute
  generalised exanthematous pustulosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Musculoskeletal
  and connective tissue disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>myalgia, osteonecrosis, muscle spasms,
  muscular weakness, arthralgia, pain in extremity, osteoporosis, increased
  blood creatine phosphokinase</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>musculoskeletal stiffness, arthritis,
  joint stiffness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Renal
  and urinary disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>acute renal failure, renal failure,
  nephrolithiasis, increased blood creatinine, proteinuria, bilirubinuria,
  dysuria, nocturia, pollakiuria</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>decreased creatinine renal clearance</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Reproductive
  system and breast disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>erectile dysfunction, gynaecomastia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>General
  disorders and administration site conditions</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>asthenia, fatigue</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>pyrexia, chest pain, peripheral oedema,
  malaise, feeling hot, irritability, pain</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>chills, abnormal feeling, xerosis</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Adverse
reactions observed with darunavir/cobicistat in adult patients</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>MedDRA
  system organ class</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Frequency
  category</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Adverse
  reaction</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Immune
  system disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>(drug) hypersensitivity</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>immune reconstitution inflammatory
  syndrome</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Metabolism
  and nutrition disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>anorexia, diabetes mellitus,
  hypercholesterolaemia, hypertriglyceridaemia, hyperlipidaemia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Psychiatric
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>abnormal dreams</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Nervous
  system disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>very common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>headache</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Gastrointestinal
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>very common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>diarrhoea, nausea</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>vomiting, abdominal pain, abdominal
  distension, dyspepsia, flatulence, </span>pancreatic enzymes increased</p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>pancreatitis acute</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Hepatobiliary
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>hepatic enzyme increased</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>hepatitis*, cytolytic hepatitis*</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Skin
  and subcutaneous tissue disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>very common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rash (including macular, maculopapular,
  papular, erythematous, pruritic rash, generalised rash, and allergic
  dermatitis)</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>angioedema, <span lang=EN-GB>pruritus, </span>urticaria</p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>drug reaction with eosinophilia and systemic symptoms*,
  Stevens&#8209;Johnson syndrome*</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>not known</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>toxic epidermal necrolysis*, acute generalised exanthematous
  pustulosis*</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Musculoskeletal
  and connective tissue disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>myalgia</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>osteonecrosis*</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Reproductive
  system and breast disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>gynaecomastia*</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>General
  disorders and administration site conditions</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>fatigue</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>asthenia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Investigations</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>increased blood creatinine</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
  lang=EN-GB>*&nbsp;&nbsp; </span><span lang=EN-GB style='font-size:9.0pt'>these
  adverse drug reactions have not been reported in clinical trial experience
  with darunavir/cobicistat but have been noted with darunavir/ritonavir
  treatment and could be expected with darunavir/cobicistat too.</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Description
of selected adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Rash</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In clinical trials, rash was mostly mild to
moderate, often occurring within the first four weeks of treatment and
resolving with continued dosing. In cases of severe skin reaction see the
warning in section 4.4. In a single arm trial investigating darunavir
800&nbsp;mg once daily in combination with cobicistat 150&nbsp;mg once daily
and other antiretrovirals 2.2% of patients discontinued treatment due to rash.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>During the clinical development program of
raltegravir in treatment&#8209;experienced patients, rash, irrespective of
causality, was more commonly observed with regimens containing PREZISTA/ritonavir
+ raltegravir compared to those containing PREZISTA/ritonavir without
raltegravir or raltegravir without PREZISTA/ritonavir. Rash considered by the
investigator to be drug&#8209;related occurred at similar rates. The exposure&#8209;adjusted
rates of rash (all causality) were 10.9, 4.2, and 3.8 per 100&nbsp;patient&#8209;years
(PYR), respectively; and for drug&#8209;related rash were 2.4, 1.1, and 2.3 per
100&nbsp;PYR, respectively. The rashes observed in clinical studies were mild
to moderate in severity and did not result in discontinuation of therapy (see
section 4.4).</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Metabolic
parameters</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Weight and levels of blood lipids and
glucose may increase during antiretroviral therapy (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Musculoskeletal
abnormalities</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Increased CPK, myalgia, myositis and
rarely, rhabdomyolysis have been reported with the use of protease inhibitors,
particularly in combination with NRTIs.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Cases of osteonecrosis have been reported,
particularly in patients with generally acknowledged risk factors, advanced HIV
disease or long&#8209;term exposure to combination antiretroviral therapy
(CART). The frequency of this is unknown (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Immune
reconstitution inflammatory syndrome</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In HIV infected patients with severe immune
deficiency at the time of initiation of combination antiretroviral therapy
(CART), an inflammatory reaction to asymptomatic or residual opportunistic
infections may arise. Autoimmune disorders (such as Graves' disease and
autoimmune hepatitis) have also been reported; however, the reported time to
onset is more variable and these events can occur many months after initiation
of treatment (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Bleeding
in haemophiliac patients</span></i></p>

<p class=MsoNormal><span lang=EN-GB>There have been reports of increased
spontaneous bleeding in haemophiliac patients receiving antiretroviral protease
inhibitors (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The safety
assessment of PREZISTA with ritonavir in paediatric patients is based on the 48&#8209;week
analysis of safety data from three Phase&nbsp;II trials. The following patient
populations were evaluated (see section 5.1):</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>80&nbsp;ART&#8209;experienced HIV&#8209;1
infected paediatric patients aged from 6 to 17&nbsp;years and weighing at least
20&nbsp;kg who received PREZISTA tablets with low dose ritonavir twice daily in
combination with other antiretroviral agents.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>21&nbsp;ART&#8209;experienced HIV&#8209;1
infected paediatric patients aged from 3 to &lt;&nbsp;6&nbsp;years and weighing
10&nbsp;kg to &lt;&nbsp;20&nbsp;kg (16&nbsp;participants from 15&nbsp;kg to &lt;&nbsp;20&nbsp;kg)
who received PREZISTA oral suspension with low dose ritonavir twice daily in
combination with other antiretroviral agents.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>12&nbsp;ART&#8209;na&iuml;ve HIV&#8209;1
infected paediatric patients aged from 12 to 17&nbsp;years and weighing at
least 40&nbsp;kg who received PREZISTA tablets with low dose ritonavir once
daily in combination with other antiretroviral agents (see section 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Overall, the safety profile in these paediatric
patients was similar to that observed in the adult population.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety assessment of PREZISTA with
cobicistat in paediatric patients was evaluated in adolescents aged&nbsp;12 to
less than 18&nbsp;years, weighing at least 40&nbsp;kg through the clinical
trial GS&#8209;US&#8209;216&#8209;0128 (treatment&#8209;experienced,
virologically suppressed, N=7). Safety analyses of this study in adolescent
subjects did not identify new safety concerns compared to the known safety
profile of darunavir and cobicistat in adult subjects.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Other
special populations</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Patients
co&#8209;infected with hepatitis&nbsp;B and/or hepatitis&nbsp;C virus</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Among 1,968&nbsp;treatment&#8209;experienced
patients receiving PREZISTA co&#8209;administered with ritonavir
600/100&nbsp;mg twice daily, 236&nbsp;patients were co&#8209;infected with
hepatitis&nbsp;B or C. Co&#8209;infected patients were more likely to have
baseline and treatment emergent hepatic transaminase elevations than those
without chronic viral hepatitis (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:silver'>the national reporting
system listed in </span></span><span lang=EN-GB style='background:silver'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix&nbsp;V</a></span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Human experience of acute overdose with
PREZISTA co&#8209;administered with cobicistat or low dose ritonavir is
limited. Single doses up to 3,200&nbsp;mg of darunavir as oral solution alone
and up to 1,600&nbsp;mg of the tablet formulation of darunavir in combination
with ritonavir have been administered to healthy volunteers without untoward
symptomatic effects.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There is no specific antidote for overdose
with PREZISTA. Treatment of overdose with PREZISTA consists of general
supportive measures including monitoring of vital signs and observation of the
clinical status of the patient. Since darunavir is highly protein bound,
dialysis is unlikely to be beneficial in significant removal of the active
substance.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pharmacotherapeutic group: Antivirals for
systemic use, protease inhibitors, ATC code: J05AE10.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Mechanism
of action</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Darunavir is an
inhibitor of the dimerisation and of the catalytic activity of the HIV&#8209;1
protease (K<sub>D</sub>&nbsp;of&nbsp;4.5&nbsp;x&nbsp;10<sup>-12</sup>M). It
selectively inhibits the cleavage of HIV encoded Gag&#8209;Pol polyproteins in
virus infected cells, thereby preventing the formation of mature infectious
virus particles.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Antiviral
activity <i>in vitro</i></span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Darunavir
exhibits activity against laboratory strains and clinical isolates of HIV&#8209;1
and laboratory strains of HIV&#8209;2 in acutely infected T&#8209;cell lines,
human peripheral blood mononuclear cells and human monocytes/macrophages with
median EC</span><sub><span lang=EN-GB>50</span></sub><span lang=EN-GB>&nbsp;values
ranging from 1.2 to 8.5&nbsp;nM (0.7 to 5.0&nbsp;ng/ml). Darunavir demonstrates
antiviral activity </span><i><span lang=EN-GB>in vitro</span></i><span
lang=EN-GB> against a broad panel of HIV&#8209;1 group M (A, B, C, D, E, F, G)
and group O primary isolates with EC</span><sub><span lang=EN-GB>50</span></sub><span
lang=EN-GB>&nbsp;values ranging from &lt;&nbsp;0.1 to 4.3&nbsp;nM.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>These EC</span><sub><span
lang=EN-GB>50</span></sub><span lang=EN-GB>&nbsp;values are well below the 50%
cellular toxicity concentration range of 87&nbsp;&micro;M to
&gt;&nbsp;100&nbsp;&micro;M.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Resistance</span></u></p>

<p class=MsoNormal style='text-autospace:none'><i><span lang=EN-GB>In vitro</span></i><span
lang=EN-GB> selection of darunavir&#8209;resistant virus from wild type HIV&#8209;1
was lengthy (&gt;&nbsp;3&nbsp;years). The selected viruses were unable to grow
in the presence of darunavir concentrations above 400&nbsp;nM. Viruses selected
in these conditions and showing decreased susceptibility to darunavir (range:
23&#8209;50&#8209;fold) harboured 2 to 4&nbsp;amino acid substitutions in the
protease gene. The decreased susceptibility to darunavir of the emerging
viruses in the selection experiment could not be explained by the emergence of
these protease mutations.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The clinical trial data from ART&#8209;experienced
patients (<i>TITAN</i> trial and the pooled analysis of the <i>POWER</i>&nbsp;1,
2 and 3 and <i>DUET</i>&nbsp;1 and 2 trials) showed that virologic response to
PREZISTA co&#8209;administered with low dose ritonavir was decreased when 3 or
more darunavir RAMs (V11I, V32I, L33F, I47V, I50V, I54L or M, T74P, L76V, I84V
and L89V) were present at baseline or when these mutations developed during
treatment.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Increasing baseline darunavir fold change in
EC<sub>50</sub> (FC) was associated with decreasing virologic response. A lower
and upper clinical cut&#8209;off of 10 and 40 were identified. Isolates with
baseline FC &#8804;&nbsp;10 are susceptible; isolates with FC &gt;&nbsp;10 to
40 have decreased susceptibility; isolates with FC &gt;&nbsp;40 are resistant
(see Clinical results).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Viruses
isolated from patients on PREZISTA/ritonavir 600/100&nbsp;mg twice daily
experiencing virologic failure by rebound that were susceptible to tipranavir
at baseline remained susceptible to tipranavir after treatment in the vast
majority of cases.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The lowest rates of developing resistant
HIV virus are observed in ART&#8209;na&iuml;ve patients who are treated for the
first time with darunavir in combination with other ART.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The table
below shows the development of HIV&#8209;1 protease mutations and loss of
susceptibility to PIs in virologic failures at endpoint in the <i>ARTEMIS</i>, <i>ODIN</i>
and <i>TITAN</i> trials.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>ARTEMIS</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Week 192</span></p>
  </td>
  <td width=237 colspan=2 valign=top style='width:177.45pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>ODIN</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Week 48</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>TITAN</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Week 48</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>PREZISTA/ ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>800/100&nbsp;mg</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>once daily</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N=343</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>PREZISTA/ ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>800/100&nbsp;mg</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>once daily</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N=294</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>PREZISTA/ ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>600/100&nbsp;mg</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>twice daily</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>N=296</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>PREZISTA/ ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>600/100&nbsp;mg</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>twice daily</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>N=298</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Total number of virologic failures</span><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:10.0pt'>, n (%)</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>55&nbsp;(16.0%)</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>65&nbsp;(22.1%)</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>54&nbsp;(18.2%)</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>31&nbsp;(10.4%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>Rebounders</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>39&nbsp;(11.4%)</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>11&nbsp;(3.7%)</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>11&nbsp;(3.7%)</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>16&nbsp;(5.4%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>Never suppressed subjects</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>16&nbsp;(4.7%)</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>54&nbsp;(18.4%)</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>43&nbsp;(14.5%)</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>15&nbsp;(5.0%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=618 colspan=5 valign=top style='width:463.8pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Number of subjects with virologic failure and paired
  baseline/endpoint genotypes, developing mutations</span><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:10.0pt'> at
  endpoint, n/N</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>Primary (major) PI mutations</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/43</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1/60</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/42</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>6/28</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>PI RAMs</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>4/43</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>7/60</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>4/42</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>10/28</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=618 colspan=5 valign=top style='width:463.8pt;border-top:windowtext;
  border-left:black;border-bottom:windowtext;border-right:black;border-style:
  solid;border-width:1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Number of subjects with virologic failure and paired
  baseline/endpoint phenotypes, showing loss of susceptibility to PIs at
  endpoint compared to baseline, n/N</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>PI</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>darunavir</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/39</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1/58</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/41</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>3/26</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>amprenavir</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/39</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1/58</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/40</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/22</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>atazanavir</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/39</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>2/56</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/40</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/22</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>indinavir</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/39</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>2/57</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/40</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1/24</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>lopinavir</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/39</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1/58</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/40</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/23</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>saquinavir</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/39</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/56</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/40</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/22</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>tipranavir</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/39</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/58</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/41</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1/25</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=618 colspan=5 valign=top style='width:463.8pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; TLOVR
  non&#8209;VF censored algorithm based on HIV&#8209;1 RNA
  &lt;&nbsp;50&nbsp;copies/ml, except for <i>TITAN</i> (HIV&#8209;1 RNA
  &lt;&nbsp;400&nbsp;copies/ml)</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>b</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=EN-GB
  style='font-size:9.0pt'>IAS&#8209;USA lists</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Low rates of developing resistant HIV&#8209;1
virus were observed in ART&#8209;na&iuml;ve patients who are treated for the
first time with darunavir/cobicistat once daily in combination with other ART,
and in ART&#8209;experienced patients with no darunavir RAMs receiving darunavir/cobicistat
in combination with other ART. The table below shows the development of HIV&#8209;1
protease mutations and resistance to PIs in virologic failures at endpoint in
the GS&#8209;US&#8209;216&#8209;130 trial.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="74%" colspan=2 valign=top style='width:74.78%;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>GS&#8209;US&#8209;216&#8209;130</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Week 48</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="34%" valign=top style='width:34.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Treatment&#8209;na&iuml;ve</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>darunavir/cobicistat 800/150&nbsp;mg</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>once daily</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N=295</span></p>
  </td>
  <td width="40%" valign=top style='width:40.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Treatment&#8209;experienced</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>darunavir/cobicistat 800/150&nbsp;mg</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>once daily</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N=18</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Number of subjects with virologic failure</span><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:10.0pt'> and
  genotype data that develop mutations</span><sup><span lang=EN-GB>b</span></sup><span
  lang=EN-GB style='font-size:10.0pt'> at endpoint, n/N</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>Primary (major) PI mutations</span></p>
  </td>
  <td width="34%" valign=top style='width:34.62%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/8</span></p>
  </td>
  <td width="40%" valign=top style='width:40.16%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1/7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>PI RAMs</span></p>
  </td>
  <td width="34%" valign=top style='width:34.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>2/8</span></p>
  </td>
  <td width="40%" valign=top style='width:40.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1/7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Number of subjects with virologic failure</span><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:10.0pt'> and
  phenotype data that show resistance to PIs at endpoint</span><sup><span
  lang=EN-GB>c</span></sup><span lang=EN-GB style='font-size:10.0pt'>, n/N</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>HIV PI</span></p>
  </td>
  <td width="34%" valign=top style='width:34.62%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="40%" valign=top style='width:40.16%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>darunavir</span></p>
  </td>
  <td width="34%" valign=top style='width:34.62%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/8</span></p>
  </td>
  <td width="40%" valign=top style='width:40.16%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>amprenavir</span></p>
  </td>
  <td width="34%" valign=top style='width:34.62%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/8</span></p>
  </td>
  <td width="40%" valign=top style='width:40.16%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>atazanavir</span></p>
  </td>
  <td width="34%" valign=top style='width:34.62%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/8</span></p>
  </td>
  <td width="40%" valign=top style='width:40.16%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>indinavir</span></p>
  </td>
  <td width="34%" valign=top style='width:34.62%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/8</span></p>
  </td>
  <td width="40%" valign=top style='width:40.16%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>lopinavir</span></p>
  </td>
  <td width="34%" valign=top style='width:34.62%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/8</span></p>
  </td>
  <td width="40%" valign=top style='width:40.16%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>saquinavir</span></p>
  </td>
  <td width="34%" valign=top style='width:34.62%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/8</span></p>
  </td>
  <td width="40%" valign=top style='width:40.16%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>tipranavir</span></p>
  </td>
  <td width="34%" valign=top style='width:34.62%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/8</span></p>
  </td>
  <td width="40%" valign=top style='width:40.16%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Virogic
  failures were defined as: never suppressed: confirmed HIV-1 RNA &lt;&nbsp;1&nbsp;log<sub>10</sub>
  reduction from baseline and &#8805;&nbsp;50&nbsp;copies/ml at the week&#8209;8;
  rebound: HIV&#8209;1 RNA &lt;&nbsp;50&nbsp;copies/ml followed by confirmed
  HIV&#8209;1 RNA to &#8805;&nbsp;400&nbsp;copies/ml or confirmed &gt;&nbsp;1&nbsp;log<sub>10</sub>
  HIV&#8209;1 RNA increase from the nadir; </span><span style='font-size:9.0pt'>discontinuations
  with HIV&#8209;1 RNA &#8805;&nbsp;400&nbsp;copies/ml at last visit</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>b</span></sup><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; IAS&#8209;USA lists</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>c</span></sup><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; In GS&#8209;US216&#8209;130
  baseline phenotype was not available</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Cross&#8209;resistance</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir FC was less than 10 for 90% of
3,309&nbsp;clinical isolates resistant to amprenavir, atazanavir, indinavir,
lopinavir, nelfinavir, ritonavir, saquinavir and/or tipranavir showing that
viruses resistant to most PIs remain susceptible to darunavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the virologic failures of the <i>ARTEMIS</i>
trial no cross&#8209;resistance with other PIs was observed.</span></p>

<p class=MsoNormal><span lang=EN-GB>In the virologic failures of the GS&#8209;US&#8209;216&#8209;130
trial no cross&#8209;resistance with other HIV PIs was observed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Clinical results</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetic enhancing effect of
cobicistat on darunavir was evaluated in a Phase&nbsp;I study in healthy
subjects that were administered darunavir 800&nbsp;mg with either cobicistat at
150&nbsp;mg or ritonavir at 100&nbsp;mg once daily. The steady&#8209;state
pharmacokinetic parameters of darunavir were comparable when boosted with
cobicistat versus ritonavir. For information on cobicistat, consult the
cobicistat Summary of Product Characteristics.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Adult
patients</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Efficacy
of darunavir 800&nbsp;mg once daily co&#8209;administered with 150&nbsp;mg
cobicistat once daily in ART&#8209;na&iuml;ve and ART&#8209;experienced
patients</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>GS&#8209;US&#8209;216&#8209;130 is a single
arm, open&#8209;label, Phase&nbsp;III trial evaluating the pharmacokinetics,
safety, tolerability, and efficacy of darunavir with cobicistat in 313&nbsp;HIV&#8209;1
infected adult patients (295&nbsp;treatment&#8209;na&iuml;ve and
18&nbsp;treatment&#8209;experienced). These patients received darunavir 800&nbsp;mg
once daily in combination with cobicistat 150&nbsp;mg once daily with an
investigator selected background regimen consisting of 2&nbsp;active NRTIs.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>HIV&#8209;1
infected patients who were eligible for this trial had a screening genotype
showing no darunavir RAMs and plasma HIV&#8209;1 RNA &#8805;&nbsp;1,000&nbsp;copies/ml.
The table below shows the efficacy data of the 48&nbsp;week analyses from the GS&#8209;US&#8209;216&#8209;130
trial:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=176 valign=top style='width:131.65pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=429 colspan=3 valign=top style='width:321.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>GS&#8209;US&#8209;216&#8209;130</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=176 style='width:131.65pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
  style='font-size:10.0pt'>Outcomes at Week&nbsp;48</span></i></p>
  </td>
  <td width=143 valign=top style='width:107.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Treatment&#8209;na&iuml;ve</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>darunavir/cobicistat 800/150&nbsp;mg once daily+ OBR</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N=295</span></p>
  </td>
  <td width=143 valign=top style='width:107.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Treatment&#8209;experienced</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>darunavir/cobicistat 800/150&nbsp;mg once daily</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>+ OBR</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N=18</span></p>
  </td>
  <td width=143 valign=top style='width:107.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>All subjects</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>darunavir/cobicistat 800/150&nbsp;mg once daily</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>+ OBR</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N=313</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=176 valign=top style='width:131.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>HIV&#8209;1 RNA
  &lt;&nbsp;50&nbsp;copies/ml</span><sup><span lang=EN-GB>a</span></sup></p>
  </td>
  <td width=143 valign=top style='width:107.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>245 (83.1%)</span></p>
  </td>
  <td width=143 valign=top style='width:107.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>8 (44.4%)</span></p>
  </td>
  <td width=143 valign=top style='width:107.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>253 (80.8%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=176 valign=top style='width:131.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>mean HIV&#8209;1&nbsp;RNA
  log change from baseline (log<sub>10</sub>&nbsp;copies/ml)</span></p>
  </td>
  <td width=143 valign=top style='width:107.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&#8209;3.01</span></p>
  </td>
  <td width=143 valign=top style='width:107.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&#8209;2.39</span></p>
  </td>
  <td width=143 valign=top style='width:107.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&#8209;2.97</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=176 valign=top style='width:131.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>CD4+ cell count mean change from baseline<sup>b</sup></span></p>
  </td>
  <td width=143 valign=top style='width:107.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>+174</span></p>
  </td>
  <td width=143 valign=top style='width:107.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>+102</span></p>
  </td>
  <td width=143 valign=top style='width:107.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>+170</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=4 valign=top style='width:6.3in;border:none;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Imputations
  according to the TLOVR algorithm</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></sup><span
  lang=EN-GB style='font-size:9.0pt'>Last Observation Carried Forward
  imputation</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Efficacy
of PREZISTA 800&nbsp;mg once daily co</span></u></i><u><span lang=EN-GB>&#8209;<i>administered
with 100&nbsp;mg ritonavir once daily in ART&#8209;na&iuml;ve patients</i></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The evidence of efficacy of
PREZISTA/ritonavir 800/100&nbsp;mg once daily is based on the analyses of 192&nbsp;week
data from the randomised, controlled, open&#8209;label Phase&nbsp;III trial <i>ARTEMIS</i>
in antiretroviral treatment&#8209;na&iuml;ve HIV&#8209;1 infected patients comparing
PREZISTA/ritonavir 800/100&nbsp;mg once daily with lopinavir/ritonavir
800/200&nbsp;mg per day (given as a twice&#8209;daily or as a once&#8209;daily
regimen). Both arms used a fixed background regimen consisting of tenofovir
disoproxil fumarate 300&nbsp;mg once daily and emtricitabine 200&nbsp;mg once
daily.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The table
below shows the efficacy data of the 48&nbsp;week and 96&nbsp;week analyses
from the <i>ARTEMIS</i> trial:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=7 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>ARTEMIS</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="18%" valign=top style='width:18.52%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="41%" colspan=3 valign=top style='width:41.06%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Week 48</span><sup><span
  lang=EN-GB>a</span></sup></p>
  </td>
  <td width="40%" colspan=3 valign=top style='width:40.42%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Week 96</span><sup><span
  lang=EN-GB>b</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="18%" valign=top style='width:18.52%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
  style='font-size:10.0pt'>Outcomes</span></i></p>
  </td>
  <td width="13%" valign=top style='width:13.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>PREZISTA/ ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>800/100&nbsp;mg once daily</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>N=343</span></p>
  </td>
  <td width="13%" valign=top style='width:13.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Lopinavir/ ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>800/200&nbsp;mg per day</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>N=346</span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Treatment difference (95% CI
  of difference)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>PREZISTA/ ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>800/100&nbsp;mg once daily</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>N=343</span></p>
  </td>
  <td width="12%" valign=top style='width:12.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Lopinavir/ ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>800/200&nbsp;mg per day</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>N=346</span></p>
  </td>
  <td width="14%" valign=top style='width:14.14%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Treatment difference (95% CI
  of difference)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="18%" valign=top style='width:18.52%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>HIV&#8209;1&nbsp;RNA &lt;&nbsp;50&nbsp;copies/ml</span><sup><span
  lang=EN-GB>c</span></sup></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>All patients</span></p>
  </td>
  <td width="13%" valign=top style='width:13.58%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>83.7%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(287)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.38%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>78.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(271)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>5.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(&#8209;0.5; 11.2)</span><sup><span
  lang=EN-GB>d</span></sup></p>
  </td>
  <td width="13%" valign=top style='width:13.42%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>79.0%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(271)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.86%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>70.8%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(245)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.14%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>8.2%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(1.7; 14.7)</span><sup><span
  lang=EN-GB>d</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="18%" valign=top style='width:18.52%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>With baseline HIV-RNA &lt;&nbsp;100,000</span></p>
  </td>
  <td width="13%" valign=top style='width:13.58%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>85.8%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(194/226)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.38%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>84.5%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(191/226)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(&#8209;5.2; 7.9)</span><sup><span lang=EN-GB>d</span></sup></p>
  </td>
  <td width="13%" valign=top style='width:13.42%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>80.5%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(182/226)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.86%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>75.2%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(170/226)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.14%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>5.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(&#8209;2.3; 13.0)</span><sup><span lang=EN-GB>d</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="18%" valign=top style='width:18.52%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>With baseline HIV-RNA &#8805;&nbsp;100,000</span></p>
  </td>
  <td width="13%" valign=top style='width:13.58%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>79.5%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(93/117)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.38%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>66.7%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(80/120)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>12.8%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(1.6; 24.1)</span><sup><span lang=EN-GB>d</span></sup></p>
  </td>
  <td width="13%" valign=top style='width:13.42%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>76.1%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(89/117)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.86%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>62.5%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(75/120)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.14%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>13.6%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(1.9; 25.3)</span><sup><span lang=EN-GB>d</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="18%" valign=top style='width:18.52%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>With baseline CD4+ cell count &lt;&nbsp;200</span></p>
  </td>
  <td width="13%" valign=top style='width:13.58%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>79.4%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(112/141)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.38%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>70.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(104/148)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>9.2%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(&#8209;0.8; 19.2)</span><sup><span lang=EN-GB>d</span></sup></p>
  </td>
  <td width="13%" valign=top style='width:13.42%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>78.7%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(111/141)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.86%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>64.9%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(96/148)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.14%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>13.9%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(3.5; 24.2)</span><sup><span lang=EN-GB>d</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="18%" valign=top style='width:18.52%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>With baseline CD4+ cell count &#8805;&nbsp;200</span></p>
  </td>
  <td width="13%" valign=top style='width:13.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>86.6%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(175/202)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>84.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(167/198)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>2.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(&#8209;4.6; 9.2)</span><sup><span lang=EN-GB>d</span></sup></p>
  </td>
  <td width="13%" valign=top style='width:13.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>79.2%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(160/202)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>75.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(149/198)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.14%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>4.0%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(&#8209;4.3; 12.2)</span><sup><span lang=EN-GB>d</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="18%" valign=top style='width:18.52%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>median CD4+&nbsp;cell count change from baseline (x
  10</span><sup><span lang=EN-GB>6</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>/L)</span><sup><span lang=EN-GB>e</span></sup></p>
  </td>
  <td width="13%" valign=top style='width:13.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>137</span></p>
  </td>
  <td width="13%" valign=top style='width:13.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>141</span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>171</span></p>
  </td>
  <td width="12%" valign=top style='width:12.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>188</span></p>
  </td>
  <td width="14%" valign=top style='width:14.14%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=7 valign=top style='width:100.0%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Data
  based on analyses at week 48</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Data
  based on analyses at week 96</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>c</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Imputations
  according to the TLOVR algorithm</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>d</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Based
  on normal approximation to the difference in % response</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>e</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Non&#8209;completer
  is failure imputation: patients who discontinued prematurely are imputed with
  a change equal to 0</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Non&#8209;inferiority in virologic response
to the PREZISTA/ritonavir treatment, defined as the percentage of patients with
plasma HIV&#8209;1 RNA level &lt;&nbsp;50&nbsp;copies/ml, was demonstrated (at
the pre&#8209;defined 12% non&#8209;inferiority margin) for both Intent&#8209;To&#8209;Treat
(ITT) and On Protocol (OP) populations in the 48&nbsp;week analysis. These
results were confirmed in the analyses of data at 96&nbsp;weeks of treatment in
the <i>ARTEMIS</i> trial. These results were sustained up to 192&nbsp;weeks of
treatment in the ARTEMIS trial.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Efficacy
of PREZISTA 600&nbsp;mg twice daily co</span></u></i><u><span lang=EN-GB>&#8209;<i>administered
with 100&nbsp;mg ritonavir twice daily in ART&#8209;experienced patients</i></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The evidence of efficacy of PREZISTA co&#8209;administered
with ritonavir (600/100&nbsp;mg twice daily) in ART&#8209;experienced patients
is based on the 96&nbsp;weeks analysis of the Phase&nbsp;III trial <i>TITAN</i>
in ART&#8209;experienced lopinavir na&iuml;ve patients, on the 48&nbsp;week
analysis of the Phase&nbsp;III trial <i>ODIN</i> in ART&#8209;experienced
patients with no DRV&#8209;RAMs, and on the analyses of 96&nbsp;weeks data from
the Phase&nbsp;IIb trials <i>POWER</i>&nbsp;1 and 2 in ART&#8209;experienced
patients with high level of PI resistance.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>TITAN</span></i></b><span lang=EN-GB>
is a randomised, controlled, open&#8209;label Phase&nbsp;III trial comparing
PREZISTA co&#8209;administered with ritonavir (600/100&nbsp;mg twice daily)
versus lopinavir/ritonavir (400/100&nbsp;mg twice daily) in ART&#8209;experienced,
lopinavir na&iuml;ve HIV&#8209;1 infected adult patients. Both arms used an
Optimised Background Regimen (OBR) consisting of at least
2&nbsp;antiretrovirals (NRTIs with or without NNRTIs).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The table
below shows the efficacy data of the 48&nbsp;week analysis from the <i>TITAN</i>
trial.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=4 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>TITAN</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="18%" valign=top style='width:18.64%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Outcomes</span></p>
  </td>
  <td width="27%" valign=top style='width:27.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT style='font-size:10.0pt'>PREZISTA/ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT style='font-size:10.0pt'>600/100&nbsp;mg twice daily +
  OBR</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT style='font-size:10.0pt'>N=298</span></p>
  </td>
  <td width="27%" valign=top style='width:27.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt'>Lopinavir/ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt'>400/100&nbsp;mg twice daily + OBR</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT style='font-size:10.0pt'>N=297</span></p>
  </td>
  <td width="27%" valign=top style='width:27.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Treatment difference</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(95% CI of difference)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="18%" valign=top style='width:18.64%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>HIV&#8209;1&nbsp;RNA
  &lt;&nbsp;50&nbsp;copies/ml</span><sup><span lang=EN-GB>a</span></sup></p>
  </td>
  <td width="27%" valign=top style='width:27.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>70.8% (211)</span></p>
  </td>
  <td width="27%" valign=top style='width:27.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>60.3% (179)</span></p>
  </td>
  <td width="27%" valign=top style='width:27.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>10.5% (2.9; 18.1)</span><sup><span lang=EN-GB>b</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="18%" valign=top style='width:18.64%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>median
  CD4+&nbsp;cell count change from baseline (x&nbsp;10</span><sup><span
  lang=EN-GB>6</span></sup><span lang=EN-GB style='font-size:10.0pt'>/L)</span><sup><span
  lang=EN-GB>c</span></sup></p>
  </td>
  <td width="27%" valign=top style='width:27.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>88</span></p>
  </td>
  <td width="27%" valign=top style='width:27.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>81</span></p>
  </td>
  <td width="27%" valign=top style='width:27.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=4 valign=top style='width:100.0%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Imputations according to the TLOVR
  algorithm</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Based
  on a normal approximation of the difference in % response</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>c</span></sup><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>NC=F</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>At 48&nbsp;weeks non&#8209;inferiority in
virologic response to the PREZISTA/ritonavir treatment, defined as the percentage
of patients with plasma HIV&#8209;1 RNA level &lt;&nbsp;400 and
&lt;&nbsp;50&nbsp;copies/ml, was demonstrated (at the pre&#8209;defined 12% non&#8209;inferiority
margin) for both ITT and OP populations. These results were confirmed in the
analysis of data at 96&nbsp;weeks of treatment in the <i>TITAN</i> trial, with
60.4% of patients in the PREZISTA/ritonavir arm having HIV&#8209;1 RNA
&lt;&nbsp;50&nbsp;copies/ml at week&nbsp;96 compared to 55.2% in the lopinavir/ritonavir
arm [difference: 5.2%, 95%&nbsp;CI (&#8209;2.8; 13.1)].</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>ODIN</span></i></b><span lang=EN-GB>
is a Phase&nbsp;III, randomised, open&#8209;label trial comparing PREZISTA/ritonavir
800/100&nbsp;mg once daily versus PREZISTA/ritonavir 600/100&nbsp;mg twice
daily in ART&#8209;experienced HIV&#8209;1 infected patients with screening
genotype resistance testing showing no darunavir RAMs (i.e. V11I, V32I, L33F,
I47V, I50V, I54M, I54L, T74P, L76V, I84V, L89V) and a screening HIV&#8209;1 RNA
&gt;&nbsp;1,000&nbsp;copies/ml. Efficacy analysis is based on 48&nbsp;weeks of
treatment (see table below). Both arms used an optimised background regimen
(OBR) of &#8805;&nbsp;2&nbsp;NRTIs.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=4 valign=top style='width:464.35pt;border:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>ODIN</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
  style='font-size:10.0pt'>Outcomes</span></i></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT style='font-size:10.0pt'>PREZISTA/ritonavir 800/100&nbsp;mg
  once daily + OBR</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT style='font-size:10.0pt'>N=294</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT style='font-size:10.0pt'>PREZISTA/ritonavir 600/100&nbsp;mg
  twice daily + OBR</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT style='font-size:10.0pt'>N=296</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Treatment difference</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(95% CI of difference)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.05pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>HIV&#8209;1&nbsp;RNA &lt;&nbsp;50&nbsp;copies/ml</span><sup><span
  lang=EN-GB>a</span></sup></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>72.1% (212)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>70.9% (210)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>1.2% (&#8209;6.1; 8.5)</span><sup><span
  lang=EN-GB>b</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.05pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>With Baseline HIV&#8209;1 RNA (copies/ml)</span></p>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;&lt;&nbsp;100,000</span></p>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>&#8805;&nbsp;100,000</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>77.6% (198/255)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>35.9% (14/39)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>73.2% (194/265)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>51.6% (16/31)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>4.4% (&#8209;3.0; 11.9)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&#8209;15.7% (&#8209;39.2; 7.7)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.05pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>With Baseline CD4+ cell count (x 10</span><sup><span
  lang=EN-GB>6</span></sup><span lang=EN-GB style='font-size:10.0pt'>/L)</span></p>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>&#8805;&nbsp;100</span></p>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>&lt;&nbsp;100</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>75.1% (184/245)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>57.1% (28/49)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>72.5% (187/258)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>60.5% (23/38)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>2.6% (&#8209;5.1; 10.3)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&#8209;3.4% (&#8209;24.5; 17.8)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>With HIV&#8209;1 clade</span></p>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>Type B</span></p>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>Type AE</span></p>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>Type C</span></p>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>Other</span><sup><span lang=EN-GB>c</span></sup></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>70.4% (126/179)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>90.5% (38/42)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>72.7% (32/44)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>55.2% (16/29)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>64.3% (128/199)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>91.2% (31/34)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>78.8% (26/33)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>83.3% (25/30)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>6.1% (&#8209;3.4; 15.6)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&#8209;0.7% (&#8209;14.0; 12.6)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&#8209;6.1% (&#8209;2.6; 13.7)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&#8209;28.2% (&#8209;51.0; &#8209;5.3)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>mean CD4+ cell
  count change from baseline</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(x 10</span><sup><span
  lang=EN-GB>6</span></sup><span lang=EN-GB style='font-size:10.0pt'>/L)</span><sup><span
  lang=EN-GB>e</span></sup></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>108</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>112</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&#8209;5</span><sup><span lang=EN-GB>d </span></sup><span
  lang=EN-GB style='font-size:10.0pt'>(&#8209;25; 16)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=4 valign=top style='width:464.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Imputations according to the TLOVR
  algorithm</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Based on a normal approximation of the
  difference in % response</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>c</span></sup><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Clades A1, D, F1, G, K, CRF02_AG,
  CRF12_BF, and CRF06_CPX</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>d</span></sup><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Difference in means</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>e</span></sup><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Last Observation Carried Forward
  imputation</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>At 48&nbsp;weeks, virologic response,
defined as the percentage of patients with plasma HIV&#8209;1 RNA level
&lt;&nbsp;50&nbsp;copies/ml, with PREZISTA/ritonavir 800/100&nbsp;mg once daily
treatment was demonstrated to be non&#8209;inferior (at the pre&#8209;defined
12% non&#8209;inferiority margin) compared to PREZISTA/ritonavir
600/100&nbsp;mg twice daily for both ITT and OP populations.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA/ritonavir 800/100&nbsp;mg once
daily in ART&#8209;experienced patients should not be used in patients with one
or more darunavir resistance associated mutations (DRV&#8209;RAMs) or HIV&#8209;1
RNA &#8805;&nbsp;100,000&nbsp;copies/ml or CD4+ cell count
&lt;&nbsp;100&nbsp;cells&nbsp;x&nbsp;10<sup>6</sup>/L (see section&nbsp;4.2 and
4.4). Limited data is available in patients with HIV&#8209;1 clades other than
B.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>POWER&nbsp;1</span></i></b><i><span
lang=EN-GB> and <b>POWER&nbsp;2</b></span></i><span lang=EN-GB> are randomised,
controlled trials comparing PREZISTA co&#8209;administered with ritonavir
(600/100&nbsp;mg twice daily) with a control group receiving an investigator&#8209;selected
PI(s) regimen in HIV&#8209;1 infected patients who had previously failed more
than 1&nbsp;PI containing regimen. An OBR consisting of at least 2&nbsp;NRTIs
with or without enfuvirtide (ENF) was used in both trials.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The table
below shows the efficacy data of the 48&#8209;week and 96&#8209;week analyses
from the pooled <i>POWER</i>&nbsp;1 and <i>POWER</i>&nbsp;2 trials.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=618 colspan=7 valign=top style='width:463.85pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>POWER&nbsp;1 and
  POWER&nbsp;2 pooled data</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=117 valign=top style='width:88.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></i></p>
  </td>
  <td width=259 colspan=3 valign=top style='width:193.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Week 48</span></p>
  </td>
  <td width=243 colspan=3 valign=top style='width:181.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Week 96</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=117 valign=top style='width:88.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
  style='font-size:10.0pt'>Outcomes</span></i></p>
  </td>
  <td width=97 valign=top style='width:72.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT style='font-size:10.0pt'>PREZISTA/ ritonavir 600/100&nbsp;mg
  twice daily n=131</span></p>
  </td>
  <td width=57 valign=top style='width:43.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Control n=124</span></p>
  </td>
  <td width=104 valign=top style='width:78.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Treatment difference</span></p>
  </td>
  <td width=96 valign=top style='width:72.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT style='font-size:10.0pt'>PREZISTA/ ritonavir 600/100&nbsp;mg
  twice daily n=131</span></p>
  </td>
  <td width=57 valign=top style='width:42.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Control n=124</span></p>
  </td>
  <td width=90 valign=top style='width:67.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Treatment difference</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=117 valign=top style='width:88.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>HIV&nbsp;RNA
  &lt;&nbsp;50&nbsp;copies/ml</span><sup><span lang=EN-GB>a</span></sup></p>
  </td>
  <td width=97 valign=top style='width:72.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>45.0%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(59)</span></p>
  </td>
  <td width=57 valign=top style='width:43.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>11.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(14)</span></p>
  </td>
  <td width=104 valign=top style='width:78.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>33.7%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(23.4%; 44.1%)</span><sup><span lang=EN-GB>c</span></sup></p>
  </td>
  <td width=96 valign=top style='width:72.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>38.9%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(51)</span></p>
  </td>
  <td width=57 valign=top style='width:42.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>8.9%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(11)</span></p>
  </td>
  <td width=90 valign=top style='width:67.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>30.1%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(20.1; 40.0)</span><sup><span lang=EN-GB>c</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=117 valign=top style='width:88.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>CD4+&nbsp;cell
  count</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>mean change from
  baseline (x 10</span><sup><span lang=EN-GB>6</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>/L)</span><sup><span lang=EN-GB>b</span></sup></p>
  </td>
  <td width=97 valign=top style='width:72.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>103</span></p>
  </td>
  <td width=57 valign=top style='width:43.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>17</span></p>
  </td>
  <td width=104 valign=top style='width:78.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>86</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(57; 114)</span><sup><span lang=EN-GB>c</span></sup></p>
  </td>
  <td width=96 valign=top style='width:72.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>133</span></p>
  </td>
  <td width=57 valign=top style='width:42.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>15</span></p>
  </td>
  <td width=90 valign=top style='width:67.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>118</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(83.9; 153.4)</span><sup><span lang=EN-GB>c</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=618 colspan=7 valign=top style='width:463.85pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Imputations according to the TLOVR
  algorithm</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Last Observation Carried Forward
  imputation</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>c</span></sup><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>95% confidence intervals.</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Analyses of data through 96&nbsp;weeks of
treatment in the <i>POWER</i> trials demonstrated sustained antiretroviral
efficacy and immunologic benefit.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Out of the 59&nbsp;patients who responded
with complete viral suppression (&lt;&nbsp;50&nbsp;copies/ml) at week&nbsp;48,
47&nbsp;patients (80% of the responders at week&nbsp;48) remained responders at
week&nbsp;96.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Baseline
genotype or phenotype and virologic outcome</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Baseline genotype and darunavir FC (shift
in susceptibility relative to reference) were shown to be a predictive factor
of virologic outcome.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Proportion
(%) of patients with response (HIV&#8209;1 RNA &lt;&nbsp;50&nbsp;copies/ml at
week 24) to PREZISTA co&#8209;administered with ritonavir (600/100&nbsp;mg
twice daily) by baseline genotype<sup>a</sup>, and baseline darunavir FC and by
use of enfuvirtide (ENF): As treated analysis of the POWER and DUET trials.</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=126 valign=top style='width:94.3pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=247 colspan=4 valign=top style='width:185.15pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Number of baseline
  mutations</span></b><b><sup><span lang=EN-GB>a</span></sup></b></p>
  </td>
  <td width=247 colspan=4 valign=top style='width:185.2pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Baseline DRV FC</span></b><b><sup><span
  lang=EN-GB>b</span></sup></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=126 style='width:94.3pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Response (HIV&#8209;1 RNA
  &lt;&nbsp;50&nbsp;copies/ml at week 24)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>%, n/N</span></p>
  </td>
  <td width=70 style='width:52.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>All ranges</span></b></p>
  </td>
  <td width=60 style='width:45.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>0&#8209;2</span></b></p>
  </td>
  <td width=54 style='width:40.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>3</span></b></p>
  </td>
  <td width=62 style='width:46.3pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>&#8805;&nbsp;4</span></b></p>
  </td>
  <td width=69 style='width:52.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>All ranges</span></b></p>
  </td>
  <td width=61 style='width:45.6pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>&#8804;&nbsp;10</span></b></p>
  </td>
  <td width=55 style='width:41.3pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>10&#8209;40</span></b></p>
  </td>
  <td width=62 style='width:46.3pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>&gt;&nbsp;40</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=126 style='width:94.3pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>All patients</span></p>
  </td>
  <td width=70 valign=top style='width:52.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>45%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>455/1,014</span></p>
  </td>
  <td width=60 valign=top style='width:45.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>54%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>359/660</span></p>
  </td>
  <td width=54 valign=top style='width:40.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>39%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>67/172</span></p>
  </td>
  <td width=62 valign=top style='width:46.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>12%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>20/171</span></p>
  </td>
  <td width=69 valign=top style='width:52.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>45%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>455/1,014</span></p>
  </td>
  <td width=61 valign=top style='width:45.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>55%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>364/659</span></p>
  </td>
  <td width=55 valign=top style='width:41.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>29%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>59/203</span></p>
  </td>
  <td width=62 valign=top style='width:46.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>8%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>9/118</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=126 style='width:94.3pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Patients with
  no/non&#8209;na&iuml;ve use of ENF</span><sup><span lang=EN-GB>c</span></sup></p>
  </td>
  <td width=70 style='width:52.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>39%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>290/741</span></p>
  </td>
  <td width=60 style='width:45.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>50%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>238/477</span></p>
  </td>
  <td width=54 style='width:40.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>29%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>35/120</span></p>
  </td>
  <td width=62 style='width:46.3pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>7%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>10/135</span></p>
  </td>
  <td width=69 style='width:52.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>39%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>290/741</span></p>
  </td>
  <td width=61 style='width:45.6pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>51%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>244/477</span></p>
  </td>
  <td width=55 style='width:41.3pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>17%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>25/147</span></p>
  </td>
  <td width=62 style='width:46.3pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>5%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>5/94</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=126 style='width:94.3pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Patients with
  na&iuml;ve use of ENF</span><sup><span lang=EN-GB>d</span></sup></p>
  </td>
  <td width=70 valign=top style='width:52.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>60%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>165/273</span></p>
  </td>
  <td width=60 valign=top style='width:45.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>66%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>121/183</span></p>
  </td>
  <td width=54 valign=top style='width:40.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>62%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>32/52</span></p>
  </td>
  <td width=62 valign=top style='width:46.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>28%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>10/36</span></p>
  </td>
  <td width=69 valign=top style='width:52.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>60%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>165/273</span></p>
  </td>
  <td width=61 valign=top style='width:45.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>66%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>120/182</span></p>
  </td>
  <td width=55 valign=top style='width:41.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>61%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>34/56</span></p>
  </td>
  <td width=62 valign=top style='width:46.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>17%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>4/24</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=620 colspan=9 style='width:464.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Number
  of mutations from the list of mutations associated with a diminished response
  to PREZISTA/ritonavir (V11I, V32I, L33F, I47V, I50V, I54L or M, T74P, L76V,
  I84V or L89V)</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; fold
  change in EC<sub>50</sub></span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>c</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; &#8220;Patients
  with no/non&#8209;na&iuml;ve use of ENF&#8221; are patients who did not use
  ENF or who used ENF but not for the first time</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>d</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; &#8220;Patients
  with na&iuml;ve use of ENF&#8221; are patients who used ENF for the first
  time</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
patients</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Efficacy
of PREZISTA with ritonavir in paediatric patients</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>ART&#8209;experienced
paediatric patients from the age of 6 to &lt;&nbsp;18&nbsp;years, and weighing
at least 20&nbsp;kg</span></u></i></p>

<p class=MsoNormal><b><i><span lang=EN-GB>DELPHI</span></i></b><span
lang=EN-GB> is an open&#8209;label, Phase&nbsp;II trial evaluating the
pharmacokinetics, safety, tolerability, and efficacy of PREZISTA with low dose
ritonavir in 80&nbsp;ART&#8209;experienced HIV&#8209;1 infected paediatric
patients aged 6 to 17&nbsp;years and weighing at least 20&nbsp;kg. These
patients received PREZISTA/ritonavir twice daily in combination with other
antiretroviral agents (see section 4.2 for dosage recommendations per body
weight). Virologic response was defined as a decrease in plasma HIV&#8209;1 RNA
viral load of at least 1.0&nbsp;log<sub>10</sub> versus baseline.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the study, patients who were at risk of
discontinuing therapy due to intolerance of ritonavir oral solution (e.g. taste
aversion) were allowed to switch to the capsule formulation. Of the
44&nbsp;patients taking ritonavir oral solution, 27 switched to the 100&nbsp;mg
capsule formulation and exceeded the weight&#8209;based ritonavir dose without
changes in observed safety.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>DELPHI</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 style='width:232.15pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Outcomes
  at week 48</span></i></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>PREZISTA/ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>N=80</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>HIV&#8209;1 RNA
  &lt;&nbsp;50&nbsp;copies/ml<sup>a</sup></span></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>47.5%
  (38)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>CD4+ cell count mean change from baseline<sup>b</sup></span></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>147</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Imputations according to the TLOVR
  algorithm.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Non&#8209;completer
  is failure imputation: patients who discontinued prematurely are imputed with
  a change equal to 0.</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>According to the TLOVR non&#8209;virologic
failure censored algorithm 24&nbsp;(30.0%) patients experienced virological
failure, of which 17&nbsp;(21.3%) patients were rebounders and 7&nbsp;(8.8%)
patients were non&#8209;responders.</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>ART&#8209;experienced
paediatric patients from the age of 3 to &lt;&nbsp;6&nbsp;years</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetics, safety, tolerability
and efficacy of PREZISTA/ritonavir twice daily in combination with other
antiretroviral agents in 21&nbsp;ART&#8209;experienced HIV&#8209;1 infected paediatric
patients aged 3 to &lt;&nbsp;6&nbsp;years and weighing 10&nbsp;kg to &lt;&nbsp;20&nbsp;kg
was evaluated in an open&#8209;label, Phase&nbsp;II trial, <b><i>ARIEL</i></b>.
Patients received a weight&#8209;based twice daily treatment regimen, patients
weighing 10&nbsp;kg to &lt;&nbsp;15&nbsp;kg received darunavir/ritonavir 25/3&nbsp;mg/kg
twice daily, and patients weighing 15&nbsp;kg to &lt;&nbsp;20&nbsp;kg received darunavir/ritonavir
375/50&nbsp;mg twice daily. At week 48, the virologic response, defined as the
percentage of patients with confirmed plasma viral load &lt;&nbsp;50&nbsp;HIV&#8209;1
RNA copies/ml, was evaluated in 16&nbsp;paediatric patients 15&nbsp;kg to &lt;&nbsp;20&nbsp;kg
and 5&nbsp;paediatric patients 10&nbsp;kg to &lt;&nbsp;15&nbsp;kg receiving
PREZISTA/ritonavir in combination with other antiretroviral agents (see section
4.2 for dosage recommendations per body weight).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>ARIEL</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=281 style='width:210.95pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Outcomes
  at week 48</span></i></p>
  </td>
  <td width=338 colspan=2 valign=top style='width:253.4pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>PREZISTA/ritonavir</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=281 style='width:210.95pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>10&nbsp;kg to &lt;&nbsp;15&nbsp;kg</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>N=5</span></p>
  </td>
  <td width=168 valign=top style='width:125.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>15&nbsp;kg to &lt;&nbsp;20&nbsp;kg</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>N=16</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=281 valign=top style='width:210.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>HIV&#8209;1 RNA
  &lt;&nbsp;50&nbsp;copies/ml<sup>a</sup></span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>80.0%
  (4)</span></p>
  </td>
  <td width=168 valign=top style='width:125.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>81.3%
  (13)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=281 valign=top style='width:210.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>CD4+ percent change from baseline<sup>b</sup></span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>4</span></p>
  </td>
  <td width=168 valign=top style='width:125.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>4</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=281 valign=top style='width:210.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>CD4+ cell count mean change from baseline<sup>b</sup></span></p>
  </td>
  <td width=170 valign=top style='width:127.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>16</span></p>
  </td>
  <td width=168 valign=top style='width:125.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>241</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Imputations
  according to the TLOVR algorithm.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; NC=F</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Limited efficacy data are available in
paediatric patients below 15&nbsp;kg and no recommendation on a posology can be
made.</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>ART&#8209;na&iuml;ve
paediatric patients from the age of 12&nbsp;years to &lt;&nbsp;18&nbsp;years,
and weighing at least 40&nbsp;kg</span></u></i></p>

<p class=MsoNormal><b><i><span lang=EN-GB>DIONE</span></i></b><span lang=EN-GB>
is an open&#8209;label, Phase&nbsp;II trial evaluating the pharmacokinetics,
safety, tolerability, and efficacy of PREZISTA with low dose ritonavir in
12&nbsp;ART&#8209;na&iuml;ve HIV&#8209;1 infected paediatric patients aged 12
to less than 18&nbsp;years and weighing at least 40&nbsp;kg. These patients
received PREZISTA/ritonavir 800/100&nbsp;mg once daily in combination with
other antiretroviral agents. Virologic response was defined as a decrease in
plasma HIV&#8209;1 RNA viral load of at least 1.0&nbsp;log<sub>10</sub> versus
baseline.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=2 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>DIONE</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=334 style='width:250.6pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Outcomes
  at week 48</span></i></p>
  </td>
  <td width=271 valign=top style='width:203.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>PREZISTA/ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>N=12</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=334 valign=top style='width:250.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>HIV&#8209;1 RNA
  &lt;&nbsp;50&nbsp;copies/ml</span><sup><span lang=EN-GB>a</span></sup></p>
  </td>
  <td width=271 valign=top style='width:203.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>83.3%
  (10)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=334 valign=top style='width:250.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>CD4+ percent change from baseline</span><sup><span
  lang=EN-GB>b</span></sup></p>
  </td>
  <td width=271 valign=top style='width:203.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>14</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=334 valign=top style='width:250.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>CD4+ cell count mean change from baseline</span><sup><span
  lang=EN-GB>b</span></sup></p>
  </td>
  <td width=271 valign=top style='width:203.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>221</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=334 valign=top style='width:250.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;1.0 log</span><sub><span
  lang=EN-GB>10</span></sub><span lang=EN-GB> decrease from baseline in plasma
  viral load</span></p>
  </td>
  <td width=271 valign=top style='width:203.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=2 valign=top style='width:6.3in;border:none;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Imputations according to the TLOVR
  algorithm.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Non&#8209;completer is failure imputation:
  patients who discontinued prematurely are imputed with a change equal to 0.</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Efficacy
of PREZISTA with cobicistat in paediatric patients</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the open&#8209;label, Phase&nbsp;II/III
trial GS&#8209;US&#8209;216&#8209;0128, the efficacy, safety, and
pharmacokinetics of darunavir 800&nbsp;mg and cobicistat 150&nbsp;mg
(administered as separate tablets) and at least 2&nbsp;NRTIs were evaluated in
7&nbsp;HIV&#8209;1 infected, treatment&#8209;experienced, virologically
suppressed adolescents weighing at least 40&nbsp;kg. Patients were on a stable
antiretroviral regimen (for at least 3&nbsp;months), consisting of darunavir
administered with ritonavir, combined with 2&nbsp;NRTIs. They were switched
from ritonavir to cobicistat 150&nbsp;mg once daily and continued darunavir
(N=7) and 2&nbsp;NRTIs.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=2 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Virologic outcome in ART&#8209;experienced,
  virologically suppressed adolescents at week&nbsp;48</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=2 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>GS&#8209;US&#8209;216&#8209;0128</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=330 valign=top style='width:247.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Outcomes at Week&nbsp;48</span></p>
  </td>
  <td width=275 valign=top style='width:206.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Darunavir/cobicistat + at least 2&nbsp;NRTIs</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(N=7)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=330 valign=top style='width:247.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>HIV&#8209;1 RNA &lt;&nbsp;50&nbsp;copies/mL
  per FDA Snapshot Approach</span></p>
  </td>
  <td width=275 valign=top style='width:206.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>85.7%
  (6)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=330 valign=top style='width:247.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>CD4+ percent median change from baseline<sup>a</sup></span></p>
  </td>
  <td width=275 valign=top style='width:206.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&#8209;6.1%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=330 valign=top style='width:247.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>CD4+ cell count median change from
  baseline<sup>a</sup></span></p>
  </td>
  <td width=275 valign=top style='width:206.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&#8209;342&nbsp;cells/mm&sup3;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=2 valign=top style='width:6.3in;border:none;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><a
  name="_Hlk34982371"><sup><span lang=EN-GB>a</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span></a><span
  lang=EN-GB style='font-size:9.0pt'>No imputation (observed data).</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Pregnancy
and postpartum</span></i></p>

<p class=MsoNormal>Darunavir/ritonavir (600/100&nbsp;mg twice daily or 800/100&nbsp;mg
once daily) in combination with a background regimen was evaluated in a
clinical trial of 36&nbsp;pregnant women (18 in each arm) during the second and
third trimesters, and postpartum. Virologic response was preserved throughout
the study period in both arms. No mother to child transmission occurred in the
infants born to the 31&nbsp;subjects who stayed on the antiretroviral treatment
through delivery. There were no new clinically relevant safety findings
compared with the known safety profile of darunavir/ritonavir in HIV&#8209;1
infected adults (see sections 4.2, 4.4 and 5.2).</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetic properties of
darunavir, co&#8209;administered with cobicistat or ritonavir, have been
evaluated in healthy adult volunteers and in HIV&#8209;1 infected patients.
Exposure to darunavir was higher in HIV&#8209;1 infected patients than in
healthy subjects. The increased exposure to darunavir in HIV&#8209;1 infected
patients compared to healthy subjects may be explained by the higher
concentrations of &#945;<sub>1</sub>&#8209;acid glycoprotein (AAG) in HIV&#8209;1
infected patients, resulting in higher darunavir binding to plasma AAG and,
therefore, higher plasma concentrations.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir is primarily metabolised by
CYP3A. Cobicistat and ritonavir inhibit CYP3A, thereby increasing the plasma
concentrations of darunavir considerably.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For information on cobicistat
pharmacokinetic properties, consult the cobicistat Summary of Product
Characteristics.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir was rapidly absorbed following
oral administration. Maximum plasma concentration of darunavir in the presence
of low dose ritonavir is generally achieved within 2.5&#8209;4.0&nbsp;hours.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The absolute oral bioavailability of a
single 600&nbsp;mg dose of darunavir alone was approximately 37% and increased
to approximately 82% in the presence of 100&nbsp;mg twice daily ritonavir. The
overall pharmacokinetic enhancement effect by ritonavir was an approximate 14&#8209;fold
increase in the systemic exposure of darunavir when a single dose of
600&nbsp;mg darunavir was given orally in combination with ritonavir at
100&nbsp;mg twice daily (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>When administered without food, the
relative bioavailability of darunavir in the presence of cobicistat or low dose
ritonavir is lower as compared to intake with food. Therefore, PREZISTA tablets
should be taken with cobicistat or ritonavir and with food. The type of food
does not affect exposure to darunavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir is approximately 95% bound to
plasma protein. Darunavir binds primarily to plasma &#945;<sub>1</sub>&#8209;acid
glycoprotein.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Following intravenous administration, the
volume of distribution of darunavir alone was
88.1&nbsp;&plusmn;&nbsp;59.0&nbsp;l (Mean&nbsp;&plusmn;&nbsp;SD) and increased
to 131&nbsp;&plusmn;&nbsp;49.9&nbsp;l (Mean&nbsp;&plusmn;&nbsp;SD) in the
presence of 100&nbsp;mg twice&#8209;daily ritonavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>In vitro</span></i><span lang=EN-GB>
experiments with human liver microsomes (HLMs) indicate that darunavir
primarily undergoes oxidative metabolism. Darunavir is extensively metabolised
by the hepatic CYP system and almost exclusively by isozyme CYP3A4. A <sup>14</sup>C&#8209;darunavir
trial in healthy volunteers showed that a majority of the radioactivity in
plasma after a single 400/100&nbsp;mg darunavir with ritonavir dose was due to
the parent active substance. At least 3&nbsp;oxidative metabolites of darunavir
have been identified in humans; all showed activity that was at least 10&#8209;fold
less than the activity of darunavir against wild type HIV.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal><span lang=EN-GB>After a 400/100&nbsp;mg&nbsp;</span><sup><span
lang=EN-GB>14</span></sup><span lang=EN-GB>C&#8209;darunavir with ritonavir
dose, approximately 79.5% and 13.9% of the administered dose of </span><sup><span
lang=EN-GB>14</span></sup><span lang=EN-GB>C&#8209;darunavir could be retrieved
in faeces and urine, respectively. Unchanged darunavir accounted for
approximately 41.2% and 7.7% of the administered dose in faeces and urine,
respectively. The terminal elimination half&#8209;life of darunavir was
approximately 15&nbsp;hours when combined with ritonavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>The intravenous clearance of darunavir
alone (150&nbsp;mg) and in the presence of low dose ritonavir was 32.8&nbsp;l/h
and 5.9&nbsp;l/h, respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetics of darunavir in
combination with ritonavir taken twice daily in 74&nbsp;treatment&#8209;experienced
paediatric patients, aged 6 to 17&nbsp;years and weighing at least 20&nbsp;kg,
showed that the administered weight&#8209;based doses of PREZISTA/ritonavir
resulted in darunavir exposure comparable to that in adults receiving
PREZISTA/ritonavir 600/100&nbsp;mg twice daily (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetics of darunavir in
combination with ritonavir taken twice daily in 14&nbsp;treatment&#8209;experienced
paediatric patients, aged 3 to &lt;&nbsp;6&nbsp;years and weighing at least 15&nbsp;kg
to &lt;&nbsp;20&nbsp;kg, showed that weight&#8209;based dosages resulted in
darunavir exposure that was comparable to that achieved in adults receiving
PREZISTA/ritonavir 600/100&nbsp;mg twice daily (see section 4.2).</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetics of darunavir in
combination with ritonavir taken once daily in 12&nbsp;ART&#8209;na&iuml;ve
paediatric patients, aged 12 to &lt;&nbsp;18&nbsp;years and weighing at least
40&nbsp;kg, showed that PREZISTA/ritonavir 800/100&nbsp;mg once daily results
in darunavir exposure that was comparable to that achieved in adults receiving
PREZISTA/ritonavir 800/100&nbsp;mg once daily. Therefore the same once daily
dosage may be used in treatment&#8209;experienced adolescents aged 12 to &lt;&nbsp;18&nbsp;years
and weighing at least 40&nbsp;kg without darunavir resistance associated
mutations (DRV&#8209;RAMs)* and who have plasma HIV&#8209;1 RNA &lt;&nbsp;100,000&nbsp;copies/ml
and CD4+ cell count &#8805;&nbsp;100&nbsp;cells&nbsp;x&nbsp;10<sup>6</sup>/L (see
section 4.2).</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=NO-NYN>*</span><span lang=NO-NYN style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp; DRV&#8209;RAMs:
V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V</span></p>

<p class=MsoNormal><span lang=NO-NYN>&nbsp;</span></p>

<p class=MsoNormal>The pharmacokinetics of darunavir in combination with
ritonavir taken once daily in 10&nbsp;treatment&#8209;experienced paediatric
patients, aged 3 to &lt;&nbsp;6&nbsp;years and weighing at least 14&nbsp;kg to
&lt;&nbsp;20&nbsp;kg, showed that weight&#8209;based dosages resulted in
darunavir exposure that was comparable to that achieved in adults receiving
PREZISTA/ritonavir 800/100&nbsp;mg once daily (see section 4.2). In addition,
pharmacokinetic modeling and simulation of darunavir exposures in paediatric
patients across the ages of 3 to &lt;&nbsp;18&nbsp;years confirmed the
darunavir exposures as observed in the clinical studies and allowed the
identification of weight&#8209;based PREZISTA/ritonavir once daily dosing
regimens for paediatric patients weighing at least 15&nbsp;kg that are either
ART&#8209;na&iuml;ve or treatment&#8209;experienced paediatric patients without
DRV&#8209;RAMs* and who have plasma HIV&#8209;1 RNA
&lt;&nbsp;100,000&nbsp;copies/ml and CD4+ cell count
&#8805;&nbsp;100&nbsp;cells&nbsp;x&nbsp;10<sup>6</sup>/L (see section 4.2).</p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=NO-NYN>*</span><span lang=NO-NYN style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp; DRV&#8209;RAMs:
V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetics of darunavir
800&nbsp;mg co&#8209;administered with cobicistat 150&nbsp;mg in paediatric
patients have been studied in 7&nbsp;adolescents aged 12 to less than
18&nbsp;years, weighing at least 40&nbsp;kg in Study GS&#8209;US&#8209;216&#8209;0128.
The geometric mean adolescent exposure (AUC<sub>tau</sub>) was similar for
darunavir and increased 19% for cobicistat compared to exposures achieved in
adults who received darunavir 800&nbsp;mg co&#8209;administered with cobicistat
150&nbsp;mg in Study GS&#8209;US&#8209;216&#8209;0130. The difference observed
for cobicistat was not considered clinically relevant.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=606
 style='width:454.5pt;margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=133 valign=top style='width:99.9pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'><a name="_Hlk30422103"></a>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=177 valign=top style='width:132.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Adults in Study GS&#8209;US&#8209;216&#8209;0130,
  week&nbsp;24</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(Reference)<sup>a</sup></span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Mean (%CV)</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>GLSM</span></b></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Adolescents in Study GS&#8209;US&#8209;216&#8209;0128,
  day&nbsp;10</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(Test)<sup>b</sup></span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Mean (%CV)</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>GLSM</span></b></p>
  </td>
  <td width=120 valign=top style='width:1.25in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>GLSM Ratio</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(90% CI)</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(Test/Reference)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=133 valign=top style='width:99.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>N</span></p>
  </td>
  <td width=177 valign=top style='width:132.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>60<sup>c</sup></span></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>7</span></p>
  </td>
  <td width=120 valign=top style='width:1.25in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=133 valign=top style='width:99.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>DRV PK
  Parameter</span></b></p>
  </td>
  <td width=177 valign=top style='width:132.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=120 valign=top style='width:1.25in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=133 valign=top style='width:99.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>AUC<sub>tau</sub> (h.ng/mL)<sup>d</sup></span></p>
  </td>
  <td width=177 valign=top style='width:132.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>81,646 (32.2)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>77,534</span></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>80,877 (29.5)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>77,217</span></p>
  </td>
  <td width=120 valign=top style='width:1.25in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1.00
  (0.79&#8209;1.26)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=133 valign=top style='width:99.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>max</sub> (ng/mL)</span></p>
  </td>
  <td width=177 valign=top style='width:132.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>7,663 (25.1)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>7,422</span></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>7,506 (21.7)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>7,319</span></p>
  </td>
  <td width=120 valign=top style='width:1.25in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.99
  (0.83&#8209;1.17)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=133 valign=top style='width:99.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>tau</sub> (ng/mL)<sup>d</sup></span></p>
  </td>
  <td width=177 valign=top style='width:132.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1,311 (74.0)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>947</span></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1,087 (91.6)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>676</span></p>
  </td>
  <td width=120 valign=top style='width:1.25in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.71
  (0.34&#8209;1.48)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=133 valign=top style='width:99.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>COBI PK
  Parameter</span></b></p>
  </td>
  <td width=177 valign=top style='width:132.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=120 valign=top style='width:1.25in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=133 valign=top style='width:99.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>AUC<sub>tau</sub> (h.ng/mL)<sup>d</sup></span></p>
  </td>
  <td width=177 valign=top style='width:132.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>7,596 (48.1)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>7,022</span></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>8,741 (34.9)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>8,330</span></p>
  </td>
  <td width=120 valign=top style='width:1.25in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1.19
  (0.95&#8209;1.48)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=133 valign=top style='width:99.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>max</sub> (ng/mL)</span></p>
  </td>
  <td width=177 valign=top style='width:132.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>991 (33.4)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>945</span></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1,116 (20.0)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1,095</span></p>
  </td>
  <td width=120 valign=top style='width:1.25in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1.16
  (1.00&#8209;1.35)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=133 valign=top style='width:99.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><a name="_Hlk36022652"><span lang=EN-GB>C<sub>tau</sub>
  (ng/mL)<sup>d</sup></span></a></p>
  </td>
  <td width=177 valign=top style='width:132.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>32.8 (289.4)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>17.2<sup>e</sup></span></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>28.3 (157.2)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>22.0<sup>e</sup></span></p>
  </td>
  <td width=120 valign=top style='width:1.25in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1.28
  (0.51&#8209;3.22)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=606 colspan=4 valign=top style='width:454.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;24
  intensive PK data from subjects who received DRV 800&nbsp;mg + COBI
  150&nbsp;mg.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Day&nbsp;10
  intensive PK data from subjects who received DRV 800&nbsp;mg + COBI
  150&nbsp;mg.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>c</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; N=59
  for AUC<sub>tau</sub> and C<sub>tau</sub>.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>d</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Concentration
  at predose (0&nbsp;hours) was used as surrogate for concentration at
  24&nbsp;hours for the purposes of estimating AUC<sub>tau</sub> and C<sub>tau </sub>in
  Study GS-US-216-0128.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>e</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; N=57
  and N=5 for GLSM of C<sub>tau</sub> in Study GS-US-216-0130 and Study
  GS-US-216-0128, respectively.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=NO-NYN>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Population pharmacokinetic analysis in HIV
infected patients showed that darunavir pharmacokinetics are not considerably
different in the age range (18 to 75&nbsp;years) evaluated in HIV infected
patients (n=12, age&nbsp;&#8805;&nbsp;65) (see section 4.4). However, only
limited data were available in patients above the age of 65&nbsp;year.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Gender</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Population pharmacokinetic analysis showed
a slightly higher darunavir exposure (16.8%) in HIV infected females compared
to males. This difference is not clinically relevant.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Renal
impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Results from a mass balance study with <sup>14</sup>C&#8209;darunavir
with ritonavir showed that approximately 7.7% of the administered dose of
darunavir is excreted in the urine unchanged.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Although darunavir has not been studied in
patients with renal impairment, population pharmacokinetic analysis showed that
the pharmacokinetics of darunavir were not significantly affected in HIV
infected patients with moderate renal impairment (CrCl between 30&#8209;60&nbsp;ml/min,
n=20) (see sections 4.2 and 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Hepatic
impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir is primarily metabolised and
eliminated by the liver. In a multiple dose study with PREZISTA co&#8209;administered
with ritonavir (600/100&nbsp;mg) twice daily, it was demonstrated that the
total plasma concentrations of darunavir in subjects with mild (Child&#8209;Pugh
Class&nbsp;A, n=8) and moderate (Child&#8209;Pugh Class&nbsp;B, n=8) hepatic
impairment were comparable with those in healthy subjects. However, unbound
darunavir concentrations were approximately 55% (Child&#8209;Pugh Class&nbsp;A)
and 100% (Child&#8209;Pugh Class&nbsp;B) higher, respectively. The clinical
relevance of this increase is unknown therefore, PREZISTA should be used with
caution. The effect of severe hepatic impairment on the pharmacokinetics of
darunavir has not been studied (see sections 4.2, 4.3 and 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Pregnancy
and postpartum</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The exposure to total darunavir and
ritonavir after intake of darunavir/ritonavir 600/100&nbsp;mg twice daily and
darunavir/ritonavir 800/100&nbsp;mg once daily as part of an antiretroviral
regimen was generally lower during pregnancy compared with postpartum. </span>However,
for unbound (i.e. active) darunavir, the pharmacokinetic parameters were less
reduced during pregnancy compared to postpartum, due to an increase in the
unbound fraction of darunavir during pregnancy compared to postpartum<span
lang=EN-GB>.</span></p>

<p class=MsoNormal>&nbsp;</p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=610 colspan=4 valign=top style='width:457.75pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Pharmacokinetic results of total darunavir after administration
  of darunavir/ritonavir at 600/100&nbsp;mg twice daily as part of an antiretroviral
  regimen, during the second trimester of pregnancy, the third trimester of pregnancy
  and postpartum</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=153 valign=top style='width:114.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pharmacokinetics
  of total darunavir</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>(mean &plusmn; SD)</span></p>
  </td>
  <td width=153 valign=top style='width:114.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Second trimester of pregnancy</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(n=12)<sup>a</sup></span></b></p>
  </td>
  <td width=153 valign=top style='width:114.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Third trimester of pregnancy</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(n=12)</span></b></p>
  </td>
  <td width=153 valign=top style='width:114.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Postpartum (6&#8209;12&nbsp;weeks)</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(n=12)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=153 style='width:114.4pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>max</sub>, ng/ml</span></p>
  </td>
  <td width=153 style='width:114.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>4,668
  &plusmn; 1,097</span></p>
  </td>
  <td width=153 style='width:114.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>5,328
  &plusmn; 1,631</span></p>
  </td>
  <td width=153 style='width:114.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>6,659
  &plusmn; 2,364</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=153 valign=bottom style='width:114.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>AUC<sub>12h</sub>, ng.h/ml</span></p>
  </td>
  <td width=153 valign=bottom style='width:114.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>39,370
  &plusmn; 9,597</span></p>
  </td>
  <td width=153 valign=bottom style='width:114.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>45,880
  &plusmn; 17,360</span></p>
  </td>
  <td width=153 valign=bottom style='width:114.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>56,890
  &plusmn; 26,340</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=153 style='width:114.4pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>min</sub>, ng/ml</span></p>
  </td>
  <td width=153 style='width:114.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1,922
  &plusmn; 825</span></p>
  </td>
  <td width=153 valign=bottom style='width:114.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2,661
  &plusmn; 1,269</span></p>
  </td>
  <td width=153 style='width:114.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2,851
  &plusmn; 2,216</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=610 colspan=4 valign=top style='width:457.75pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>n=11 for AUC<sub>12h</sub></span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=4 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Pharmacokinetic results of total darunavir after administration
  of darunavir/ritonavir at 800/100&nbsp;mg once daily as part of an antiretroviral
  regimen, during the second trimester of pregnancy, the third trimester of pregnancy
  and postpartum</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=151 valign=top style='width:113.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pharmacokinetics
  of total darunavir</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>(mean &plusmn; SD)</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>Second trimester of pregnancy</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>(n=17)</span></b></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>Third Trimester of pregnancy</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>(n=15)</span></b></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>Postpartum (6&#8209;12&nbsp;weeks)</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>(n=16)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=151 style='width:113.4pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>max</sub>, ng/ml</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>4,964
  &plusmn; 1,505</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>5,132
  &plusmn; 1,198</span></p>
  </td>
  <td width=151 valign=bottom style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>7,310
  &plusmn; 1,704</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=151 valign=bottom style='width:113.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>AUC<sub>24h</sub>, ng.h/ml</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>62,289
  &plusmn; 16,234</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>61,112
  &plusmn; 13,790</span></p>
  </td>
  <td width=151 valign=bottom style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>92,116
  &plusmn; 29,241</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=151 style='width:113.4pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>min</sub>, ng/ml</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1,248
  &plusmn; 542</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1,075
  &plusmn; 594</span></p>
  </td>
  <td width=151 valign=bottom style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1,473
  &plusmn; 1,141</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>In women receiving darunavir/ritonavir
600/100&nbsp;mg twice daily during the second trimester of pregnancy, mean
intra&#8209;individual values for total darunavir C<sub>max</sub>, AUC<sub>12h</sub>
and C<sub>min</sub> were 28%, 26% and 26% lower, respectively, as compared with
postpartum; during the third trimester of pregnancy, total darunavir C<sub>max</sub>,
AUC<sub>12h</sub> and C<sub>min</sub> values were 18%, 16% lower and 2% higher,
respectively, as compared with postpartum.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In women receiving darunavir/ritonavir
800/100&nbsp;mg once daily during the second trimester of pregnancy, mean intra&#8209;individual
values for total darunavir C<sub>max</sub>, AUC<sub>24h</sub> and C<sub>min</sub>
were 33%, 31% and 30% lower, respectively, as compared with postpartum; during
the third trimester of pregnancy, total darunavir C<sub>max</sub>, AUC<sub>24h</sub>
and C<sub>min</sub> values were 29%, 32% and 50% lower, respectively, as
compared with postpartum.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Treatment with darunavir/cobicistat 800/150&nbsp;mg
once daily during pregnancy results in low darunavir exposure. In women
receiving darunavir/cobicistat during the second trimester of pregnancy, mean
intra-individual values for total darunavir C<sub>max</sub>, AUC<sub>24h</sub>
and C<sub>min</sub> were 49%, 56% and 92% lower, respectively, as compared with
postpartum; during the third trimester of pregnancy, total darunavir C<sub>max</sub>,
AUC<sub>24h</sub> and C<sub>min</sub> values were 37%, 50% and 89% lower,
respectively, as compared with postpartum. The unbound fraction was also
substantially reduced, including around 90% reductions of C<sub>min</sub>
levels. The main cause of these low exposures is a marked reduction in
cobicistat exposure as a consequence of pregnancy-associated enzyme induction
(see below).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=638 colspan=4 valign=top style='width:6.65in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Pharmacokinetic results of total darunavir after
  administration of darunavir/cobicistat 800/150&nbsp;mg once daily as part of
  an antiretroviral regimen, during the second trimester of pregnancy,
  the&nbsp;third trimester of pregnancy, and postpartum</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=160 valign=top style='width:119.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pharmacokinetics
  of total darunavir</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(mean
  &plusmn; SD)</span></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Second trimester of&nbsp;pregnancy</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(n=7)</span></b></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Third trimester of&nbsp;pregnancy</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(n=6)</span></b></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Postpartum (6&#8209;12&nbsp;weeks)</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(n=6)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=160 valign=top style='width:119.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>max</sub>, ng/mL</span></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>4,340
  &plusmn; 1,616</span></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>4,910
  &plusmn; 970</span></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>7,918
  &plusmn; 2,199</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=160 valign=top style='width:119.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>AUC<sub>24h</sub>, ng.h/mL</span></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>47,293
  &plusmn; 19,058</span></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>47,991
  &plusmn; 9,879</span></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>99,613
  &plusmn; 34,862</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=160 valign=top style='width:119.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>min</sub>, ng/mL</span></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>168
  &plusmn; 149</span></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>184
  &plusmn; 99</span></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1,538
  &plusmn; 1,344</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The exposure to cobicistat was lower during
pregnancy, potentially leading to suboptimal boosting of darunavir. During the
second trimester of pregnancy, cobicistat C<sub>max</sub>, AUC<sub>24h</sub>,
and C<sub>min</sub> were 50%, 63%, and 83% lower, respectively, as compared
with postpartum. During the third trimester of pregnancy, cobicistat C<sub>max</sub>,
AUC<sub>24h</sub>, and C<sub>min</sub>, were 27%, 49%, and 83% lower,
respectively, as compared with postpartum.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical
safety data</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Animal toxicology studies have been
conducted at exposures up to clinical exposure levels with darunavir alone, in
mice, rats and dogs and in combination with ritonavir in rats and dogs.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In repeated&#8209;dose toxicology studies
in mice, rats and dogs, there were only limited effects of treatment with
darunavir. In rodents the target organs identified were the haematopoietic
system, the blood coagulation system, liver and thyroid. A variable but limited
decrease in red blood cell&#8209;related parameters was observed, together with
increases in activated partial thromboplastin time.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Changes were observed in liver (hepatocyte
hypertrophy, vacuolation, increased liver enzymes) and thyroid (follicular
hypertrophy). In the rat, the combination of darunavir with ritonavir lead to a
small increase in effect on RBC parameters, liver and thyroid and increased
incidence of islet fibrosis in the pancreas (in male rats only) compared to
treatment with darunavir alone. In the dog, no major toxicity findings or
target organs were identified up to exposures equivalent to clinical exposure
at the recommended dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In a study conducted in rats, the number of
corpora lutea and implantations were decreased in the presence of maternal
toxicity. Otherwise, there were no effects on mating or fertility with
darunavir treatment up to 1,000&nbsp;mg/kg/day and exposure levels below (AUC&#8209;0.5&nbsp;fold)
of that in human at the clinically recommended dose. Up to same dose levels,
there was no teratogenicity with darunavir in rats and rabbits when treated
alone nor in mice when treated in combination with ritonavir. The exposure
levels were lower than those with the recommended clinical dose in humans. In a
pre&#8209; and postnatal development assessment in rats, darunavir with and
without ritonavir, caused a transient reduction in body weight gain of the
offspring pre&#8209;weaning and there was a slight delay in the opening of eyes
and ears. Darunavir in combination with ritonavir caused a reduction in the
number of pups that exhibited the startle response on day 15 of lactation and a
reduced pup survival during lactation. These effects may be secondary to pup
exposure to the active substance via the milk and/or maternal toxicity. No post
weaning functions were affected with darunavir alone or in combination with
ritonavir. In juvenile rats receiving darunavir up to days 23&#8209;26,
increased mortality was observed with convulsions in some animals. Exposure in
plasma, liver and brain was considerably higher than in adult rats after
comparable doses in mg/kg between days 5 and 11 of age. After day 23 of life,
the exposure was comparable to that in adult rats. The increased exposure was
likely at least partly due to immaturity of the drug&#8209;metabolising enzymes
in juvenile animals. No treatment related mortalities were noted in juvenile
rats dosed at 1,000&nbsp;mg/kg darunavir (single dose) on day 26 of age or at
500&nbsp;mg/kg (repeated dose) from day 23 to 50 of age, and the exposures and
toxicity profile were comparable to those observed in adult rats.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Due to uncertainties regarding the rate of
development of the human blood brain barrier and liver enzymes, PREZISTA with
low dose ritonavir should not be used in paediatric patients below 3&nbsp;years
of age.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir was evaluated for carcinogenic
potential by oral gavage administration to mice and rats up to 104&nbsp;weeks.
Daily doses of 150, 450 and 1,000&nbsp;mg/kg were administered to mice and
doses of 50, 150 and 500&nbsp;mg/kg were administered to rats. Dose&#8209;related
increases in the incidences of hepatocellular adenomas and carcinomas were
observed in males and females of both species. Thyroid follicular cell adenomas
were noted in male rats. Administration of darunavir did not cause a
statistically significant increase in the incidence of any other benign or
malignant neoplasm in mice or rats. The observed hepatocellular and thyroid
tumours in rodents are considered to be of limited relevance to humans.
Repeated administration of darunavir to rats caused hepatic microsomal enzyme
induction and increased thyroid hormone elimination, which predispose rats, but
not humans, to thyroid neoplasms. At the highest tested doses, the systemic
exposures (based on AUC) to darunavir were between 0.4&#8209; and 0.7&#8209;fold
(mice) and 0.7&#8209; and 1&#8209;fold (rats), relative to those observed in
humans at the recommended therapeutic doses.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>After
2&nbsp;years administration of darunavir at exposures at or below the human
exposure, kidney changes were observed in mice (nephrosis) and rats (chronic
progressive nephropathy).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir was not mutagenic or genotoxic in
a battery of </span><i><span lang=EN-GB>in vitro</span></i><span lang=EN-GB>
and </span><i><span lang=EN-GB>in vivo</span></i><span lang=EN-GB> assays
including bacterial reverse mutation (Ames), chromosomal aberration in human
lymphocytes and </span><i><span lang=EN-GB>in vivo</span></i><span lang=EN-GB>
micronucleus test in mice.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp;&nbsp; List
of excipients</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hydroxypropyl cellulose</span></p>

<p class=MsoNormal><span lang=EN-GB>Microcrystalline cellulose</span></p>

<p class=MsoNormal><span lang=EN-GB>Carmellose sodium</span></p>

<p class=MsoNormal><span lang=EN-GB>Citric acid monohydrate</span></p>

<p class=MsoNormal><span lang=EN-GB>Sucralose</span></p>

<p class=MsoNormal><span lang=EN-GB>Strawberry cream flavour</span></p>

<p class=MsoNormal><span lang=EN-GB>Masking flavour</span></p>

<p class=MsoNormal><span lang=EN-GB>Sodium methyl parahydroxybenzoate (E219)</span></p>

<p class=MsoNormal><span lang=EN-GB>Hydrochloric acid (for pH adjustment)</span></p>

<p class=MsoNormal><span lang=EN-GB>Purified water</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf
life</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>2&nbsp;years</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for storage</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not store above 30&deg;C.</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not refrigerate or freeze. Avoid
exposure to excessive heat.</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in the original container.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature
and contents of container</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Amber&#8209;coloured multiple&#8209;dose glass
bottle for 200&nbsp;ml suspension with a polypropylene closure with LDPE liner packaged
with a 6&nbsp;ml oral dosing pipette with 0.2&nbsp;ml gradations. The bottle
neck is filled with a low density polyethylene (LDPE) insert that accommodates
the dosing pipette.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA oral suspension is available in
packs of one bottle.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for disposal and
other handling</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Shake the bottle vigorously prior to each
dose. The supplied oral dosing pipette should not be used for any other medicinal
products.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="_Hlk45782216"><span lang=EN-GB>Any unused medicinal
product or waste material should be disposed of in accordance with local
requirements.</span></a></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Janssen&#8209;Cilag&nbsp;International&nbsp;NV</span></p>

<p class=MsoNormal><span lang=EN-GB>Turnhoutseweg&nbsp;30</span></p>

<p class=MsoNormal><span lang=EN-GB>B&#8209;2340&nbsp;Beerse</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/380/006</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of first authorisation: 12 February
2007</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of latest renewal: 19 September 2013</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this medicinal
product is available on the website of the European Medicines Agency <a
href="http://www.ema.europa.eu/"><span style='text-decoration:none'><u>http://www.ema.europa.eu</u></span></a>.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA 75&nbsp;mg film&#8209;coated
tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA 150&nbsp;mg film&#8209;coated
tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA 600&nbsp;mg film&#8209;coated
tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA
75&nbsp;mg film&#8209;coated tablets</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Each film&#8209;coated tablet contains
75&nbsp;mg of darunavir (as ethanolate).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA
150&nbsp;mg film&#8209;coated tablets</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Each film&#8209;coated tablet contains
150&nbsp;mg of darunavir (as ethanolate).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA
600&nbsp;mg film&#8209;coated tablets</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Each film&#8209;coated tablet contains
600&nbsp;mg of darunavir (as ethanolate).</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipient with known effect</span></u><span
lang=EN-GB>: Each tablet contains a maximum of 2.750&nbsp;mg sunset yellow FCF
(E110).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For the full list of excipients, see
section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA
75&nbsp;mg film&#8209;coated tablets</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Film&#8209;coated tablet.</span></p>

<p class=MsoNormal><span lang=EN-GB>White caplet shaped tablet of 9.2&nbsp;mm,
debossed with &#8220;75&#8221; on one side and &#8220;TMC&#8221; on the other
side.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA
150&nbsp;mg film&#8209;coated tablets</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Film&#8209;coated tablet.</span></p>

<p class=MsoNormal><span lang=EN-GB>White oval shaped tablet of 13.7&nbsp;mm,
debossed with &#8220;150&#8221; on one side and &#8220;TMC&#8221; on the other
side.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA
600&nbsp;mg film&#8209;coated tablets</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Film&#8209;coated tablet.</span></p>

<p class=MsoNormal><span lang=EN-GB>Orange oval shaped tablet of 21.1&nbsp;mm,
debossed with &#8220;600MG&#8221; on one side and &#8220;TMC&#8221; on the
other side.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CLINICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic
indications</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA, co&#8209;administered with low
dose ritonavir is indicated in combination with other antiretroviral medicinal
products for the treatment of patients with human immunodeficiency virus (HIV&#8209;1)
infection (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>PREZISTA 75&nbsp;mg,
150&nbsp;mg, and 600&nbsp;mg tablets may be used to provide suitable dose
regimens (see section 4.2):</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For the treatment of HIV&#8209;1 infection in antiretroviral
treatment (ART)&#8209;experienced adult patients, including those that have
been highly pre&#8209;treated.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For the treatment of HIV&#8209;1 infection in paediatric
patients from the age of 3&nbsp;years and at least 15&nbsp;kg body weight.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In deciding to initiate treatment with
PREZISTA co&#8209;administered with low dose ritonavir, careful consideration
should be given to the treatment history of the individual patient and the
patterns of mutations associated with different agents. Genotypic or phenotypic
testing (when available) and treatment history should guide the use of PREZISTA
(see sections 4.2, 4.4 and 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology
and method of administration</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Therapy should be initiated by a healthcare
provider experienced in the management of HIV infection. After therapy with
PREZISTA has been initiated, patients should be advised not to alter the dosage,
dose form or discontinue therapy without discussing with their healthcare
provider.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA must always be given orally with
low dose ritonavir as a pharmacokinetic enhancer and in combination with other
antiretroviral medicinal products. The Summary of Product Characteristics of
ritonavir must, therefore, be consulted prior to initiation of therapy with
PREZISTA.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is also available as an oral
suspension for use in patients who are unable to swallow PREZISTA tablets
(please refer to the Summary of Product Characteristics for PREZISTA oral
suspension).</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB>ART&#8209;experienced adult patients</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The recommended
dose regimen is 600&nbsp;mg twice daily taken with ritonavir 100&nbsp;mg twice
daily taken with food. PREZISTA 75&nbsp;mg, 150&nbsp;mg, and 600 mg&nbsp;tablets
can be used to construct the twice daily 600&nbsp;mg regimen.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The use of
75&nbsp;mg and 150&nbsp;mg tablets to achieve the recommended dose is
appropriate when there is a possibility of hypersensitivity to specific
colouring agents, or difficulty in swallowing the 600&nbsp;mg tablets.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB>ART&#8209;na&iuml;ve adult patients</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>For dosage
recommendations in ART&#8209;na&iuml;ve patients see the Summary of Product
Characteristics for PREZISTA 400&nbsp;mg and 800&nbsp;mg tablets.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>ART&#8209;na&iuml;ve
paediatric patients (3 to 17&nbsp;years of age and weighing at least
15&nbsp;kg)</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The weight&#8209;based
dose of PREZISTA and ritonavir in paediatric patients is provided in the table
below.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:462.1pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Recommended dose for treatment&#8209;na&iuml;ve
  paediatric patients</span></b><b><span lang=EN-GB> (3 to </span><span
  lang=EN-GB>17&nbsp;years)</span></b><span lang=EN-GB> <b>with PREZISTA
  tablets and ritonavir<sup>a</sup></b></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=214 valign=top style='width:160.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Body weight (kg)</span></b></p>
  </td>
  <td width=402 valign=top style='width:301.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Dose (once daily with food)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=214 valign=top style='width:160.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;15&nbsp;kg to
  &lt;&nbsp;30&nbsp;kg</span></p>
  </td>
  <td width=402 valign=top style='width:301.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>600&nbsp;mg PREZISTA/100&nbsp;mg
  ritonavir once daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=214 valign=top style='width:160.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;30&nbsp;kg to
  &lt;&nbsp;40&nbsp;kg</span></p>
  </td>
  <td width=402 valign=top style='width:301.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>675&nbsp;mg PREZISTA/100&nbsp;mg
  ritonavir once daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=214 valign=top style='width:160.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;40&nbsp;kg</span></p>
  </td>
  <td width=402 valign=top style='width:301.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>800&nbsp;mg PREZISTA/100&nbsp;mg ritonavir
  once daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:462.1pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>ritonavir oral solution: 80&nbsp;mg/ml</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>ART&#8209;experienced
paediatric patients (3 to 17&nbsp;years of age and weighing at least 15&nbsp;kg)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA twice daily taken with ritonavir
taken with food is usually recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A once daily dose regimen of PREZISTA taken
with ritonavir taken with food may be used in patients with prior exposure to
antiretroviral medicinal products but without darunavir resistance associated
mutations (DRV&#8209;RAMs)* and who have plasma HIV&#8209;1 RNA
&lt;&nbsp;100,000&nbsp;copies/ml and CD4+ cell count
&#8805;&nbsp;100&nbsp;cells&nbsp;x&nbsp;10<sup>6</sup>/L.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=NO-NYN>*&nbsp;&nbsp; </span><span lang=NO-NYN style='font-size:9.0pt'>DRV&#8209;RAMs:
V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V</span></p>

<p class=MsoNormal><span lang=NO-NYN>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The weight&#8209;based dose of PREZISTA and
ritonavir in paediatric patients is provided in the table below. </span><span
lang=EN-GB>The recommended dose of PREZISTA with low dose ritonavir should not
exceed the recommended adult dose (600/100&nbsp;mg twice daily or
800/100&nbsp;mg once daily).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Recommended dose for treatment&#8209;experienced
  paediatric patients (3 to 17&nbsp;years) with PREZISTA tablets and ritonavir<sup>a</sup></span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=140 valign=top style='width:104.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Body weight (kg)</span></b></p>
  </td>
  <td width=240 valign=top style='width:179.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Dose (once daily with food)</span></b></p>
  </td>
  <td width=240 valign=top style='width:179.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Dose </span></b><b><span lang=EN-GB>(twice daily
  with food)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=140 valign=top style='width:104.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;15&nbsp;kg&#8211;&lt;&nbsp;30&nbsp;kg</span></p>
  </td>
  <td width=240 valign=top style='width:179.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>600&nbsp;mg PREZISTA/100&nbsp;mg
  ritonavir once daily</span></p>
  </td>
  <td width=240 valign=top style='width:179.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>375&nbsp;mg PREZISTA/50&nbsp;mg ritonavir
  twice daily<sup> </sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=140 valign=top style='width:104.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;30&nbsp;kg&#8211;&lt;&nbsp;40&nbsp;kg</span></p>
  </td>
  <td width=240 valign=top style='width:179.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>675&nbsp;mg PREZISTA/100&nbsp;mg
  ritonavir once daily</span></p>
  </td>
  <td width=240 valign=top style='width:179.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>450&nbsp;mg PREZISTA/60&nbsp;mg ritonavir
  twice daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=140 valign=top style='width:104.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;40&nbsp;kg</span></p>
  </td>
  <td width=240 valign=top style='width:179.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>800&nbsp;mg PREZISTA/100&nbsp;mg
  ritonavir once daily</span></p>
  </td>
  <td width=240 valign=top style='width:179.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>600&nbsp;mg PREZISTA/100&nbsp;mg
  ritonavir twice daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>ritonavir oral solution: 80&nbsp;mg/ml</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>For ART&#8209;experienced
paediatric patients HIV genotypic testing is recommended. However, when HIV
genotypic testing is not feasible, the PREZISTA/ritonavir once daily dosing
regimen is recommended in HIV protease inhibitor&#8209;na&iuml;ve paediatric
patients and the twice daily dosing regimen is recommended in HIV protease
inhibitor&#8209;experienced patients.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The use of only 75&nbsp;mg and 150&nbsp;mg
tablets or the 100&nbsp;mg/ml oral suspension to achieve the recommended dose
of PREZISTA could be appropriate when there is a possibility of
hypersensitivity to specific colouring agents.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Advice on
missed doses</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In case a dose of PREZISTA and/or ritonavir
is missed within 6&nbsp;hours of the time it is usually taken, patients should
be instructed to take the prescribed dose of PREZISTA and ritonavir with food
as soon as possible. If this is noticed later than 6&nbsp;hours after the time
it is usually taken, the missed dose should not be taken and the patient should
resume the usual dosing schedule.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This guidance is based on the 15&nbsp;hour
half&#8209;life of darunavir in the presence of ritonavir and the recommended
dosing interval of approximately 12&nbsp;hours.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="_Hlk36030457"></a><a name="_Hlk36030189"><span
lang=EN-GB>If a patient vomits within 4&nbsp;hours of taking the medicine,
another dose of PREZISTA with ritonavir should be taken with food as soon as
possible. </span></a><span lang=EN-GB>If a patient vomits more than 4&nbsp;hours
after taking the medicine, the patient does not need to take another dose of
PREZISTA with ritonavir until the next regularly scheduled time.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Special
populations</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Limited information is available in this
population, and therefore, PREZISTA should be used with caution in this age
group (see sections 4.4 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Hepatic
impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir is metabolised by the hepatic
system. No dose adjustment is recommended in patients with mild (Child&#8209;Pugh
Class&nbsp;A) or moderate (Child&#8209;Pugh Class&nbsp;B) hepatic impairment,
however, PREZISTA should be used with caution in these patients. No
pharmacokinetic data are available in patients with severe hepatic impairment.
Severe hepatic impairment could result in an increase of darunavir exposure and
a worsening of its safety profile. Therefore, PREZISTA must not be used in
patients with severe hepatic impairment (Child&#8209;Pugh Class&nbsp;C) (see
sections 4.3, 4.4 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="OLE_LINK2"><i><span
lang=EN-GB>Renal impairment</span></i></a></p>

<p class=MsoNormal><span lang=EN-GB>No dose adjustment is required in patients
with renal impairment (see sections 4.4 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA/ritonavir should not be used in </span><span
lang=EN-GB>children with a body weight of less than 15&nbsp;kg as the dose for
this population has not been established in a sufficient number of patients
(see section&nbsp;5.1). PREZISTA/ritonavir should not be used in children below
3&nbsp;years of age because of safety concerns (see&nbsp;sections 4.4 and 5.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB>The weight-based dose regimen for PREZISTA and ritonavir is provided
in the tables above.</span></p>

<p class=MsoNormal><span lang=NO-NYN>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Pregnancy
and postpartum</span></i></p>

<p class=MsoNormal><span lang=EN-GB>No dose adjustment is required for
darunavir/ritonavir during pregnancy and postpartum. PREZISTA/ritonavir</span>
should be used during pregnancy only if the potential benefit justifies the
potential risk <span lang=EN-GB>(see sections 4.4, 4.6 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Patients should be instructed to take
PREZISTA with low dose ritonavir within 30&nbsp;minutes after completion of a
meal. The type of food does not affect the exposure to darunavir (see sections
4.4, 4.5 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hypersensitivity to the active substance or
to any of the excipients listed in section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients with severe (Child&#8209;Pugh
Class&nbsp;C) hepatic impairment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Combination of rifampicin with PREZISTA
with concomitant low dose ritonavir (see section 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Co&#8209;administration with the
combination product lopinavir/ritonavir (see section 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Co&#8209;administration with herbal
preparations containing St&nbsp;John&#8217;s&nbsp;wort (</span><i><span
lang=EN-GB>Hypericum perforatum</span></i><span lang=EN-GB>) (see section 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="OLE_LINK1"><span lang=EN-GB>Co&#8209;administration
of PREZISTA with low dose ritonavir, with active substances that are highly
dependent on CYP3A for clearance and for which elevated plasma concentrations
are associated with serious and/or life&#8209;threatening events. These active
substances include e.g.:</span></a></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>alfuzosin</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>amiodarone, bepridil, dronedarone, ivabradine, quinidine,
ranolazine</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>astemizole, terfenadine</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>colchicine when used in patients with renal
and/or hepatic impairment (see section 4.5)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ergot derivatives (e.g. dihydroergotamine,
ergometrine, ergotamine, methylergonovine)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>elbasvir/grazoprevir</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cisapride</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dapoxetine</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>domperidone</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>naloxegol</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lurasidone, pimozide, </span><span lang=EN-GB>quetiapine,
</span><span lang=EN-GB>sertindole (</span><span lang=EN-GB>see section 4.5</span><span
lang=EN-GB>)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>triazolam, midazolam administered orally (for
caution on parenterally administered midazolam, see section 4.5)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sildenafil &#8209; when used for the treatment
of pulmonary arterial hypertension, </span><span lang=EN-GB>avanafil</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>simvastatin, lovastatin and lomitapide (see
section 4.5)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dabigatran, ticagrelor (see section 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special
warnings and precautions for use</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>While effective viral suppression with
antiretroviral therapy has been proven to substantially reduce the risk of
sexual transmission, a residual risk cannot be excluded. Precautions to prevent
transmission should be taken in accordance with national guidelines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Regular assessment of virological response
is advised. In the setting of lack or loss of virological response, resistance
testing should be performed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA must always be given orally with
low dose ritonavir as a pharmacokinetic enhancer and in combination with other
antiretroviral medicinal products (see section 5.2). The Summary of Product
Characteristics of ritonavir as appropriate, must therefore be consulted prior
to initiation of therapy with PREZISTA.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Increasing the dose of ritonavir from that
recommended in section 4.2 did not significantly affect darunavir
concentrations It is not recommended to alter the dose of ritonavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir binds predominantly to </span><span
lang=EN-GB style='font-family:Symbol'>a</span><sub><span lang=EN-GB>1</span></sub><span
lang=EN-GB>&#8209;acid glycoprotein. This protein binding is concentration&#8209;dependent
indicative for saturation of binding. Therefore, protein displacement of
medicinal products highly bound to </span><span lang=EN-GB style='font-family:
Symbol'>a</span><sub><span lang=EN-GB>1</span></sub><span lang=EN-GB>&#8209;acid
glycoprotein cannot be ruled out (see section 4.5).</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>ART&#8209;experienced
patients &#8211; once daily dosing</span></u></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA used in combination with
cobicistat or low dose ritonavir once daily in ART&#8209;experienced patients
should not be used in patients with one or more darunavir resistance associated
mutations (DRV&#8209;RAMs) or HIV&#8209;1 RNA &#8805;&nbsp;100,000&nbsp;copies/ml
or CD4+ cell count &lt;&nbsp;100&nbsp;cells&nbsp;x&nbsp;10<sup>6</sup>/L (see
section 4.2). Combinations with optimised background regimen (OBRs) other than
&#8805;&nbsp;2&nbsp;NRTIs have not been studied in this population. Limited
data are available in patients with HIV&#8209;1 clades other than B (see
section 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is not recommended for use in paediatric
patients below 3&nbsp;years of age or less than 15&nbsp;kg body weight (see
sections 4.2 and 5.3).</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal>PREZISTA/ritonavir should be used during pregnancy only if
the potential benefit justifies the potential risk. <span lang=EN-GB>Caution
should be used in pregnant women with concomitant medications which may further
decrease</span> darunavir exposure (see sections 4.5 and 5.2).</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Elderly</span></u></p>

<p class=MsoNormal><span lang=EN-GB>As limited information is available on the
use of PREZISTA in patients aged&nbsp;65 and over, caution should be exercised
in the administration of PREZISTA in elderly patients, reflecting the greater
frequency of decreased hepatic function and of concomitant disease or other
therapy (see sections 4.2 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Severe
skin reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>During the darunavir/ritonavir clinical
development program (N=3,063), severe skin reactions, which may be accompanied
with fever and/or elevations of transaminases, have been reported in 0.4% of
patients. DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) and Stevens&#8209;Johnson
Syndrome has been rarely (&lt;&nbsp;0.1%) reported, and during post&#8209;marketing
experience toxic epidermal necrolysis and acute generalised exanthematous
pustulosis have been reported. PREZISTA should be discontinued immediately if
signs or symptoms of severe skin reactions develop. These can include, but are
not limited to, severe rash or rash accompanied by fever, general malaise,
fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis,
hepatitis and/or eosinophilia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Rash occurred more commonly in treatment&#8209;experienced
patients receiving regimens containing PREZISTA/ritonavir + raltegravir
compared to patients receiving PREZISTA/ritonavir without raltegravir or
raltegravir without PREZISTA (see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir contains a sulphonamide moiety.
PREZISTA should be used with caution in patients with a known sulphonamide
allergy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Hepatotoxicity</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Drug&#8209;induced hepatitis (e.g. acute
hepatitis, cytolytic hepatitis) has been reported with PREZISTA. During the
darunavir/ritonavir clinical development program (N=3,063), hepatitis was
reported in 0.5% of patients receiving combination antiretroviral therapy with
PREZISTA/ritonavir. Patients with pre&#8209;existing liver dysfunction,
including chronic active hepatitis B or C, have an increased risk for liver
function abnormalities including severe and potentially fatal hepatic adverse reactions.
In case of concomitant antiviral therapy for hepatitis&nbsp;B or C, please
refer to the relevant product information for these medicinal products.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Appropriate laboratory testing should be
conducted prior to initiating therapy with PREZISTA/ritonavir and patients
should be monitored during treatment. Increased AST/ALT monitoring should be
considered in patients with underlying chronic hepatitis, cirrhosis, or in
patients who have pre&#8209;treatment elevations of transaminases, especially
during the first several months of PREZISTA/ritonavir treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If there is evidence of new or worsening
liver dysfunction (including clinically significant elevation of liver enzymes
and/or symptoms such as fatigue, anorexia, nausea, jaundice, dark urine, liver
tenderness, hepatomegaly) in patients using PREZISTA/ritonavir, interruption or
discontinuation of treatment should be considered promptly.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Patients with coexisting conditions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB>Hepatic impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of PREZISTA have
not been established in patients with severe underlying liver disorders and
PREZISTA is therefore contraindicated in patients with severe hepatic
impairment. Due to an increase in the unbound darunavir plasma concentrations,
PREZISTA should be used with caution in patients with mild or moderate hepatic
impairment (see sections 4.2, 4.3 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Renal
impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>No special precautions or dose adjustments for
darunavir/ritonavir are required in patients with renal impairment. As
darunavir and ritonavir are highly bound to plasma proteins, it is unlikely
that they will be significantly removed by haemodialysis or peritoneal
dialysis. Therefore, no special precautions or dose adjustments are required in
these patients (see sections 4.2 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Haemophiliac
patients</span></i></p>

<p class=MsoNormal><span lang=EN-GB>There have been reports of increased
bleeding, including spontaneous skin haematomas and haemarthrosis in patients
with haemophilia type A and B treated with PIs. In some patients additional
factor VIII was given. In more than half of the reported cases, treatment with
PIs was continued or reintroduced if treatment had been discontinued. A causal
relationship has been suggested, although the mechanism of action has not been
elucidated. Haemophiliac patients should, therefore, be made aware of the
possibility of increased bleeding.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Weight
and metabolic parameters</span></i></p>

<p class=MsoNormal><span lang=EN-GB>An increase in weight and in levels of
blood lipids and glucose may occur during antiretroviral therapy. Such changes
may in part be linked to disease control and life style. For lipids, there is
in some cases evidence for a treatment effect, while for weight gain there is
no strong evidence relating this to any particular treatment. For monitoring of
blood lipids and glucose reference is made to established HIV treatment
guidelines. Lipid disorders should be managed as clinically appropriate.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Osteonecrosis</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Although the aetiology is considered to be
multifactorial (including corticosteroid use, alcohol consumption, severe
immunosuppression, higher body mass index), cases of osteonecrosis have been
reported particularly in patients with advanced HIV disease and/or long&#8209;term
exposure to combination antiretroviral therapy (CART). Patients should be
advised to seek medical advice if they experience joint aches and pain, joint
stiffness or difficulty in movement.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Immune reconstitution
inflammatory syndrome</span></u></p>

<p class=MsoNormal><span lang=EN-GB>In HIV infected patients with severe immune
deficiency at the time of initiation of combination antiretroviral therapy
(CART), an inflammatory reaction to asymptomatic or residual opportunistic
pathogens may arise and cause serious clinical conditions, or aggravation of
symptoms. Typically, such reactions have been observed within the first weeks
or months of initiation of CART. Relevant examples are cytomegalovirus
retinitis, generalised and/or focal mycobacterial infections and pneumonia
caused by <i>Pneumocystis jirovecii</i> (formerly known as <i>Pneumocystis
carinii</i>). Any inflammatory symptoms should be evaluated and treatment
instituted when necessary. In addition, reactivation of herpes simplex and
herpes zoster has been observed in clinical studies with PREZISTA co&#8209;administered
with low dose ritonavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Autoimmune disorders (such as Graves'
disease and autoimmune hepatitis) have also been reported to occur in the
setting of immune reactivation; however, the reported time to onset is more
variable and these events can occur many months after initiation of treatment
(see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Interactions
with medicinal products</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Several of the interaction studies have
been performed with darunavir at lower than recommended doses. The effects on
co&#8209;administered medicinal products may thus be underestimated and
clinical monitoring of safety may be indicated. For full information on
interactions with other medicinal products see section 4.5.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Efavirenz in combination with boosted PREZISTA
once daily may result in sub&#8209;optimal darunavir C<sub>min</sub>. If
efavirenz is to be used in combination with PREZISTA, the PREZISTA/ritonavir 600/100&nbsp;mg
twice daily regimen should be used (see section 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Life&#8209;threatening and fatal drug
interactions have been reported in patients treated with colchicine and strong
inhibitors of CYP3A and P&#8209;glycoprotein (P&#8209;gp; see sections 4.3 and 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA 600&nbsp;mg tablets contain sunset
yellow FCF (E110) which may cause an allergic reaction.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA <a name="_Hlk40251412">75&nbsp;mg,
150&nbsp;mg, </a>and 600&nbsp;mg tablets contain less than 1&nbsp;mmol sodium
(23&nbsp;mg) per tablet, that is to say essentially &#8216;sodium&#8209;free&#8217;.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction
with other medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Interaction studies have only been
performed in adults.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><u><span
lang=EN-GB>Medicinal products that may be affected by darunavir boosted with
ritonavir</span></u></b></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir and ritonavir are inhibitors of
CYP3A</span><span lang=EN-GB>, CYP2D6 and P&#8209;gp</span><span lang=EN-GB>.
Co&#8209;administration of darunavir/ritonavir with medicinal products
primarily metabolised by CYP3A and/or CYP2D6 or transported by P&#8209;gp may
result in increased systemic exposure to such medicinal products, which could
increase or prolong their therapeutic effect and adverse reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Co&#8209;administration of darunavir/ritonavir
with drugs that have active metabolite(s) formed by CYP3A may result in reduced
plasma concentrations of these active metabolite(s), potentially leading to
loss of their therapeutic effect (see the Interaction table below).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA co&#8209;administered with low
dose ritonavir must not be combined with medicinal products that are highly
dependent on CYP3A for clearance and for which increased systemic exposure is
associated with serious and/or life&#8209;threatening events (narrow
therapeutic index) (see section 4.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The overall pharmacokinetic enhancement
effect by ritonavir was an approximate 14&#8209;fold increase in the systemic
exposure of darunavir when a single dose of 600&nbsp;mg darunavir was given
orally in combination with ritonavir at 100&nbsp;mg twice daily. Therefore,
PREZISTA must only be used in combination with low dose ritonavir as a
pharmacokinetic enhancer (see sections 4.4 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A clinical study utilising a cocktail of
medicinal products that are metabolised by cytochromes CYP2C9, CYP2C19 and
CYP2D6 demonstrated an increase in CYP2C9 and CYP2C19 activity and inhibition
of CYP2D6 activity in the presence of darunavir/ritonavir, which may be
attributed to the presence of low dose ritonavir. Co&#8209;administration of
darunavir and ritonavir with medicinal products which are primarily metabolised
by CYP2D6 (such as flecainide, propafenone, metoprolol) may result in increased
plasma concentrations of these medicinal products, which could increase or
prolong their therapeutic effect and adverse reactions. Co&#8209;administration
of darunavir and ritonavir with medicinal products primarily metabolised by
CYP2C9 (such as warfarin) and CYP2C19 (such as methadone) may result in
decreased systemic exposure to such medicinal products, which could decrease or
shorten their therapeutic effect.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Although the effect on CYP2C8 has only been
studied <i>in vitro</i>, co&#8209;administration of darunavir and ritonavir and
medicinal products primarily metabolised by CYP2C8 (such as paclitaxel,
rosiglitazone, repaglinide) may result in decreased systemic exposure to such
medicinal products, which could decrease or shorten their therapeutic effect.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Ritonavir inhibits the transporters P&#8209;glycoprotein,
OATP1B1 and OATP1B3, and co&#8209;administration with substrates of these
transporters can result in increased plasma concentrations of these compounds
(e.g. dabigatran etexilate, digoxin, statins and bosentan; see the Interaction
table below).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><u><span
lang=EN-GB>Medicinal products that affect darunavir/ritonavir exposure</span></u></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Darunavir and
ritonavir are metabolised by CYP3A. Medicinal products that induce CYP3A
activity would be expected to increase the clearance of darunavir and
ritonavir, resulting in lowered plasma concentrations of darunavir and
ritonavir (e.g. rifampicin, St&nbsp;John&#8217;s&nbsp;wort, lopinavir). Co&#8209;administration
of darunavir and ritonavir and other medicinal products that inhibit CYP3A may
decrease the clearance of darunavir and ritonavir and may result in increased
plasma concentrations of darunavir and ritonavir (e.g. indinavir, azole
antifungals like clotrimazole). These interactions are described in the
interaction table below.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><u><span
lang=EN-GB>Interaction table</span></u></b></p>

<p class=MsoNormal><span lang=EN-GB>Interactions between PREZISTA/ritonavir and
antiretroviral and non&#8209;antiretroviral medicinal products are listed in
the table below. The direction of the arrow for each pharmacokinetic parameter
is based on the 90% confidence interval of the geometric mean ratio being
within (&#8596;), below (&#8595;) or above (&#8593;) the 80&#8209;125% range (not
determined as &#8220;ND&#8221;).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Several of the interaction studies
(indicated by <sup>#</sup> in the table below) have been performed at lower
than recommended doses of darunavir or with a different dosing regimen (see
section 4.2 Posology). The effects on co&#8209;administered medicinal products
may thus be underestimated and clinical monitoring of safety may be indicated.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The below list of examples of drug-drug
interactions is not comprehensive and therefore the label of each drug that is
co-administered with PREZISTA should be consulted for information related to
the route of metabolism, interaction pathways, potential risks, and specific
actions to be taken with regards to co&#8209;administration.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>INTERACTIONS AND DOSE
  RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>Medicinal products by therapeutic areas</span></b></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>Interaction</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>Geometric mean change (%)</span></b></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>Recommendations concerning co&#8209;administration</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>HIV ANTIRETROVIRALS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>Integrase strand transfer
  inhibitors</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>Dolutegravir</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>dolutegravir AUC
  &#8595; 22%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>dolutegravir C<sub>24h</sub>
  &#8595; 38%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>dolutegravir</span><span
  lang=EN-GB style='font-size:10.0pt'> C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 11%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir
  &#8596;*</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>*</span><span
  lang=EN-GB style='font-size:9.0pt'> Using cross&#8209;study comparisons to
  historical pharmacokinetic data</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>PREZISTA co&#8209;administered with low dose ritonavir and dolutegravir
  can be used without dose adjustment.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Raltegravir</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Some clinical
  studies suggest raltegravir may cause a modest decrease in darunavir plasma
  concentrations.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>At present the effect of raltegravir on darunavir plasma concentrations
  does not appear to be clinically relevant.</span><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'> PREZISTA co&#8209;administered
  with low dose ritonavir and raltegravir can be used without dose adjustments.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>Nucleo(s/t)ide reverse
  transcriptase inhibitors (NRTIs)</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Didanosine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>400&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>didanosine AUC
  &#8595; 9%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>didanosine C<sub>min</sub>
  ND</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>didanosine</span><span
  lang=EN-GB style='font-size:10.0pt'> C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 16%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir C<sub>max</sub>
  &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>PREZISTA co&#8209;administered with low dose ritonavir and didanosine
  can be used without dose adjustments.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>Didanosine is to be administered on an empty stomach, thus it should be
  administered 1&nbsp;hour before or 2&nbsp;hours after PREZISTA/ritonavir
  given with food.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Tenofovir </span><span lang=EN-GB style='font-size:
  10.0pt'>disoproxil</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>245&nbsp;mg once daily</span><sup><span lang=EN-GB>&#8225;</span></sup></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>tenofovir AUC
  &#8593; 22%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>tenofovir C<sub>min</sub>
  &#8593; 37%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>tenofovir C</span><sub><span
  lang=EN-GB style='font-size:10.0pt'>max</span></sub><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 24%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir AUC &#8593; 21%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>min</sub> &#8593; 24%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>max</sub> &#8593; 16%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(&#8593;
  tenofovir from effect on MDR&#8209;1 transport in the renal tubules)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Monitoring of
  renal function may be indicated when PREZISTA co&#8209;administered with low
  dose ritonavir is given in combination with tenofovir disoproxil,
  particularly in patients with underlying systemic or renal disease, or in
  patients taking nephrotoxic agents.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><a name="_Hlk498001110"><span
  lang=EN-GB style='font-size:10.0pt'>Emtricitabine/tenofovir alafenamide</span></a></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Tenofovir alafenamide</span><span
  lang=EN-GB style='font-size:10.0pt'> </span><span lang=PT style='font-size:
  10.0pt'>&#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Tenofovir
  &#8593;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The recommended
  dose of emtricitabine/tenofovir alafenamide is 200/10 mg once daily when used
  with PREZISTA with low dose ritonavir.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Abacavir</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Emtricitabine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Lamivudine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Stavudine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Zidovudine</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. </span><span
  lang=EN-GB style='font-size:10.0pt;layout-grid-mode:line'>Based on the
  different elimination pathways </span><span lang=EN-GB style='font-size:10.0pt'>of
  the other NRTIs zidovudine, emtricitabine, stavudine, lamivudine, that are
  primarily renally excreted, and abacavir for which metabolism is not mediated
  by CYP450, no interactions are expected for these medicinal compounds and
  PREZISTA co&#8209;administered with low dose ritonavir.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>PREZISTA co&#8209;administered
  with low dose ritonavir can be used with these NRTIs without dose adjustment.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><i><span
  lang=EN-GB style='font-size:10.0pt'>Non-nucleo(s/t)ide reverse transcriptase
  inhibitors (NNRTIs)</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Efavirenz</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>600&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>efavirenz AUC
  &#8593; 21%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>efavirenz C<sub>min</sub>
  &#8593; 17%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>efavirenz C<sub>max</sub>
  &#8593; 15%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir AUC &#8595; 13%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>min</sub> &#8595; 31%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>max </sub>&#8595; 15%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(&#8593;
  efavirenz from CYP3A inhibition)</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(&#8595;
  darunavir from CYP3A induction)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Clinical
  monitoring for central nervous system toxicity associated with increased
  exposure to efavirenz may be indicated when PREZISTA co&#8209;administered
  with low dose ritonavir is given in combination with efavirenz.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Efavirenz in
  combination with PREZISTA/ritonavir 800/100&nbsp;mg once daily may result in
  sub&#8209;optimal darunavir C<sub>min</sub>. If efavirenz is to be used in
  combination with PREZISTA/ritonavir, the PREZISTA/ritonavir 600/100&nbsp;mg
  twice daily regimen should be used (see section 4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Etravirine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>100&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>etravirine AUC
  &#8595; 37%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>etravirine C<sub>min</sub>
  &#8595; 49%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>etravirine C<sub>max
  </sub>&#8595; 32%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8593; 15%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir C<sub>min</sub>
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir C<sub>max</sub>
  &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>PREZISTA co&#8209;administered with low dose ritonavir and etravirine 200&nbsp;mg
  twice daily<b> </b>can be used<b> </b>without dose adjustments.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Nevirapine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>200&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>nevirapine AUC
  &#8593; 27%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>nevirapine C<sub>min</sub>
  &#8593; 47%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>nevirapine C</span><sub><span
  lang=EN-GB style='font-size:10.0pt'>max</span></sub><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 18%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir: concentrations were consistent with
  historical data</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(&#8593;
  nevirapine from CYP3A inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>PREZISTA co&#8209;administered with low dose ritonavir and nevirapine
  can be used without dose adjustments.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Rilpivirine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>150&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rilpivirine AUC
  &#8593; 130%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rilpivirine C<sub>min</sub>
  &#8593; 178%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rilpivirine C<sub>max</sub>
  &#8593; 79%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir C<sub>min</sub>
  &#8595; 11%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir C<sub>max</sub>
  &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>PREZISTA co&#8209;administered with low dose ritonavir and rilpivirine
  can be used without dose adjustments.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
  style='font-size:10.0pt'>HIV Protease inhibitors (PIs) &#8209; without
  additional co&#8209;administration of low dose ritonavir</span></i></b><sup><span
  lang=EN-GB>&#8224;</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Atazanavir</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>300&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>atazanavir AUC
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>atazanavir C<sub>min</sub>
  &#8593; 52%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>atazanavir C</span><sub><span
  lang=EN-GB style='font-size:10.0pt'>max</span></sub><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 11%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir AUC &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>min</sub> &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>max</sub> &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Atazanavir:
  comparison of atazanavir/ritonavir 300/100&nbsp;mg once daily vs. atazanavir
  300&nbsp;mg once daily in combination with darunavir/ritonavir
  400/100&nbsp;mg twice daily.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Darunavir:
  comparison of darunavir/ritonavir 400/100&nbsp;mg twice daily vs.
  darunavir/ritonavir 400/100&nbsp;mg twice daily in combination with
  atazanavir 300&nbsp;mg once daily.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>PREZISTA co&#8209;administered with low dose ritonavir and atazanavir
  can be used without dose adjustments.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Indinavir</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>800&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=FR style='font-size:10.0pt'>indinavir AUC
  &#8593; 23%</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:10.0pt'>indinavir C<sub>min</sub>
  &#8593; 125%</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:10.0pt'>indinavir C<sub>max</sub>
  &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=FR>#</span></sup><span lang=FR
  style='font-size:10.0pt'>darunavir AUC &#8593; 24%</span></p>
  <p class=MsoNormal><sup><span lang=FR>#</span></sup><span lang=FR
  style='font-size:10.0pt'>darunavir C<sub>min</sub> &#8593; 44%</span></p>
  <p class=MsoNormal><sup><span lang=FR>#</span></sup><span lang=FR
  style='font-size:10.0pt'>darunavir C<sub>max</sub> &#8593; 11%</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:10.0pt'>Indinavir:
  comparison of indinavir/ritonavir 800/100&nbsp;mg twice daily vs.
  indinavir/darunavir/ritonavir 800/400/100&nbsp;mg twice daily.</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:10.0pt'>Darunavir:
  comparison of darunavir/ritonavir 400/100&nbsp;mg twice daily vs.
  darunavir/ritonavir 400/100&nbsp;mg in combination with indinavir 800&nbsp;mg
  twice daily.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>When used in
  combination with PREZISTA co&#8209;administered with low dose ritonavir, dose
  adjustment of indinavir from 800&nbsp;mg twice daily to 600&nbsp;mg twice
  daily may be warranted in case of intolerance.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Saquinavir</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>1,000&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir AUC &#8595; 26%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>min</sub> &#8595; 42%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>max</sub> &#8595; 17%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>saquinavir AUC
  &#8595; 6%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>saquinavir C<sub>min</sub>
  &#8595; 18%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>saquinavir C<sub>max</sub>
  &#8595; 6%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Saquinavir:
  comparison of saquinavir/ritonavir 1,000/100&nbsp;mg twice daily vs.
  saquinavir/darunavir/ritonavir 1,000/400/100&nbsp;mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Darunavir:
  comparison of darunavir/ritonavir 400/100&nbsp;mg twice daily vs.
  darunavir/ritonavir 400/100&nbsp;mg in combination with saquinavir
  1,000&nbsp;mg twice daily.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>It is not
  recommended to combine PREZISTA co&#8209;administered with low dose ritonavir
  with saquinavir.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
  style='font-size:10.0pt'>HIV Protease inhibitors (PIs) &#8209; with co&#8209;administration
  of low dose ritonavir</span></i></b><b><sup><span lang=EN-GB>&#8224;</span></sup></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Lopinavir/ritonavir</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>400/100&nbsp;mg twice daily</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Lopinavir/ritonavir</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>533/133.3&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lopinavir AUC
  &#8593; 9%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lopinavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 23%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lopinavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 2%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8595; 38%</span><sup><span lang=EN-GB>&#8225;</span></sup></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 51%</span><sup><span lang=EN-GB>&#8225;</span></sup></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 21%</span><sup><span lang=EN-GB>&#8225;</span></sup></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lopinavir AUC
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lopinavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 13%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lopinavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 11%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8595; 41%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 55%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 21%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>&#8225;</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> based upon non dose normalised values</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Due to a
  decrease in the exposure (AUC) of darunavir by 40%, appropriate doses of the
  combination have not been established. Hence, concomitant use of PREZISTA co&#8209;administered
  with low dose ritonavir and the combination product lopinavir/ritonavir is
  contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>CCR5 ANTAGONIST</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Maraviroc</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>150&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>maraviroc AUC
  &#8593; 305%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>maraviroc </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub> ND</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>maraviroc </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 129%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir,
  ritonavir concentrations were consistent with historical data</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>The maraviroc dose should be 150&nbsp;mg twice daily when co&#8209;administered
  with PREZISTA with low dose ritonavir.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span style='font-size:
  10.0pt'>&#945;1-ADRENORECEPTOR ANTAGONIST</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span style='font-size:10.0pt'>Alfuzosin</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Based on
  theoretical considerations PREZISTA is expected to increase </span><span
  style='font-size:10.0pt'>alfuzosin </span><span lang=EN-GB style='font-size:
  10.0pt'>plasma concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:10.0pt'>Co-administration
  of </span><span lang=EN-GB style='font-size:10.0pt'>PREZISTA </span><span
  lang=EN-GB style='font-size:10.0pt;layout-grid-mode:line'>with low dose
  ritonavir</span><span lang=EN-GB style='font-size:10.0pt'> </span><span
  style='font-size:10.0pt'>and alfuzosin is contraindicated </span><span
  lang=EN-GB style='font-size:10.0pt'>(see section&nbsp;4.3)</span><span
  style='font-size:10.0pt'>.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANAESTHETIC</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Alfentanil</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. The
  metabolism of alfentanil is mediated via CYP3A, and may as such be inhibited
  by PREZISTA co&#8209;administered with low dose ritonavir.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The concomitant
  use with PREZISTA and low dose ritonavir may require to lower the dose of
  alfentanil and requires monitoring for risks of prolonged or delayed
  respiratory depression.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIANGINA/</span></b><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIARRHYTHMIC</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Disopyramide</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Flecainide</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Lidocaine (systemic)</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Mexiletine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Propafenone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Amiodarone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Bepridil</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Dronedarone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Ivabradine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Quinidine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Ranolazine</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  PREZISTA is expected to increase these antiarrhythmic plasma concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A and/or
  CYP2D6 inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Caution is
  warranted and therapeutic concentration monitoring, if available, is
  recommended for these antiarrhythmics when co&#8209;administered with
  PREZISTA with low dose ritonavir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>PREZISTA co&#8209;administered
  with low dose ritonavir and amiodarone, bepridil, dronedarone, ivabradine, quinidine,
  or ranolazine is contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Digoxin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>0.4&nbsp;mg single dose</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>digoxin AUC
  &#8593; 61%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>digoxin </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> ND</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>digoxin </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 29%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(&#8593; digoxin
  from probable inhibition of P&#8209;gp)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Given that digoxin
  has a narrow therapeutic index, it is recommended that the lowest possible
  dose of digoxin should initially be prescribed in case digoxin is given to
  patients on darunavir/ritonavir therapy. The digoxin dose should be carefully
  titrated to obtain the desired clinical effect while assessing the overall
  clinical state of the subject.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIBIOTIC</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Clarithromycin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>500&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>clarithromycin
  AUC &#8593; 57%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>clarithromycin </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 174%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>clarithromycin </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 26%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir AUC &#8595; 13%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir </span><span lang=EN-GB style='font-size:
  10.0pt'>C<sub>min</sub></span><span lang=EN-GB style='font-size:10.0pt'>
  &#8593; 1%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir </span><span lang=EN-GB style='font-size:
  10.0pt'>C<sub>max</sub></span><span lang=EN-GB style='font-size:10.0pt'>
  &#8595; 17%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>14&#8209;OH&#8209;clarithromycin
  concentrations were not detectable when combined with PREZISTA/ritonavir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(&#8593;
  clarithromycin from CYP3A inhibition and possible P&#8209;gp inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Caution should
  be exercised when clarithromycin is combined with PREZISTA co&#8209;administered
  with low dose ritonavir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>For patients
  with renal impairment the Summary of Product Characteristics for
  clarithromycin should be consulted for the recommended dose.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTICOAGULANT/</span></b><b><span lang=EN-GB
  style='font-size:10.0pt'>PLATELET AGGREGATION INHIBITOR</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Apixaban</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Edoxaban</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Rivaroxaban</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. Co&#8209;administration
  of PREZISTA with these anticoagulants may increase concentrations of the
  anticoagulant, which may lead to an increased bleeding risk.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A and/or P&#8209;gp
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The use of boosted
  PREZISTA and these anticoagulants is not recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Dabigatran</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Ticagrelor</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Clopidogrel</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. Co&#8209;administration
  with boosted PREZISTA may lead to a substantial increase in exposure to dabigatran
  or ticagrelor.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. Co&#8209;administration
  of clopidogrel with boosted PREZISTA is expected to decrease clopidogrel
  active metabolite plasma concentration, which may reduce the antiplatelet
  activity of clopidogrel.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant
  administration of boosted PREZISTA with dabigatran or ticagrelor is
  contraindicated (see section&nbsp;4.3).</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration
  of clopidogrel with boosted PREZISTA is not recommended.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Use of other
  antiplatelets not affected by CYP inhibition or induction (e.g. prasugrel) is
  recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Warfarin</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Warfarin concentrations may be affected when co&#8209;administered with
  darunavir with low dose ritonavir.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>It is
  recommended that the international normalised ratio (INR) be monitored when
  warfarin is combined with PREZISTA co&#8209;administered with low dose
  ritonavir.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTICONVULSANTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Phenobarbital</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Phenytoin</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. Phenobarbital
  and phenytoin are expected to decrease plasma concentrations of darunavir and
  its pharmacoenhancer.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(induction of
  CYP450 enzymes)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>PREZISTA co&#8209;administered
  with low dose ritonavir should not be used in combination with these
  medicines.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Carbamazepine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>200&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>carbamazepine
  AUC &#8593; 45%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>carbamazepine </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 54%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>carbamazepine </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 43%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 15%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>No dose
  adjustment for PREZISTA/ritonavir is recommended. If there is a need to
  combine PREZISTA/ritonavir and carbamazepine, patients should be monitored
  for potential carbamazepine&#8209;related adverse events. Carbamazepine
  concentrations should be monitored and its dose should be titrated for
  adequate response. Based upon the findings, the carbamazepine dose may need
  to be reduced by 25% to 50% in the presence of PREZISTA/ritonavir.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Clonazepam</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. </span><span
  lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration of boosted </span><span
  lang=EN-GB style='font-size:10.0pt'>PREZISTA with clonazepam may increase
  concentrations of clonazepam. (CYP3A inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Clinical
  monitoring is recommended when co&#8209;administering boosted PREZISTA with clonazepam.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIDEPRESSANTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Paroxetine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>20&nbsp;mg once daily</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Sertraline</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>50&nbsp;mg once daily</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Amitriptyline</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Desipramine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Imipramine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Nortriptyline</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Trazodone</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>paroxetine</span><span
  lang=IT style='font-size:10.0pt'> AUC &#8595; 39%</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>paroxetine</span><span
  lang=IT style='font-size:10.0pt'> </span><span lang=IT style='font-size:10.0pt'>C<sub>min</sub></span><span
  lang=IT style='font-size:10.0pt'> &#8595;</span><span lang=IT
  style='font-size:10.0pt'> 37%</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>paroxetine</span><span
  lang=IT style='font-size:10.0pt'> </span><span lang=IT style='font-size:10.0pt'>C<sub>max</sub></span><span
  lang=IT style='font-size:10.0pt'> &#8595; 36%</span></p>
  <p class=MsoNormal><sup><span lang=IT>#</span></sup><span lang=IT
  style='font-size:10.0pt'>darunavir AUC &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=IT>#</span></sup><span lang=IT
  style='font-size:10.0pt'>darunavir </span><span lang=IT style='font-size:
  10.0pt'>C<sub>min</sub></span><span lang=IT style='font-size:10.0pt'> &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=IT>#</span></sup><span lang=IT
  style='font-size:10.0pt'>darunavir </span><span lang=IT style='font-size:
  10.0pt'>C<sub>max</sub></span><span lang=IT style='font-size:10.0pt'> &#8596;</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>sertraline AUC
  &#8595; 49%</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>sertraline </span><span
  lang=IT style='font-size:10.0pt'>C<sub>min</sub></span><span lang=IT
  style='font-size:10.0pt'> &#8595;</span><span lang=IT style='font-size:10.0pt'>
  49%</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>sertraline </span><span
  lang=IT style='font-size:10.0pt'>C<sub>max</sub></span><span lang=IT
  style='font-size:10.0pt'> &#8595; 44%</span></p>
  <p class=MsoNormal><sup><span lang=IT>#</span></sup><span lang=IT
  style='font-size:10.0pt'>darunavir AUC &#8596;</span></p>
  <p class=MsoNormal><sup>#</sup><span style='font-size:10.0pt'>darunavir </span><span
  style='font-size:10.0pt'>C<sub>min</sub></span><span style='font-size:10.0pt'>
  &#8595; 6%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir </span><span lang=EN-GB style='font-size:
  10.0pt'>C<sub>max</sub></span><span lang=EN-GB style='font-size:10.0pt'>
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant use
  of PREZISTA co&#8209;administered with low dose ritonavir and these
  antidepressants may increase concentrations of the antidepressant.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP2D6 and/or
  CYP3A inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>If
  antidepressants are co&#8209;administered with PREZISTA with low dose
  ritonavir, the recommended approach is a dose titration of the antidepressant
  based on a clinical assessment of antidepressant response. In addition,
  patients on a stable dose of these antidepressants who start treatment with
  PREZISTA with low dose ritonavir should be monitored for antidepressant
  response.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Clinical
  monitoring is recommended when co&#8209;administering PREZISTA with low dose
  ritonavir with these antidepressants and a dose adjustment of the
  antidepressant may be needed.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIEMETICS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Domperidone</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co-administration
  of domperidone with boosted PREZISTA is contraindicated.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIFUNGALS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Voriconazole</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Ritonavir may decrease plasma concentrations of voriconazole.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(induction of
  CYP450 enzymes)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Voriconazole
  should not be combined with PREZISTA co&#8209;administered with low dose
  ritonavir unless an assessment of the benefit/risk ratio justifies the use of
  voriconazole.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Fluconazole</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Isavuconazole</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Itraconazole</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Posaconazole</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Clotrimazole</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  PREZISTA may increase antifungal plasma concentrations and posaconazole,
  isavuconazole, itraconazole, or fluconazole may increase darunavir
  concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A </span><span
  lang=EN-GB style='font-size:10.0pt'>and/or P&#8209;gp </span><span
  lang=EN-GB style='font-size:10.0pt'>inhibition)</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Concomitant systemic use of clotrimazole and darunavir co&#8209;administered
  with low dose ritonavir may increase plasma concentrations of darunavir and/or
  clotrimazole.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC<sub>24h</sub>
  &#8593; 33% (based on population pharmacokinetic model)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Caution is
  warranted and clinical monitoring is recommended. When co&#8209;administration
  is required the daily dose of itraconazole should not exceed 200&nbsp;mg.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIGOUT MEDICINES</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Colchicine</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. Concomitant
  use of colchicine and darunavir co&#8209;administered with low dose ritonavir
  may increase the exposure to colchicine.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A and/ or P&#8209;gp
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>A reduction in
  colchicine dosage or an interruption of colchicine treatment is recommended
  in patients with normal renal or hepatic function if treatment with PREZISTA
  co&#8209;administered with low dose ritonavir is required. For patients with
  renal or hepatic impairment colchicine with PREZISTA co&#8209;administered
  with low dose ritonavir is contraindicated (see sections 4.3 and 4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIMALARIALS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Artemether/Lumefantrine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>80/480&nbsp;mg, 6&nbsp;doses at 0, 8, 24, 36, 48,
  and 60&nbsp;hours</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>artemether AUC
  &#8595; 16%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>artemether C<sub>min</sub>
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>artemether C<sub>max</sub>
  &#8595; 18%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>dihydroartemisinin
  AUC &#8595; 18%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>dihydroartemisinin
  C<sub>min</sub> &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>dihydroartemisinin
  C<sub>max</sub> &#8595; 18%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lumefantrine AUC
  &#8593; 175%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lumefantrine C<sub>min</sub>
  &#8593; 126%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lumefantrine C<sub>max</sub>
  &#8593; 65%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir C<sub>min</sub>
  &#8595; 13%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir C<sub>max</sub>
  &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The combination
  of PREZISTA and artemether/lumefantrine can be used without dose adjustments;
  however, due to the increase in lumefantrine exposure, the combination should
  be used with caution.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIMYCOBACTERIALS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Rifampicin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Rifapentine</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Rifapentine and rifampicin are strong CYP3A inducers and have been shown to
  cause profound decreases in concentrations of other protease inhibitors,
  which can result in virological failure and resistance development (CYP450
  enzyme induction). During attempts to overcome the decreased exposure by
  increasing the dose of other protease inhibitors with low dose ritonavir, a
  high frequency of liver reactions was seen with rifampicin.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The combination
  of rifapentine and PREZISTA with concomitant low dose ritonavir is not
  recommended.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The combination
  of rifampicin and PREZISTA with concomitant low dose ritonavir is
  contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Rifabutin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>150&nbsp;mg once every other day</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rifabutin AUC</span><sup><span
  lang=EN-GB>**</span></sup><span lang=EN-GB style='font-size:10.0pt'> &#8593;
  55%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rifabutin C<sub>min</sub></span><sup><span
  lang=EN-GB>**</span></sup><span lang=EN-GB style='font-size:10.0pt'> &#8593;
  ND</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rifabutin C<sub>max</sub></span><sup><span
  lang=EN-GB>**</span></sup><span lang=EN-GB style='font-size:10.0pt'> &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8593; 53%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 68</span><span lang=EN-GB style='font-size:
  10.0pt'>%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 39%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>**</span></sup><span lang=EN-GB
  style='font-size:10.0pt'> </span><span lang=EN-GB style='font-size:9.0pt'>sum
  of active moieties of rifabutin (parent drug +&nbsp;25&#8209;<i>O&#8209;</i>desacetyl
  metabolite)</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The interaction
  trial showed a comparable daily systemic exposure for rifabutin between
  treatment at 300&nbsp;mg once daily alone and 150&nbsp;mg once every other
  day in combination with PREZISTA/ritonavir (600/100&nbsp;mg twice daily) with
  an about 10&#8209;fold increase in the daily exposure to the active
  metabolite 25&#8209;<i>O&#8209;</i>desacetylrifabutin. Furthermore, AUC of
  the sum of active moieties of rifabutin (parent drug +&nbsp;25&#8209;<i>O&#8209;</i>desacetyl
  metabolite) was increased 1.6&#8209;fold, while C<sub>max</sub> remained
  comparable.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Data on
  comparison with a 150&nbsp;mg once daily reference dose is lacking.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(Rifabutin is an
  inducer and substrate of CYP3A.) An increase of systemic exposure to
  darunavir was observed when PREZISTA co&#8209;administered with 100&nbsp;mg
  ritonavir was co&#8209;administered with rifabutin (150&nbsp;mg once every
  other day).</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>A dosage
  reduction of rifabutin by 75% of the usual dose of 300&nbsp;mg/day (i.e.
  rifabutin 150&nbsp;mg once every other day) and increased monitoring for
  rifabutin related adverse events is warranted in patients receiving the
  combination with PREZISTA co&#8209;administered with ritonavir. In case of
  safety issues, a further increase of the dosing interval for rifabutin and/or
  monitoring of rifabutin levels should be considered.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Consideration
  should be given to official guidance on the appropriate treatment of
  tuberculosis in HIV infected patients.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Based upon the
  safety profile of PREZISTA/ritonavir, the increase in darunavir exposure in
  the presence of rifabutin does not warrant a dose adjustment for
  PREZISTA/ritonavir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Based on
  pharmacokinetic modeling, this dosage reduction of 75% is also applicable if
  patients receive rifabutin at doses other than 300&nbsp;mg/day.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTINEOPLASTICS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Dasatinib</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Nilotinib</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Vinblastine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Vincristine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Everolimus</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Irinotecan</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  PREZISTA is expected to increase these antineoplastic plasma concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>Concentrations of these medicinal products may be
  increased when co&#8209;administered with PREZISTA with low dose ritonavir
  resulting in the potential for increased adverse events usually associated
  with these agents.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Caution should
  be exercised when combining one of these antineoplastic agents with PREZISTA
  with low dose ritonavir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant use
  of everolimus or irinotecan and PREZISTA co&#8209;administered with low dose
  ritonavir is not recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIPSYCHOTICS/</span></b><b><span lang=EN-GB
  style='font-size:10.0pt'>NEUROLEPTICS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Quetiapine</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. PREZISTA
  is expected to increase these antipsychotic plasma concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant
  administration of PREZISTA with low dose ritonavir and quetiapine is
  contraindicated as it may increase quetiapine&#8209;related toxicity.
  Increased concentrations of quetiapine may lead to coma (see
  section&nbsp;4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Perphenazine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Risperidone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Thioridazine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Lurasidone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Pimozide</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Sertindole</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  PREZISTA is expected to increase these antipsychotic plasma concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A, CYP2D6
  and/or P&#8209;gp inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>A dose decrease
  may be needed for these drugs when co&#8209;administered with PREZISTA co&#8209;administered
  with low dose ritonavir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant administration
  of PREZISTA with low dose ritonavir and lurasidone, pimozide or sertindole is
  contraindicated (see section&nbsp;4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>&#946;-BLOCKERS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Carvedilol</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Metoprolol</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Timolol</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  PREZISTA is expected to increase these &#946;&#8209;blocker plasma
  concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP2D6
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Clinical
  monitoring is recommended when co&#8209;administering PREZISTA with &#946;&#8209;blockers.
  A lower dose of the &#946;&#8209;blocker should be considered.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>CALCIUM CHANNEL BLOCKERS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Amlodipine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Diltiazem</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Felodipine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Nicardipine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Nifedipine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Verapamil</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  PREZISTA co&#8209;administered with low dose ritonavir can be expected to
  increase the plasma concentrations of calcium channel blockers.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A and/or
  CYP2D6 inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Clinical
  monitoring of therapeutic and adverse effects is recommended when these
  medicines are concomitantly administered with PREZISTA with low dose
  ritonavir.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB style='font-size:10.0pt'>CORTICOSTEROIDS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Corticosteroids primarily metabolised by CYP3A
  (including betamethasone, budesonide, fluticasone, mometasone, prednisone,
  triamcinolone)</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Fluticasone: in
  a clinical study where ritonavir 100&nbsp;mg capsules twice daily were co&#8209;administered
  with 50&nbsp;</span><span lang=EN-GB style='font-size:10.0pt;font-family:
  Symbol'>m</span><span lang=EN-GB style='font-size:10.0pt'>g intranasal
  fluticasone propionate (4&nbsp;times daily) for 7&nbsp;days in healthy
  subjects, fluticasone propionate plasma concentrations increased
  significantly, whereas the intrinsic cortisol levels decreased by
  approximately 86% (90% CI 82&#8209;89%). Greater effects may be expected when
  fluticasone is inhaled. Systemic corticosteroid effects including
  Cushing&#8217;s syndrome and adrenal suppression have been reported in
  patients receiving ritonavir and inhaled or intranasally administered
  fluticasone. The effects of high fluticasone systemic exposure on ritonavir
  plasma levels are unknown.</span></p>
  <p class=MsoNormal><span style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span style='font-size:10.0pt'>Other corticosteroids: interaction
  not studied. Plasma concentrations of these medicinal products may be
  increased when co-administered with PREZISTA </span><span lang=EN-GB
  style='font-size:10.0pt'>with low dose ritonavir</span><span
  style='font-size:10.0pt'>, resulting in reduced serum cortisol
  concentrations.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:10.0pt'>Concomitant use of PREZISTA
  </span><span lang=EN-GB style='font-size:10.0pt'>with low dose ritonavir</span><span
  lang=EN-GB style='font-size:10.0pt'> </span><span style='font-size:10.0pt'>and
  corticosteroids that are metabolised by CYP3A (e.g. fluticasone propionate or
  other inhaled or nasal corticosteroids) may increase the risk of development
  of systemic corticosteroid effects, including Cushing&#8217;s syndrome and
  adrenal suppression.</span></p>
  <p class=MsoNormal><span style='font-size:10.0pt'>Co-administration with
  CYP3A-metabolised corticosteroids is not recommended unless the potential
  benefit to the patient outweighs the risk, in which case patients should be
  monitored for systemic corticosteroid effects.</span></p>
  <p class=MsoNormal><span style='font-size:10.0pt'>Alternative corticosteroids
  which are less dependent on CYP3A metabolism e.g. beclomethasone for
  intranasal or inhalational use should be considered, particularly for long
  term use.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Dexamethasone</span><span lang=EN-GB
  style='font-size:10.0pt'> (systemic)</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Dexamethasone may decrease plasma concentrations of darunavir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  induction)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Systemic
  dexamethasone should be used with caution when combined with PREZISTA co&#8209;administered
  with low dose ritonavir.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ENDOTHELIN RECEPTOR ANTAGONISTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Bosentan</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Concomitant use of bosentan and PREZISTA co&#8209;administered with low dose
  ritonavir may increase plasma concentrations of bosentan.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Bosentan is
  expected to decrease plasma concentrations of darunavir and/or its
  pharmacoenhancer.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A induction)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>When
  administered concomitantly with PREZISTA and low dose ritonavir, the
  patient&#8217;s tolerability of bosentan should be monitored.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>HEPATITIS C VIRUS (HCV) DIRECT&#8209;ACTING
  ANTIVIRALS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
  style='font-size:10.0pt'>NS3&#8209;4A protease inhibitors</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span style='font-size:10.0pt'>Elbasvir/grazoprevir</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>PREZISTA with
  low dose ritonavir m</span><span style='font-size:10.0pt'>ay increase the
  exposure to grazoprevir.</span></p>
  <p class=MsoNormal><span style='font-size:10.0pt'>(CYP3A and OATP1B inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:10.0pt'>Concomitant use of PREZISTA
  </span><span lang=EN-GB style='font-size:10.0pt'>with low dose ritonavir</span><span
  style='font-size:10.0pt'> and</span><span style='font-size:10.0pt'>
  elbasvir/grazoprevir is contraindicated </span><span lang=EN-GB
  style='font-size:10.0pt'>(see section&nbsp;4.3)</span><span style='font-size:
  10.0pt'>.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Glecaprevir/pibrentasvir</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Based on
  theoretical considerations boosted PREZISTA may increase the exposure to glecaprevir
  and pibrentasvir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(P&#8209;gp,
  BCRP and/or OATP1B1/3 inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>It is not
  recommended to co&#8209;administer boosted PREZISTA with
  glecaprevir/pibrentasvir.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB style='font-size:10.0pt'>HERBAL PRODUCTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>St&nbsp;John's&nbsp;wort</span><span lang=EN-GB
  style='font-size:10.0pt'> <i>(Hypericum perforatum)</i></span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. </span><span
  lang=EN-GB style='font-size:10.0pt'>St&nbsp;John&#8217;s&nbsp;wort is
  expected to decrease the plasma concentrations of darunavir and ritonavir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP450
  induction)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>PREZISTA co&#8209;administered
  with low dose ritonavir must not be used concomitantly with products
  containing St&nbsp;John&#8217;s&nbsp;wort (<i>Hypericum perforatum</i>) (see
  section 4.3). If a patient is already taking St&nbsp;John&#8217;s&nbsp;wort,
  stop St&nbsp;John&#8217;s&nbsp;wort and if possible check viral levels.
  Darunavir exposure (and also ritonavir exposure) may increase on stopping
  St&nbsp;John&#8217;s&nbsp;wort. The inducing effect may persist for at least
  2&nbsp;weeks after cessation of treatment with
  St&nbsp;John&#8217;s&nbsp;wort.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB style='font-size:10.0pt'>HMG&nbsp;CO&#8209;A REDUCTASE INHIBITORS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Lovastatin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Simvastatin</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Lovastatin and simvastatin are expected to have markedly increased plasma
  concentrations when co&#8209;administered with PREZISTAco&#8209;administered
  with low dose ritonavir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Increased plasma
  concentrations of lovastatin or simvastatin may cause myopathy, including
  rhabdomyolysis. Concomitant use of PREZISTA co&#8209;administered with low
  dose ritonavir with lovastatin and simvastatin is therefore contraindicated
  (see section 4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Atorvastatin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>10&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>atorvastatin</span><span
  lang=EN-GB style='font-size:10.0pt'> AUC &#8593; 3&#8209;4 fold</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>atorvastatin</span><span
  lang=EN-GB style='font-size:10.0pt'> </span><span lang=EN-GB
  style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; </span><span lang=EN-GB style='font-size:
  9.0pt'>&#8776;</span><span lang=EN-GB style='font-size:10.0pt'>5.5&#8209;10
  fold</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>atorvastatin</span><span
  lang=EN-GB style='font-size:10.0pt'> </span><span lang=EN-GB
  style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; &#8776;2 fold</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir/ritonavir</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>When
  administration of atorvastatin and PREZISTA co&#8209;administered with low
  dose ritonavir is desired, it is recommended to start with an atorvastatin
  dose of 10&nbsp;mg once daily. A gradual dose increase of atorvastatin may be
  tailored to the clinical response.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Pravastatin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>40&nbsp;mg single dose</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>pravastatin AUC
  &#8593; 81%</span><sup><span lang=EN-GB>&para;</span></sup></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>pravastatin </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> ND</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>pravastatin </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 63%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>&para;</span></sup><span lang=EN-GB
  style='font-size:9.0pt'> an up to five-fold increase was seen in a limited
  subset of subjects</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>When
  administration of pravastatin and PREZISTA co&#8209;administered with low
  dose ritonavir is required, it is recommended to start with the lowest
  possible dose of pravastatin and titrate up to the desired clinical effect
  while monitoring for safety.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Rosuvastatin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>10&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rosuvastatin AUC
  &#8593; 48%</span><sup><span lang=EN-GB>&#9553;</span></sup></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rosuvastatin C<sub>max</sub>
  &#8593; 144%</span><sup><span lang=EN-GB>&#9553;</span></sup></p>
  <p class=MsoNormal><sup><span lang=EN-GB>&#9553;</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> based on published data with
  darunavir/ritonavir</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>When
  administration of rosuvastatin and PREZISTA co&#8209;administered with low
  dose ritonavir is required, it is recommended to start with the lowest
  possible dose of rosuvastatin and titrate up to the desired clinical effect
  while monitoring for safety.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><a name="_Hlk498286662"><b><span
  lang=EN-GB style='font-size:10.0pt'>OTHER LIPID MODIFYING AGENTS</span></b></a></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Lomitapide</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Based on
  theoretical considerations boosted PREZISTA is expected to increase the
  exposure of lomitapide when co-administered.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co-administration
  is </span><span lang=EN-GB style='font-size:10.0pt'>contraindicated (see
  section 4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>H</span></b><b><sub><span lang=EN-GB>2</span></sub></b><b><span
  lang=EN-GB style='font-size:10.0pt'>&#8209;RECEPTOR ANTAGONISTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Ranitidine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>150&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir AUC &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir </span><span lang=EN-GB style='font-size:
  10.0pt'>C<sub>min</sub></span><span lang=EN-GB style='font-size:10.0pt'>
  &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir </span><span lang=EN-GB style='font-size:
  10.0pt'>C<sub>max</sub></span><span lang=EN-GB style='font-size:10.0pt'>
  &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>PREZISTA co&#8209;administered
  with low dose ritonavir can be co&#8209;administered with H<sub>2</sub>&#8209;receptor
  antagonists without dose adjustments.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><a name="_Hlk45880688"><b><span
  lang=EN-GB style='font-size:10.0pt'>IMMUNOSUPPRESSANTS</span></b></a></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Ciclosporin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Sirolimus</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Tacrolimus</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Everolimus</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Exposure to these immunosuppressants will be increased when co&#8209;administered
  with PREZISTA co&#8209;administered with low dose ritonavir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Therapeutic drug
  monitoring of the immunosuppressive agent must be done when co&#8209;administration
  occurs.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant use
  of everolimus and PREZISTA co&#8209;administered with low dose ritonavir is
  not recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB style='font-size:10.0pt'>INHALED BETA AGONISTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Salmeterol</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Concomitant use of salmeterol and darunavir co&#8209;administered with low
  dose ritonavir may increase plasma concentrations of salmeterol.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant use
  of salmeterol and PREZISTA co&#8209;administered with low dose ritonavir is
  not recommended. The combination may result in increased risk of
  cardiovascular adverse event with salmeterol, including QT prolongation,
  palpitations and sinus tachycardia.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB style='font-size:10.0pt'>NARCOTIC ANALGESICS / TREATMENT OF OPIOID
  DEPENDENCE</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Methadone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>individual dose ranging from 55&nbsp;mg to
  150&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT-BR style='font-size:10.0pt'>R(&#8209;)&nbsp;methadone</span><span
  lang=PT-BR style='font-size:10.0pt'> AUC &#8595; 16%</span></p>
  <p class=MsoNormal><span lang=PT-BR style='font-size:10.0pt'>R(&#8209;)&nbsp;methadone</span><span
  lang=PT-BR style='font-size:10.0pt'> </span><span lang=PT-BR
  style='font-size:10.0pt'>C<sub>min</sub></span><span lang=PT-BR
  style='font-size:10.0pt'> &#8595; 15%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>R(&#8209;)&nbsp;methadone</span><span
  lang=EN-GB style='font-size:10.0pt'> </span><span lang=EN-GB
  style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 24%</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>No adjustment of
  methadone dosage is required when initiating co&#8209;administration with
  PREZISTA/ritonavir. However, increased methadone dose may be necessary when
  concomitantly administered for a longer period of time due to induction of
  metabolism by ritonavir. Therefore, clinical monitoring is recommended, as
  maintenance therapy may need to be adjusted in some patients.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Buprenorphine/naloxone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>8/2&nbsp;mg&#8211;16/4&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>buprenorphine
  AUC &#8595; 11%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>buprenorphine </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>buprenorphine </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 8%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>norbuprenorphine
  AUC &#8593; 46%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>norbuprenorphine
  </span><span lang=EN-GB style='font-size:10.0pt'>C<sub>min </sub></span><span
  lang=EN-GB style='font-size:10.0pt'>&#8593; </span><span lang=EN-GB
  style='font-size:10.0pt'>71%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>norbuprenorphine
  </span><span lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub> </span><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;</span><span lang=EN-GB
  style='font-size:10.0pt'> 36%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>naloxone AUC
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>naloxone C<sub>min</sub>
  ND</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>naloxone C<sub>max</sub>
  &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The clinical
  relevance of the increase in norbuprenorphine pharmacokinetic parameters has
  not been established. Dose adjustment for buprenorphine may not be necessary
  when co&#8209;administered with PREZISTA/ritonavir but a careful clinical
  monitoring for signs of opiate toxicity is recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Fentanyl</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Oxycodone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Tramadol</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Based on
  theoretical considerations boosted PREZISTA may increase plasma
  concentrations of these analgesics.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP2D6 and/or
  CYP3A inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Clinical
  monitoring is recommended when co&#8209;administering boosted </span><span
  lang=EN-GB style='font-size:10.0pt'>PREZISTA</span><span lang=EN-GB
  style='font-size:10.0pt'> with these analgesics.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>OESTROGEN&#8209;BASED</span></b><b><span lang=EN-GB
  style='font-size:10.0pt'> CONTRACEPTIVES</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Drospirenone Ethinylestradiol
  (3&nbsp;mg/0.02&nbsp;mg once daily)</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Ethinylestradiol</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Norethindrone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>35&nbsp;</span><span lang=EN-GB style='font-size:
  10.0pt;font-family:Symbol'>m</span><span lang=EN-GB style='font-size:10.0pt'>g/1&nbsp;mg
  once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied with
  darunavir/ritonavir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>ethinylestradiol
  AUC &#8595; 44%</span><sup><span lang=EN-GB>&#946;</span></sup></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>ethinylestradiol
  </span><span lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span
  lang=EN-GB style='font-size:10.0pt'> &#8595; 62%</span><sup><span lang=EN-GB>&#946;</span></sup></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>ethinylestradiol
  </span><span lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span
  lang=EN-GB style='font-size:10.0pt'> &#8595; 32%</span><sup><span lang=EN-GB>&#946;</span></sup></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>norethindrone</span><span
  lang=EN-GB style='font-size:10.0pt'> AUC &#8595; 14%</span><sup><span
  lang=EN-GB>&#946;</span></sup></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>norethindrone</span><span
  lang=EN-GB style='font-size:10.0pt'> </span><span lang=EN-GB
  style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595;</span><span lang=EN-GB style='font-size:
  10.0pt'> 30%</span><sup><span lang=EN-GB>&#946;</span></sup></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>norethindrone</span><span
  lang=EN-GB style='font-size:10.0pt'> </span><span lang=EN-GB
  style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8596;</span><sup><span lang=EN-GB>&#946;</span></sup></p>
  <p class=MsoNormal><sup><span lang=EN-GB>&#946;</span></sup><span lang=EN-GB
  style='font-size:10.0pt'> </span><span lang=EN-GB style='font-size:9.0pt'>with
  darunavir/ritonavir</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>When PREZISTA is co-administered with a
  drospirenone-containing product, clinical monitoring is recommended due to
  the potential for hyperkalaemia.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Alternative or
  additional contraceptive measures are recommended when oestrogen&#8209;based
  contraceptives are co&#8209;administered with PREZISTA and low dose
  ritonavir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Patients using
  oestrogens as hormone replacement therapy should be clinically monitored for
  signs of oestrogen deficiency.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB style='font-size:10.0pt'>OPIOID ANTAGONIST</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Naloxegol</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT-BR style='font-size:10.0pt'>Not studied.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration
  of boosted PREZISTA and naloxegol is contraindicated.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>PHOSPHODIESTERASE, TYPE 5 (PDE&#8209;5) INHIBITORS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>For the
  treatment of erectile dysfunction</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Avanafil</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Sildenafil</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Tadalafil</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Vardenafil</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>In an
  interaction study </span><sup><span lang=EN-GB>#</span></sup><span
  lang=EN-GB style='font-size:10.0pt'>, a comparable systemic exposure to
  sildenafil was observed for a single intake of 100&nbsp;mg sildenafil alone
  and a single intake of 25&nbsp;mg sildenafil co&#8209;administered with</span><span
  lang=EN-GB style='font-size:10.0pt'> PREZISTA and low dose ritonavir.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The combination
  of avanafil and PREZISTA with low dose ritonavir is contraindicated (see section
  4.3). </span><span lang=EN-GB style='font-size:10.0pt'>Concomitant use of
  other PDE&#8209;5 inhibitors for the treatment of erectile dysfunction with
  PREZISTA co&#8209;administered with low dose ritonavir should be done with
  caution. If concomitant use of PREZISTA co&#8209;administered with low dose
  ritonavir with sildenafil, vardenafil or tadalafil is indicated, sildenafil
  at a single dose not exceeding 25&nbsp;mg in 48&nbsp;hours, vardenafil at a
  single dose not exceeding 2.5&nbsp;mg in 72&nbsp;hours or tadalafil at a
  single dose not exceeding 10&nbsp;mg in 72&nbsp;hours is recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>For the
  treatment of pulmonary arterial hypertension</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Sildenafil</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Tadalafil</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Concomitant use of sildenafil or tadalafil for the treatment of pulmonary
  arterial hypertension and darunavir co&#8209;administered with low dose
  ritonavir may increase plasma concentrations of sildenafil or tadalafil.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>A safe and
  effective dose of sildenafil for the treatment of pulmonary arterial
  hypertension co&#8209;administered with PREZISTA and low dose ritonavir has
  not been established. There is an increased potential for sildenafil&#8209;associated
  adverse events (including visual disturbances, hypotension, prolonged
  erection and syncope). Therefore, co&#8209;administration of PREZISTA with
  low dose ritonavir and sildenafil when used for the treatment of pulmonary
  arterial hypertension is contraindicated (see section 4.3).</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration
  of tadalafil for the treatment of pulmonary arterial hypertension with
  PREZISTA and low dose ritonavir is not recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>PROTON PUMP INHIBITORS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Omeprazole</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>20&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir AUC &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir </span><span lang=EN-GB style='font-size:
  10.0pt'>C<sub>min</sub></span><span lang=EN-GB style='font-size:10.0pt'>
  &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir </span><span lang=EN-GB style='font-size:
  10.0pt'>C<sub>max</sub></span><span lang=EN-GB style='font-size:10.0pt'>
  &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>PREZISTA co&#8209;administered
  with low dose ritonavir can be co&#8209;administered with proton pump
  inhibitors without dose adjustments.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>SEDATIVES/HYPNOTICS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Buspirone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Clorazepate</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Diazepam</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Estazolam</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Flurazepam</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT-BR
  style='font-size:10.0pt'>Midazolam</span><span lang=PT style='font-size:10.0pt'>
  (parenteral)</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Zolpidem</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Midazolam (oral)</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Triazolam</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Sedative/hypnotics are extensively metabolised by CYP3A. Co&#8209;administration
  with PREZISTA/ritonavir may cause a large increase in the concentration of
  these medicines.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>If parenteral midazolam
  is co&#8209;administered with PREZISTA co&#8209;administered with low dose
  ritonavir it may cause a large increase in the concentration of this
  benzodiazepine. Data from concomitant use of parenteral midazolam with other
  protease inhibitors suggest a possible 3&#8209;4 fold increase in midazolam
  plasma levels.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Clinical
  monitoring is recommended when co&#8209;administering PREZISTA with these
  sedatives/hypnotics and a lower dose of the sedatives/hypnotics should be
  considered.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>If parenteral
  midazolam is co&#8209;administered with PREZISTA with low dose ritonavir, it
  should be done in an intensive care unit (ICU) or similar setting, which
  ensures close clinical monitoring and appropriate medical management in case
  of respiratory depression and/or prolonged sedation. Dose adjustment for
  midazolam should be considered, especially if more than a single dose of
  midazolam is administered.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>PREZISTA with
  low dose ritonavir with triazolam or oral midazolam is contraindicated (see
  section 4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>TREATMENT FOR PREMATURE EJACULATION</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Dapoxetine</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. </span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co-administration
  of boosted PREZISTA with dapoxetine is contraindicated.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>UROLOGICAL DRUGS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Fesoterodine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Solifenacin</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. </span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Use with caution.
  Monitor for fesoterodine or solifenacin adverse reactions, dose reduction of
  fesoterodine or solifenacin may be necessary.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:none;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><b><sup><span
  lang=EN-GB>#</span></sup></b><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Studies have been performed at lower than
  recommended doses of darunavir or with a different dosing regimen (see
  section 4.2 Posology).</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><b><sup><span
  lang=EN-GB>&#8224;</span></sup></b><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>The efficacy and safety of the use of
  PREZISTA with 100&nbsp;mg ritonavir and any other HIV PI (e.g.
  (fos)amprenavir and tipranavir) has not been established in HIV patients.
  According to current treatment guidelines, dual therapy with protease
  inhibitors is generally not recommended.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>&#8225;</span></sup><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Study was conducted with tenofovir
  disoproxil fumarate 300&nbsp;mg once daily.</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility,
pregnancy and lactation</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal><span lang=EN-GB>As a general rule, when deciding to use
antiretroviral agents for the treatment of HIV infection in pregnant women and
consequently for reducing the risk of HIV vertical transmission to the newborn,
the animal data as well as the clinical experience in pregnant women should be
taken into account.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There are no adequate and well controlled
studies on pregnancy outcome with darunavir in pregnant women. Studies in
animals do not indicate direct harmful effects with respect to pregnancy,
embryonal/foetal development, parturition or postnatal development (see section
5.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA co&#8209;administered with low
dose ritonavir should be used during pregnancy only if the potential benefit
justifies the potential risk.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Breast&#8209;feeding</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>It is not known
whether darunavir is excreted in human milk. Studies in rats have demonstrated
that darunavir is excreted in milk and at high levels (1,000&nbsp;mg/kg/day)
resulted in toxicity. Because of both the potential for HIV transmission and
the potential for adverse reactions in breast&#8209;fed infants, mothers should
be instructed not to breast&#8209;feed under any circumstances if they are
receiving PREZISTA.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal><span lang=EN-GB>No human data on the effect of darunavir on
fertility are available. There was no effect on mating or fertility with
darunavir treatment in rats (see section 5.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects
on ability to drive and use machines</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA in combination with ritonavir has
no or negligible influence on the ability to drive and use machines. However,
dizziness has been reported in some patients during treatment with regimens
containing PREZISTA co&#8209;administered with low dose ritonavir and should be
borne in mind when considering a patient&#8217;s ability to drive or operate
machinery (see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable
effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="OLE_LINK3"><span
lang=EN-GB>&nbsp;</span></a></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Summary
of the safety profile</span></u></p>

<p class=MsoNormal><span lang=EN-GB>During the clinical development program
(N=2,613 treatment&#8209;experienced subjects who initiated therapy with
PREZISTA/ritonavir 600/100&nbsp;mg twice daily), 51.3% of subjects experienced
at least one adverse reaction. The total mean treatment duration for subjects
was 95.3&nbsp;weeks. The most frequent adverse reactions reported in clinical
trials and as spontaneous reports are diarrhoea, nausea, rash, headache and
vomiting. The most frequent serious reactions are acute renal failure,
myocardial infarction, immune reconstitution inflammatory syndrome,
thrombocytopenia, osteonecrosis, diarrhoea, hepatitis and pyrexia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the 96&nbsp;week analysis, the safety
profile of PREZISTA/ritonavir 800/100&nbsp;mg once daily in treatment&#8209;na&iuml;ve
subjects was similar to that seen with PREZISTA/ritonavir 600/100&nbsp;mg twice
daily in treatment&#8209;experienced subjects except for nausea which was
observed more frequently in treatment&#8209;na&iuml;ve subjects. This was
driven by mild intensity nausea. No new safety findings were identified in the
192&nbsp;week analysis of the treatment&#8209;na&iuml;ve subjects in which the
mean treatment duration of PREZISTA/ritonavir 800/100&nbsp;mg once daily was
162.5&nbsp;weeks.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Adverse reactions are listed by system
organ class (SOC) and frequency category. Within each frequency category,
adverse reactions are presented in order of decreasing seriousness. Frequency
categories are defined as follows: very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100
to &lt;&nbsp;1/10), uncommon (&#8805;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare
(&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000) and not known (frequency cannot be
estimated from the available data).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Adverse
reactions observed with darunavir/ritonavir in clinical trials and post&#8209;marketing</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>MedDRA system
  organ class</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Frequency
  category</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Adverse
  reaction</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Infections
  and infestations</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>herpes simplex</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Blood
  and lymphatic system disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>thrombocytopenia, neutropenia, anaemia,
  leukopenia</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>increased eosinophil count</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Immune
  system disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>immune reconstitution inflammatory syndrome,
  (drug) hypersensitivity</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Endocrine
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>hypothyroidism, increased blood thyroid
  stimulating hormone</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
  lang=EN-GB>Metabolism and nutrition disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>diabetes mellitus, hypertriglyceridaemia,
  hypercholesterolaemia, hyperlipidaemia</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>gout, anorexia, decreased appetite,
  decreased weight, increased weight, hyperglycaemia, insulin resistance,
  decreased high density lipoprotein, increased appetite, polydipsia, increased
  blood lactate dehydrogenase</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Psychiatric
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>insomnia</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon </span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>depression, disorientation, anxiety,
  sleep disorder, abnormal dreams, nightmare, decreased libido</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>confusional state, altered mood,
  restlessness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Nervous
  system disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>headache, peripheral neuropathy,
  dizziness</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>lethargy, paraesthesia, hypoaesthesia,
  dysgeusia, disturbance in attention, memory impairment, somnolence</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>syncope, convulsion, ageusia, sleep phase
  rhythm disturbance</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Eye
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>conjunctival hyperaemia, dry eye</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>visual disturbance</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Ear and
  labyrinth disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>vertigo</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Cardiac
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>myocardial
  infarction, angina pectoris, prolonged electrocardiogram QT, tachycardia</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>acute myocardial infarction, sinus
  bradycardia, palpitations</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Vascular
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>hypertension, flushing</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Respiratory,
  thoracic and mediastinal disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>dyspnoea, cough, epistaxis, throat
  irritation</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rhinorrhoea</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Gastrointestinal
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>very common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>diarrhoea</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>vomiting, nausea, abdominal pain,
  increased blood amylase, dyspepsia, abdominal distension, flatulence</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>pancreatitis, gastritis,
  gastrooesophageal reflux disease, aphthous stomatitis, retching, dry mouth,
  abdominal discomfort, constipation, increased lipase, eructation, oral
  dysaesthesia</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>stomatitis, haematemesis, cheilitis, dry
  lip, coated tongue</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Hepatobiliary
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>increased alanine aminotransferase</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>hepatitis, cytolytic hepatitis, hepatic
  steatosis, hepatomegaly, increased transaminase, increased aspartate
  aminotransferase, increased blood bilirubin, increased blood alkaline
  phosphatase, increased gamma&#8209;glutamyltransferase</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
  lang=EN-GB>Skin and subcutaneous tissue disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rash (including macular, maculopapular,
  papular, erythematous and pruritic rash), pruritus</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>angioedema, generalised rash, allergic
  dermatitis, urticaria, eczema, erythema, hyperhidrosis, night sweats,
  alopecia, acne, dry skin, nail pigmentation</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>DRESS, Stevens&#8209;Johnson syndrome,
  erythema multiforme, dermatitis, seborrhoeic dermatitis, skin lesion,
  xeroderma</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>not known</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>toxic epidermal necrolysis, acute
  generalised exanthematous pustulosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Musculoskeletal
  and connective tissue disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>myalgia, osteonecrosis, muscle spasms,
  muscular weakness, arthralgia, pain in extremity, osteoporosis, increased
  blood creatine phosphokinase</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>musculoskeletal stiffness, arthritis,
  joint stiffness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Renal
  and urinary disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>acute renal failure, renal failure,
  nephrolithiasis, increased blood creatinine, proteinuria, bilirubinuria,
  dysuria, nocturia, pollakiuria</span></p>
  <p class=MsoNormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>decreased creatinine renal clearance</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Reproductive
  system and breast disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>erectile dysfunction, gynaecomastia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>General
  disorders and administration site conditions</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>asthenia, fatigue</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>pyrexia, chest pain, peripheral oedema,
  malaise, feeling hot, irritability, pain</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>chills, abnormal feeling, xerosis</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Description
of selected adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Rash</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In clinical trials, rash was mostly mild to
moderate, often occurring within the first four weeks of treatment and
resolving with continued dosing. In cases of severe skin reaction see the
warning in section 4.4.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>During the clinical development program of
raltegravir in treatment&#8209;experienced patients, rash, irrespective of
causality, was more commonly observed with regimens containing PREZISTA/ritonavir
+ raltegravir compared to those containing PREZISTA/ritonavir without
raltegravir or raltegravir without PREZISTA/ritonavir. Rash considered by the
investigator to be drug&#8209;related occurred at similar rates. The exposure&#8209;adjusted
rates of rash (all causality) were 10.9, 4.2, and 3.8 per 100&nbsp;patient&#8209;years
(PYR), respectively; and for drug&#8209;related rash were 2.4, 1.1, and 2.3 per
100&nbsp;PYR, respectively. The rashes observed in clinical studies were mild
to moderate in severity and did not result in discontinuation of therapy (see
section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Metabolic
parameters</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Weight and levels of blood lipids and
glucose may increase during antiretroviral therapy (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Musculoskeletal
abnormalities</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Increased CPK, myalgia, myositis and
rarely, rhabdomyolysis have been reported with the use of protease inhibitors,
particularly in combination with NRTIs.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Cases of osteonecrosis have been reported,
particularly in patients with generally acknowledged risk factors, advanced HIV
disease or long&#8209;term exposure to combination antiretroviral therapy
(CART). The frequency of this is unknown (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Immune
reconstitution </span></i><i><span lang=EN-GB>inflammatory syndrome</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In HIV infected patients with severe immune
deficiency at the time of initiation of combination antiretroviral therapy
(CART), an inflammatory reaction to asymptomatic or residual opportunistic
infections may arise. Autoimmune disorders (such as Graves' disease and
autoimmune hepatitis) have also been reported; however, the reported time to
onset is more variable and these events can occur many months after initiation
of treatment (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Bleeding
in haemophiliac patients</span></i></p>

<p class=MsoNormal><span lang=EN-GB>There have been reports of increased
spontaneous bleeding in haemophiliac patients receiving antiretroviral protease
inhibitors (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The safety
assessment in paediatric patients is based on the 48&#8209;week analysis of
safety data from three Phase&nbsp;II trials. The following patient populations
were evaluated (see section 5.1):</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>80&nbsp;ART&#8209;experienced HIV&#8209;1
infected paediatric patients aged from 6 to 17&nbsp;years and weighing at least
20&nbsp;kg who received PREZISTA tablets with low dose ritonavir twice daily in
combination with other antiretroviral agents.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>21&nbsp;ART&#8209;experienced HIV&#8209;1
infected paediatric patients aged from 3 to &lt;&nbsp;6&nbsp;years and weighing
10&nbsp;kg to &lt;&nbsp;20&nbsp;kg (16&nbsp;participants from 15&nbsp;kg to
&lt;&nbsp;20&nbsp;kg) who received PREZISTA oral suspension with low dose
ritonavir twice daily in combination with other antiretroviral agents.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>12&nbsp;ART&#8209;na&iuml;ve HIV&#8209;1
infected paediatric patients aged from 12 to 17&nbsp;years and weighing at
least 40&nbsp;kg who received PREZISTA tablets with low dose ritonavir once
daily in combination with other antiretroviral agents (see section 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Overall, the safety profile in these paediatric
patients was similar to that observed in the adult population.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Other special populations</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB>Patients co&#8209;infected with hepatitis&nbsp;B and/or
hepatitis&nbsp;C virus</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Among 1,968&nbsp;treatment&#8209;experienced
patients receiving PREZISTA co&#8209;administered with ritonavir
600/100&nbsp;mg twice daily, 236&nbsp;patients were co&#8209;infected with
hepatitis&nbsp;B or C. Co&#8209;infected patients were more likely to have
baseline and treatment emergent hepatic transaminase elevations than those
without chronic viral hepatitis (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:silver'>the national reporting
system listed in </span></span><span lang=EN-GB style='background:silver'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix&nbsp;V</a></span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Human experience of acute overdose with
PREZISTA co&#8209;administered with low dose ritonavir is limited. Single doses
up to 3,200&nbsp;mg of darunavir as oral solution alone and up to 1,600&nbsp;mg
of the tablet formulation of darunavir in combination with ritonavir have been
administered to healthy volunteers without untoward symptomatic effects.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There is no specific antidote for overdose
with PREZISTA. Treatment of overdose with PREZISTA consists of general
supportive measures including monitoring of vital signs and observation of the
clinical status of the patient. Since darunavir is highly protein bound,
dialysis is unlikely to be beneficial in significant removal of the active
substance.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pharmacotherapeutic group: Antivirals for
systemic use, protease inhibitors, ATC code: J05AE10.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Mechanism
of action</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Darunavir is an
inhibitor of the dimerisation and of the catalytic activity of the HIV&#8209;1
protease (K<sub>D</sub>&nbsp;of&nbsp;4.5&nbsp;x&nbsp;10<sup>-12</sup>M). It
selectively inhibits the cleavage of HIV encoded Gag&#8209;Pol polyproteins in
virus infected cells, thereby preventing the formation of mature infectious
virus particles.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Antiviral
activity <i>in vitro</i></span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Darunavir
exhibits activity against laboratory strains and clinical isolates of HIV&#8209;1
and laboratory strains of HIV&#8209;2 in acutely infected T&#8209;cell lines,
human peripheral blood mononuclear cells and human monocytes/macrophages with
median EC</span><sub><span lang=EN-GB>50</span></sub><span lang=EN-GB>&nbsp;values
ranging from 1.2 to 8.5&nbsp;nM (0.7 to 5.0&nbsp;ng/ml). Darunavir demonstrates
antiviral activity </span><i><span lang=EN-GB>in vitro</span></i><span
lang=EN-GB> against a broad panel of HIV&#8209;1 group M (A, B, C, D, E, F, G)
and group O primary isolates with EC</span><sub><span lang=EN-GB>50</span></sub><span
lang=EN-GB>&nbsp;values ranging from &lt;&nbsp;0.1 to 4.3&nbsp;nM.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>These EC</span><sub><span
lang=EN-GB>50</span></sub><span lang=EN-GB>&nbsp;values are well below the 50%
cellular toxicity concentration range of 87&nbsp;&micro;M to
&gt;&nbsp;100&nbsp;&micro;M.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Resistance</span></u></p>

<p class=MsoNormal style='text-autospace:none'><a name="OLE_LINK5"><i><span
lang=EN-GB>In vitro</span></i><span lang=EN-GB> selection of darunavir&#8209;resistant
virus from wild type HIV&#8209;1 was lengthy (&gt;&nbsp;3&nbsp;years). The
selected viruses were unable to grow in the presence of darunavir
concentrations above 400&nbsp;nM. Viruses selected in these conditions and
showing decreased susceptibility to darunavir (range: 23&#8209;50&#8209;fold)
harboured 2 to 4&nbsp;amino acid substitutions in the protease gene. The
decreased susceptibility to darunavir of the emerging viruses in the selection
experiment could not be explained by the emergence of these protease mutations.</span></a></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The clinical trial data from ART&#8209;experienced
patients (<i>TITAN</i> trial and the pooled analysis of the <i>POWER</i>&nbsp;1,
2 and 3 and <i>DUET</i>&nbsp;1 and 2 trials) showed that virologic response to
PREZISTA co&#8209;administered with low dose ritonavir was decreased when 3 or
more darunavir RAMs (V11I, V32I, L33F, I47V, I50V, I54L or M, T74P, L76V, I84V
and L89V) were present at baseline or when these mutations developed during
treatment.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Increasing baseline darunavir fold change
in EC<sub>50</sub> (FC) was associated with decreasing virologic response. A
lower and upper clinical cut&#8209;off of 10 and 40 were identified. Isolates
with baseline FC &#8804;&nbsp;10 are susceptible; isolates with FC &gt;&nbsp;10
to 40 have decreased susceptibility; isolates with FC &gt;&nbsp;40 are resistant
(see Clinical results).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Viruses
isolated from patients on PREZISTA/ritonavir 600/100&nbsp;mg twice daily
experiencing virologic failure by rebound that were susceptible to tipranavir
at baseline remained susceptible to tipranavir after treatment in the vast
majority of cases.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The lowest rates of developing resistant
HIV virus are observed in ART&#8209;na&iuml;ve patients who are treated for the
first time with darunavir in combination with other ART.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The table
below shows the development of HIV&#8209;1 protease mutations and loss of
susceptibility to PIs in virologic failures at endpoint in the <i>ARTEMIS</i>, <i>ODIN</i>
and <i>TITAN</i> trials.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>ARTEMIS</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Week 192</span></p>
  </td>
  <td width=237 colspan=2 valign=top style='width:177.45pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>ODIN</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Week 48</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>TITAN</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Week 48</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>PREZISTA/ ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>800/100&nbsp;mg</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>once daily</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N=343</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>PREZISTA/ ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>800/100&nbsp;mg</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>once daily</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N=294</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>PREZISTA/ ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>600/100&nbsp;mg</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>twice daily</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>N=296</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>PREZISTA/ ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>600/100&nbsp;mg</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>twice daily</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>N=298</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Total number of virologic failures</span><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:10.0pt'>, n (%)</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>55&nbsp;(16.0%)</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>65&nbsp;(22.1%)</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>54&nbsp;(18.2%)</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>31&nbsp;(10.4%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>Rebounders</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>39&nbsp;(11.4%)</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>11&nbsp;(3.7%)</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>11&nbsp;(3.7%)</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>16&nbsp;(5.4%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>Never suppressed subjects</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>16&nbsp;(4.7%)</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>54&nbsp;(18.4%)</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>43&nbsp;(14.5%)</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>15&nbsp;(5.0%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=618 colspan=5 valign=top style='width:463.8pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Number of subjects with virologic failure and paired
  baseline/endpoint genotypes, developing mutations</span><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:10.0pt'> at
  endpoint, n/N</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>Primary (major) PI mutations</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/43</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1/60</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/42</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>6/28</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>PI RAMs</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>4/43</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>7/60</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>4/42</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>10/28</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=618 colspan=5 valign=top style='width:463.8pt;border-top:none;
  border-left:solid black 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Number of subjects with virologic failure and paired
  baseline/endpoint phenotypes, showing loss of susceptibility to PIs at
  endpoint compared to baseline, n/N</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>PI</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>darunavir</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/39</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1/58</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/41</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>3/26</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>amprenavir</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/39</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1/58</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/40</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/22</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>atazanavir</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/39</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>2/56</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/40</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/22</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>indinavir</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/39</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>2/57</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/40</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1/24</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>lopinavir</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/39</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1/58</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/40</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/23</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>saquinavir</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/39</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/56</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/40</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/22</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>tipranavir</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/39</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/58</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/41</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1/25</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=618 colspan=5 valign=top style='width:463.8pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; TLOVR
  non&#8209;VF censored algorithm based on HIV&#8209;1 RNA
  &lt;&nbsp;50&nbsp;copies/ml, except for <i>TITAN</i> (HIV&#8209;1 RNA
  &lt;&nbsp;400&nbsp;copies/ml)</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>b</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=EN-GB
  style='font-size:9.0pt'>IAS&#8209;USA lists</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Cross&#8209;resistance</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir FC was less than 10 for 90% of
3,309&nbsp;clinical isolates resistant to amprenavir, atazanavir, indinavir,
lopinavir, nelfinavir, ritonavir, saquinavir and/or tipranavir showing that
viruses resistant to most PIs remain susceptible to darunavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the virologic failures of the <i>ARTEMIS</i>
trial no cross&#8209;resistance with other PIs was observed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Clinical
results</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Adult
patients</span></u></p>

<p class=MsoNormal><span lang=EN-GB>For clinical trial results in ART&#8209;na&iuml;ve
adult patients, refer to the Summary of Product Characteristics for PREZISTA
400&nbsp;mg and 800&nbsp;mg tablets or 100&nbsp;mg/ml oral suspension.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Efficacy
of PREZISTA 600&nbsp;mg twice daily co</span></u></i><u><span lang=EN-GB>&#8209;<i>administered
with 100&nbsp;mg ritonavir twice daily in ART&#8209;experienced patients</i></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The evidence of efficacy of PREZISTA co&#8209;administered
with ritonavir (600/100&nbsp;mg twice daily) in ART&#8209;experienced patients
is based on the 96&nbsp;weeks analysis of the Phase&nbsp;III trial <i>TITAN</i>
in ART&#8209;experienced lopinavir na&iuml;ve patients, on the 48&nbsp;week
analysis of the Phase&nbsp;III trial <i>ODIN</i> in ART&#8209;experienced
patients with no DRV&#8209;RAMs, and on the analyses of 96&nbsp;weeks data from
the Phase&nbsp;IIb trials <i>POWER</i>&nbsp;1 and 2 in ART&#8209;experienced
patients with high level of PI resistance.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>TITAN</span></i></b><span lang=EN-GB>
is a randomised, controlled, open&#8209;label Phase&nbsp;III trial comparing
PREZISTA co&#8209;administered with ritonavir (600/100&nbsp;mg twice daily)
versus lopinavir/ritonavir (400/100&nbsp;mg twice daily) in ART&#8209;experienced,
lopinavir na&iuml;ve HIV&#8209;1 infected adult patients. Both arms used an
Optimised Background Regimen (OBR) consisting of at least
2&nbsp;antiretrovirals (NRTIs with or without NNRTIs).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The table
below shows the efficacy data of the 48&nbsp;week analysis from the <i>TITAN</i>
trial.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=4 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>TITAN</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="18%" valign=top style='width:18.64%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Outcomes</span></p>
  </td>
  <td width="27%" valign=top style='width:27.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=PT style='font-size:10.0pt'>PREZISTA/ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=PT style='font-size:10.0pt'>600/100&nbsp;mg
  twice daily + OBR</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=PT style='font-size:10.0pt'>N=298</span></p>
  </td>
  <td width="27%" valign=top style='width:27.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span style='font-size:10.0pt'>Lopinavir/ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span style='font-size:10.0pt'>400/100&nbsp;mg twice
  daily + OBR</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=PT style='font-size:10.0pt'>N=297</span></p>
  </td>
  <td width="27%" valign=top style='width:27.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>Treatment
  difference</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>(95% CI
  of difference)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="18%" valign=top style='width:18.64%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>HIV&#8209;1&nbsp;RNA
  &lt;&nbsp;50&nbsp;copies/ml</span><sup><span lang=EN-GB>a</span></sup></p>
  </td>
  <td width="27%" valign=top style='width:27.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>70.8% (211)</span></p>
  </td>
  <td width="27%" valign=top style='width:27.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>60.3% (179)</span></p>
  </td>
  <td width="27%" valign=top style='width:27.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>10.5% (2.9; 18.1)</span><sup><span lang=EN-GB>b</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="18%" valign=top style='width:18.64%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>median
  CD4+&nbsp;cell count change from baseline (x&nbsp;10</span><sup><span
  lang=EN-GB>6</span></sup><span lang=EN-GB style='font-size:10.0pt'>/L)</span><sup><span
  lang=EN-GB>c</span></sup></p>
  </td>
  <td width="27%" valign=top style='width:27.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>88</span></p>
  </td>
  <td width="27%" valign=top style='width:27.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>81</span></p>
  </td>
  <td width="27%" valign=top style='width:27.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=4 valign=top style='width:100.0%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Imputations according to the TLOVR
  algorithm</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Based
  on a normal approximation of the difference in % response</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>c</span></sup><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>NC=F</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>At 48&nbsp;weeks non&#8209;inferiority in
virologic response to the PREZISTA/ritonavir treatment, defined as the
percentage of patients with plasma HIV&#8209;1 RNA level &lt;&nbsp;400 and
&lt;&nbsp;50&nbsp;copies/ml, was demonstrated (at the pre&#8209;defined 12% non&#8209;inferiority
margin) for both ITT and OP populations. These results were confirmed in the
analysis of data at 96&nbsp;weeks of treatment in the <i>TITAN</i> trial, with
60.4% of patients in the PREZISTA/ritonavir arm having HIV&#8209;1 RNA
&lt;&nbsp;50&nbsp;copies/ml at week&nbsp;96 compared to 55.2% in the lopinavir/ritonavir
arm [difference: 5.2%, 95%&nbsp;CI (&#8209;2.8; 13.1)].</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal><b><i><span lang=EN-GB>ODIN</span></i></b><span lang=EN-GB>
is a Phase&nbsp;III, randomised, open&#8209;label trial comparing PREZISTA/ritonavir
800/100&nbsp;mg once daily versus PREZISTA/ritonavir 600/100&nbsp;mg twice
daily in ART&#8209;experienced HIV&#8209;1 infected patients with screening
genotype resistance testing showing no darunavir RAMs (i.e. V11I, V32I, L33F,
I47V, I50V, I54M, I54L, T74P, L76V, I84V, L89V) and a screening HIV&#8209;1 RNA
&gt;&nbsp;1,000&nbsp;copies/ml. Efficacy analysis is based on 48&nbsp;weeks of
treatment (see table below). Both arms used an optimised background regimen
(OBR) of &#8805;&nbsp;2&nbsp;NRTIs.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=4 valign=top style='width:464.35pt;border:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>ODIN</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
  style='font-size:10.0pt'>Outcomes</span></i></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT style='font-size:10.0pt'>PREZISTA/ritonavir 800/100&nbsp;mg
  once daily + OBR</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT style='font-size:10.0pt'>N=294</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT style='font-size:10.0pt'>PREZISTA/ritonavir 600/100&nbsp;mg
  twice daily + OBR</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT style='font-size:10.0pt'>N=296</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Treatment difference</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(95% CI of difference)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.05pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>HIV&#8209;1&nbsp;RNA &lt;&nbsp;50&nbsp;copies/ml</span><sup><span
  lang=EN-GB>a</span></sup></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>72.1% (212)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>70.9% (210)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>1.2% (&#8209;6.1; 8.5)</span><sup><span
  lang=EN-GB>b</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.05pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>With Baseline HIV&#8209;1 RNA (copies/ml)</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;&lt;&nbsp;100,000</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8805;&nbsp;100,000</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>77.6% (198/255)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>35.9% (14/39)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>73.2% (194/265)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>51.6% (16/31)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>4.4% (&#8209;3.0; 11.9)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&#8209;15.7% (&#8209;39.2;
  7.7)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.05pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>With Baseline CD4+ cell count (x 10</span><sup><span
  lang=EN-GB>6</span></sup><span lang=EN-GB style='font-size:10.0pt'>/L)</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8805;&nbsp;100</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&lt;&nbsp;100</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>75.1% (184/245)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>57.1% (28/49)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>72.5% (187/258)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>60.5% (23/38)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>2.6% (&#8209;5.1; 10.3)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&#8209;3.4% (&#8209;24.5;
  17.8)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>With HIV&#8209;1 clade</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Type B</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Type AE</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Type C</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Other</span><sup><span lang=EN-GB>c</span></sup></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>70.4% (126/179)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>90.5% (38/42)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>72.7% (32/44)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>55.2% (16/29)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>64.3% (128/199)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>91.2% (31/34)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>78.8% (26/33)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>83.3% (25/30)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>6.1% (&#8209;3.4; 15.6)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&#8209;0.7% (&#8209;14.0;
  12.6)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&#8209;6.1% (&#8209;2.6;
  13.7)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&#8209;28.2% (&#8209;51.0; &#8209;5.3)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>mean CD4+ cell count change from baseline</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>(x 10</span><sup><span lang=EN-GB>6</span></sup><span
  lang=EN-GB style='font-size:10.0pt'>/L)</span><sup><span lang=EN-GB>e</span></sup></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>108</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>112</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&#8209;5</span><sup><span
  lang=EN-GB>d </span></sup><span lang=EN-GB style='font-size:10.0pt'>(&#8209;25;
  16)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=4 valign=top style='width:464.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Imputations according to the TLOVR
  algorithm</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;page-break-after:
  avoid'><sup><span lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:
  10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=EN-GB style='font-size:
  9.0pt'>Based on a normal approximation of the difference in % response</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;page-break-after:
  avoid'><sup><span lang=EN-GB>c</span></sup><span lang=EN-GB style='font-size:
  10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=EN-GB style='font-size:
  9.0pt'>Clades A1, D, F1, G, K, CRF02_AG, CRF12_BF, and CRF06_CPX</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;page-break-after:
  avoid'><sup><span lang=EN-GB>d</span></sup><span lang=EN-GB style='font-size:
  10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=EN-GB style='font-size:
  9.0pt'>Difference in means</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;page-break-after:
  avoid'><sup><span lang=EN-GB>e</span></sup><span lang=EN-GB style='font-size:
  10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=EN-GB style='font-size:
  9.0pt'>Last Observation Carried Forward imputation</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>At 48&nbsp;weeks, virologic response,
defined as the percentage of patients with plasma HIV&#8209;1 RNA level
&lt;&nbsp;50&nbsp;copies/ml, with PREZISTA/ritonavir 800/100&nbsp;mg once daily
treatment was demonstrated to be non&#8209;inferior (at the pre&#8209;defined
12% non&#8209;inferiority margin) compared to PREZISTA/ritonavir
600/100&nbsp;mg twice daily for both ITT and OP populations.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA/ritonavir 800/100&nbsp;mg once
daily in ART&#8209;experienced patients should not be used in patients with one
or more darunavir resistance associated mutations (DRV&#8209;RAMs) or HIV&#8209;1
RNA &#8805;&nbsp;100,000&nbsp;copies/ml or CD4+ cell count &lt;&nbsp;100&nbsp;cells&nbsp;x&nbsp;10<sup>6</sup>/L
(see section 4.2 and 4.4). Limited data is available in patients with HIV&#8209;1
clades other than B.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>POWER&nbsp;1</span></i></b><i><span
lang=EN-GB> and <b>POWER&nbsp;2</b></span></i><span lang=EN-GB> are randomised,
controlled trials comparing PREZISTA co&#8209;administered with ritonavir
(600/100&nbsp;mg twice daily) with a control group receiving an investigator&#8209;selected
PI(s) regimen in HIV&#8209;1 infected patients who had previously failed more
than 1&nbsp;PI containing regimen. An OBR consisting of at least 2&nbsp;NRTIs
with or without enfuvirtide (ENF) was used in both trials.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The table
below shows the efficacy data of the 48&#8209;week and 96&#8209;week analyses
from the pooled <i>POWER</i>&nbsp;1 and <i>POWER</i>&nbsp;2 trials.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=618 colspan=7 valign=top style='width:463.85pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>POWER&nbsp;1 and
  POWER&nbsp;2 pooled data</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=117 valign=top style='width:88.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></i></p>
  </td>
  <td width=259 colspan=3 valign=top style='width:193.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Week 48</span></p>
  </td>
  <td width=243 colspan=3 valign=top style='width:181.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Week 96</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=117 valign=top style='width:88.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
  style='font-size:10.0pt'>Outcomes</span></i></p>
  </td>
  <td width=97 valign=top style='width:72.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT style='font-size:10.0pt'>PREZISTA/ ritonavir 600/100&nbsp;mg
  twice daily n=131</span></p>
  </td>
  <td width=57 valign=top style='width:43.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Control n=124</span></p>
  </td>
  <td width=104 valign=top style='width:78.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Treatment difference</span></p>
  </td>
  <td width=96 valign=top style='width:72.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT style='font-size:10.0pt'>PREZISTA/ ritonavir 600/100&nbsp;mg
  twice daily n=131</span></p>
  </td>
  <td width=57 valign=top style='width:42.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Control n=124</span></p>
  </td>
  <td width=90 valign=top style='width:67.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Treatment difference</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=117 valign=top style='width:88.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>HIV&nbsp;RNA
  &lt;&nbsp;50&nbsp;copies/ml</span><sup><span lang=EN-GB>a</span></sup></p>
  </td>
  <td width=97 valign=top style='width:72.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>45.0%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(59)</span></p>
  </td>
  <td width=57 valign=top style='width:43.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>11.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(14)</span></p>
  </td>
  <td width=104 valign=top style='width:78.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>33.7%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(23.4%; 44.1%)</span><sup><span lang=EN-GB>c</span></sup></p>
  </td>
  <td width=96 valign=top style='width:72.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>38.9%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(51)</span></p>
  </td>
  <td width=57 valign=top style='width:42.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>8.9%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(11)</span></p>
  </td>
  <td width=90 valign=top style='width:67.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>30.1%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(20.1; 40.0)</span><sup><span lang=EN-GB>c</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=117 valign=top style='width:88.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>CD4+&nbsp;cell
  count</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>mean change from
  baseline (x 10</span><sup><span lang=EN-GB>6</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>/L)</span><sup><span lang=EN-GB>b</span></sup></p>
  </td>
  <td width=97 valign=top style='width:72.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>103</span></p>
  </td>
  <td width=57 valign=top style='width:43.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>17</span></p>
  </td>
  <td width=104 valign=top style='width:78.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>86</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(57; 114)</span><sup><span lang=EN-GB>c</span></sup></p>
  </td>
  <td width=96 valign=top style='width:72.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>133</span></p>
  </td>
  <td width=57 valign=top style='width:42.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>15</span></p>
  </td>
  <td width=90 valign=top style='width:67.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>118</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(83.9; 153.4)</span><sup><span lang=EN-GB>c</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=618 colspan=7 valign=top style='width:463.85pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Imputations according to the TLOVR
  algorithm</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Last Observation Carried Forward
  imputation</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>c</span></sup><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>95% confidence intervals.</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Analyses of data through 96&nbsp;weeks of
treatment in the <i>POWER</i> trials demonstrated sustained antiretroviral
efficacy and immunologic benefit.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Out of the 59&nbsp;patients who responded
with complete viral suppression (&lt;&nbsp;50&nbsp;copies/ml) at week&nbsp;48,
47&nbsp;patients (80% of the responders at week&nbsp;48) remained responders at
week&nbsp;96.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Baseline
genotype or phenotype and virologic outcome</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Baseline genotype and darunavir FC (shift
in susceptibility relative to reference) were shown to be a predictive factor
of virologic outcome.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Proportion
(%) of patients with response (HIV&#8209;1 RNA &lt;&nbsp;50&nbsp;copies/ml at
week 24) to PREZISTA co&#8209;administered with ritonavir (600/100&nbsp;mg twice
daily) by baseline genotype<sup>a</sup>, and baseline darunavir FC and by use
of enfuvirtide (ENF): As treated analysis of the POWER and DUET trials.</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=126 valign=top style='width:94.3pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=247 colspan=4 valign=top style='width:185.15pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Number of baseline
  mutations</span></b><b><sup><span lang=EN-GB>a</span></sup></b></p>
  </td>
  <td width=247 colspan=4 valign=top style='width:185.2pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Baseline DRV FC</span></b><b><sup><span
  lang=EN-GB>b</span></sup></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=126 style='width:94.3pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Response (HIV&#8209;1 RNA
  &lt;&nbsp;50&nbsp;copies/ml at week 24)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>%, n/N</span></p>
  </td>
  <td width=70 style='width:52.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>All ranges</span></b></p>
  </td>
  <td width=60 style='width:45.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>0&#8209;2</span></b></p>
  </td>
  <td width=54 style='width:40.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>3</span></b></p>
  </td>
  <td width=62 style='width:46.3pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>&#8805;&nbsp;4</span></b></p>
  </td>
  <td width=69 style='width:52.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>All ranges</span></b></p>
  </td>
  <td width=61 style='width:45.6pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>&#8804;&nbsp;10</span></b></p>
  </td>
  <td width=55 style='width:41.3pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>10&#8209;40</span></b></p>
  </td>
  <td width=62 style='width:46.3pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>&gt;&nbsp;40</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=126 style='width:94.3pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>All patients</span></p>
  </td>
  <td width=70 valign=top style='width:52.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>45%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>455/1,014</span></p>
  </td>
  <td width=60 valign=top style='width:45.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>54%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>359/660</span></p>
  </td>
  <td width=54 valign=top style='width:40.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>39%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>67/172</span></p>
  </td>
  <td width=62 valign=top style='width:46.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>12%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>20/171</span></p>
  </td>
  <td width=69 valign=top style='width:52.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>45%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>455/1,014</span></p>
  </td>
  <td width=61 valign=top style='width:45.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>55%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>364/659</span></p>
  </td>
  <td width=55 valign=top style='width:41.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>29%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>59/203</span></p>
  </td>
  <td width=62 valign=top style='width:46.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>8%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>9/118</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=126 style='width:94.3pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Patients with
  no/non&#8209;na&iuml;ve use of ENF</span><sup><span lang=EN-GB>c</span></sup></p>
  </td>
  <td width=70 style='width:52.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>39%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>290/741</span></p>
  </td>
  <td width=60 style='width:45.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>50%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>238/477</span></p>
  </td>
  <td width=54 style='width:40.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>29%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>35/120</span></p>
  </td>
  <td width=62 style='width:46.3pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>7%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>10/135</span></p>
  </td>
  <td width=69 style='width:52.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>39%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>290/741</span></p>
  </td>
  <td width=61 style='width:45.6pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>51%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>244/477</span></p>
  </td>
  <td width=55 style='width:41.3pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>17%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>25/147</span></p>
  </td>
  <td width=62 style='width:46.3pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>5%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>5/94</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=126 style='width:94.3pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Patients with
  na&iuml;ve use of ENF</span><sup><span lang=EN-GB>d</span></sup></p>
  </td>
  <td width=70 valign=top style='width:52.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>60%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>165/273</span></p>
  </td>
  <td width=60 valign=top style='width:45.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>66%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>121/183</span></p>
  </td>
  <td width=54 valign=top style='width:40.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>62%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>32/52</span></p>
  </td>
  <td width=62 valign=top style='width:46.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>28%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>10/36</span></p>
  </td>
  <td width=69 valign=top style='width:52.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>60%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>165/273</span></p>
  </td>
  <td width=61 valign=top style='width:45.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>66%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>120/182</span></p>
  </td>
  <td width=55 valign=top style='width:41.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>61%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>34/56</span></p>
  </td>
  <td width=62 valign=top style='width:46.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>17%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>4/24</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=620 colspan=9 style='width:464.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Number
  of mutations from the list of mutations associated with a diminished response
  to PREZISTA/ritonavir (V11I, V32I, L33F, I47V, I50V, I54L or M, T74P, L76V,
  I84V or L89V)</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></sup><span
  lang=EN-GB style='font-size:9.0pt'>fold change in EC<sub>50</sub></span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>c</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; &#8220;Patients
  with no/non&#8209;na&iuml;ve use of ENF&#8221; are patients who did not use
  ENF or who used ENF but not for the first time</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>d</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; &#8220;Patients
  with na&iuml;ve use of ENF&#8221; are patients who used ENF for the first
  time</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
patients</span></u></p>

<p class=MsoNormal><span lang=EN-GB>For clinical trial results in ART&#8209;na&iuml;ve
paediatric patients aged 12 to 17&nbsp;years, refer to the Summary of Product
Characteristics for PREZISTA 400&nbsp;mg and 800&nbsp;mg tablets or PREZISTA
100&nbsp;mg/ml oral suspension.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="OLE_LINK15"><i><u><span
lang=EN-GB>ART&#8209;experienced paediatric patients from the age of 6 to
&lt;&nbsp;18&nbsp;years, and weighing at least 20&nbsp;kg</span></u></i></a></p>

<p class=MsoNormal><b><i><span lang=EN-GB>DELPHI</span></i></b><span
lang=EN-GB> is an open&#8209;label, Phase&nbsp;II trial evaluating the
pharmacokinetics, safety, tolerability, and efficacy of PREZISTA with low dose
ritonavir in 80&nbsp;ART&#8209;experienced HIV&#8209;1 infected paediatric
patients aged 6 to 17&nbsp;years and weighing at least 20&nbsp;kg. These
patients received PREZISTA/ritonavir twice daily in combination with other
antiretroviral agents (see section 4.2 for dosage recommendations per body
weight). Virologic response was defined as a decrease in plasma HIV&#8209;1 RNA
viral load of at least 1.0&nbsp;log<sub>10</sub> versus baseline.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the study, patients who were at risk of
discontinuing therapy due to intolerance of ritonavir oral solution (e.g. taste
aversion) were allowed to switch to the capsule formulation. Of the
44&nbsp;patients taking ritonavir oral solution, 27 switched to the 100&nbsp;mg
capsule formulation and exceeded the weight&#8209;based ritonavir dose without
changes in observed safety.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>DELPHI</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 style='width:232.15pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Outcomes
  at week 48</span></i></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>PREZISTA/ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>N=80</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>HIV&#8209;1 RNA
  &lt;&nbsp;50&nbsp;copies/ml<sup>a</sup></span></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>47.5%
  (38)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>CD4+ cell count mean change from baseline<sup>b</sup></span></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>147</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Imputations according to the TLOVR
  algorithm.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Non&#8209;completer
  is failure imputation: patients who discontinued prematurely are imputed with
  a change equal to 0.</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>According to the TLOVR non&#8209;virologic
failure censored algorithm 24&nbsp;(30.0%) patients experienced virological
failure, of which 17&nbsp;(21.3%) patients were rebounders and 7&nbsp;(8.8%)
patients were non&#8209;responders.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>ART&#8209;experienced
paediatric patients from the age of 3 to &lt;&nbsp;6&nbsp;years</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetics, safety, tolerability
and efficacy of PREZISTA/ritonavir twice daily in combination with other
antiretroviral agents in 21&nbsp;ART&#8209;experienced HIV&#8209;1 infected paediatric
patients aged 3 to &lt;&nbsp;6&nbsp;years and weighing 10&nbsp;kg to
&lt;&nbsp;20&nbsp;kg was evaluated in an open&#8209;label, Phase&nbsp;II trial,
<b><i>ARIEL</i></b>. Patients received a weight&#8209;based twice daily
treatment regimen, patients weighing 10&nbsp;kg to &lt;&nbsp;15&nbsp;kg received
darunavir/ritonavir 25/3&nbsp;mg/kg twice daily, and patients weighing
15&nbsp;kg to &lt;&nbsp;20&nbsp;kg received darunavir/ritonavir 375/50&nbsp;mg twice
daily. At week 48, the virologic response, defined as the percentage of
patients with confirmed plasma viral load &lt;&nbsp;50&nbsp;HIV&#8209;1 RNA
copies/ml, was evaluated in 16&nbsp;paediatric patients 15&nbsp;kg to &lt;&nbsp;20&nbsp;kg
and 5&nbsp;paediatric patients 10&nbsp;kg to &lt;&nbsp;15&nbsp;kg receiving
PREZISTA/ritonavir in combination with other antiretroviral agents (see section
4.2 for dosage recommendations per body weight).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>ARIEL</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=291 style='width:218.05pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Outcomes
  at week 48</span></i></p>
  </td>
  <td width=328 colspan=2 valign=top style='width:246.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>PREZISTA/ritonavir</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=291 style='width:218.05pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>10&nbsp;kg to &lt;&nbsp;15&nbsp;kg</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>N=5</span></p>
  </td>
  <td width=158 valign=top style='width:118.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>15&nbsp;kg to &lt;&nbsp;20&nbsp;kg</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>N=16</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=291 valign=top style='width:218.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>HIV&#8209;1 RNA
  &lt;&nbsp;50&nbsp;copies/ml<sup>a</sup></span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>80.0%
  (4)</span></p>
  </td>
  <td width=158 valign=top style='width:118.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>81.3%
  (13)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=291 valign=top style='width:218.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>CD4+ percent change from baseline<sup>b</sup></span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>4</span></p>
  </td>
  <td width=158 valign=top style='width:118.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>4</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=291 valign=top style='width:218.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>CD4+ cell count mean change from baseline<sup>b</sup></span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>16</span></p>
  </td>
  <td width=158 valign=top style='width:118.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>241</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Imputations
  according to the TLOVR algorithm.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; NC=F</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Limited efficacy data are available in
paediatric patients below 15&nbsp;kg and no recommendation on a posology can be
made.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Pregnancy
and postpartum</span></i></p>

<p class=MsoNormal>Darunavir/ritonavir (600/100&nbsp;mg twice daily or
800/100&nbsp;mg once daily) in combination with a background regimen was
evaluated in a clinical trial of 36&nbsp;pregnant women (18 in each arm) during
the second and third trimesters, and postpartum. Virologic response was
preserved throughout the study period in both arms. No mother to child
transmission occurred in the infants born to the 31&nbsp;subjects who stayed on
the antiretroviral treatment through delivery. There were no new clinically
relevant safety findings compared with the known safety profile of
darunavir/ritonavir in HIV&#8209;1 infected adults (see sections 4.2, 4.4 and
5.2).</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetic properties of
darunavir, co&#8209;administered with ritonavir, have been evaluated in healthy
adult volunteers and in HIV&#8209;1 infected patients. Exposure to darunavir
was higher in HIV&#8209;1 infected patients than in healthy subjects. The
increased exposure to darunavir in HIV&#8209;1 infected patients compared to
healthy subjects may be explained by the higher concentrations of &#945;<sub>1</sub>&#8209;acid
glycoprotein (AAG) in HIV&#8209;1 infected patients, resulting in higher
darunavir binding to plasma AAG and, therefore, higher plasma concentrations.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir is primarily metabolised by
CYP3A. Ritonavir inhibits CYP3A, thereby increasing the plasma concentrations
of darunavir considerably.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir was rapidly absorbed following
oral administration. Maximum plasma concentration of darunavir in the presence
of low dose ritonavir is generally achieved within 2.5&#8209;4.0&nbsp;hours.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The absolute oral bioavailability of a
single 600&nbsp;mg dose of darunavir alone was approximately 37% and increased
to approximately 82% in the presence of 100&nbsp;mg twice daily ritonavir. The
overall pharmacokinetic enhancement effect by ritonavir was an approximate 14&#8209;fold
increase in the systemic exposure of darunavir when a single dose of
600&nbsp;mg darunavir was given orally in combination with ritonavir at
100&nbsp;mg twice daily (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>When administered without food, the
relative bioavailability of darunavir in the presence of low dose ritonavir is
30% lower as compared to intake with food. Therefore, PREZISTA tablets should
be taken with ritonavir and with food. The type of food does not affect
exposure to darunavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir is approximately 95% bound to
plasma protein. Darunavir binds primarily to plasma &#945;<sub>1</sub>&#8209;acid
glycoprotein.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Following intravenous administration, the
volume of distribution of darunavir alone was
88.1&nbsp;&plusmn;&nbsp;59.0&nbsp;l (Mean&nbsp;&plusmn;&nbsp;SD) and increased
to 131&nbsp;&plusmn;&nbsp;49.9&nbsp;l (Mean&nbsp;&plusmn;&nbsp;SD) in the
presence of 100&nbsp;mg twice&#8209;daily ritonavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>In vitro</span></i><span lang=EN-GB>
experiments with human liver microsomes (HLMs) indicate that darunavir primarily
undergoes oxidative metabolism. Darunavir is extensively metabolised by the
hepatic CYP system and almost exclusively by isozyme CYP3A4. A <sup>14</sup>C&#8209;darunavir
trial in healthy volunteers showed that a majority of the radioactivity in
plasma after a single 400/100&nbsp;mg darunavir with ritonavir dose was due to
the parent active substance. At least 3&nbsp;oxidative metabolites of darunavir
have been identified in humans; all showed activity that was at least 10&#8209;fold
less than the activity of darunavir against wild type HIV.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal><span lang=EN-GB>After a 400/100&nbsp;mg&nbsp;</span><sup><span
lang=EN-GB>14</span></sup><span lang=EN-GB>C&#8209;darunavir with ritonavir
dose, approximately 79.5% and 13.9% of the administered dose of </span><sup><span
lang=EN-GB>14</span></sup><span lang=EN-GB>C&#8209;darunavir could be retrieved
in faeces and urine, respectively. Unchanged darunavir accounted for
approximately 41.2% and 7.7% of the administered dose in faeces and urine,
respectively. The terminal elimination half&#8209;life of darunavir was
approximately 15&nbsp;hours when combined with ritonavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>The intravenous clearance of darunavir
alone (150&nbsp;mg) and in the presence of low dose ritonavir was 32.8&nbsp;l/h
and 5.9&nbsp;l/h, respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetics of darunavir in
combination with ritonavir taken twice daily in 74&nbsp;treatment&#8209;experienced
paediatric patients, aged 6 to 17&nbsp;years and weighing at least 20&nbsp;kg,
showed that the administered weight&#8209;based doses of PREZISTA/ritonavir
resulted in darunavir exposure comparable to that in adults receiving
PREZISTA/ritonavir 600/100&nbsp;mg twice daily (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetics of darunavir in
combination with ritonavir taken twice daily in 14&nbsp;treatment&#8209;experienced
paediatric patients, aged 3 to &lt;&nbsp;6&nbsp;years and weighing at least 15&nbsp;kg
to &lt;&nbsp;20&nbsp;kg, showed that weight&#8209;based dosages resulted in
darunavir exposure that was comparable to that achieved in adults receiving
PREZISTA/ritonavir 600/100&nbsp;mg twice daily (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetics of darunavir in
combination with ritonavir taken once daily in 12&nbsp;ART&#8209;na&iuml;ve
paediatric patients, aged 12 to &lt;&nbsp;18&nbsp;years and weighing at least
40&nbsp;kg, showed that PREZISTA/ritonavir 800/100&nbsp;mg once daily results
in darunavir exposure that was comparable to that achieved in adults receiving
PREZISTA/ritonavir 800/100&nbsp;mg once daily. Therefore the same once daily
dosage may be used in treatment&#8209;experienced adolescents aged 12 to &lt;&nbsp;18&nbsp;years
and weighing at least 40&nbsp;kg without darunavir resistance associated
mutations (DRV&#8209;RAMs)* and who have plasma HIV&#8209;1 RNA &lt;&nbsp;100,000&nbsp;copies/ml
and CD4+ cell count &#8805;&nbsp;100&nbsp;cells&nbsp;x&nbsp;10<sup>6</sup>/L (see
section 4.2).</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=NO-NYN>*</span><span lang=NO-NYN style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp; DRV&#8209;RAMs:
V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V</span></p>

<p class=MsoNormal><span lang=NO-NYN>&nbsp;</span></p>

<p class=MsoNormal>The pharmacokinetics of darunavir in combination with
ritonavir taken once daily in 10&nbsp;treatment&#8209;experienced paediatric
patients, aged 3 to &lt;&nbsp;6&nbsp;years and weighing at least 14&nbsp;kg to
&lt;&nbsp;20&nbsp;kg, showed that weight&#8209;based dosages resulted in
darunavir exposure that was comparable to that achieved in adults receiving
PREZISTA/ritonavir 800/100&nbsp;mg once daily (see section 4.2). In addition,
pharmacokinetic modeling and simulation of darunavir exposures in paediatric
patients across the ages of 3 to &lt;&nbsp;18&nbsp;years confirmed the
darunavir exposures as observed in the clinical studies and allowed the
identification of weight&#8209;based PREZISTA/ritonavir once daily dosing
regimens for paediatric patients weighing at least 15&nbsp;kg that are either
ART&#8209;na&iuml;ve or treatment&#8209;experienced paediatric patients without
DRV&#8209;RAMs* and who have plasma HIV&#8209;1 RNA
&lt;&nbsp;100,000&nbsp;copies/ml and CD4+ cell count
&#8805;&nbsp;100&nbsp;cells&nbsp;x&nbsp;10<sup>6</sup>/L (see section 4.2).</p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=NO-NYN>*</span><span lang=NO-NYN style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp; DRV&#8209;RAMs:
V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V</span></p>

<p class=MsoNormal><span lang=NO-NYN>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Population pharmacokinetic analysis in HIV
infected patients showed that darunavir pharmacokinetics are not considerably
different in the age range (18 to 75&nbsp;years) evaluated in HIV infected
patients (n=12, age&nbsp;&#8805;&nbsp;65) (see section 4.4). However, only
limited data were available in patients above the age of 65&nbsp;year.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Gender</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Population pharmacokinetic analysis showed
a slightly higher darunavir exposure (16.8%) in HIV infected females compared
to males. This difference is not clinically relevant.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Renal
impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Results from a mass balance study with <sup>14</sup>C&#8209;darunavir
with ritonavir showed that approximately 7.7% of the administered dose of
darunavir is excreted in the urine unchanged.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Although darunavir has not been studied in
patients with renal impairment, population pharmacokinetic analysis showed that
the pharmacokinetics of darunavir were not significantly affected in HIV
infected patients with moderate renal impairment (CrCl between 30&#8209;60&nbsp;ml/min,
n=20) (see sections 4.2 and 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="OLE_LINK13"><i><span
lang=EN-GB>Hepatic impairment</span></i></a></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir is primarily metabolised and
eliminated by the liver. In a multiple dose study with PREZISTA co&#8209;administered
with ritonavir (600/100&nbsp;mg) twice daily, it was demonstrated that the
total plasma concentrations of darunavir in subjects with mild (Child&#8209;Pugh
Class&nbsp;A, n=8) and moderate (Child&#8209;Pugh Class&nbsp;B, n=8) hepatic
impairment were comparable with those in healthy subjects. However, unbound
darunavir concentrations were approximately 55% (Child&#8209;Pugh Class&nbsp;A)
and 100% (Child&#8209;Pugh Class&nbsp;B) higher, respectively. The clinical
relevance of this increase is unknown therefore, PREZISTA should be used with
caution. The effect of severe hepatic impairment on the pharmacokinetics of
darunavir has not been studied (see sections 4.2, 4.3 and 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Pregnancy
and postpartum</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The exposure to total darunavir and
ritonavir after intake of darunavir/ritonavir 600/100&nbsp;mg twice daily and
darunavir/ritonavir 800/100&nbsp;mg once daily as part of an antiretroviral
regimen was generally lower during pregnancy compared with postpartum. </span>However,
for unbound (i.e. active) darunavir, the pharmacokinetic parameters were less
reduced during pregnancy compared to postpartum, due to an increase in the
unbound fraction of darunavir during pregnancy compared to postpartum<span
lang=EN-GB>.</span></p>

<p class=MsoNormal>&nbsp;</p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=610 colspan=4 valign=top style='width:457.75pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Pharmacokinetic results of total darunavir after
  administration of </span></b><b><span lang=EN-GB>darunavir/ritonavir at
  600/100&nbsp;mg twice daily as part of an antiretroviral regimen, during the
  second trimester of pregnancy, the third trimester of pregnancy and
  postpartum</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=153 valign=top style='width:114.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pharmacokinetics
  of total darunavir</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>(mean &plusmn; SD)</span></p>
  </td>
  <td width=153 valign=top style='width:114.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Second trimester of pregnancy</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(n=12)<sup>a</sup></span></b></p>
  </td>
  <td width=153 valign=top style='width:114.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Third trimester of pregnancy</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(n=12)</span></b></p>
  </td>
  <td width=153 valign=top style='width:114.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Postpartum (6&#8209;12&nbsp;weeks)</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(n=12)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=153 style='width:114.4pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>max</sub>, ng/ml</span></p>
  </td>
  <td width=153 style='width:114.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>4,668
  &plusmn; 1,097</span></p>
  </td>
  <td width=153 style='width:114.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>5,328
  &plusmn; 1,631</span></p>
  </td>
  <td width=153 style='width:114.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>6,659
  &plusmn; 2,364</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=153 valign=bottom style='width:114.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>AUC<sub>12h</sub>, ng.h/ml</span></p>
  </td>
  <td width=153 valign=bottom style='width:114.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>39,370
  &plusmn; 9,597</span></p>
  </td>
  <td width=153 valign=bottom style='width:114.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>45,880
  &plusmn; 17,360</span></p>
  </td>
  <td width=153 valign=bottom style='width:114.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>56,890
  &plusmn; 26,340</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=153 style='width:114.4pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>min</sub>, ng/ml</span></p>
  </td>
  <td width=153 style='width:114.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1,922
  &plusmn; 825</span></p>
  </td>
  <td width=153 valign=bottom style='width:114.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2,661
  &plusmn; 1,269</span></p>
  </td>
  <td width=153 style='width:114.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2,851
  &plusmn; 2,216</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=610 colspan=4 valign=top style='width:457.75pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>n=11 for AUC<sub>12h</sub></span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal>&nbsp;</p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=4 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Pharmacokinetic results of total darunavir after
  administration of darunavir/ritonavir at 800/100&nbsp;mg once daily as part
  of an antiretroviral regimen, during the second trimester of pregnancy, the
  third trimester of pregnancy and postpartum</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=151 valign=top style='width:113.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pharmacokinetics
  of total darunavir</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>(mean &plusmn; SD)</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>Second trimester of pregnancy</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>(n=17)</span></b></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>Third Trimester of pregnancy</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>(n=15)</span></b></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>Postpartum (6&#8209;12&nbsp;weeks)</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>(n=16)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=151 style='width:113.4pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>max</sub>, ng/ml</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>4,964
  &plusmn; 1,505</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>5,132
  &plusmn; 1,198</span></p>
  </td>
  <td width=151 valign=bottom style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>7,310
  &plusmn; 1,704</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=151 valign=bottom style='width:113.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>AUC<sub>24h</sub>, ng.h/ml</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>62,289
  &plusmn; 16,234</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>61,112
  &plusmn; 13,790</span></p>
  </td>
  <td width=151 valign=bottom style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>92,116
  &plusmn; 29,241</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=151 style='width:113.4pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>min</sub>, ng/ml</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1,248
  &plusmn; 542</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1,075
  &plusmn; 594</span></p>
  </td>
  <td width=151 valign=bottom style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1,473
  &plusmn; 1,141</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>In women receiving darunavir/ritonavir
600/100&nbsp;mg twice daily during the second trimester of pregnancy, mean
intra&#8209;individual values for total darunavir C<sub>max</sub>, AUC<sub>12h</sub>
and C<sub>min</sub> were 28%, 26% and 26% lower, respectively, as compared with
postpartum; during the third trimester of pregnancy, total darunavir C<sub>max</sub>,
AUC<sub>12h</sub> and C<sub>min</sub> values were 18%, 16% lower and 2% higher,
respectively, as compared with postpartum.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In women receiving darunavir/ritonavir
800/100&nbsp;mg once daily during the second trimester of pregnancy, mean intra&#8209;individual
values for total darunavir C<sub>max</sub>, AUC<sub>24h</sub> and C<sub>min</sub>
were 33%, 31% and 30% lower, respectively, as compared with postpartum; during
the third trimester of pregnancy, total darunavir C<sub>max</sub>, AUC<sub>24h</sub>
and C<sub>min</sub> values were 29%, 32% and 50% lower, respectively, as
compared with postpartum.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical
safety data</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Animal toxicology studies have been conducted
at exposures up to clinical exposure levels with darunavir alone, in mice, rats
and dogs and in combination with ritonavir in rats and dogs.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In repeated&#8209;dose toxicology studies
in mice, rats and dogs, there were only limited effects of treatment with
darunavir. In rodents the target organs identified were the haematopoietic
system, the blood coagulation system, liver and thyroid. A variable but limited
decrease in red blood cell&#8209;related parameters was observed, together with
increases in activated partial thromboplastin time.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Changes were observed in liver (hepatocyte
hypertrophy, vacuolation, increased liver enzymes) and thyroid (follicular
hypertrophy). In the rat, the combination of darunavir with ritonavir lead to a
small increase in effect on RBC parameters, liver and thyroid and increased
incidence of islet fibrosis in the pancreas (in male rats only) compared to
treatment with darunavir alone. In the dog, no major toxicity findings or
target organs were identified up to exposures equivalent to clinical exposure
at the recommended dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In a study conducted in rats, the number of
corpora lutea and implantations were decreased in the presence of maternal
toxicity. Otherwise, there were no effects on mating or fertility with
darunavir treatment up to 1,000&nbsp;mg/kg/day and exposure levels below (AUC&#8209;0.5&nbsp;fold)
of that in human at the clinically recommended dose. Up to same dose levels,
there was no teratogenicity with darunavir in rats and rabbits when treated
alone nor in mice when treated in combination with ritonavir. The exposure
levels were lower than those with the recommended clinical dose in humans. In a
pre&#8209; and postnatal development assessment in rats, darunavir with and
without ritonavir, caused a transient reduction in body weight gain of the
offspring pre&#8209;weaning and there was a slight delay in the opening of eyes
and ears. Darunavir in combination with ritonavir caused a reduction in the
number of pups that exhibited the startle response on day 15 of lactation and a
reduced pup survival during lactation. These effects may be secondary to pup
exposure to the active substance via the milk and/or maternal toxicity. No post
weaning functions were affected with darunavir alone or in combination with
ritonavir. In juvenile rats receiving darunavir up to days 23&#8209;26,
increased mortality was observed with convulsions in some animals. Exposure in
plasma, liver and brain was considerably higher than in adult rats after
comparable doses in mg/kg between days 5 and 11 of age. After day 23 of life,
the exposure was comparable to that in adult rats. The increased exposure was
likely at least partly due to immaturity of the drug&#8209;metabolising enzymes
in juvenile animals. No treatment related mortalities were noted in juvenile
rats dosed at 1,000&nbsp;mg/kg darunavir (single dose) on day 26 of age or at
500&nbsp;mg/kg (repeated dose) from day 23 to 50 of age, and the exposures and
toxicity profile were comparable to those observed in adult rats.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Due to uncertainties regarding the rate of
development of the human blood brain barrier and liver enzymes, PREZISTA with
low dose ritonavir should not be used in paediatric patients below 3&nbsp;years
of age.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir was evaluated for carcinogenic
potential by oral gavage administration to mice and rats up to 104&nbsp;weeks.
Daily doses of 150, 450 and 1,000&nbsp;mg/kg were administered to mice and
doses of 50, 150 and 500&nbsp;mg/kg were administered to rats. Dose&#8209;related
increases in the incidences of hepatocellular adenomas and carcinomas were
observed in males and females of both species. Thyroid follicular cell adenomas
were noted in male rats. Administration of darunavir did not cause a
statistically significant increase in the incidence of any other benign or
malignant neoplasm in mice or rats. The observed hepatocellular and thyroid
tumours in rodents are considered to be of limited relevance to humans.
Repeated administration of darunavir to rats caused hepatic microsomal enzyme
induction and increased thyroid hormone elimination, which predispose rats, but
not humans, to thyroid neoplasms. At the highest tested doses, the systemic
exposures (based on AUC) to darunavir were between 0.4&#8209; and 0.7&#8209;fold
(mice) and 0.7&#8209; and 1&#8209;fold (rats), relative to those observed in
humans at the recommended therapeutic doses.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>After
2&nbsp;years administration of darunavir at exposures at or below the human
exposure, kidney changes were observed in mice (nephrosis) and rats (chronic
progressive nephropathy).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir was not mutagenic or genotoxic in
a battery of </span><i><span lang=EN-GB>in vitro</span></i><span lang=EN-GB>
and </span><i><span lang=EN-GB>in vivo</span></i><span lang=EN-GB> assays
including bacterial reverse mutation (Ames), chromosomal aberration in human
lymphocytes and </span><i><span lang=EN-GB>in vivo</span></i><span lang=EN-GB>
micronucleus test in mice.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp;&nbsp; List
of excipients</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA
75&nbsp;mg film&#8209;coated tablets</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Tablet
core</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Microcrystalline cellulose</span></p>

<p class=MsoNormal><span lang=EN-GB>Colloidal anhydrous silica</span></p>

<p class=MsoNormal><span lang=EN-GB>Crospovidone</span></p>

<p class=MsoNormal><span lang=EN-GB>Magnesium stearate</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Tablet
film&#8209;coat</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Poly(vinyl alcohol) &#8211; partially
hydrolysed</span></p>

<p class=MsoNormal>Macrogol 3350</p>

<p class=MsoNormal>Titanium dioxide (E171)</p>

<p class=MsoNormal>Talc</p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA 150&nbsp;mg
film&#8209;coated tablets</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Tablet
core</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Microcrystalline cellulose</span></p>

<p class=MsoNormal><span lang=EN-GB>Colloidal anhydrous silica</span></p>

<p class=MsoNormal><span lang=EN-GB>Crospovidone</span></p>

<p class=MsoNormal><span lang=EN-GB>Magnesium stearate</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Tablet
film&#8209;coat</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Poly(vinyl alcohol) &#8211; partially
hydrolysed</span></p>

<p class=MsoNormal>Macrogol 3350</p>

<p class=MsoNormal>Titanium dioxide (E171)</p>

<p class=MsoNormal>Talc</p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA 600&nbsp;mg
film&#8209;coated tablets</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Tablet
core</span></u></p>

<p class=MsoNormal><span lang=IT>Microcrystalline cellulose</span></p>

<p class=MsoNormal><span lang=IT>Colloidal anhydrous silica</span></p>

<p class=MsoNormal><span lang=IT>Crospovidone</span></p>

<p class=MsoNormal><span lang=EN-GB>Magnesium stearate</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Tablet
film&#8209;coat</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Poly(vinyl alcohol) &#8211; partially
hydrolysed</span></p>

<p class=MsoNormal><span lang=EN-GB>Macrogol 3350</span></p>

<p class=MsoNormal><span lang=EN-GB>Titanium dioxide (E171)</span></p>

<p class=MsoNormal><span lang=EN-GB>Talc</span></p>

<p class=MsoNormal><span lang=EN-GB>Sunset yellow FCF (E110)</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</b></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf
life</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>3&nbsp;years</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for storage</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product does not require any
special storage conditions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature
and contents of container</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA 75&nbsp;mg
film&#8209;coated tablets</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Opaque, white, high density polyethylene
(HDPE) plastic, 160&nbsp;ml bottle containing 480&nbsp;tablets, fitted with
polypropylene (PP) child resistant closure.</span></p>

<p class=MsoNormal><span lang=EN-GB>Pack size of one bottle.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA 150&nbsp;mg
film&#8209;coated tablets</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Opaque, white, high density polyethylene
(HDPE) plastic, 160&nbsp;ml bottle containing 240&nbsp;tablets, fitted with
polypropylene (PP) child resistant closure.</span></p>

<p class=MsoNormal><span lang=EN-GB>Pack size of one bottle.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA 600&nbsp;mg
film&#8209;coated tablets</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Opaque, white, high density polyethylene
(HDPE) plastic, 160&nbsp;ml bottle containing 60&nbsp;tablets, fitted with
polypropylene (PP) child resistant closure.</span></p>

<p class=MsoNormal><span lang=EN-GB>Pack size of one bottle.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for disposal</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Janssen&#8209;Cilag&nbsp;International&nbsp;NV</span></p>

<p class=MsoNormal><span lang=EN-GB>Turnhoutseweg&nbsp;30</span></p>

<p class=MsoNormal><span lang=EN-GB>B&#8209;2340&nbsp;Beerse</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA 75&nbsp;mg
film&#8209;coated tablets</span></u></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/380/005</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA 150&nbsp;mg
film&#8209;coated tablets</span></u></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/380/004</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA 600&nbsp;mg
film&#8209;coated tablets</span></u></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/380/002</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of first authorisation: 12 February
2007</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of latest renewal: 19 September 2013</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this medicinal product
is available on the website of the European Medicines Agency </span><span
lang=EN-GB style='color:blue'><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></span><span
lang=EN-GB>.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA 400&nbsp;mg film&#8209;coated
tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA 800&nbsp;mg film&#8209;coated
tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA
400&nbsp;mg film&#8209;coated tablets</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Each film&#8209;coated tablet contains
400&nbsp;mg of darunavir (as ethanolate).</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipient with known effect</span></u><span
lang=EN-GB>: Each tablet contains 0.834&nbsp;mg sunset yellow FCF (E110).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA
800&nbsp;mg film&#8209;coated tablets</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Each film&#8209;coated tablet contains
800&nbsp;mg of darunavir (as ethanolate).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For the full list of excipients, see
section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA
400&nbsp;mg film&#8209;coated tablets</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Film&#8209;coated tablet.</span></p>

<p class=MsoNormal><span lang=EN-GB>Light orange oval shaped tablet of
19.1&nbsp;mm, debossed with &#8220;400MG&#8221; on one side and
&#8220;TMC&#8221; on the other side.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA
800&nbsp;mg film&#8209;coated tablets</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Film&#8209;coated tablet.</span></p>

<p class=MsoNormal><span lang=EN-GB>Dark red oval shaped tablet of
20.0&nbsp;mm, debossed with &#8220;800&#8221; on one side and &#8220;T&#8221;
on the other side.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CLINICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic
indications</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA, co&#8209;administered with low
dose ritonavir is indicated in combination with other antiretroviral medicinal
products for the treatment of patients with human immunodeficiency virus (HIV&#8209;1)
infection.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA, co&#8209;administered with
cobicistat is indicated in combination with other antiretroviral medicinal
products for the treatment of human immunodeficiency virus (HIV&#8209;1)
infection in adults and adolescents (aged 12&nbsp;years and older, weighing at
least 40&nbsp;kg) (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>PREZISTA
400&nbsp;mg and 800&nbsp;mg tablets may be used to provide suitable dose
regimens for the treatment of HIV&#8209;1 infection in adult and paediatric
patients from the age of 3&nbsp;years and at least 40&nbsp;kg body weight who
are:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>antiretroviral therapy (ART)&#8209;na&iuml;ve
(see section 4.2).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ART&#8209;experienced with no darunavir
resistance associated mutations (DRV&#8209;RAMs) and who have plasma HIV&#8209;1
RNA &lt;&nbsp;100,000&nbsp;copies/ml and CD4+ cell count &#8805;&nbsp;100&nbsp;cells&nbsp;x&nbsp;10<sup>6</sup>/L.
In deciding to initiate treatment with PREZISTA in such ART&#8209;experienced patients,
genotypic testing should guide the use of PREZISTA (see sections 4.2, 4.3, 4.4
and 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology
and method of administration</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Therapy should be initiated by a healthcare
provider experienced in the management of HIV infection. After therapy with
PREZISTA has been initiated, patients should be advised not to alter the
dosage, dose form or discontinue therapy without discussing with their
healthcare provider.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The interaction profile of darunavir
depends on whether ritonavir or cobicistat is used as pharmacokinetic enhancer.
Darunavir may therefore have different contraindications and recommendations
for concomitant medications depending on whether the compound is boosted with
ritonavir or cobicistat (see sections 4.3, 4.4 and 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA must always be given orally with cobicistat
or low dose ritonavir as a pharmacokinetic enhancer and in combination with
other antiretroviral medicinal products. The Summary of Product Characteristics
of cobicistat or ritonavir as appropriate, must therefore be consulted prior to
initiation of therapy with PREZISTA. Cobicistat is not indicated for use in
twice daily regimens or for use in the paediatric population less than
12&nbsp;years of age weighing less than 40&nbsp;kg.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is also available as an oral
suspension for use in patients who are unable to swallow PREZISTA tablets
(please refer to the Summary of Product Characteristics for PREZISTA oral
suspension).</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>ART&#8209;na&iuml;ve
adult patients</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dose regimen is 800&nbsp;mg
once daily taken with cobicistat 150&nbsp;mg once daily or ritonavir 100&nbsp;mg
once daily taken with food. PREZISTA 400&nbsp;mg and 800&nbsp;mg tablets can be
used to construct the once daily 800&nbsp;mg regimen.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>ART&#8209;experienced
adult patients</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dose regimens are as
follows:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In ART&#8209;experienced patients with no
darunavir resistance associated mutations (DRV&#8209;RAMs)* and who have plasma
HIV&#8209;1 RNA &lt;&nbsp;100,000&nbsp;copies/ml and CD4+ cell count &#8805;&nbsp;100&nbsp;cells&nbsp;x&nbsp;10<sup>6</sup>/L
(see section 4.1) a regimen of 800&nbsp;mg once daily with cobicistat 150&nbsp;mg
once daily or ritonavir 100&nbsp;mg once daily taken with food may be used.
PREZISTA 400&nbsp;mg and 800&nbsp;mg tablets can be used to construct the once
daily 800&nbsp;mg regimen.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In all other ART&#8209;experienced patients or
if HIV&#8209;1 genotype testing is not available, the recommended dose regimen
is 600&nbsp;mg twice daily taken with ritonavir 100&nbsp;mg twice daily taken
with food. See the Summary of Product Characteristics for PREZISTA 100&nbsp;mg/ml
oral suspension, 75&nbsp;mg, 150&nbsp;mg or 600&nbsp;mg tablets.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=NO-NYN>*&nbsp;&nbsp; </span><span lang=NO-NYN style='font-size:9.0pt'>DRV&#8209;RAMs:
</span><span lang=NO-NYN style='font-size:9.0pt'>V11I, V32I, L33F, I47V, I50V,
I54M, I54L, T74P, L76V, I84V and L89V</span></p>

<p class=MsoNormal><i><span lang=NO-NYN>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>ART&#8209;na&iuml;ve
paediatric patients (3 to 17&nbsp;years of age and weighing at least
40&nbsp;kg)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dose regimen is 800&nbsp;mg
once daily with ritonavir 100&nbsp;mg once daily taken with food or 800&nbsp;mg
once daily with cobicistat 150&nbsp;mg once daily taken with food (in
adolescent patients 12&nbsp;years of age or older). PREZISTA 400&nbsp;mg and 800&nbsp;mg
tablets can be used to construct the once daily 800&nbsp;mg regimen. The dose
of cobicistat to be used with PREZISTA in children less than 12&nbsp;years of
age has not been established.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>ART&#8209;experienced
paediatric patients (3 to 17&nbsp;years of age and weighing at least
40&nbsp;kg)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The dose of cobicistat to be used with
PREZISTA in children less than 12&nbsp;years of age has not been established.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The
recommended dose regimens are as follows:</span></p>

<p class=MsoNormal><span lang=EN-GB>In ART&#8209;experienced patients without DRV&#8209;RAMs*
and who have plasma HIV&#8209;1 RNA &lt;&nbsp;100,000&nbsp;copies/ml and CD4+
cell count &#8805;&nbsp;100&nbsp;cells&nbsp;x&nbsp;10<sup>6</sup>/L (see
section 4.1) a regimen of 800&nbsp;mg once daily with ritonavir 100&nbsp;mg
once daily taken with food or 800&nbsp;mg once daily with cobicistat
150&nbsp;mg once daily taken with food (in adolescent patients 12&nbsp;years of
age or older) may be used. PREZISTA 400&nbsp;mg and 800&nbsp;mg tablets can be
used to construct the once daily 800&nbsp;mg regimen The dose of cobicistat to
be used with PREZISTA in children less than 12&nbsp;years of age has not been
established.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In all other ART&#8209;experienced patients or
if HIV&#8209;1 genotype testing is not available, the recommended dose regimen is
described in the Summary of Product Characteristics for PREZISTA 100&nbsp;mg/ml
oral suspension,75&nbsp;mg, 150&nbsp;mg and 600&nbsp;mg tablets.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=NO-NYN>*&nbsp;&nbsp; </span><span lang=NO-NYN style='font-size:9.0pt'>DRV&#8209;RAMs:
</span><span lang=NO-NYN style='font-size:9.0pt'>V11I, V32I, L33F, I47V, I50V,
I54M, I54L, T74P, L76V, I84V and L89V</span></p>

<p class=MsoNormal><span lang=NO-NYN>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Advice on
missed doses</span></i></p>

<p class=MsoNormal><span lang=EN-GB>If a once daily dose of PREZISTA and/or
cobicistat or ritonavir is missed within 12&nbsp;hours of the time it is
usually taken, patients should be instructed to take the prescribed dose of
PREZISTA and cobicistat or ritonavir with food as soon as possible. If this is
noticed later than 12&nbsp;hours after the time it is usually taken, the missed
dose should not be taken and the patient should resume the usual dosing
schedule.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This guidance is based on the half&#8209;life
of darunavir in the presence of cobicistat or ritonavir and the recommended
dosing interval of approximately 24&nbsp;hours.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="_Hlk36030487"><span lang=EN-GB>If a patient vomits
within 4&nbsp;hours of taking the medicine, another dose of PREZISTA with
cobicistat or ritonavir should be taken with food as soon as possible. If a
patient vomits more than 4&nbsp;hours after taking the medicine, the patient
does not need to take another dose of PREZISTA with cobicistat or ritonavir
until the next regularly scheduled time.</span></a></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="_Hlk31174935"><u><span
lang=EN-GB>Special populations</span></u></a></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Limited information is available in this population,
and therefore, PREZISTA should be used with caution in this age group (see
sections 4.4 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Hepatic
impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir is metabolised by the hepatic
system. No dose adjustment is recommended in patients with mild (Child&#8209;Pugh
Class&nbsp;A) or moderate (Child&#8209;Pugh Class&nbsp;B) hepatic impairment,
however, PREZISTA should be used with caution in these patients. No
pharmacokinetic data are available in patients with severe hepatic impairment.
Severe hepatic impairment could result in an increase of darunavir exposure and
a worsening of its safety profile. Therefore, PREZISTA must not be used in
patients with severe hepatic impairment (Child&#8209;Pugh Class&nbsp;C) (see
sections 4.3, 4.4 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Renal
impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>No dose adjustment is required for
darunavir/ritonavir in patients with renal impairment (see sections 4.4 and
5.2). Cobicistat has not been studied in patients receiving dialysis, and,
therefore, no recommendation can be made for the use of darunavir/cobicistat in
these patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Cobicistat inhibits the tubular secretion
of creatinine and may cause modest increases in serum creatinine and modest
declines in creatinine clearance. Hence, the use of creatinine clearance as an
estimate of renal elimination capacity may be misleading. Cobicistat as a pharmacokinetic
enhancer of darunavir should, therefore, not be initiated in patients with
creatine clearance less than 70&nbsp;ml/min if any co&#8209;administered agent
requires dose adjustment based on creatinine clearance: e.g. emtricitabine,
lamivudine, tenofovir disoproxil (as fumarate, phosphate or succinate) or
adefovir dipovoxil.</span></p>

<p class=MsoNormal><span lang=EN-GB>For information on cobicistat, consult the
cobicistat Summary of Product Characteristics.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>PREZISTA
should not be used in children</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>below 3&nbsp;years of age, because of safety
concerns (see sections&nbsp;4.4 and 5.3), or,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>less than 15&nbsp;kg body weight, as the dose
for this population has not been established in a sufficient number of patients
(see section&nbsp;5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>PREZISTA taken with
cobicistat should not be used in children aged&nbsp;3 to 11&nbsp;years of age
weighing &lt;&nbsp;40&nbsp;kg as the dose of cobicistat to be used in these
children has not been established (see sections&nbsp;4.4 and 5.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA</span><span lang=EN-GB> 400 and
800&nbsp;mg tablets are not suitable for this patient population. Other
formulations are available, see the Summary of Product Characteristics for
PREZISTA 75&nbsp;mg, 150&nbsp;mg, 600&nbsp;mg tablets and 100&nbsp;mg/ml oral
suspension.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Pregnancy
and postpartum</span></i></p>

<p class=MsoNormal><span lang=EN-GB>No dose adjustment is required for
darunavir/ritonavir during pregnancy and postpartum. PREZISTA/ritonavir</span>
should be used during pregnancy only if the potential benefit justifies the
potential risk<span lang=EN-GB> (see sections 4.4, 4.6 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Treatment with darunavir/cobicistat
800/150&nbsp;mg during pregnancy results in low darunavir exposure (see
sections&nbsp;4.4 and 5.2). Therefore, therapy with PREZISTA/cobicistat should
not be initiated during pregnancy, and women who become pregnant during therapy
with PREZISTA/cobicistat should be switched to an alternative regimen (see
sections&nbsp;4.4 and 4.6). PREZISTA/ritonavir may be considered as an alternative.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Patients should
be instructed to take PREZISTA with cobicistat or low dose ritonavir within
30&nbsp;minutes after completion of a meal. The type of food does not affect
the exposure to darunavir (see sections 4.4, 4.5 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hypersensitivity to the active substance or
to any of the excipients listed in section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients with severe (Child&#8209;Pugh
Class&nbsp;C) hepatic impairment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Concomitant treatment with any of the
following medicinal products given the expected decrease in plasma
concentrations of darunavir, ritonavir and cobicistat and the potential for
loss of therapeutic effect (see sections 4.4 and 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Applicable
to darunavir boosted with either ritonavir or cobicistat:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The combination product lopinavir/ritonavir (see
section 4.5).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The strong CYP3A inducers rifampicin and herbal
preparations containing St&nbsp;John&#8217;s&nbsp;wort (<i>Hypericum perforatum</i>).
Co&#8209;administration is expected to reduce plasma concentrations of
darunavir, ritonavir and cobicistat, which could lead to loss of therapeutic
effect and possible development of resistance (see sections 4.4 and 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Applicable
to darunavir boosted with cobicistat, not when boosted with ritonavir:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Darunavir boosted with cobicistat is more
sensitive for CYP3A induction than darunavir boosted with ritonavir.
Concomitant use with strong CYP3A inducers is contraindicated, since these may
reduce the exposure to cobicistat and darunavir leading to loss of therapeutic
effect. Strong CYP3A inducers include e.g. carbamazepine, phenobarbital and
phenytoin (see sections 4.4 and 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir boosted with either ritonavir or
cobicistat inhibits the elimination of active substances that are highly
dependent on CYP3A for clearance, which results in increased exposure to the co&#8209;administered
medicinal product. Therefore, concomitant treatment with such medicinal
products for which elevated plasma concentrations are associated with serious
and/or life&#8209;threatening events is contraindicated (applies to darunavir
boosted with either ritonavir or cobicistat). These active substances include
e.g.:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>alfuzosin</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>amiodarone, bepridil, dronedarone, ivabradine, quinidine,
ranolazine</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>astemizole, terfenadine</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>colchicine when used in patients with renal
and/or hepatic impairment (see section 4.5)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ergot derivatives (e.g. dihydroergotamine,
ergometrine, ergotamine, methylergonovine)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>elbasvir/grazoprevir</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cisapride</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dapoxetine</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>domperidone</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>naloxegol</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lurasidone, pimozide, quetiapine, sertindole
(see section 4.5)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>triazolam, midazolam administered orally (for
caution on parenterally administered midazolam, see section 4.5)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sildenafil - when used for the treatment of
pulmonary arterial hypertension, avanafil</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>simvastatin, lovastatin and lomitapide (see
section 4.5)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dabigatran, ticagrelor (see section 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special
warnings and precautions for use</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>While effective viral suppression with
antiretroviral therapy has been proven to substantially reduce the risk of
sexual transmission, a residual risk cannot be excluded. Precautions to prevent
transmission should be taken in accordance with national guidelines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Regular assessment of virological response
is advised. In the setting of lack or loss of virological response, resistance
testing should be performed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA 400&nbsp;mg or 800&nbsp;mg must
always be given orally with cobicistat or low dose ritonavir as a
pharmacokinetic enhancer and in combination with other antiretroviral medicinal
products (see section 5.2). The Summary of Product Characteristics of
cobicistat or ritonavir as appropriate, must therefore be consulted prior to
initiation of therapy with PREZISTA.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Increasing the dose of ritonavir from that
recommended in section 4.2 did not significantly affect darunavir
concentrations. It is not recommended to alter the dose of cobicistat or ritonavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir binds predominantly to </span><span
lang=EN-GB style='font-family:Symbol'>a</span><sub><span lang=EN-GB>1</span></sub><span
lang=EN-GB>&#8209;acid glycoprotein. This protein binding is concentration&#8209;dependent
indicative for saturation of binding. Therefore, protein displacement of
medicinal products highly bound to </span><span lang=EN-GB style='font-family:
Symbol'>a</span><sub><span lang=EN-GB>1</span></sub><span lang=EN-GB>&#8209;acid
glycoprotein cannot be ruled out (see section 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>ART&#8209;experienced
patients &#8211; once daily dosing</span></u></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA used in combination with
cobicistat or low dose ritonavir once daily in ART&#8209;experienced patients
should not be used in patients with one or more darunavir resistance associated
mutations (DRV&#8209;RAMs) or HIV&#8209;1 RNA &#8805;&nbsp;100,000&nbsp;copies/ml
or CD4+ cell count &lt;&nbsp;100&nbsp;cells&nbsp;x&nbsp;10<sup>6</sup>/L (see
section 4.2). Combinations with optimised background regimen (OBRs) other than
&#8805;&nbsp;2&nbsp;NRTIs have not been studied in this population. Limited
data are available in patients with HIV&#8209;1 clades other than B (see
section 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is not recommended for use in paediatric
patients below 3&nbsp;years of age or less than 15&nbsp;kg body weight (see
sections 4.2 and 5.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal>PREZISTA/ritonavir should be used during pregnancy only if
the potential benefit justifies the potential risk. <span lang=EN-GB>Caution
should be used in pregnant women with concomitant medications which may further
decrease</span> darunavir exposure (see sections 4.5 and 5.2).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Treatment with darunavir/cobicistat 800/150&nbsp;mg once
daily during the second and third trimester has been shown to result in low
darunavir exposure, with a reduction of around 90% in C<sub>min</sub> levels
(see section&nbsp;5.2). Cobicistat levels decrease and may not provide
sufficient boosting. The substantial reduction in darunavir exposure may result
in virological failure and an increased risk of mother to child transmission of
HIV infection. Therefore, therapy with PREZISTA/cobicistat should not be
initiated during pregnancy, <span lang=EN-GB>and women who become pregnant
during therapy with PREZISTA/cobicistat should be switched to an alternative
regimen </span>(see sections&nbsp;4.2 and 4.6). PREZISTA given with low dose
ritonavir may be considered as an alternative.</p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Elderly</span></u></p>

<p class=MsoNormal><span lang=EN-GB>As limited information is available on the use
of PREZISTA in patients aged&nbsp;65 and over, caution should be exercised in
the administration of PREZISTA in elderly patients, reflecting the greater
frequency of decreased hepatic function and of concomitant disease or other
therapy (see sections 4.2 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Severe
skin reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>During the darunavir/ritonavir clinical
development program (N=3,063), severe skin reactions, which may be accompanied
with fever and/or elevations of transaminases, have been reported in 0.4% of
patients. DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) and Stevens&#8209;Johnson
Syndrome has been rarely (&lt;&nbsp;0.1%) reported, and during post&#8209;marketing
experience toxic epidermal necrolysis and acute generalised exanthematous
pustulosis have been reported. PREZISTA should be discontinued immediately if
signs or symptoms of severe skin reactions develop. These can include, but are
not limited to, severe rash or rash accompanied by fever, general malaise,
fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis
and/or eosinophilia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Rash occurred more commonly in treatment&#8209;experienced
patients receiving regimens containing PREZISTA/ritonavir + raltegravir
compared to patients receiving PREZISTA/ritonavir without raltegravir or
raltegravir without PREZISTA (see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir contains a sulphonamide moiety.
PREZISTA should be used with caution in patients with a known sulphonamide
allergy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Hepatotoxicity</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Drug&#8209;induced hepatitis (e.g. acute
hepatitis, cytolytic hepatitis) has been reported with PREZISTA. During the darunavir/ritonavir
clinical development program (N=3,063), hepatitis was reported in 0.5% of
patients receiving combination antiretroviral therapy with PREZISTA/ritonavir.
Patients with pre&#8209;existing liver dysfunction, including chronic active
hepatitis B or C, have an increased risk for liver function abnormalities
including severe and potentially fatal hepatic adverse reactions. In case of
concomitant antiviral therapy for hepatitis&nbsp;B or C, please refer to the
relevant product information for these medicinal products.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Appropriate laboratory testing should be
conducted prior to initiating therapy with PREZISTA used in combination with
cobicistat or low dose ritonavir and patients should be monitored during
treatment. Increased AST/ALT monitoring should be considered in patients with
underlying chronic hepatitis, cirrhosis, or in patients who have pre&#8209;treatment
elevations of transaminases, especially during the first several months of
PREZISTA used in combination with cobicistat or low dose ritonavir treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If there is evidence of new or worsening
liver dysfunction (including clinically significant elevation of liver enzymes
and/or symptoms such as fatigue, anorexia, nausea, jaundice, dark urine, liver
tenderness, hepatomegaly) in patients using PREZISTA used in combination with
cobicistat or low dose ritonavir, interruption or discontinuation of treatment
should be considered promptly.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Patients
with coexisting conditions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Hepatic
impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of PREZISTA have
not been established in patients with severe underlying liver disorders and
PREZISTA is therefore contraindicated in patients with severe hepatic
impairment. Due to an increase in the unbound darunavir plasma concentrations,
PREZISTA should be used with caution in patients with mild or moderate hepatic
impairment (see sections 4.2, 4.3 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Renal
impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>No special precautions or dose adjustments for
darunavir/ritonavir are required in patients with renal impairment. As
darunavir and ritonavir are highly bound to plasma proteins, it is unlikely
that they will be significantly removed by haemodialysis or peritoneal
dialysis. Therefore, no special precautions or dose adjustments are required in
these patients (see sections 4.2 and 5.2). Cobicistat has not been studied in
patients receiving dialysis, therefore, no recommendation can be made for the
use of darunavir/cobicistat in these patients (see section 4.2).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Cobicistat decreases the estimated
creatinine clearance due to inhibition of tubular secretion of creatinine. This
should be taken into consideration if darunavir with cobicistat is administered
to patients in whom the estimated creatinine clearance is used to adjust doses
of co&#8209;administered medicinal products (see section 4.2 and cobicistat
SmPC).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There are currently inadequate data to
determine whether co&#8209;administration of tenofovir disoproxil and
cobicistat is associated with a greater risk of renal adverse reactions
compared with regimens that include tenofovir disoproxil without cobicistat.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Haemophiliac
patients</span></i></p>

<p class=MsoNormal><span lang=EN-GB>There have been reports of increased
bleeding, including spontaneous skin haematomas and haemarthrosis in patients
with haemophilia type A and B treated with PIs. In some patients additional
factor VIII was given. In more than half of the reported cases, treatment with
PIs was continued or reintroduced if treatment had been discontinued. A causal
relationship has been suggested, although the mechanism of action has not been
elucidated. Haemophiliac patients should, therefore, be made aware of the
possibility of increased bleeding.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Weight
and metabolic parameters</span></i></p>

<p class=MsoNormal><span lang=EN-GB>An increase in weight and in levels of
blood lipids and glucose may occur during antiretroviral therapy. Such changes
may in part be linked to disease control and life style. For lipids, there is
in some cases evidence for a treatment effect, while for weight gain there is
no strong evidence relating this to any particular treatment. For monitoring of
blood lipids and glucose reference is made to established HIV treatment
guidelines. Lipid disorders should be managed as clinically appropriate.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Osteonecrosis</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Although the aetiology is considered to be
multifactorial (including corticosteroid use, alcohol consumption, severe
immunosuppression, higher body mass index), cases of osteonecrosis have been
reported particularly in patients with advanced HIV disease and/or long&#8209;term
exposure to combination antiretroviral therapy (CART). Patients should be
advised to seek medical advice if they experience joint aches and pain, joint
stiffness or difficulty in movement.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Immune reconstitution
inflammatory syndrome</span></u></p>

<p class=MsoNormal><span lang=EN-GB>In HIV infected patients with severe immune
deficiency at the time of initiation of combination antiretroviral therapy
(CART), an inflammatory reaction to asymptomatic or residual opportunistic
pathogens may arise and cause serious clinical conditions, or aggravation of
symptoms. Typically, such reactions have been observed within the first weeks
or months of initiation of CART. Relevant examples are cytomegalovirus
retinitis, generalised and/or focal mycobacterial infections and pneumonia
caused by <i>Pneumocystis jirovecii</i> (formerly known as <i>Pneumocystis
carinii</i>). Any inflammatory symptoms should be evaluated and treatment
instituted when necessary. In addition, reactivation of herpes simplex and
herpes zoster has been observed in clinical studies with PREZISTA co&#8209;administered
with low dose ritonavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Autoimmune disorders (such as Graves'
disease and autoimmune hepatitis) have also been reported to occur in the
setting of immune reactivation; however, the reported time to onset is more
variable and these events can occur many months after initiation of treatment
(see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Interactions
with medicinal products</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Several of the interaction studies have
been performed with darunavir at lower than recommended doses. The effects on
co&#8209;administered medicinal products may thus be underestimated and
clinical monitoring of safety may be indicated. For full information on
interactions with other medicinal products see section 4.5.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Pharmacokinetic
enhancer and concomitant medications</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Darunavir
has different interaction profiles depending on whether the compound is boosted
with ritonavir or cobicistat:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Darunavir boosted with cobicistat is more
sensitive for CYP3A induction: concomitant use of darunavir/cobicistat and
strong CYP3A inducers is therefore contraindicated (see section 4.3), and
concomitant use with weak to moderate CYP3A inducers is not recommended (see
section 4.5). Concomitant use of darunavir/ritonavir and darunavir/cobicistat
with lopinavir/ritonavir, rifampicin and herbal products containing St&nbsp;John&#8217;s&nbsp;wort,
<i>Hypericum perforatum</i>, is contraindicated (see section 4.5).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Unlike ritonavir, cobicistat does not have
inducing effects on enzymes or transport proteins (see section 4.5). If switching
the pharmacoenhancer from ritonavir to cobicistat, caution is required during
the first two weeks of treatment with darunavir/cobicistat, particularly if
doses of any concomitantly administered medicinal products have been titrated
or adjusted during use of ritonavir as a pharmacoenhancer. A dose reduction of
the co&#8209;administered drug may be needed in these cases.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Efavirenz in combination with boosted PREZISTA
may result in sub&#8209;optimal darunavir C<sub>min</sub>. If efavirenz is to
be used in combination with PREZISTA, the PREZISTA/ritonavir 600/100&nbsp;mg
twice daily regimen should be used. See the Summary of Product Characteristics
for PREZISTA 75&nbsp;mg, 150&nbsp;mg and 600&nbsp;mg tablets (see section 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Life&#8209;threatening and fatal drug
interactions have been reported in patients treated with colchicine and strong
inhibitors of CYP3A and P&#8209;glycoprotein (P&#8209;gp; see sections 4.3 and
4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA 400&nbsp;mg tablets contain sunset
yellow FCF (E110) which may cause an allergic reaction.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA 400&nbsp;mg and 800&nbsp;mg
tablets contain less than 1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is
to say essentially &#8216;sodium&#8209;free&#8217;.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction
with other medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The interaction profile of darunavir may
differ depending on whether ritonavir or cobicistat is used as
pharmacoenhancer. The recommendations given for concomitant use of darunavir
and other medicinal products may therefore differ depending on whether darunavir
is boosted with ritonavir or cobicistat (see sections 4.3 and 4.4), and caution
is also required during the first time of treatment if switching the
pharmacoenhancer from ritonavir to cobicistat (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><u><span
lang=EN-GB>Medicinal products that affect darunavir exposure (ritonavir as
pharmacoenhancer)</span></u></b></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir and ritonavir are metabolised by
CYP3A. Medicinal products that induce CYP3A activity would be expected to
increase the clearance of darunavir and ritonavir, resulting in lowered plasma
concentrations of these compounds and consequently that of darunavir, leading
to loss of therapeutic effect and possible development of resistance (see
sections 4.3 and 4.4). CYP3A inducers that are contraindicated include
rifampicin, St&nbsp;John&#8217;s&nbsp;wort and lopinavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Co&#8209;administration of darunavir and
ritonavir with other medicinal products that inhibit CYP3A may decrease the
clearance of darunavir and ritonavir, which may result in increased plasma
concentrations of darunavir and ritonavir. Co&#8209;administration with strong
CYP3A4 inhibitors is not recommended and caution is warranted, these
interactions are described in the interaction table below (e.g. indinavir,
azole antifungals like clotrimazole).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><u><span lang=EN-GB>Medicinal
products that affect darunavir exposure (cobicistat as pharmacoenhancer)</span></u></b></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir and cobicistat are metabolised by
CYP3A, and co&#8209;administration with CYP3A inducers may therefore result in
subtherapeutic plasma exposure to darunavir. Darunavir boosted with cobicistat
is more sensitive to CYP3A induction than ritonavir&#8209;boosted darunavir: co&#8209;administration
of darunavir/cobicistat with medicinal products that are strong inducers of
CYP3A (e.g. St&nbsp;John&#8217;s&nbsp;wort, rifampicin, carbamazepine,
phenobarbital, and phenytoin) is contraindicated (see section 4.3). Co&#8209;administration
of darunavir/cobicistat with weak to moderate CYP3A inducers (e.g. efavirenz,
etravirine, nevirapine, fluticasone, and bosentan) is not recommended (see
interaction table below).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For co&#8209;administration with strong
CYP3A4 inhibitors, the same recommendations apply independent of whether
darunavir is boosted with ritonavir or with cobicistat (see section above).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><u><span lang=EN-GB>Medicinal
products that may be affected by darunavir boosted with ritonavir</span></u></b></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir and ritonavir are inhibitors of
CYP3A, </span><span lang=EN-GB>CYP2D6 and P&#8209;gp</span><span lang=EN-GB>.
Co&#8209;administration of darunavir/ritonavir with medicinal products
primarily metabolised by CYP3A and/or CYP2D6 or transported by P&#8209;gp may
result in increased systemic exposure to such medicinal products, which could
increase or prolong their therapeutic effect and adverse reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir co&#8209;administered with low
dose ritonavir must not be combined with medicinal products that are highly
dependent on CYP3A for clearance and for which increased systemic exposure is
associated with serious and/or life&#8209;threatening events (narrow
therapeutic index) (see section 4.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Co&#8209;administration of boosted darunavir
with drugs that have active metabolite(s) formed by CYP3A may result in reduced
plasma concentrations of these active metabolite(s), potentially leading to
loss of their therapeutic effect (see the Interaction table below).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The overall pharmacokinetic enhancement
effect by ritonavir was an approximate 14&#8209;fold increase in the systemic
exposure of darunavir when a single dose of 600&nbsp;mg darunavir was given
orally in combination with ritonavir at 100&nbsp;mg twice daily. Therefore,
darunavir must only be used in combination with a pharmacokinetic enhancer (see
sections 4.4 and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A clinical study utilising a cocktail of
medicinal products that are metabolised by cytochromes CYP2C9, CYP2C19 and
CYP2D6 demonstrated an increase in CYP2C9 and CYP2C19 activity and inhibition
of CYP2D6 activity in the presence of darunavir/ritonavir, which may be
attributed to the presence of low dose ritonavir. Co&#8209;administration of
darunavir and ritonavir with medicinal products which are primarily metabolised
by CYP2D6 (such as flecainide, propafenone, metoprolol) may result in increased
plasma concentrations of these medicinal products, which could increase or
prolong their therapeutic effect and adverse reactions. Co&#8209;administration
of darunavir and ritonavir with medicinal products primarily metabolised by
CYP2C9 (such as warfarin) and CYP2C19 (such as methadone) may result in
decreased systemic exposure to such medicinal products, which could decrease or
shorten their therapeutic effect.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Although the effect on CYP2C8 has only been
studied <i>in vitro</i>, co&#8209;administration of darunavir and ritonavir and
medicinal products primarily metabolised by CYP2C8 (such as paclitaxel,
rosiglitazone, repaglinide) may result in decreased systemic exposure to such
medicinal products, which could decrease or shorten their therapeutic effect.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Ritonavir inhibits the transporters P&#8209;glycoprotein,
OATP1B1 and OATP1B3, and co&#8209;administration with substrates of these
transporters can result in increased plasma concentrations of these compounds
(e.g. dabigatran etexilate, digoxin, statins and bosentan; see the Interaction
table below).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><u><span lang=EN-GB>Medicinal
products that may be affected by darunavir boosted with cobicistat</span></u></b></p>

<p class=MsoNormal><span lang=EN-GB>The recommendations for darunavir boosted
with ritonavir are adequate also for darunavir boosted with cobicistat with
regard to substrates of CYP3A4, CYP2D6, P&#8209;glycoprotein, OATP1B1 and
OATP1B3 (see contraindications and recommendations presented in the section
above). Cobicistat 150&nbsp;mg given with darunavir 800&nbsp;mg once daily
enhances darunavir pharmacokinetic parameters in a comparable way to ritonavir
(see section 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Unlike ritonavir, cobicistat does not
induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or UGT1A1. For further
information on cobicistat, consult the cobicistat Summary of Product Characteristics.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><u><span
lang=EN-GB>Interaction table</span></u></b></p>

<p class=MsoNormal><span lang=EN-GB>Interaction studies have only been
performed in adults.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Several of the interaction studies
(indicated by </span><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB> in
the table below) have been performed at lower than recommended doses of
darunavir or with a different dosing regimen (see section 4.2 Posology). The
effects on co&#8209;administered medicinal products may thus be underestimated
and clinical monitoring of safety may be indicated.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The interaction profile of darunavir
depends on whether ritonavir or cobicistat is used as pharmacokinetic enhancer.
Darunavir may therefore have different recommendations for concomitant
medications depending on whether the compound is boosted with ritonavir or
cobicistat. No interaction studies presented in the table have been performed
with darunavir boosted with cobicistat. The same recommendations apply, unless
specifically indicated. For further information on cobicistat, consult the
cobicistat Summary of Product Characteristics.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Interactions between darunavir/ritonavir
and antiretroviral and non&#8209;antiretroviral medicinal products are listed
in the table below. The direction of the arrow for each pharmacokinetic
parameter is based on the 90% confidence interval of the geometric mean ratio
being within (&#8596;), below (&#8595;) or above (&#8593;) the 80&#8209;125%
range (not determined as &#8220;ND&#8221;).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the table below the specific
pharmacokinetic enhancer is specified when recommendations differ. When the
recommendation is the same for PREZISTA when co&#8209;administered with a low
dose ritonavir or cobicistat, the term &#8220;boosted PREZISTA&#8221; is used.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The below list of examples of drug&#8209;drug
interactions is not comprehensive and therefore the label of each drug that is
co-administered with PREZISTA should be consulted for information related to
the route of metabolism, interaction pathways, potential risks, and specific
actions to be taken with regards to co&#8209;administration.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>INTERACTIONS AND DOSE
  RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>Medicinal products by therapeutic areas</span></b></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>Interaction</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>Geometric mean change (%)</span></b></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>Recommendations concerning co&#8209;administration</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>HIV ANTIRETROVIRALS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>Integrase strand transfer
  inhibitors</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>Dolutegravir</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>dolutegravir AUC
  &#8595; 22%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>dolutegravir C<sub>24h</sub>
  &#8595; 38%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>dolutegravir</span><span
  lang=EN-GB style='font-size:10.0pt'> C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 11%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir
  &#8596;*</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>*</span><span
  lang=EN-GB style='font-size:9.0pt'> Using cross&#8209;study comparisons to
  historical pharmacokinetic data</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>Boosted PREZISTA and dolutegravir can be used without dose adjustment.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Raltegravir</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Some clinical
  studies suggest raltegravir may cause a modest decrease in darunavir plasma
  concentrations.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>At present the effect of raltegravir on darunavir plasma concentrations
  does not appear to be clinically relevant.</span><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'> Boosted PREZISTA and
  raltegravir can be used without dose adjustments.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>Nucleo(s/t)ide reverse
  transcriptase inhibitors (NRTIs)</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Didanosine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>400&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>didanosine AUC
  &#8595; 9%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>didanosine C<sub>min</sub>
  ND</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>didanosine</span><span
  lang=EN-GB style='font-size:10.0pt'> C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 16%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir C<sub>max</sub>
  &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>Boosted PREZISTA and didanosine can be used without dose adjustments.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>Didanosine is to be administered on an empty stomach, thus it should be
  administered 1&nbsp;hour before or 2&nbsp;hours after boosted PREZISTA given
  with food.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Tenofovir </span><span lang=EN-GB style='font-size:
  10.0pt'>disoproxil</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>245&nbsp;mg once daily</span><sup><span lang=EN-GB>&#8225;</span></sup></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>tenofovir AUC
  &#8593; 22%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>tenofovir C<sub>min</sub>
  &#8593; 37%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>tenofovir C</span><sub><span
  lang=EN-GB style='font-size:10.0pt'>max</span></sub><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 24%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir AUC &#8593; 21%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>min</sub> &#8593; 24%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>max</sub> &#8593; 16%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(&#8593;
  tenofovir from effect on MDR&#8209;1 transport in the renal tubules)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Monitoring of
  renal function may be indicated when boosted PREZISTA is given in combination
  with tenofovir disoproxil, particularly in patients with underlying systemic
  or renal disease, or in patients taking nephrotoxic agents.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>PREZISTA co&#8209;administered
  with cobicistat lowers the creatinine clearance. Refer to section 4.4 if
  creatinine clearance is used for dose adjustment of tenofovir disoproxil.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Emtricitabine/tenofovir alafenamide </span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Tenofovir
  alafenamide</span><span lang=EN-GB style='font-size:10.0pt'> </span><span
  lang=PT style='font-size:10.0pt'>&#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Tenofovir
  &#8593;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The recommended
  dose of emtricitabine/tenofovir alafenamide is 200/10 mg once daily when used
  with boosted PREZISTA. </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Abacavir</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Emtricitabine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Lamivudine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Stavudine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Zidovudine</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. </span><span
  lang=EN-GB style='font-size:10.0pt;layout-grid-mode:line'>Based on the
  different elimination pathways </span><span lang=EN-GB style='font-size:10.0pt'>of
  the other NRTIs zidovudine, emtricitabine, stavudine, lamivudine, that are
  primarily renally excreted, and abacavir for which metabolism is not mediated
  by CYP450, no interactions are expected for these medicinal compounds and boosted
  PREZISTA.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Boosted PREZISTA
  can be used with these NRTIs without dose adjustment.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>PREZISTA co&#8209;administered
  with cobicistat lowers the creatinine clearance. Refer to section 4.4 if
  creatinine clearance is used for dose adjustment of emtricitabine or
  lamivudine.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><i><span
  lang=EN-GB style='font-size:10.0pt'>Non-nucleo(s/t)ide reverse transcriptase
  inhibitors (NNRTIs)</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Efavirenz</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>600&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>efavirenz AUC
  &#8593; 21%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>efavirenz C<sub>min</sub>
  &#8593; 17%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>efavirenz C<sub>max</sub>
  &#8593; 15%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir AUC &#8595; 13%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>min</sub> &#8595; 31%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>max </sub>&#8595; 15%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(&#8593;
  efavirenz from CYP3A inhibition)</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(&#8595;
  darunavir from CYP3A induction)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Clinical
  monitoring for central nervous system toxicity associated with increased
  exposure to efavirenz may be indicated when PREZISTA co&#8209;administered
  with low dose ritonavir is given in combination with efavirenz.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Efavirenz in
  combination with PREZISTA/ritonavir 800/100&nbsp;mg once daily may result in
  sub&#8209;optimal darunavir C<sub>min</sub>. If efavirenz is to be used in
  combination with PREZISTA/ritonavir, the PREZISTA/ritonavir 600/100&nbsp;mg
  twice daily regimen should be used (see section 4.4).</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration
  with PREZISTA co&#8209;administered with cobicistat is not recommended (see
  section 4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Etravirine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>100&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>etravirine AUC
  &#8595; 37%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>etravirine C<sub>min</sub>
  &#8595; 49%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>etravirine C<sub>max
  </sub>&#8595; 32%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8593; 15%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir C<sub>min</sub>
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir C<sub>max</sub>
  &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>PREZISTA co&#8209;administered with low dose ritonavir and etravirine 200&nbsp;mg
  twice daily<b> </b>can be used<b> </b>without dose adjustments.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration
  with PREZISTA co&#8209;administered with cobicistat is not recommended (see
  section 4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Nevirapine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>200&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>nevirapine AUC
  &#8593; 27%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>nevirapine C<sub>min</sub>
  &#8593; 47%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>nevirapine C</span><sub><span
  lang=EN-GB style='font-size:10.0pt'>max</span></sub><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 18%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir: concentrations were consistent with
  historical data</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(&#8593;
  nevirapine from CYP3A inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>PREZISTA co&#8209;administered with low dose ritonavir and nevirapine
  can be used without dose adjustments.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration
  with PREZISTA co&#8209;administered with cobicistat is not recommended (see
  section 4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Rilpivirine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>150&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rilpivirine AUC
  &#8593; 130%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rilpivirine C<sub>min</sub>
  &#8593; 178%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rilpivirine C<sub>max</sub>
  &#8593; 79%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir C<sub>min</sub>
  &#8595; 11%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir C<sub>max</sub>
  &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>Boosted PREZISTA and rilpivirine can be used without dose adjustments.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
  style='font-size:10.0pt'>HIV Protease inhibitors (PIs) &#8209; without
  additional co&#8209;administration of low dose ritonavir</span></i></b><sup><span
  lang=EN-GB>&#8224;</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Atazanavir</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>300&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>atazanavir AUC
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>atazanavir C<sub>min</sub>
  &#8593; 52%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>atazanavir C</span><sub><span
  lang=EN-GB style='font-size:10.0pt'>max</span></sub><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 11%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir AUC &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>min</sub> &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>max</sub> &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Atazanavir:
  comparison of atazanavir/ritonavir 300/100&nbsp;mg once daily vs. atazanavir
  300&nbsp;mg once daily in combination with darunavir/ritonavir
  400/100&nbsp;mg twice daily.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Darunavir:
  comparison of darunavir/ritonavir 400/100&nbsp;mg twice daily vs.
  darunavir/ritonavir 400/100&nbsp;mg twice daily in combination with
  atazanavir 300&nbsp;mg once daily.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>PREZISTA co&#8209;administered with low dose ritonavir and atazanavir
  can be used without dose adjustments.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>PREZISTA</span><span lang=EN-GB style='font-size:10.0pt'> co&#8209;administered
  with </span><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:line'>cobicistat
  should not be used in combination with another antiretroviral agent that
  requires pharmacoenhancement by means of co&#8209;administration with an
  inhibitor of CYP3A4 (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Indinavir</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>800&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=FR style='font-size:10.0pt'>indinavir AUC
  &#8593; 23%</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:10.0pt'>indinavir C<sub>min</sub>
  &#8593; 125%</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:10.0pt'>indinavir C<sub>max</sub>
  &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=FR>#</span></sup><span lang=FR
  style='font-size:10.0pt'>darunavir AUC &#8593; 24%</span></p>
  <p class=MsoNormal><sup><span lang=FR>#</span></sup><span lang=FR
  style='font-size:10.0pt'>darunavir C<sub>min</sub> &#8593; 44%</span></p>
  <p class=MsoNormal><sup><span lang=FR>#</span></sup><span lang=FR
  style='font-size:10.0pt'>darunavir C<sub>max</sub> &#8593; 11%</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:10.0pt'>Indinavir:
  comparison of indinavir/ritonavir 800/100&nbsp;mg twice daily vs.
  indinavir/darunavir/ritonavir 800/400/100&nbsp;mg twice daily.</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:10.0pt'>Darunavir:
  comparison of darunavir/ritonavir 400/100&nbsp;mg twice daily vs.
  darunavir/ritonavir 400/100&nbsp;mg in combination with indinavir 800&nbsp;mg
  twice daily.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>When used in
  combination with PREZISTA co&#8209;administered with low dose ritonavir, dose
  adjustment of indinavir from 800&nbsp;mg twice daily to 600&nbsp;mg twice
  daily may be warranted in case of intolerance.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>PREZISTA co&#8209;administered
  with cobicistat should not be used in combination with another antiretroviral
  agent that requires pharmacoenhancement by means of co&#8209;administration
  with an inhibitor of CYP3A4 (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Saquinavir</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>1,000&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir AUC &#8595; 26%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>min</sub> &#8595; 42%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir C<sub>max</sub> &#8595; 17%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>saquinavir AUC
  &#8595; 6%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>saquinavir C<sub>min</sub>
  &#8595; 18%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>saquinavir C<sub>max</sub>
  &#8595; 6%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Saquinavir:
  comparison of saquinavir/ritonavir 1,000/100&nbsp;mg twice daily vs.
  saquinavir/darunavir/ritonavir 1,000/400/100&nbsp;mg twice daily</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Darunavir:
  comparison of darunavir/ritonavir 400/100&nbsp;mg twice daily vs.
  darunavir/ritonavir 400/100&nbsp;mg in combination with saquinavir
  1,000&nbsp;mg twice daily.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>It is not
  recommended to combine PREZISTA co&#8209;administered with low dose ritonavir
  with saquinavir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>PREZISTA co&#8209;administered
  with cobicistat should not be used in combination with another antiretroviral
  agent that requires pharmacoenhancement by means of co&#8209;administration
  with an inhibitor of CYP3A4 (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
  style='font-size:10.0pt'>HIV Protease inhibitors (PIs) &#8209; with co&#8209;administration
  of low dose ritonavir</span></i></b><b><sup><span lang=EN-GB>&#8224;</span></sup></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Lopinavir/ritonavir</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>400/100&nbsp;mg twice daily</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Lopinavir/ritonavir</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>533/133.3&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lopinavir AUC
  &#8593; 9%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lopinavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 23%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lopinavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 2%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8595; 38%</span><sup><span lang=EN-GB>&#8225;</span></sup></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 51%</span><sup><span lang=EN-GB>&#8225;</span></sup></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 21%</span><sup><span lang=EN-GB>&#8225;</span></sup></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lopinavir AUC
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lopinavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 13%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lopinavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 11%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8595; 41%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 55%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 21%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>&#8225;</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> based upon non dose normalised values</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Due to a
  decrease in the exposure (AUC) of darunavir by 40%, appropriate doses of the
  combination have not been established. Hence, concomitant use of boosted
  PREZISTA and the combination product lopinavir/ritonavir is contraindicated
  (see section 4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>CCR5 ANTAGONIST</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Maraviroc</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>150&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>maraviroc AUC
  &#8593; 305%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>maraviroc </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub> ND</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>maraviroc </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 129%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir,
  ritonavir concentrations were consistent with historical data</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>The maraviroc dose should be 150&nbsp;mg twice daily when co&#8209;administered
  with boosted PREZISTA.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span style='font-size:
  10.0pt'>&#945;1-ADRENORECEPTOR ANTAGONIST</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span style='font-size:10.0pt'>Alfuzosin</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Based on
  theoretical considerations PREZISTA is expected to increase </span><span
  style='font-size:10.0pt'>alfuzosin </span><span lang=EN-GB style='font-size:
  10.0pt'>plasma concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:10.0pt'>Co-administration
  of </span><span lang=EN-GB style='font-size:10.0pt'>boosted PREZISTA</span><span
  lang=EN-GB style='font-size:10.0pt'> </span><span style='font-size:10.0pt'>and
  alfuzosin is contraindicated </span><span lang=EN-GB style='font-size:10.0pt'>(see
  section&nbsp;4.3)</span><span style='font-size:10.0pt'>.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANAESTHETIC</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Alfentanil</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. The
  metabolism of alfentanil is mediated via CYP3A, and may as such be inhibited
  by boosted PREZISTA.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>The concomitant use with boosted PREZISTA may
  require to lower the dose of alfentanil and requires monitoring for risks of
  prolonged or delayed respiratory depression.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIANGINA/</span></b><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIARRHYTHMIC</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Disopyramide</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Flecainide</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Lidocaine (systemic)</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Mexiletine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Propafenone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Amiodarone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Bepridil</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Dronedarone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Ivabradine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Quinidine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Ranolazine</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Boosted PREZISTA is expected to increase these antiarrhythmic plasma
  concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A and/or CYP2D6
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Caution is
  warranted and therapeutic concentration monitoring, if available, is
  recommended for these antiarrhythmics when co&#8209;administered with boosted
  PREZISTA.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co-administration
  of boosted PREZISTA and amiodarone, bepridil, dronedarone, ivabradine, quinidine,
  or ranolazine is contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Digoxin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>0.4&nbsp;mg single dose</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>digoxin AUC
  &#8593; 61%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>digoxin </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> ND</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>digoxin </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 29%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(&#8593; digoxin
  from probable inhibition of P&#8209;gp)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Given that
  digoxin has a narrow therapeutic index, it is recommended that the lowest
  possible dose of digoxin should initially be prescribed in case digoxin is
  given to patients on boosted PREZISTA therapy. The digoxin dose should be
  carefully titrated to obtain the desired clinical effect while assessing the
  overall clinical state of the subject.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIBIOTIC</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Clarithromycin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>500&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>clarithromycin
  AUC &#8593; 57%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>clarithromycin </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 174%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>clarithromycin </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 26%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir AUC &#8595; 13%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir </span><span lang=EN-GB style='font-size:
  10.0pt'>C<sub>min</sub></span><span lang=EN-GB style='font-size:10.0pt'>
  &#8593; 1%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir </span><span lang=EN-GB style='font-size:
  10.0pt'>C<sub>max</sub></span><span lang=EN-GB style='font-size:10.0pt'>
  &#8595; 17%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>14&#8209;OH&#8209;clarithromycin
  concentrations were not detectable when combined with PREZISTA/ritonavir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(&#8593;
  clarithromycin from CYP3A inhibition and possible P&#8209;gp inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Caution should
  be exercised when clarithromycin is combined with boosted PREZISTA.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>For patients
  with renal impairment the Summary of Product Characteristics for
  clarithromycin should be consulted for the recommended dose.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTICOAGULANT</span></b><b><span lang=EN-GB
  style='font-size:10.0pt'>/PLATELET AGGREGATION INHIBITOR</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Apixaban</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Edoxaban</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Rivaroxaban</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. Co&#8209;administration
  of boosted PREZISTA with these anticoagulants may increase concentrations of
  the anticoagulant, which may lead to an increased bleeding risk.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A and/or P&#8209;gp
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The use of
  boosted PREZISTA and these anticoagulants is not recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Dabigatran</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Ticagrelor</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Clopidogrel</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. Co&#8209;administration
  with boosted PREZISTA may lead to a substantial increase in exposure to dabigatran
  or ticagrelor.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. Co&#8209;administration
  of clopidogrel with boosted PREZISTA is expected to decrease clopidogrel
  active metabolite plasma concentration, which may reduce the antiplatelet
  activity of clopidogrel</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant
  administration of boosted PREZISTA with dabigatran or ticagrelor is
  contraindicated (see section&nbsp;4.3).</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration
  of clopidogrel with boosted PREZISTA is not recommended.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Use of other
  antiplatelets not affected by CYP inhibition or induction (e.g. prasugrel) is
  recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Warfarin</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Warfarin concentrations may be affected when co&#8209;administered with boosted
  PREZISTA.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>It is
  recommended that the international normalised ratio (INR) be monitored when
  warfarin is combined with boosted PREZISTA.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTICONVULSANTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Phenobarbital</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Phenytoin</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Phenobarbital and phenytoin are expected to decrease plasma concentrations of
  darunavir and its pharmacoenhancer.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(induction of
  CYP450 enzymes)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>PREZISTA co&#8209;administered
  with low dose ritonavir should not be used in combination with these
  medicines.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The use of these
  medicines with PREZISTA/cobicistat is contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Carbamazepine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>200&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>carbamazepine
  AUC &#8593; 45%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>carbamazepine </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 54%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>carbamazepine </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 43%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 15%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>No dose
  adjustment for PREZISTA/ritonavir is recommended. If there is a need to
  combine PREZISTA/ritonavir and carbamazepine, patients should be monitored
  for potential carbamazepine&#8209;related adverse events. Carbamazepine
  concentrations should be monitored and its dose should be titrated for
  adequate response. Based upon the findings, the carbamazepine dose may need
  to be reduced by 25% to 50% in the presence of PREZISTA/ritonavir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The use of
  carbamazepine with PREZISTA co&#8209;administered with cobicistat is
  contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Clonazepam</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. </span><span
  lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration of boosted </span><span
  lang=EN-GB style='font-size:10.0pt'>PREZISTA with clonazepam may increase
  concentrations of clonazepam. (CYP3A inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Clinical
  monitoring is recommended when co&#8209;administering boosted PREZISTA with clonazepam.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIDEPRESSANTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Paroxetine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>20&nbsp;mg once daily</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Sertraline</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>50&nbsp;mg once daily</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Amitriptyline</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Desipramine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Imipramine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Nortriptyline</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Trazodone</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>paroxetine</span><span
  lang=IT style='font-size:10.0pt'> AUC &#8595; 39%</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>paroxetine</span><span
  lang=IT style='font-size:10.0pt'> </span><span lang=IT style='font-size:10.0pt'>C<sub>min</sub></span><span
  lang=IT style='font-size:10.0pt'> &#8595;</span><span lang=IT
  style='font-size:10.0pt'> 37%</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>paroxetine</span><span
  lang=IT style='font-size:10.0pt'> </span><span lang=IT style='font-size:10.0pt'>C<sub>max</sub></span><span
  lang=IT style='font-size:10.0pt'> &#8595; 36%</span></p>
  <p class=MsoNormal><sup><span lang=IT>#</span></sup><span lang=IT
  style='font-size:10.0pt'>darunavir AUC &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=IT>#</span></sup><span lang=IT
  style='font-size:10.0pt'>darunavir </span><span lang=IT style='font-size:
  10.0pt'>C<sub>min</sub></span><span lang=IT style='font-size:10.0pt'> &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=IT>#</span></sup><span lang=IT
  style='font-size:10.0pt'>darunavir </span><span lang=IT style='font-size:
  10.0pt'>C<sub>max</sub></span><span lang=IT style='font-size:10.0pt'> &#8596;</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>sertraline AUC
  &#8595; 49%</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>sertraline </span><span
  lang=IT style='font-size:10.0pt'>C<sub>min</sub></span><span lang=IT
  style='font-size:10.0pt'> &#8595;</span><span lang=IT style='font-size:10.0pt'>
  49%</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>sertraline </span><span
  lang=IT style='font-size:10.0pt'>C<sub>max</sub></span><span lang=IT
  style='font-size:10.0pt'> &#8595; 44%</span></p>
  <p class=MsoNormal><sup><span lang=IT>#</span></sup><span lang=IT
  style='font-size:10.0pt'>darunavir AUC &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=IT>#</span></sup><span lang=IT
  style='font-size:10.0pt'>darunavir </span><span lang=IT style='font-size:
  10.0pt'>C<sub>min</sub></span><span lang=IT style='font-size:10.0pt'> &#8595;
  6%</span></p>
  <p class=MsoNormal><sup><span lang=IT>#</span></sup><span lang=IT
  style='font-size:10.0pt'>darunavir </span><span lang=IT style='font-size:
  10.0pt'>C<sub>max</sub></span><span lang=IT style='font-size:10.0pt'> &#8596;</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>In contrast to
  these data with PREZISTA/ritonavir, PREZISTA/cobicistat may increase these
  antidepressant plasma concentrations (CYP2D6 and/or CYP3A inhibition).</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant use
  of boosted PREZISTA and these antidepressants may increase concentrations of
  the antidepressant.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP2D6 and/or
  CYP3A inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>If
  antidepressants are co&#8209;administered with boosted PREZISTA, the
  recommended approach is a dose titration of the antidepressant based on a
  clinical assessment of antidepressant response. In addition, patients on a
  stable dose of these antidepressants who start treatment with boosted
  PREZISTA should be monitored for antidepressant response.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Clinical
  monitoring is recommended when co&#8209;administering boosted PREZISTA with these
  antidepressants and a dose adjustment of the antidepressant may be needed.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTI&#8209;DIABETICS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Metformin</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Based on theoretical considerations PREZISTA co&#8209;administered with
  cobicistat is expected to increase metformin plasma concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(MATE1
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Careful patient
  monitoring and dose adjustment of metformin is recommended in patients who
  are taking </span><span lang=EN-GB style='font-size:10.0pt'>PREZISTA co&#8209;administered
  with cobicistat.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(not applicable
  for </span><span lang=EN-GB style='font-size:10.0pt'>PREZISTA co&#8209;administered
  with ritonavir)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIEMETICS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Domperidone</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co-administration
  of domperidone with boosted PREZISTA is contraindicated.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIFUNGALS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Voriconazole</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Ritonavir may decrease plasma concentrations of voriconazole.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(induction of
  CYP450 enzymes)</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concentrations
  of voriconazole may increase or decrease when co&#8209;administered with
  PREZISTA co&#8209;administered with cobicistat.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(inhibition of
  CYP450 enzymes)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Voriconazole
  should not be combined with boosted PREZISTA unless an assessment of the
  benefit/risk ratio justifies the use of voriconazole.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Fluconazole</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Isavuconazole</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Itraconazole</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Posaconazole</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Clotrimazole</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Boosted PREZISTA may increase antifungal plasma concentrations and
  posaconazole, isavuconazole, itraconazole or fluconazole may increase
  darunavir concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A and/or P&#8209;gp
  inhibition)</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Concomitant systemic use of clotrimazole and boosted PREZISTA may increase
  plasma concentrations of darunavir and/or clotrimazole.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC<sub>24h</sub>
  &#8593; 33% (based on population pharmacokinetic model)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Caution is
  warranted and clinical monitoring is recommended.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;When co&#8209;administration
  is required the daily dose of itraconazole should not exceed 200&nbsp;mg.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIGOUT MEDICINES</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Colchicine</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Concomitant use of colchicine and boosted PREZISTA may increase the exposure
  to colchicine.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A and/ or P&#8209;gp
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>A reduction in
  colchicine dosage or an interruption of colchicine treatment is recommended
  in patients with normal renal or hepatic function if treatment with boosted
  PREZISTA is required. For patients with renal or hepatic impairment
  colchicine with boosted PREZISTA is contraindicated (see sections 4.3 and 4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIMALARIALS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Artemether/Lumefantrine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>80/480&nbsp;mg, 6&nbsp;doses at 0, 8, 24, 36, 48,
  and 60&nbsp;hours</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>artemether AUC
  &#8595; 16%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>artemether C<sub>min</sub>
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>artemether C<sub>max</sub>
  &#8595; 18%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>dihydroartemisinin
  AUC &#8595; 18%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>dihydroartemisinin
  C<sub>min</sub> &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>dihydroartemisinin
  C<sub>max</sub> &#8595; 18%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lumefantrine AUC
  &#8593; 175%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lumefantrine C<sub>min</sub>
  &#8593; 126%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>lumefantrine C<sub>max</sub>
  &#8593; 65%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir C<sub>min</sub>
  &#8595; 13%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir C<sub>max</sub>
  &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The combination
  of boosted PREZISTA and artemether/lumefantrine can be used without dose
  adjustments; however, due to the increase in lumefantrine exposure, the
  combination should be used with caution.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIMYCOBACTERIALS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Rifampicin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Rifapentine</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Rifapentine and rifampicin are strong CYP3A inducers and have been shown to
  cause profound decreases in concentrations of other protease inhibitors,
  which can result in virological failure and resistance development (CYP450
  enzyme induction). During attempts to overcome the decreased exposure by
  increasing the dose of other protease inhibitors with low dose ritonavir, a
  high frequency of liver reactions was seen with rifampicin.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The combination
  of rifapentine and boosted PREZISTA is not recommended.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The combination
  of rifampicin and boosted PREZISTA is contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Rifabutin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>150&nbsp;mg once every other day</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rifabutin AUC</span><sup><span
  lang=EN-GB>**</span></sup><span lang=EN-GB style='font-size:10.0pt'> &#8593;
  55%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rifabutin C<sub>min</sub></span><sup><span
  lang=EN-GB>**</span></sup><span lang=EN-GB style='font-size:10.0pt'> &#8593;
  ND</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rifabutin C<sub>max</sub></span><sup><span
  lang=EN-GB>**</span></sup><span lang=EN-GB style='font-size:10.0pt'> &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir AUC
  &#8593; 53%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 68</span><span lang=EN-GB style='font-size:
  10.0pt'>%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>darunavir </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 39%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>**</span></sup><span lang=EN-GB
  style='font-size:10.0pt'> </span><span lang=EN-GB style='font-size:9.0pt'>sum
  of active moieties of rifabutin (parent drug +&nbsp;25&#8209;<i>O&#8209;</i>desacetyl
  metabolite)</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The interaction
  trial showed a comparable daily systemic exposure for rifabutin between
  treatment at 300&nbsp;mg once daily alone and 150&nbsp;mg once every other
  day in combination with PREZISTA/ritonavir (600/100&nbsp;mg twice daily) with
  an about 10&#8209;fold increase in the daily exposure to the active
  metabolite 25&#8209;<i>O&#8209;</i>desacetylrifabutin. Furthermore, AUC of
  the sum of active moieties of rifabutin (parent drug +&nbsp;25&#8209;<i>O&#8209;</i>desacetyl
  metabolite) was increased 1.6&#8209;fold, while C<sub>max</sub> remained
  comparable.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Data on
  comparison with a 150&nbsp;mg once daily reference dose is lacking.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(Rifabutin is an
  inducer and substrate of CYP3A.) An increase of systemic exposure to
  darunavir was observed when PREZISTA co&#8209;administered with 100&nbsp;mg
  ritonavir was co&#8209;administered with rifabutin (150&nbsp;mg once every
  other day).</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>A dosage
  reduction of rifabutin by 75% of the usual dose of 300&nbsp;mg/day (i.e.
  rifabutin 150&nbsp;mg once every other day) and increased monitoring for
  rifabutin related adverse events is warranted in patients receiving the
  combination with PREZISTA co&#8209;administered with ritonavir. In case of
  safety issues, a further increase of the dosing interval for rifabutin and/or
  monitoring of rifabutin levels should be considered.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Consideration
  should be given to official guidance on the appropriate treatment of
  tuberculosis in HIV infected patients.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Based upon the
  safety profile of PREZISTA/ritonavir, the increase in darunavir exposure in
  the presence of rifabutin does not warrant a dose adjustment for
  PREZISTA/ritonavir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Based on
  pharmacokinetic modeling, this dosage reduction of 75% is also applicable if
  patients receive rifabutin at doses other than 300&nbsp;mg/day.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration
  of PREZISTA co&#8209;administered with cobicistat and rifabutin is not
  recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTINEOPLASTICS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Dasatinib</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Nilotinib</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Vinblastine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Vincristine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Everolimus</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Irinotecan</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Boosted PREZISTA is expected to increase these antineoplastic plasma
  concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>Concentrations of these medicinal products may be
  increased when co&#8209;administered with boosted PREZISTA resulting in the
  potential for increased adverse events usually associated with these agents.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Caution should
  be exercised when combining one of these antineoplastic agents with boosted
  PREZISTA.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant use
  of everolimus or irinotecan and boosted PREZISTA is not recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ANTIPSYCHOTICS</span></b><b><span lang=EN-GB
  style='font-size:10.0pt'>/NEUROLEPTICS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Quetiapine</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Boosted PREZISTA is expected to increase these antipsychotic plasma
  concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant
  administration of boosted PREZISTA and quetiapine is contraindicated as it
  may increase quetiapine&#8209;related toxicity. Increased concentrations of
  quetiapine may lead to coma (see section&nbsp;4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Perphenazine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Risperidone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Thioridazine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Lurasidone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Pimozide</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=IT style='font-size:
  10.0pt'>Sertindole</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Boosted PREZISTA is expected to increase these antipsychotic plasma
  concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A, CYP2D6
  and/or P&#8209;gp inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>A dose decrease
  may be needed for these drugs when co&#8209;administered with boosted
  PREZISTA.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant administration
  of boosted PREZISTA and lurasidone, pimozide or sertindole is contraindicated
  (see section&nbsp;4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>&#946;-BLOCKERS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Carvedilol</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Metoprolol</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Timolol</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Boosted PREZISTA is expected to increase these &#946;&#8209;blocker plasma
  concentrations.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP2D6
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Clinical
  monitoring is recommended when co&#8209;administering boosted PREZISTA with
  &#946;&#8209;blockers. A lower dose of the &#946;&#8209;blocker should be
  considered.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>CALCIUM CHANNEL BLOCKERS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Amlodipine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Diltiazem</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Felodipine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Nicardipine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Nifedipine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Verapamil</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Boosted PREZISTA can be expected to increase the plasma concentrations of
  calcium channel blockers.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A and/or
  CYP2D6 inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Clinical
  monitoring of therapeutic and adverse effects is recommended when these
  medicines are concomitantly administered with boosted PREZISTA.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB style='font-size:10.0pt'>CORTICOSTEROIDS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Corticosteroids primarily metabolised by CYP3A
  (including betamethasone, budesonide, fluticasone, mometasone, prednisone,
  triamcinolone)</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Fluticasone: in
  a clinical study where ritonavir 100&nbsp;mg capsules twice daily were co&#8209;administered
  with 50&nbsp;</span><span lang=EN-GB style='font-size:10.0pt;font-family:
  Symbol'>m</span><span lang=EN-GB style='font-size:10.0pt'>g intranasal
  fluticasone propionate (4&nbsp;times daily) for 7&nbsp;days in healthy
  subjects, fluticasone propionate plasma concentrations increased
  significantly, whereas the intrinsic cortisol levels decreased by
  approximately 86% (90% CI 82&#8209;89%). Greater effects may be expected when
  fluticasone is inhaled. Systemic corticosteroid effects including
  Cushing&#8217;s syndrome and adrenal suppression have been reported in
  patients receiving ritonavir and inhaled or intranasally administered
  fluticasone. The effects of high fluticasone systemic exposure on ritonavir
  plasma levels are unknown.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span style='font-size:10.0pt'>Other corticosteroids: interaction
  not studied. Plasma concentrations of these medicinal products may be
  increased when co-administered with boosted PREZISTA, resulting in reduced
  serum cortisol concentrations.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:10.0pt'>Concomitant use of boosted
  PREZISTA and corticosteroids that are metabolised by CYP3A (e.g. fluticasone
  propionate or other inhaled or nasal corticosteroids) may increase the risk
  of development of systemic corticosteroid effects, including Cushing&#8217;s
  syndrome and adrenal suppression.</span></p>
  <p class=MsoNormal><span style='font-size:10.0pt'>Co-administration with
  CYP3A-metabolised corticosteroids is not recommended unless the potential
  benefit to the patient outweighs the risk, in which case patients should be
  monitored for systemic corticosteroid effects.</span></p>
  <p class=MsoNormal><span style='font-size:10.0pt'>Alternative corticosteroids
  which are less dependent on CYP3A metabolism e.g. beclomethasone for
  intranasal or inhalational use should be considered, particularly for long
  term use.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Dexamethasone</span><span lang=EN-GB
  style='font-size:10.0pt'> (systemic)</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Dexamethasone may decrease plasma concentrations of darunavir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  induction)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Systemic
  dexamethasone should be used with caution when combined with boosted
  PREZISTA.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>ENDOTHELIN RECEPTOR ANTAGONISTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Bosentan</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Concomitant use of bosentan and boosted PREZISTA may increase plasma concentrations
  of bosentan.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Bosentan is
  expected to decrease plasma concentrations of darunavir and/or its
  pharmacoenhancer.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  induction)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>When
  administered concomitantly with PREZISTA and low dose ritonavir, the
  patient&#8217;s tolerability of bosentan should be monitored.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co-administration
  of PREZISTA co-administered with cobicistat and bosentan is not recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>HEPATITIS C VIRUS (HCV) DIRECT&#8209;ACTING
  ANTIVIRALS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB
  style='font-size:10.0pt'>NS3&#8209;4A protease inhibitors</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span style='font-size:10.0pt'>Elbasvir/grazoprevir</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Boosted PREZISTA
  m</span><span style='font-size:10.0pt'>ay increase the exposure to grazoprevir.</span></p>
  <p class=MsoNormal><span style='font-size:10.0pt'>(CYP3A and OATP1B inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:10.0pt'>Concomitant use of boosted PREZISTA
  and elbasvir/grazoprevir is contraindicated </span><span lang=EN-GB
  style='font-size:10.0pt'>(see section&nbsp;4.3)</span><span style='font-size:
  10.0pt'>.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Glecaprevir/pibrentasvir</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Based on
  theoretical considerations boosted PREZISTA may increase the exposure to glecaprevir
  and pibrentasvir.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(P&#8209;gp,
  BCRP and/or OATP1B1/3 inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>It is not
  recommended to co&#8209;administer boosted PREZISTA with
  glecaprevir/pibrentasvir.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB style='font-size:10.0pt'>HERBAL PRODUCTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>St&nbsp;John's&nbsp;wort</span><span lang=EN-GB
  style='font-size:10.0pt'> <i>(Hypericum perforatum)</i></span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied. </span><span
  lang=EN-GB style='font-size:10.0pt'>St&nbsp;John&#8217;s&nbsp;wort is
  expected to decrease the plasma concentrations of darunavir or its
  pharmacoenhancers.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP450
  induction)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Boosted PREZISTA
  must not be used concomitantly with products containing
  St&nbsp;John&#8217;s&nbsp;wort (<i>Hypericum perforatum</i>) (see section
  4.3). If a patient is already taking St&nbsp;John&#8217;s&nbsp;wort, stop
  St&nbsp;John&#8217;s&nbsp;wort and if possible check viral levels. Darunavir
  exposure (and also ritonavir exposure) may increase on stopping
  St&nbsp;John&#8217;s&nbsp;wort. The inducing effect may persist for at least
  2&nbsp;weeks after cessation of treatment with
  St&nbsp;John&#8217;s&nbsp;wort.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB style='font-size:10.0pt'>HMG&nbsp;CO&#8209;A REDUCTASE INHIBITORS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Lovastatin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Simvastatin</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Lovastatin and simvastatin are expected to have markedly increased plasma
  concentrations when co&#8209;administered with boosted PREZISTA.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Increased plasma
  concentrations of lovastatin or simvastatin may cause myopathy, including
  rhabdomyolysis. Concomitant use of </span><span lang=EN-GB style='font-size:
  10.0pt'>boosted </span><span lang=EN-GB style='font-size:10.0pt'>PREZISTA
  with lovastatin and simvastatin is therefore contraindicated (see section
  4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Atorvastatin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>10&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>atorvastatin</span><span
  lang=EN-GB style='font-size:10.0pt'> AUC &#8593; 3&#8209;4 fold</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>atorvastatin</span><span
  lang=EN-GB style='font-size:10.0pt'> </span><span lang=EN-GB
  style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; </span><span lang=EN-GB style='font-size:
  9.0pt'>&#8776;</span><span lang=EN-GB style='font-size:10.0pt'>5.5&#8209;10
  fold</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>atorvastatin</span><span
  lang=EN-GB style='font-size:10.0pt'> </span><span lang=EN-GB
  style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; &#8776;2 fold</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB> </span><span
  lang=EN-GB style='font-size:9.0pt'>darunavir/ritonavir</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  style='font-size:10.0pt'>atorvastatin AUC &#8593; 290%</span><sup><span
  lang=EN-GB> &#937;</span></sup></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  style='font-size:10.0pt'>atorvastatin C<sub>max</sub> &#8593; 319%</span><sup><span
  lang=EN-GB> &#937;</span></sup></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  style='font-size:10.0pt'>atorvastatin C<sub>min</sub> ND</span><sup><span
  lang=EN-GB> &#937;</span></sup></p>
  <p class=MsoNormal style='text-autospace:none'><sup><span lang=EN-GB>&#937;</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> with darunavir/cobicistat 800/150&nbsp;mg</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>When
  administration of atorvastatin and boosted PREZISTA is desired, it is
  recommended to start with an atorvastatin dose of 10&nbsp;mg once daily. A
  gradual dose increase of atorvastatin may be tailored to the clinical
  response.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Pravastatin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>40&nbsp;mg single dose</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>pravastatin AUC
  &#8593; 81%</span><sup><span lang=EN-GB>&para;</span></sup></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>pravastatin </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> ND</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>pravastatin </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8593; 63%</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>&para;</span></sup><span lang=EN-GB
  style='font-size:9.0pt'> an up to five-fold increase was seen in a limited
  subset of subjects</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>When
  administration of pravastatin and boosted PREZISTA is required, it is
  recommended to start with the lowest possible dose of pravastatin and titrate
  up to the desired clinical effect while monitoring for safety.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Rosuvastatin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>10&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rosuvastatin AUC
  &#8593; 48%</span><sup><span lang=EN-GB>&#9553;</span></sup></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>rosuvastatin C<sub>max</sub>
  &#8593; 144%</span><sup><span lang=EN-GB>&#9553;</span></sup></p>
  <p class=MsoNormal><sup><span lang=EN-GB>&#9553;</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> based on published data with
  darunavir/ritonavir</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:10.0pt'>rosuvastatin
  AUC &#8593; 93%</span><sup><span lang=EN-GB>&sect;</span></sup></p>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:10.0pt'>rosuvastatin
  C<sub>max</sub> &#8593; 277%</span><sup><span lang=EN-GB>&sect;</span></sup></p>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:10.0pt'>rosuvastatin
  C<sub>min</sub> ND</span><sup><span lang=EN-GB>&sect;</span></sup></p>
  <p class=MsoNormal style='text-autospace:none'><sup><span lang=EN-GB>&sect;</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> with darunavir/cobicistat 800/150&nbsp;mg</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>When
  administration of rosuvastatin and boosted PREZISTA is required, it is
  recommended to start with the lowest possible dose of rosuvastatin and
  titrate up to the desired clinical effect while monitoring for safety.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>OTHER LIPID MODIFYING AGENTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Lomitapide</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Based on
  theoretical considerations boosted PREZISTA is expected to increase the
  exposure of lomitapide when co-administered.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co-administration
  is </span><span lang=EN-GB style='font-size:10.0pt'>contraindicated (see
  section 4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>H</span></b><b><sub><span lang=EN-GB>2</span></sub></b><b><span
  lang=EN-GB style='font-size:10.0pt'>&#8209;RECEPTOR ANTAGONISTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Ranitidine</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>150&nbsp;mg twice daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir AUC &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir </span><span lang=EN-GB style='font-size:
  10.0pt'>C<sub>min</sub></span><span lang=EN-GB style='font-size:10.0pt'>
  &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir </span><span lang=EN-GB style='font-size:
  10.0pt'>C<sub>max</sub></span><span lang=EN-GB style='font-size:10.0pt'>
  &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Boosted PREZISTA
  can be co&#8209;administered with H<sub>2</sub>&#8209;receptor antagonists
  without dose adjustments.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>IMMUNOSUPPRESSANTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Ciclosporin</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Sirolimus</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Tacrolimus</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Everolimus</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Exposure to these immunosuppressants will be increased when co&#8209;administered
  with boosted PREZISTA.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Therapeutic drug
  monitoring of the immunosuppressive agent must be done when co&#8209;administration
  occurs.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant use
  of everolimus and boosted PREZISTA is not recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB style='font-size:10.0pt'>INHALED BETA AGONISTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Salmeterol</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Concomitant use of salmeterol and boosted darunavir may increase plasma
  concentrations of salmeterol.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant use
  of salmeterol and boosted PREZISTA is not recommended. The combination may
  result in increased risk of cardiovascular adverse event with salmeterol,
  including QT prolongation, palpitations and sinus tachycardia.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB style='font-size:10.0pt'>NARCOTIC ANALGESICS / TREATMENT OF OPIOID
  DEPENDENCE</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Methadone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>individual dose ranging from 55&nbsp;mg to
  150&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT-BR style='font-size:10.0pt'>R(&#8209;)&nbsp;methadone</span><span
  lang=PT-BR style='font-size:10.0pt'> AUC &#8595; 16%</span></p>
  <p class=MsoNormal><span lang=PT-BR style='font-size:10.0pt'>R(&#8209;)&nbsp;methadone</span><span
  lang=PT-BR style='font-size:10.0pt'> </span><span lang=PT-BR
  style='font-size:10.0pt'>C<sub>min</sub></span><span lang=PT-BR
  style='font-size:10.0pt'> &#8595; 15%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>R(&#8209;)&nbsp;methadone</span><span
  lang=EN-GB style='font-size:10.0pt'> </span><span lang=EN-GB
  style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 24%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>PREZISTA/cobicistat
  may, in contrast, increase methadone plasma concentrations (see cobicistat
  SmPC).</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>No adjustment of
  methadone dosage is required when initiating co&#8209;administration with boosted
  PREZISTA. However, adjustment of the methadone dose may be necessary when
  concomitantly administered for a longer period of time. Therefore, clinical
  monitoring is recommended, as maintenance therapy may need to be adjusted in
  some patients.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Buprenorphine/naloxone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>8/2&nbsp;mg&#8211;16/4&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>buprenorphine
  AUC &#8595; 11%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>buprenorphine </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>buprenorphine </span><span
  lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span><span lang=EN-GB
  style='font-size:10.0pt'> &#8595; 8%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>norbuprenorphine
  AUC &#8593; 46%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>norbuprenorphine
  </span><span lang=EN-GB style='font-size:10.0pt'>C<sub>min </sub></span><span
  lang=EN-GB style='font-size:10.0pt'>&#8593; </span><span lang=EN-GB
  style='font-size:10.0pt'>71%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>norbuprenorphine
  </span><span lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub> </span><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;</span><span lang=EN-GB
  style='font-size:10.0pt'> 36%</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>naloxone AUC
  &#8596;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>naloxone C<sub>min</sub>
  ND</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>naloxone C<sub>max</sub>
  &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The clinical
  relevance of the increase in norbuprenorphine pharmacokinetic parameters has
  not been established. Dose adjustment for buprenorphine may not be necessary
  when co&#8209;administered with </span><span lang=EN-GB style='font-size:
  10.0pt'>boosted </span><span lang=EN-GB style='font-size:10.0pt'>PREZISTA but
  a careful clinical monitoring for signs of opiate toxicity is recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Fentanyl</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Oxycodone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Tramadol</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Based on
  theoretical considerations boosted PREZISTA may increase plasma
  concentrations of these analgesics.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP2D6 and/or
  CYP3A inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Clinical
  monitoring is recommended when co&#8209;administering </span><span
  lang=EN-GB style='font-size:10.0pt'>boosted PREZISTA</span><span lang=EN-GB
  style='font-size:10.0pt'> with these analgesics.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>OESTROGEN&#8209;BASED</span></b><b><span lang=EN-GB
  style='font-size:10.0pt'> CONTRACEPTIVES</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Drospirenone Ethinylestradiol
  (3&nbsp;mg/0.02&nbsp;mg once daily)</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Ethinylestradiol</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Norethindrone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>35&nbsp;</span><span lang=EN-GB style='font-size:
  10.0pt;font-family:Symbol'>m</span><span lang=EN-GB style='font-size:10.0pt'>g/1&nbsp;mg
  once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=IT
  style='font-size:10.0pt'>drospirenone AUC &#8593; 58%</span><sup><span
  lang=IT>&#8364;</span></sup></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=IT
  style='font-size:10.0pt'>drospirenone C<sub>min</sub> ND</span><sup><span
  lang=IT>&#8364;</span></sup></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=IT
  style='font-size:10.0pt'>drospirenone C<sub>max</sub> &#8593; 15%</span><sup><span
  lang=IT>&#8364;</span></sup></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=IT
  style='font-size:10.0pt'>ethinylestradiol AUC </span><span style='font-size:
  10.0pt;font-family:Symbol'>&macr;</span><span lang=IT style='font-size:10.0pt'>
  30%</span><sup><span lang=IT>&#8364;</span></sup></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>ethinylestradiol C<sub>min</sub>
  ND</span><sup><span lang=IT>&#8364;</span></sup></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=IT
  style='font-size:10.0pt'>ethinylestradiol C<sub>max</sub> </span><span
  style='font-size:10.0pt;font-family:Symbol'>&macr;</span><span lang=IT
  style='font-size:10.0pt'> 14%</span><sup><span lang=IT>&#8364;</span></sup></p>
  <p class=MsoNormal><sup><span lang=IT>&#8364;</span></sup><span lang=IT
  style='font-size:9.0pt'> </span><span lang=IT style='font-size:9.0pt'>with
  darunavir/cobicistat</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>ethinylestradiol
  AUC &#8595; 44%</span><sup><span lang=EN-GB>&#946;</span></sup></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>ethinylestradiol </span><span
  lang=IT style='font-size:10.0pt'>C<sub>min</sub></span><span lang=IT
  style='font-size:10.0pt'> &#8595; 62%</span><sup><span lang=EN-GB>&#946;</span></sup></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>ethinylestradiol </span><span
  lang=IT style='font-size:10.0pt'>C<sub>max</sub></span><span lang=IT
  style='font-size:10.0pt'> &#8595; 32%</span><sup><span lang=EN-GB>&#946;</span></sup></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>norethindrone</span><span
  lang=IT style='font-size:10.0pt'> AUC &#8595; 14%</span><sup><span
  lang=EN-GB>&#946;</span></sup></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>norethindrone</span><span
  lang=IT style='font-size:10.0pt'> </span><span lang=IT style='font-size:10.0pt'>C<sub>min</sub></span><span
  lang=IT style='font-size:10.0pt'> &#8595;</span><span lang=IT
  style='font-size:10.0pt'> 30%</span><sup><span lang=EN-GB>&#946;</span></sup></p>
  <p class=MsoNormal><span lang=IT style='font-size:10.0pt'>norethindrone</span><span
  lang=IT style='font-size:10.0pt'> </span><span lang=IT style='font-size:10.0pt'>C<sub>max</sub></span><span
  lang=IT style='font-size:10.0pt'> &#8596;</span><sup><span lang=EN-GB>&#946;</span></sup></p>
  <p class=MsoNormal><sup><span lang=EN-GB>&#946;</span></sup><span lang=EN-GB
  style='font-size:10.0pt'> </span><span lang=IT style='font-size:9.0pt'>with
  darunavir/ritonavir</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>When PREZISTA is co-administered with a
  drospirenone-containing product, clinical monitoring is recommended due to
  the potential for hyperkalaemia.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Alternative or
  additional contraceptive measures are recommended when oestrogen&#8209;based
  contraceptives are co&#8209;administered with boosted PREZISTA. Patients
  using oestrogens as hormone replacement therapy should be clinically
  monitored for signs of oestrogen deficiency.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB style='font-size:10.0pt'>OPIOID ANTAGONIST</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Naloxegol</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT-BR style='font-size:10.0pt'>Not studied.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration
  of boosted PREZISTA and naloxegol is contraindicated.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>PHOSPHODIESTERASE, TYPE 5 (PDE&#8209;5) INHIBITORS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>For the
  treatment of erectile dysfunction</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Avanafil</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Sildenafil</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Tadalafil</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Vardenafil</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>In an
  interaction study </span><sup><span lang=EN-GB>#</span></sup><span
  lang=EN-GB style='font-size:10.0pt'>, a comparable systemic exposure to
  sildenafil was observed for a single intake of 100&nbsp;mg sildenafil alone
  and a single intake of 25&nbsp;mg sildenafil co&#8209;administered with</span><span
  lang=EN-GB style='font-size:10.0pt'> PREZISTA and low dose ritonavir.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The combination
  of avanafil and boosted PREZISTA is contraindicated (see section 4.3).</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Concomitant use
  of other PDE&#8209;5 inhibitors for the treatment of erectile dysfunction
  with </span><span lang=EN-GB style='font-size:10.0pt'>boosted </span><span
  lang=EN-GB style='font-size:10.0pt'>PREZISTA should be done with caution. If
  concomitant use of </span><span lang=EN-GB style='font-size:10.0pt'>boosted </span><span
  lang=EN-GB style='font-size:10.0pt'>PREZISTA with sildenafil, vardenafil or
  tadalafil is indicated, sildenafil at a single dose not exceeding 25&nbsp;mg
  in 48&nbsp;hours, vardenafil at a single dose not exceeding 2.5&nbsp;mg in
  72&nbsp;hours or tadalafil at a single dose not exceeding 10&nbsp;mg in
  72&nbsp;hours is recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>For the
  treatment of pulmonary arterial hypertension</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Sildenafil</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Tadalafil</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Concomitant use of sildenafil or tadalafil for the treatment of pulmonary
  arterial hypertension and boosted PREZISTA may increase plasma concentrations
  of sildenafil or tadalafil.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(CYP3A
  inhibition)</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>A safe and
  effective dose of sildenafil for the treatment of pulmonary arterial
  hypertension co&#8209;administered with boosted PREZISTA has not been
  established. There is an increased potential for sildenafil&#8209;associated
  adverse events (including visual disturbances, hypotension, prolonged
  erection and syncope). Therefore, co&#8209;administration of boosted PREZISTA
  and sildenafil when used for the treatment of pulmonary arterial hypertension
  is contraindicated (see section 4.3).</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration
  of tadalafil for the treatment of pulmonary arterial hypertension with
  boosted PREZISTA is not recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>PROTON PUMP INHIBITORS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Omeprazole</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>20&nbsp;mg once daily</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir AUC &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir </span><span lang=EN-GB style='font-size:
  10.0pt'>C<sub>min</sub></span><span lang=EN-GB style='font-size:10.0pt'>
  &#8596;</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>#</span></sup><span lang=EN-GB
  style='font-size:10.0pt'>darunavir </span><span lang=EN-GB style='font-size:
  10.0pt'>C<sub>max</sub></span><span lang=EN-GB style='font-size:10.0pt'>
  &#8596;</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Boosted PREZISTA
  can be co&#8209;administered with proton pump inhibitors without dose
  adjustments.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>SEDATIVES/HYPNOTICS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Buspirone</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Clorazepate</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Diazepam</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Estazolam</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Flurazepam</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=PT style='font-size:
  10.0pt'>Midazolam (parenteral)</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Zolpidem</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Midazolam (oral)</span></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Triazolam</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.
  Sedative/hypnotics are extensively metabolised by CYP3A. Co&#8209;administration
  with boosted PREZISTA may cause a large increase in the concentration of
  these medicines.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>If parenteral
  midazolam is co&#8209;administered with boosted PREZISTA it may cause a large
  increase in the concentration of this benzodiazepine. Data from concomitant
  use of parenteral midazolam with other protease inhibitors suggest a possible
  3&#8209;4 fold increase in midazolam plasma levels.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Clinical
  monitoring is recommended when co&#8209;administering boosted PREZISTA with
  these sedatives/hypnotics and a lower dose of the sedatives/hypnotics should
  be considered.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>If parenteral
  midazolam is co&#8209;administered with boosted PREZISTA, it should be done
  in an intensive care unit (ICU) or similar setting, which ensures close
  clinical monitoring and appropriate medical management in case of respiratory
  depression and/or prolonged sedation. Dose adjustment for midazolam should be
  considered, especially if more than a single dose of midazolam is
  administered.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Boosted PREZISTA
  with triazolam or oral midazolam is contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>TREATMENT FOR PREMATURE EJACULATION</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Dapoxetine</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Co-administration
  of boosted PREZISTA with dapoxetine is contraindicated.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>UROLOGICAL DRUGS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=163 valign=top style='width:122.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.5pt'><a name="_Hlk525849621"><span
  lang=EN-GB style='font-size:10.0pt'>Fesoterodine</span></a></p>
  <p class=MsoNormal style='margin-left:8.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Solifenacin</span></p>
  </td>
  <td width=239 valign=top style='width:179.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Not studied.</span></p>
  </td>
  <td width=203 valign=top style='width:152.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Use with caution.
  Monitor for fesoterodine or solifenacin adverse reactions, dose reduction of
  fesoterodine or solifenacin may be necessary.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:none;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><b><sup><span
  lang=EN-GB>#</span></sup></b><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Studies
  have been performed at lower than recommended doses of darunavir or with a
  different dosing regimen (see section 4.2 Posology).</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><b><sup><span
  lang=EN-GB>&#8224;</span></sup></b><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; The
  efficacy and safety of the use of PREZISTA with 100&nbsp;mg ritonavir and any
  other HIV PI (e.g. (fos)amprenavir and tipranavir) has not been established
  in HIV patients. According to current treatment guidelines, dual therapy with
  protease inhibitors is generally not recommended.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>&#8225;</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Study
  was conducted with tenofovir disoproxil fumarate 300&nbsp;mg once daily.</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility,
pregnancy and lactation</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal><span lang=EN-GB>As a general rule, when deciding to use
antiretroviral agents for the treatment of HIV infection in pregnant women and
consequently for reducing the risk of HIV vertical transmission to the newborn,
the animal data as well as the clinical experience in pregnant women should be
taken into account.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There are no adequate and well controlled
studies on pregnancy outcome with darunavir in pregnant women. Studies in
animals do not indicate direct harmful effects with respect to pregnancy,
embryonal/foetal development, parturition or postnatal development (see section
5.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA co&#8209;administered with low
dose ritonavir should be used during pregnancy only if the potential benefit
justifies the potential risk.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Treatment with darunavir/cobicistat
800/150&nbsp;mg during pregnancy results in low darunavir exposure (see section&nbsp;5.2),
which may be associated with an increased risk of treatment failure and an
increased risk of HIV transmission to the child. Therapy with PREZISTA/cobicistat
should not be initiated during pregnancy, and women who become pregnant during
therapy with PREZISTA/cobicistat should be switched to an alternative regimen (see
sections&nbsp;4.2 and 4.4).</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Breast&#8209;feeding</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>It is not known
whether darunavir is excreted in human milk. Studies in rats have demonstrated
that darunavir is excreted in milk and at high levels (1,000&nbsp;mg/kg/day)
resulted in toxicity. Because of both the potential for HIV transmission and the
potential for adverse reactions in breast&#8209;fed infants, mothers should be
instructed not to breast&#8209;feed under any circumstances if they are
receiving PREZISTA.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal><span lang=EN-GB>No human data on the effect of darunavir on
fertility are available. There was no effect on mating or fertility with
darunavir treatment in rats (see section 5.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects
on ability to drive and use machines</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA in combination with cobicistat or ritonavir
has no or negligible influence on the ability to drive and use machines.
However, dizziness has been reported in some patients during treatment with
regimens containing PREZISTA co&#8209;administered with cobicistat or low dose
ritonavir and should be borne in mind when considering a patient&#8217;s
ability to drive or operate machinery (see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable
effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Summary
of the safety profile</span></u></p>

<p class=MsoNormal><span lang=EN-GB>During the clinical development program
(N=2,613 treatment&#8209;experienced subjects who initiated therapy with
PREZISTA/ritonavir 600/100&nbsp;mg twice daily), 51.3% of subjects experienced at
least one adverse reaction. The total mean treatment duration for subjects was
95.3&nbsp;weeks. The most frequent adverse reactions reported in clinical
trials and as spontaneous reports are diarrhoea, nausea, rash, headache and
vomiting. The most frequent serious reactions are acute renal failure,
myocardial infarction, immune reconstitution inflammatory syndrome,
thrombocytopenia, osteonecrosis, diarrhoea, hepatitis and pyrexia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the 96&nbsp;week analysis, the safety
profile of PREZISTA/ritonavir 800/100&nbsp;mg once daily in treatment&#8209;na&iuml;ve
subjects was similar to that seen with PREZISTA/ritonavir 600/100&nbsp;mg twice
daily in treatment&#8209;experienced subjects except for nausea which was
observed more frequently in treatment&#8209;na&iuml;ve subjects. This was
driven by mild intensity nausea. No new safety findings were identified in the
192&nbsp;week analysis of the treatment&#8209;na&iuml;ve subjects in which the
mean treatment duration of PREZISTA/ritonavir 800/100&nbsp;mg once daily was
162.5&nbsp;weeks.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>During the Phase&nbsp;III clinical trial GS&#8209;US&#8209;216&#8209;130
with darunavir/cobicistat (N=313&nbsp;treatment&#8209;na&iuml;ve and treatment&#8209;experienced
subjects), 66.5% of subjects experienced at least one adverse reaction. The
mean treatment duration was 58.4&nbsp;weeks. The most frequent adverse
reactions reported were diarrhoea (28%), nausea (23%), and rash (16%). Serious
adverse reactions are diabetes mellitus, (drug) hypersensitivity, immune
reconstitution inflammatory syndrome, rash and vomiting.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For information on cobicistat, consult the
cobicistat Summary of Product Characteristics.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Adverse reactions are listed by system
organ class (SOC) and frequency category. Within each frequency category,
adverse reactions are presented in order of decreasing seriousness. Frequency
categories are defined as follows: very common (&#8805;&nbsp;1/10), common
(&#8805;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&#8805;&nbsp;1/1,000 to
&lt;&nbsp;1/100), rare (&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000) and not
known (frequency cannot be estimated from the available data).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Adverse
reactions observed with darunavir/ritonavir in clinical trials and post&#8209;marketing</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>MedDRA system
  organ class</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Frequency
  category</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Adverse
  reaction</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Infections
  and infestations</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>herpes simplex</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Blood
  and lymphatic system disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>thrombocytopenia, neutropenia, anaemia,
  leukopenia</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>increased eosinophil count</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Immune
  system disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>immune reconstitution inflammatory syndrome,
  (drug) hypersensitivity</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Endocrine
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>hypothyroidism, increased blood thyroid
  stimulating hormone</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
  lang=EN-GB>Metabolism and nutrition disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>diabetes mellitus, hypertriglyceridaemia,
  hypercholesterolaemia, hyperlipidaemia</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>gout, anorexia, decreased appetite,
  decreased weight, increased weight, hyperglycaemia, insulin resistance,
  decreased high density lipoprotein, increased appetite, polydipsia, increased
  blood lactate dehydrogenase</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Psychiatric
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>insomnia</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon </span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>depression, disorientation, anxiety,
  sleep disorder, abnormal dreams, nightmare, decreased libido</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>confusional state, altered mood, restlessness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Nervous
  system disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>headache, peripheral neuropathy,
  dizziness</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>lethargy, paraesthesia, hypoaesthesia,
  dysgeusia, disturbance in attention, memory impairment, somnolence</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>syncope, convulsion, ageusia, sleep phase
  rhythm disturbance</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Eye
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>conjunctival hyperaemia, dry eye</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>visual disturbance</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Ear and
  labyrinth disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>vertigo</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Cardiac
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>myocardial infarction, angina pectoris,
  prolonged electrocardiogram QT, tachycardia</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>acute myocardial infarction, sinus
  bradycardia, palpitations</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Vascular
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>hypertension, flushing</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Respiratory,
  thoracic and mediastinal disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>dyspnoea, cough, epistaxis, throat
  irritation</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rhinorrhoea</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Gastrointestinal
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>very common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>diarrhoea</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>vomiting, nausea, abdominal pain,
  increased blood amylase, dyspepsia, abdominal distension, flatulence</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>pancreatitis, gastritis,
  gastrooesophageal reflux disease, aphthous stomatitis, retching, dry mouth,
  abdominal discomfort, constipation, increased lipase, eructation, oral
  dysaesthesia</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>stomatitis, haematemesis, cheilitis, dry
  lip, coated tongue</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Hepatobiliary
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>increased alanine aminotransferase</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>hepatitis, cytolytic hepatitis, hepatic
  steatosis, hepatomegaly, increased transaminase, increased aspartate
  aminotransferase, increased blood bilirubin, increased blood alkaline
  phosphatase, increased gamma&#8209;glutamyltransferase</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
  lang=EN-GB>Skin and subcutaneous tissue disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rash (including macular, maculopapular,
  papular, erythematous and pruritic rash), pruritus</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>angioedema, generalised rash, allergic
  dermatitis, urticaria, eczema, erythema, hyperhidrosis, night sweats,
  alopecia, acne, dry skin, nail pigmentation</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>DRESS, Stevens&#8209;Johnson syndrome,
  erythema multiforme, dermatitis, seborrhoeic dermatitis, skin lesion,
  xeroderma</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>not known</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>toxic epidermal necrolysis, acute
  generalised exanthematous pustulosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Musculoskeletal
  and connective tissue disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>myalgia, osteonecrosis, muscle spasms,
  muscular weakness, arthralgia, pain in extremity, osteoporosis, increased
  blood creatine phosphokinase</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>musculoskeletal stiffness, arthritis,
  joint stiffness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Renal
  and urinary disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>acute renal failure, renal failure,
  nephrolithiasis, increased blood creatinine, proteinuria, bilirubinuria,
  dysuria, nocturia, pollakiuria</span></p>
  <p class=MsoNormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>decreased creatinine renal clearance</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Reproductive
  system and breast disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>erectile dysfunction, gynaecomastia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=2 valign=top style='width:461.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>General
  disorders and administration site conditions</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>asthenia, fatigue</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>pyrexia, chest pain, peripheral oedema,
  malaise, feeling hot, irritability, pain</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:230.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=308 valign=top style='width:230.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>chills, abnormal feeling, xerosis</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Adverse
reactions observed with darunavir/cobicistat in adult patients</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>MedDRA
  system organ class</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Frequency
  category</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Adverse
  reaction</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Immune
  system disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>(drug) hypersensitivity</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>immune reconstitution inflammatory
  syndrome</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Metabolism
  and nutrition disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>anorexia, diabetes mellitus,
  hypercholesterolaemia, hypertriglyceridaemia, hyperlipidaemia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Psychiatric
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>abnormal dreams</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Nervous
  system disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>very common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>headache</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Gastrointestinal
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>very common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>diarrhoea, nausea</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>vomiting, abdominal pain, abdominal
  distension, dyspepsia, flatulence, </span>pancreatic enzymes increased</p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>pancreatitis acute</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Hepatobiliary
  disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>hepatic enzyme increased</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>hepatitis*, cytolytic hepatitis*</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Skin
  and subcutaneous tissue disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>very common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rash (including macular, maculopapular,
  papular, erythematous, pruritic rash, generalised rash, and allergic
  dermatitis)</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>angioedema, <span lang=EN-GB>pruritus, </span>urticaria</p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>rare</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>drug reaction with eosinophilia and systemic symptoms*, Stevens&#8209;Johnson
  syndrome*</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>not known</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>toxic epidermal necrolysis*, acute generalised
  exanthematous pustulosis*</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Musculoskeletal
  and connective tissue disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>myalgia</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>osteonecrosis*</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Reproductive
  system and breast disorders</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>gynaecomastia*</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>General
  disorders and administration site conditions</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>fatigue</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>uncommon</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>asthenia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Investigations</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>common</span></p>
  </td>
  <td width=309 valign=top style='width:231.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>increased blood creatinine</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=2 valign=top style='width:464.05pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
  lang=EN-GB>*&nbsp;&nbsp; </span><span lang=EN-GB style='font-size:9.0pt'>these
  adverse drug reactions have not been reported in clinical trial experience
  with darunavir/cobicistat but have been noted with darunavir/ritonavir
  treatment and could be expected with darunavir/cobicistat too.</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Description
of selected adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Rash</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In clinical trials, rash was mostly mild to
moderate, often occurring within the first four weeks of treatment and
resolving with continued dosing. In cases of severe skin reaction see the
warning in section 4.4. In a single arm trial investigating darunavir
800&nbsp;mg once daily in combination with cobicistat 150&nbsp;mg once daily
and other antiretrovirals 2.2% of patients discontinued treatment due to rash.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>During the clinical development program of
raltegravir in treatment&#8209;experienced patients, rash, irrespective of
causality, was more commonly observed with regimens containing PREZISTA/ritonavir
+ raltegravir compared to those containing PREZISTA/ritonavir without
raltegravir or raltegravir without PREZISTA/ritonavir. Rash considered by the
investigator to be drug&#8209;related occurred at similar rates. The exposure&#8209;adjusted
rates of rash (all causality) were 10.9, 4.2, and 3.8 per 100&nbsp;patient&#8209;years
(PYR), respectively; and for drug&#8209;related rash were 2.4, 1.1, and 2.3 per
100&nbsp;PYR, respectively. The rashes observed in clinical studies were mild
to moderate in severity and did not result in discontinuation of therapy (see
section 4.4).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Metabolic
parameters</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Weight and levels of blood lipids and
glucose may increase during antiretroviral therapy (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB>Musculoskeletal abnormalities</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Increased CPK,
myalgia, myositis and rarely, rhabdomyolysis have been reported with the use of
protease inhibitors, particularly in combination with NRTIs.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Cases of
osteonecrosis have been reported, particularly in patients with generally
acknowledged risk factors, advanced HIV disease or long&#8209;term exposure to
combination antiretroviral therapy (CART). The frequency of this is unknown
(see section 4.4).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB>Immune reconstitution </span></i><i><span lang=EN-GB>inflammatory syndrome</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In HIV infected patients with severe immune
deficiency at the time of initiation of combination antiretroviral therapy
(CART), an inflammatory reaction to asymptomatic or residual opportunistic
infections may arise. Autoimmune disorders (such as Graves' disease and
autoimmune hepatitis) have also been reported; however, the reported time to
onset is more variable and these events can occur many months after initiation
of treatment (see section 4.4).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB>Bleeding in haemophiliac patients</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>There have been
reports of increased spontaneous bleeding in haemophiliac patients receiving
antiretroviral protease inhibitors (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The safety
assessment of PREZISTA with ritonavir in paediatric patients is based on the 48&#8209;week
analysis of safety data from three Phase&nbsp;II trials. The following patient
populations were evaluated (see section 5.1):</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>80&nbsp;ART&#8209;experienced HIV&#8209;1
infected paediatric patients aged from 6 to 17&nbsp;years and weighing at least
20&nbsp;kg who received PREZISTA tablets with low dose ritonavir twice daily in
combination with other antiretroviral agents.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>21&nbsp;ART&#8209;experienced HIV&#8209;1
infected paediatric patients aged from 3 to &lt;&nbsp;6&nbsp;years and weighing
10&nbsp;kg to &lt;&nbsp;20&nbsp;kg (16&nbsp;participants from 15&nbsp;kg to
&lt;&nbsp;20&nbsp;kg) who received PREZISTA oral suspension with low dose
ritonavir twice daily in combination with other antiretroviral agents.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>12&nbsp;ART&#8209;na&iuml;ve HIV&#8209;1
infected paediatric patients aged from 12 to 17&nbsp;years and weighing at
least 40&nbsp;kg who received PREZISTA tablets with low dose ritonavir once
daily in combination with other antiretroviral agents (see section 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Overall, the safety profile in these
paediatric patients was similar to that observed in the adult population.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety assessment of PREZISTA with
cobicistat in paediatric patients was evaluated in adolescents aged&nbsp;12 to
less than 18&nbsp;years, weighing at least 40&nbsp;kg through the clinical
trial GS&#8209;US&#8209;216&#8209;0128 (treatment&#8209;experienced,
virologically suppressed, N=7). Safety analyses of this study in adolescent
subjects did not identify new safety concerns compared to the known safety
profile of darunavir and cobicistat in adult subjects.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Other
special populations</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Patients
co&#8209;infected with hepatitis&nbsp;B and/or hepatitis&nbsp;C virus</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Among 1,968&nbsp;treatment&#8209;experienced
patients receiving PREZISTA co&#8209;administered with ritonavir
600/100&nbsp;mg twice daily, 236&nbsp;patients were co&#8209;infected with
hepatitis&nbsp;B or C. Co&#8209;infected patients were more likely to have
baseline and treatment emergent hepatic transaminase elevations than those
without chronic viral hepatitis (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:silver'>the national reporting
system listed in </span></span><span lang=EN-GB style='background:silver'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix&nbsp;V</a></span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Human experience of acute overdose with
PREZISTA co&#8209;administered with cobicistat or low dose ritonavir is
limited. Single doses up to 3,200&nbsp;mg of darunavir as oral solution alone
and up to 1,600&nbsp;mg of the tablet formulation of darunavir in combination
with ritonavir have been administered to healthy volunteers without untoward
symptomatic effects.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There is no specific antidote for overdose
with PREZISTA. Treatment of overdose with PREZISTA consists of general
supportive measures including monitoring of vital signs and observation of the
clinical status of the patient. Since darunavir is highly protein bound,
dialysis is unlikely to be beneficial in significant removal of the active
substance.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pharmacotherapeutic group: Antivirals for
systemic use, protease inhibitors, ATC code: J05AE10.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Mechanism
of action</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Darunavir is an
inhibitor of the dimerisation and of the catalytic activity of the HIV&#8209;1
protease (K<sub>D</sub>&nbsp;of&nbsp;4.5&nbsp;x&nbsp;10<sup>-12</sup>M). It
selectively inhibits the cleavage of HIV encoded Gag&#8209;Pol polyproteins in
virus infected cells, thereby preventing the formation of mature infectious
virus particles.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Antiviral
activity <i>in vitro</i></span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Darunavir
exhibits activity against laboratory strains and clinical isolates of HIV&#8209;1
and laboratory strains of HIV&#8209;2 in acutely infected T&#8209;cell lines,
human peripheral blood mononuclear cells and human monocytes/macrophages with
median EC<sub>50</sub>&nbsp;values ranging from 1.2 to 8.5&nbsp;nM (0.7 to
5.0&nbsp;ng/ml). Darunavir demonstrates antiviral activity <i>in vitro</i>
against a broad panel of HIV&#8209;1 group M (A, B, C, D, E, F, G) and group O
primary isolates with EC<sub>50</sub>&nbsp;values ranging from &lt;&nbsp;0.1 to
4.3&nbsp;nM.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>These EC<sub>50</sub>&nbsp;values
are well below the 50% cellular toxicity concentration range of
87&nbsp;&micro;M to &gt;&nbsp;100&nbsp;&micro;M.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Resistance</span></u></p>

<p class=MsoNormal style='text-autospace:none'><i><span lang=EN-GB>In vitro</span></i><span
lang=EN-GB> selection of darunavir&#8209;resistant virus from wild type HIV&#8209;1
was lengthy (&gt;&nbsp;3&nbsp;years). The selected viruses were unable to grow
in the presence of darunavir concentrations above 400&nbsp;nM. Viruses selected
in these conditions and showing decreased susceptibility to darunavir (range:
23&#8209;50&#8209;fold) harboured 2 to 4&nbsp;amino acid substitutions in the
protease gene. The decreased susceptibility to darunavir of the emerging
viruses in the selection experiment could not be explained by the emergence of
these protease mutations.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The clinical trial data from ART&#8209;experienced
patients (<i>TITAN</i> trial and the pooled analysis of the <i>POWER</i>&nbsp;1,
2 and 3 and <i>DUET</i>&nbsp;1 and 2 trials) showed that virologic response to
PREZISTA co&#8209;administered with low dose ritonavir was decreased when 3 or
more darunavir RAMs (V11I, V32I, L33F, I47V, I50V, I54L or M, T74P, L76V, I84V
and L89V) were present at baseline or when these mutations developed during
treatment.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Increasing baseline darunavir fold change
in EC<sub>50</sub> (FC) was associated with decreasing virologic response. A
lower and upper clinical cut&#8209;off of 10 and 40 were identified. Isolates
with baseline FC &#8804;&nbsp;10 are susceptible; isolates with FC &gt;&nbsp;10
to 40 have decreased susceptibility; isolates with FC &gt;&nbsp;40 are
resistant (see Clinical results).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Viruses
isolated from patients on PREZISTA/ritonavir 600/100&nbsp;mg twice daily
experiencing virologic failure by rebound that were susceptible to tipranavir
at baseline remained susceptible to tipranavir after treatment in the vast
majority of cases.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The lowest rates of developing resistant
HIV virus are observed in ART&#8209;na&iuml;ve patients who are treated for the
first time with darunavir in combination with other ART.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The table
below shows the development of HIV&#8209;1 protease mutations and loss of
susceptibility to PIs in virologic failures at endpoint in the <i>ARTEMIS</i>, <i>ODIN</i>
and <i>TITAN</i> trials.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>ARTEMIS</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Week 192</span></p>
  </td>
  <td width=237 colspan=2 valign=top style='width:177.45pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>ODIN</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Week 48</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>TITAN</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Week 48</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>PREZISTA/ ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>800/100&nbsp;mg</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>once daily</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N=343</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>PREZISTA/ ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>800/100&nbsp;mg</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>once daily</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N=294</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>PREZISTA/ ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>600/100&nbsp;mg</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>twice daily</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>N=296</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>PREZISTA/ ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>600/100&nbsp;mg</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>twice daily</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=PT
  style='font-size:10.0pt'>N=298</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Total number of virologic failures</span><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:10.0pt'>, n (%)</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>55&nbsp;(16.0%)</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>65&nbsp;(22.1%)</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>54&nbsp;(18.2%)</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>31&nbsp;(10.4%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>Rebounders</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>39&nbsp;(11.4%)</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>11&nbsp;(3.7%)</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>11&nbsp;(3.7%)</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>16&nbsp;(5.4%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>Never suppressed subjects</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>16&nbsp;(4.7%)</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>54&nbsp;(18.4%)</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>43&nbsp;(14.5%)</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>15&nbsp;(5.0%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=618 colspan=5 valign=top style='width:463.8pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Number of subjects with virologic failure and paired
  baseline/endpoint genotypes, developing mutations</span><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:10.0pt'> at endpoint,
  n/N</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>Primary (major) PI mutations</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/43</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1/60</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/42</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>6/28</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>PI RAMs</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>4/43</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>7/60</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>4/42</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>10/28</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=618 colspan=5 valign=top style='width:463.8pt;border-top:none;
  border-left:solid black 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Number of subjects with virologic failure and paired
  baseline/endpoint phenotypes, showing loss of susceptibility to PIs at
  endpoint compared to baseline, n/N</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>PI</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>darunavir</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>0/39</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>1/58</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>0/41</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>3/26</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>amprenavir</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>0/39</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>1/58</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>0/40</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>0/22</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>atazanavir</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>0/39</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>2/56</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>0/40</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>0/22</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>indinavir</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/39</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>2/57</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/40</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1/24</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>lopinavir</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/39</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1/58</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/40</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/23</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>saquinavir</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/39</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/56</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/40</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/22</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.5pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>tipranavir</span></p>
  </td>
  <td width=109 valign=top style='width:82.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/39</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/58</span></p>
  </td>
  <td width=114 valign=top style='width:85.35pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/41</span></p>
  </td>
  <td width=124 valign=top style='width:92.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1/25</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=618 colspan=5 valign=top style='width:463.8pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; TLOVR
  non&#8209;VF censored algorithm based on HIV&#8209;1 RNA
  &lt;&nbsp;50&nbsp;copies/ml, except for <i>TITAN</i> (HIV&#8209;1 RNA
  &lt;&nbsp;400&nbsp;copies/ml)</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>b</span></sup><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; IAS&#8209;USA lists</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Low rates of developing resistant HIV&#8209;1
virus were observed in ART&#8209;na&iuml;ve patients who are treated for the
first time with darunavir/cobicistat once daily in combination with other ART,
and in ART&#8209;experienced patients with no darunavir RAMs receiving darunavir/cobicistat
in combination with other ART. The table below shows the development of HIV&#8209;1
protease mutations and resistance to PIs in virologic failures at endpoint in
the GS&#8209;US&#8209;216&#8209;130 trial.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="74%" colspan=2 valign=top style='width:74.78%;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>GS&#8209;US&#8209;216&#8209;130</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Week 48</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="34%" valign=top style='width:34.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Treatment&#8209;na&iuml;ve</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>darunavir/cobicistat 800/150&nbsp;mg</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>once daily</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N=295</span></p>
  </td>
  <td width="40%" valign=top style='width:40.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Treatment&#8209;experienced</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>darunavir/cobicistat 800/150&nbsp;mg</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>once daily</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N=18</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Number of subjects with virologic failure</span><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:10.0pt'> and
  genotype data that develop mutations</span><sup><span lang=EN-GB>b</span></sup><span
  lang=EN-GB style='font-size:10.0pt'> at endpoint, n/N</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>Primary (major) PI mutations</span></p>
  </td>
  <td width="34%" valign=top style='width:34.62%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/8</span></p>
  </td>
  <td width="40%" valign=top style='width:40.16%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1/7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>PI RAMs</span></p>
  </td>
  <td width="34%" valign=top style='width:34.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>2/8</span></p>
  </td>
  <td width="40%" valign=top style='width:40.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1/7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Number of subjects with virologic failure</span><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:10.0pt'> and
  phenotype data that show resistance to PIs at endpoint</span><sup><span
  lang=EN-GB>c</span></sup><span lang=EN-GB style='font-size:10.0pt'>, n/N</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>HIV PI</span></p>
  </td>
  <td width="34%" valign=top style='width:34.62%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="40%" valign=top style='width:40.16%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>darunavir</span></p>
  </td>
  <td width="34%" valign=top style='width:34.62%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/8</span></p>
  </td>
  <td width="40%" valign=top style='width:40.16%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>amprenavir</span></p>
  </td>
  <td width="34%" valign=top style='width:34.62%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/8</span></p>
  </td>
  <td width="40%" valign=top style='width:40.16%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>atazanavir</span></p>
  </td>
  <td width="34%" valign=top style='width:34.62%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/8</span></p>
  </td>
  <td width="40%" valign=top style='width:40.16%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>indinavir</span></p>
  </td>
  <td width="34%" valign=top style='width:34.62%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/8</span></p>
  </td>
  <td width="40%" valign=top style='width:40.16%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>lopinavir</span></p>
  </td>
  <td width="34%" valign=top style='width:34.62%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/8</span></p>
  </td>
  <td width="40%" valign=top style='width:40.16%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>saquinavir</span></p>
  </td>
  <td width="34%" valign=top style='width:34.62%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/8</span></p>
  </td>
  <td width="40%" valign=top style='width:40.16%;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="25%" valign=top style='width:25.22%;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>tipranavir</span></p>
  </td>
  <td width="34%" valign=top style='width:34.62%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/8</span></p>
  </td>
  <td width="40%" valign=top style='width:40.16%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0/7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Virologic
  failures were defined as: never suppressed: confirmed HIV-1 RNA
  &lt;&nbsp;1&nbsp;log<sub>10</sub> reduction from baseline and
  &#8805;&nbsp;50&nbsp;copies/ml at the week&#8209;8; rebound: HIV&#8209;1 RNA
  &lt;&nbsp;50&nbsp;copies/ml followed by confirmed HIV&#8209;1 RNA to
  &#8805;&nbsp;400&nbsp;copies/ml or confirmed &gt;&nbsp;1&nbsp;log<sub>10</sub>
  HIV&#8209;1 RNA increase from the nadir; </span><span style='font-size:9.0pt'>discontinuations
  with HIV&#8209;1 RNA &#8805;&nbsp;400&nbsp;copies/ml at last visit</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>b</span></sup><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; IAS&#8209;USA lists</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB>c</span></sup><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; In GS&#8209;US216&#8209;130
  baseline phenotype was not available</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Cross&#8209;resistance</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir FC was less than 10 for 90% of
3,309&nbsp;clinical isolates resistant to amprenavir, atazanavir, indinavir,
lopinavir, nelfinavir, ritonavir, saquinavir and/or tipranavir showing that
viruses resistant to most PIs remain susceptible to darunavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the virologic failures of the <i>ARTEMIS</i>
trial no cross&#8209;resistance with other PIs was observed.</span></p>

<p class=MsoNormal><span lang=EN-GB>In the virologic failures of the GS&#8209;US&#8209;216&#8209;130
trial no cross&#8209;resistance with other HIV PIs was observed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Clinical
results</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetic enhancing effect of
cobicistat on darunavir was evaluated in a Phase&nbsp;I study in healthy
subjects that were administered darunavir 800&nbsp;mg with either cobicistat at
150&nbsp;mg or ritonavir at 100&nbsp;mg once daily. The steady&#8209;state
pharmacokinetic parameters of darunavir were comparable when boosted with
cobicistat versus ritonavir. For information on cobicistat, consult the
cobicistat Summary of Product Characteristics.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Adult
patients</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Efficacy
of darunavir 800&nbsp;mg once daily co&#8209;administered with 150&nbsp;mg
cobicistat once daily in ART&#8209;na&iuml;ve and ART&#8209;experienced
patients</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>GS&#8209;US&#8209;216&#8209;130 is a single
arm, open&#8209;label, Phase&nbsp;III trial evaluating the pharmacokinetics,
safety, tolerability, and efficacy of darunavir with cobicistat in 313&nbsp;HIV&#8209;1
infected adult patients (295&nbsp;treatment&#8209;na&iuml;ve and
18&nbsp;treatment&#8209;experienced). These patients received darunavir
800&nbsp;mg once daily in combination with cobicistat 150&nbsp;mg once daily
with an investigator selected background regimen consisting of 2&nbsp;active
NRTIs.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>HIV&#8209;1
infected patients who were eligible for this trial had a screening genotype
showing no darunavir RAMs and plasma HIV&#8209;1 RNA &#8805;&nbsp;1,000&nbsp;copies/ml.
The table below shows the efficacy data of the 48&nbsp;week analyses from the
GS&#8209;US&#8209;216&#8209;130 trial:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=176 valign=top style='width:131.65pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=429 colspan=3 valign=top style='width:321.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>GS&#8209;US&#8209;216&#8209;130</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=176 style='width:131.65pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
  style='font-size:10.0pt'>Outcomes at Week&nbsp;48</span></i></p>
  </td>
  <td width=143 valign=top style='width:107.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Treatment&#8209;na&iuml;ve</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>darunavir/cobicistat 800/150&nbsp;mg once daily</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>+ OBR</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N=295</span></p>
  </td>
  <td width=143 valign=top style='width:107.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Treatment&#8209;experienced</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>darunavir/cobicistat 800/150&nbsp;mg once daily</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>+ OBR</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N=18</span></p>
  </td>
  <td width=143 valign=top style='width:107.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>All subjects</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>darunavir/cobicistat 800/150&nbsp;mg once daily</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>+ OBR</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N=313</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=176 valign=top style='width:131.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>HIV&#8209;1 RNA
  &lt;&nbsp;50&nbsp;copies/ml</span><sup><span lang=EN-GB>a</span></sup></p>
  </td>
  <td width=143 valign=top style='width:107.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>245 (83.1%)</span></p>
  </td>
  <td width=143 valign=top style='width:107.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>8 (44.4%)</span></p>
  </td>
  <td width=143 valign=top style='width:107.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>253 (80.8%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=176 valign=top style='width:131.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>mean HIV&#8209;1&nbsp;RNA
  log change from baseline (log<sub>10</sub>&nbsp;copies/ml)</span></p>
  </td>
  <td width=143 valign=top style='width:107.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&#8209;3.01</span></p>
  </td>
  <td width=143 valign=top style='width:107.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&#8209;2.39</span></p>
  </td>
  <td width=143 valign=top style='width:107.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&#8209;2.97</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=176 valign=top style='width:131.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>CD4+ cell count
  mean change from baseline</span><sup><span lang=EN-GB>b</span></sup></p>
  </td>
  <td width=143 valign=top style='width:107.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>+174</span></p>
  </td>
  <td width=143 valign=top style='width:107.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>+102</span></p>
  </td>
  <td width=143 valign=top style='width:107.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>+170</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=4 valign=top style='width:6.3in;border:none;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></sup><span
  lang=EN-GB style='font-size:9.0pt'>Imputations according to the TLOVR
  algorithm</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></sup><span
  lang=EN-GB style='font-size:9.0pt'>Last Observation Carried Forward
  imputation</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Efficacy
of PREZISTA 800&nbsp;mg once daily co</span></u></i><u><span lang=EN-GB>&#8209;<i>administered
with 100&nbsp;mg ritonavir once daily in ART&#8209;na&iuml;ve patients</i></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The evidence of efficacy of
PREZISTA/ritonavir 800/100&nbsp;mg once daily is based on the analyses of 192&nbsp;week
data from the randomised, controlled, open&#8209;label Phase&nbsp;III trial <i>ARTEMIS</i>
in antiretroviral treatment&#8209;na&iuml;ve HIV&#8209;1 infected patients
comparing PREZISTA/ritonavir 800/100&nbsp;mg once daily with
lopinavir/ritonavir 800/200&nbsp;mg per day (given as a twice&#8209;daily or as
a once&#8209;daily regimen). Both arms used a fixed background regimen
consisting of tenofovir disoproxil fumarate 300&nbsp;mg once daily and
emtricitabine 200&nbsp;mg once daily.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The table
below shows the efficacy data of the 48&nbsp;week and 96&nbsp;week analyses
from the <i>ARTEMIS</i> trial:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=7 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>ARTEMIS</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="18%" valign=top style='width:18.52%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="41%" colspan=3 valign=top style='width:41.06%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Week 48</span><sup><span
  lang=EN-GB>a</span></sup></p>
  </td>
  <td width="40%" colspan=3 valign=top style='width:40.42%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Week 96</span><sup><span
  lang=EN-GB>b</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="18%" valign=top style='width:18.52%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
  style='font-size:10.0pt'>Outcomes</span></i></p>
  </td>
  <td width="13%" valign=top style='width:13.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>PREZISTA/ ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>800/100&nbsp;mg once daily</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>N=343</span></p>
  </td>
  <td width="13%" valign=top style='width:13.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Lopinavir/ ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>800/200&nbsp;mg per day</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>N=346</span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Treatment difference (95% CI
  of difference)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>PREZISTA/ ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>800/100&nbsp;mg once daily</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>N=343</span></p>
  </td>
  <td width="12%" valign=top style='width:12.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Lopinavir/ ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>800/200&nbsp;mg per day</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>N=346</span></p>
  </td>
  <td width="14%" valign=top style='width:14.14%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Treatment difference (95% CI
  of difference)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="18%" valign=top style='width:18.52%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>HIV&#8209;1&nbsp;RNA &lt;&nbsp;50&nbsp;copies/ml</span><sup><span
  lang=EN-GB>c</span></sup></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>All patients</span></p>
  </td>
  <td width="13%" valign=top style='width:13.58%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>83.7%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(287)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.38%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>78.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(271)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>5.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(&#8209;0.5; 11.2)</span><sup><span
  lang=EN-GB>d</span></sup></p>
  </td>
  <td width="13%" valign=top style='width:13.42%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>79.0%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(271)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.86%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>70.8%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(245)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.14%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>8.2%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(1.7; 14.7)</span><sup><span
  lang=EN-GB>d</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="18%" valign=top style='width:18.52%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>With baseline HIV-RNA &lt;&nbsp;100,000</span></p>
  </td>
  <td width="13%" valign=top style='width:13.58%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>85.8%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(194/226)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.38%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>84.5%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(191/226)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>1.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(&#8209;5.2; 7.9)</span><sup><span
  lang=EN-GB>d</span></sup></p>
  </td>
  <td width="13%" valign=top style='width:13.42%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>80.5%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(182/226)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.86%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>75.2%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(170/226)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.14%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>5.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(&#8209;2.3; 13.0)</span><sup><span
  lang=EN-GB>d</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="18%" valign=top style='width:18.52%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>With baseline HIV-RNA &#8805;&nbsp;100,000</span></p>
  </td>
  <td width="13%" valign=top style='width:13.58%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>79.5%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(93/117)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.38%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>66.7%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(80/120)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>12.8%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(1.6; 24.1)</span><sup><span lang=EN-GB>d</span></sup></p>
  </td>
  <td width="13%" valign=top style='width:13.42%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>76.1%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(89/117)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.86%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>62.5%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(75/120)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.14%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>13.6%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(1.9; 25.3)</span><sup><span lang=EN-GB>d</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="18%" valign=top style='width:18.52%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>With baseline CD4+ cell count &lt;&nbsp;200</span></p>
  </td>
  <td width="13%" valign=top style='width:13.58%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>79.4%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(112/141)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.38%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>70.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(104/148)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>9.2%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(&#8209;0.8; 19.2)</span><sup><span lang=EN-GB>d</span></sup></p>
  </td>
  <td width="13%" valign=top style='width:13.42%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>78.7%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(111/141)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.86%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>64.9%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(96/148)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.14%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>13.9%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(3.5; 24.2)</span><sup><span lang=EN-GB>d</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="18%" valign=top style='width:18.52%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>With baseline CD4+ cell count &#8805;&nbsp;200</span></p>
  </td>
  <td width="13%" valign=top style='width:13.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>86.6%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(175/202)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>84.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(167/198)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>2.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(&#8209;4.6; 9.2)</span><sup><span lang=EN-GB>d</span></sup></p>
  </td>
  <td width="13%" valign=top style='width:13.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>79.2%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(160/202)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>75.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(149/198)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.14%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>4.0%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(&#8209;4.3; 12.2)</span><sup><span lang=EN-GB>d</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="18%" valign=top style='width:18.52%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>median
  CD4+&nbsp;cell count change from baseline (x 10</span><sup><span lang=EN-GB>6</span></sup><span
  lang=EN-GB style='font-size:10.0pt'>/L)</span><sup><span lang=EN-GB>e</span></sup></p>
  </td>
  <td width="13%" valign=top style='width:13.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>137</span></p>
  </td>
  <td width="13%" valign=top style='width:13.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>141</span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>171</span></p>
  </td>
  <td width="12%" valign=top style='width:12.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>188</span></p>
  </td>
  <td width="14%" valign=top style='width:14.14%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=7 valign=top style='width:100.0%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Data
  based on analyses at week 48</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Data
  based on analyses at week 96</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>c</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Imputations
  according to the TLOVR algorithm</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>d</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Based
  on normal approximation to the difference in % response</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>e</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Non&#8209;completer
  is failure imputation: patients who discontinued prematurely are imputed with
  a change equal to 0</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Non&#8209;inferiority in virologic response
to the PREZISTA/ritonavir treatment, defined as the percentage of patients with
plasma HIV&#8209;1 RNA level &lt;&nbsp;50&nbsp;copies/ml, was demonstrated (at
the pre&#8209;defined 12% non&#8209;inferiority margin) for both Intent&#8209;To&#8209;Treat
(ITT) and On Protocol (OP) populations in the 48&nbsp;week analysis. These
results were confirmed in the analyses of data at 96&nbsp;weeks of treatment in
the <i>ARTEMIS</i> trial. These results were sustained up to 192&nbsp;weeks of
treatment in the ARTEMIS trial.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Efficacy
of PREZISTA 800&nbsp;mg once daily co</span></u></i><u><span lang=EN-GB>&#8209;<i>administered
with 100&nbsp;mg ritonavir once daily in ART&#8209;experienced patients</i></span></u></p>

<p class=MsoNormal><b><i><span lang=EN-GB>ODIN</span></i></b><span lang=EN-GB>
is a Phase&nbsp;III, randomised, open&#8209;label trial comparing PREZISTA/ritonavir
800/100&nbsp;mg once daily versus PREZISTA/ritonavir 600/100&nbsp;mg twice
daily in ART&#8209;experienced HIV&#8209;1 infected patients with screening
genotype resistance testing showing no darunavir RAMs (i.e. V11I, V32I, L33F,
I47V, I50V, I54M, I54L, T74P, L76V, I84V, L89V) and a screening HIV&#8209;1 RNA
&gt;&nbsp;1,000&nbsp;copies/ml. Efficacy analysis is based on 48&nbsp;weeks of
treatment (see table below). Both arms used an optimised background regimen
(OBR) of &#8805;&nbsp;2&nbsp;NRTIs.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=4 valign=top style='width:464.35pt;border:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>ODIN</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
  style='font-size:10.0pt'>Outcomes</span></i></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT style='font-size:10.0pt'>PREZISTA/ritonavir 800/100&nbsp;mg
  once daily + OBR</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT style='font-size:10.0pt'>N=294</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT style='font-size:10.0pt'>PREZISTA/ritonavir 600/100&nbsp;mg
  twice daily + OBR</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=PT style='font-size:10.0pt'>N=296</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Treatment difference</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(95% CI of difference)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.05pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>HIV&#8209;1&nbsp;RNA &lt;&nbsp;50&nbsp;copies/ml</span><sup><span
  lang=EN-GB>a</span></sup></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>72.1% (212)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>70.9% (210)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>1.2% (&#8209;6.1; 8.5)</span><sup><span
  lang=EN-GB>b</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.05pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>With Baseline HIV&#8209;1 RNA (copies/ml)</span></p>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;&lt;&nbsp;100,000</span></p>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>&#8805;&nbsp;100,000</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>77.6% (198/255)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>35.9% (14/39)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>73.2% (194/265)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>51.6% (16/31)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>4.4% (&#8209;3.0; 11.9)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&#8209;15.7% (&#8209;39.2; 7.7)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.05pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>With Baseline CD4+ cell count (x 10</span><sup><span
  lang=EN-GB>6</span></sup><span lang=EN-GB style='font-size:10.0pt'>/L)</span></p>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>&#8805;&nbsp;100</span></p>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>&lt;&nbsp;100</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>75.1% (184/245)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>57.1% (28/49)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>72.5% (187/258)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>60.5% (23/38)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>2.6% (&#8209;5.1; 10.3)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&#8209;3.4% (&#8209;24.5; 17.8)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>With HIV&#8209;1 clade</span></p>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>Type B</span></p>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>Type AE</span></p>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>Type C</span></p>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB
  style='font-size:10.0pt'>Other</span><sup><span lang=EN-GB>c</span></sup></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>70.4% (126/179)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>90.5% (38/42)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>72.7% (32/44)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>55.2% (16/29)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>64.3% (128/199)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>91.2% (31/34)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>78.8% (26/33)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>83.3% (25/30)</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>6.1% (&#8209;3.4; 15.6)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&#8209;0.7% (&#8209;14.0; 12.6)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&#8209;6.1% (&#8209;2.6; 13.7)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&#8209;28.2% (&#8209;51.0; &#8209;5.3)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>mean CD4+ cell
  count change from baseline</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(x 10</span><sup><span
  lang=EN-GB>6</span></sup><span lang=EN-GB style='font-size:10.0pt'>/L)</span><sup><span
  lang=EN-GB>e</span></sup></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>108</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>112</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&#8209;5</span><sup><span lang=EN-GB>d </span></sup><span
  lang=EN-GB style='font-size:10.0pt'>(&#8209;25; 16)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=4 valign=top style='width:464.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Imputations
  according to the TLOVR algorithm</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Based
  on a normal approximation of the difference in % response</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>c</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Clades
  A1, D, F1, G, K, CRF02_AG, CRF12_BF, and CRF06_CPX</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>d</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Difference
  in means</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>e</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Last
  Observation Carried Forward imputation</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>At 48&nbsp;weeks, virologic response,
defined as the percentage of patients with plasma HIV&#8209;1 RNA level
&lt;&nbsp;50&nbsp;copies/ml, with PREZISTA/ritonavir 800/100&nbsp;mg once daily
treatment was demonstrated to be non&#8209;inferior (at the pre&#8209;defined
12% non&#8209;inferiority margin) compared to PREZISTA/ritonavir
600/100&nbsp;mg twice daily for both ITT and OP populations.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA/ritonavir 800/100&nbsp;mg once
daily in ART&#8209;experienced patients should not be used in patients with one
or more darunavir resistance associated mutations (DRV&#8209;RAMs) or HIV&#8209;1
RNA &#8805;&nbsp;100,000&nbsp;copies/ml or CD4+ cell count &lt;&nbsp;100&nbsp;cells&nbsp;x&nbsp;10<sup>6</sup>/L
(see section 4.2 and 4.4). Limited data is available in patients with HIV&#8209;1
clades other than B.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
patients</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>ART&#8209;na&iuml;ve
paediatric patients from the age of 12&nbsp;years to &lt;&nbsp;18&nbsp;years, and
weighing at least 40&nbsp;kg</span></i></p>

<p class=MsoNormal><b><i><span lang=EN-GB>DIONE</span></i></b><span lang=EN-GB>
is an open&#8209;label, Phase&nbsp;II trial evaluating the pharmacokinetics,
safety, tolerability, and efficacy of PREZISTA with low dose ritonavir in
12&nbsp;ART&#8209;na&iuml;ve HIV&#8209;1 infected paediatric patients aged 12
to less than 18&nbsp;years and weighing at least 40&nbsp;kg. These patients
received PREZISTA/ritonavir 800/100&nbsp;mg once daily in combination with
other antiretroviral agents. Virologic response was defined as a decrease in
plasma HIV&#8209;1 RNA viral load of at least 1.0&nbsp;log<sub>10</sub> versus
baseline.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=2 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>DIONE</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=335 style='width:251.3pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Outcomes
  at week 48</span></i></p>
  </td>
  <td width=270 valign=top style='width:202.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>PREZISTA/ritonavir</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>N=12</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=335 valign=top style='width:251.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>HIV&#8209;1 RNA
  &lt;&nbsp;50&nbsp;copies/ml<sup>a</sup></span></p>
  </td>
  <td width=270 valign=top style='width:202.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>83.3%
  (10)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=335 valign=top style='width:251.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>CD4+ percent change from baseline<sup>b</sup></span></p>
  </td>
  <td width=270 valign=top style='width:202.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>14</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=335 valign=top style='width:251.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>CD4+ cell count mean change from baseline<sup>b</sup></span></p>
  </td>
  <td width=270 valign=top style='width:202.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>221</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=335 valign=top style='width:251.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;1.0 log<sub>10</sub>
  decrease from baseline in plasma viral load</span></p>
  </td>
  <td width=270 valign=top style='width:202.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=2 valign=top style='width:6.3in;border:none;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Imputations according to the TLOVR
  algorithm.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>Non&#8209;completer is failure imputation:
  patients who discontinued prematurely are imputed with a change equal to 0.</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the open&#8209;label, Phase&nbsp;II/III
trial GS&#8209;US&#8209;216&#8209;0128, the efficacy, safety, and
pharmacokinetics of darunavir 800&nbsp;mg and cobicistat 150&nbsp;mg
(administered as separate tablets) and at least 2&nbsp;NRTIs were evaluated in
7&nbsp;HIV&#8209;1 infected, treatment&#8209;experienced, virologically
suppressed adolescents weighing at least 40 kg. Patients were on a stable
antiretroviral regimen (for at least 3&nbsp;months), consisting of darunavir
administered with ritonavir, combined with 2&nbsp;NRTIs. They were switched
from ritonavir to cobicistat 150&nbsp;mg once daily and continued darunavir
(N=7) and 2&nbsp;NRTIs.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=2 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Virologic outcome in ART&#8209;experienced,
  virologically suppressed adolescents at week&nbsp;48</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=2 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>GS&#8209;US&#8209;216&#8209;0128</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=330 valign=top style='width:247.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Outcomes at Week&nbsp;48</span></p>
  </td>
  <td width=275 valign=top style='width:206.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Darunavir/cobicistat + at least 2&nbsp;NRTIs</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(N=7)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=330 valign=top style='width:247.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>HIV&#8209;1 RNA &lt;&nbsp;50&nbsp;copies/mL
  per FDA Snapshot Approach</span></p>
  </td>
  <td width=275 valign=top style='width:206.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>85.7%
  (6)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=330 valign=top style='width:247.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>CD4+ percent median change from baseline<sup>a</sup></span></p>
  </td>
  <td width=275 valign=top style='width:206.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&#8209;6.1%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=330 valign=top style='width:247.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>CD4+ cell count median change from
  baseline<sup>a</sup></span></p>
  </td>
  <td width=275 valign=top style='width:206.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&#8209;342
  cells/mm&sup3;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=2 valign=top style='width:6.3in;border:none;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>No imputation (observed data).</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For additional clinical study results in
ART&#8209;experienced adults and paediatric patients, refer to the Summary of
Product Characteristics for PREZISTA 75&nbsp;mg, 150&nbsp;mg or 600&nbsp;mg
tablets and 100&nbsp;mg/ml oral suspension.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Pregnancy
and postpartum</span></i></p>

<p class=MsoNormal>Darunavir/ritonavir (600/100&nbsp;mg twice daily or
800/100&nbsp;mg once daily) in combination with a background regimen was
evaluated in a clinical trial of 36&nbsp;pregnant women (18 in each arm) during
the second and third trimesters, and postpartum. Virologic response was
preserved throughout the study period in both arms. No mother to child
transmission occurred in the infants born to the 31&nbsp;subjects who stayed on
the antiretroviral treatment through delivery. There were no new clinically
relevant safety findings compared with the known safety profile of
darunavir/ritonavir in HIV&#8209;1 infected adults (see sections 4.2, 4.4 and
5.2).</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetic properties of
darunavir, co&#8209;administered with cobicistat or ritonavir, have been
evaluated in healthy adult volunteers and in HIV&#8209;1 infected patients.
Exposure to darunavir was higher in HIV&#8209;1 infected patients than in
healthy subjects. The increased exposure to darunavir in HIV&#8209;1 infected
patients compared to healthy subjects may be explained by the higher
concentrations of &#945;<sub>1</sub>&#8209;acid glycoprotein (AAG) in HIV&#8209;1
infected patients, resulting in higher darunavir binding to plasma AAG and,
therefore, higher plasma concentrations.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir is primarily metabolised by
CYP3A. Cobicistat and ritonavir inhibit CYP3A, thereby increasing the plasma
concentrations of darunavir considerably.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For information on cobicistat
pharmacokinetic properties, consult the cobicistat Summary of Product Characteristics.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir was rapidly absorbed following
oral administration. Maximum plasma concentration of darunavir in the presence
of low dose ritonavir is generally achieved within 2.5&#8209;4.0&nbsp;hours.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The absolute oral bioavailability of a
single 600&nbsp;mg dose of darunavir alone was approximately 37% and increased
to approximately 82% in the presence of 100&nbsp;mg twice daily ritonavir. The
overall pharmacokinetic enhancement effect by ritonavir was an approximate 14&#8209;fold
increase in the systemic exposure of darunavir when a single dose of
600&nbsp;mg darunavir was given orally in combination with ritonavir at
100&nbsp;mg twice daily (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>When administered without food, the
relative bioavailability of darunavir in the presence of cobicistat or low dose
ritonavir is lower as compared to intake with food. Therefore, PREZISTA tablets
should be taken with cobicistat or ritonavir and with food. The type of food
does not affect exposure to darunavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir is approximately 95% bound to plasma
protein. Darunavir binds primarily to plasma &#945;<sub>1</sub>&#8209;acid
glycoprotein.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Following intravenous administration, the
volume of distribution of darunavir alone was
88.1&nbsp;&plusmn;&nbsp;59.0&nbsp;l (Mean&nbsp;&plusmn;&nbsp;SD) and increased
to 131&nbsp;&plusmn;&nbsp;49.9&nbsp;l (Mean&nbsp;&plusmn;&nbsp;SD) in the
presence of 100&nbsp;mg twice&#8209;daily ritonavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>In vitro</span></i><span lang=EN-GB>
experiments with human liver microsomes (HLMs) indicate that darunavir
primarily undergoes oxidative metabolism. Darunavir is extensively metabolised
by the hepatic CYP system and almost exclusively by isozyme CYP3A4. A <sup>14</sup>C&#8209;darunavir
trial in healthy volunteers showed that a majority of the radioactivity in
plasma after a single 400/100&nbsp;mg darunavir with ritonavir dose was due to
the parent active substance. At least 3&nbsp;oxidative metabolites of darunavir
have been identified in humans; all showed activity that was at least 10&#8209;fold
less than the activity of darunavir against wild type HIV.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal><span lang=EN-GB>After a 400/100&nbsp;mg&nbsp;<sup>14</sup>C&#8209;darunavir
with ritonavir dose, approximately 79.5% and 13.9% of the administered dose of <sup>14</sup>C&#8209;darunavir
could be retrieved in faeces and urine, respectively. Unchanged darunavir
accounted for approximately 41.2% and 7.7% of the administered dose in faeces
and urine, respectively. The terminal elimination half&#8209;life of darunavir
was approximately 15&nbsp;hours when combined with ritonavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>The intravenous clearance of darunavir
alone (150&nbsp;mg) and in the presence of low dose ritonavir was 32.8&nbsp;l/h
and 5.9&nbsp;l/h, respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetics of darunavir in
combination with ritonavir taken twice daily in 74&nbsp;treatment&#8209;experienced
paediatric patients, aged 6 to 17&nbsp;years and weighing at least 20&nbsp;kg,
showed that the administered weight&#8209;based doses of PREZISTA/ritonavir
resulted in darunavir exposure comparable to that in adults receiving PREZISTA/ritonavir
600/100&nbsp;mg twice daily (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetics of darunavir in
combination with ritonavir taken twice daily in 14&nbsp;treatment&#8209;experienced
paediatric patients, aged 3 to &lt;&nbsp;6&nbsp;years and weighing at least 15&nbsp;kg
to &lt;&nbsp;20&nbsp;kg, showed that weight&#8209;based dosages resulted in
darunavir exposure that was comparable to that achieved in adults receiving
PREZISTA/ritonavir 600/100&nbsp;mg twice daily (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetics of darunavir in
combination with ritonavir taken once daily in 12&nbsp;ART&#8209;na&iuml;ve
paediatric patients, aged 12 to &lt;&nbsp;18&nbsp;years and weighing at least
40&nbsp;kg, showed that PREZISTA/ritonavir 800/100&nbsp;mg once daily results
in darunavir exposure that was comparable to that achieved in adults receiving
PREZISTA/ritonavir 800/100&nbsp;mg once daily. Therefore the same once daily
dosage may be used in treatment&#8209;experienced adolescents aged 12 to &lt;&nbsp;18&nbsp;years
and weighing at least 40&nbsp;kg without darunavir resistance associated
mutations (DRV&#8209;RAMs)* and who have plasma HIV&#8209;1 RNA &lt;&nbsp;100,000&nbsp;copies/ml
and CD4+ cell count &#8805;&nbsp;100&nbsp;cells&nbsp;x&nbsp;10<sup>6</sup>/L (see
section 4.2).</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=NO-NYN>*</span><span lang=NO-NYN style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp; DRV&#8209;RAMs:
V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V</span></p>

<p class=MsoNormal><span lang=NO-NYN>&nbsp;</span></p>

<p class=MsoNormal>The pharmacokinetics of darunavir in combination with
ritonavir taken once daily in 10&nbsp;treatment&#8209;experienced paediatric
patients, aged 3 to &lt;&nbsp;6&nbsp;years and weighing at least 14&nbsp;kg to
&lt;&nbsp;20&nbsp;kg, showed that weight&#8209;based dosages resulted in
darunavir exposure that was comparable to that achieved in adults receiving
PREZISTA/ritonavir 800/100&nbsp;mg once daily (see section 4.2). In addition,
pharmacokinetic modeling and simulation of darunavir exposures in paediatric
patients across the ages of 3 to &lt;&nbsp;18&nbsp;years confirmed the
darunavir exposures as observed in the clinical studies and allowed the
identification of weight&#8209;based PREZISTA/ritonavir once daily dosing
regimens for paediatric patients weighing at least 15&nbsp;kg that are either
ART&#8209;na&iuml;ve or treatment&#8209;experienced paediatric patients without
DRV&#8209;RAMs* and who have plasma HIV&#8209;1 RNA &lt;&nbsp;100,000&nbsp;copies/ml
and CD4+ cell count &#8805;&nbsp;100&nbsp;cells&nbsp;x&nbsp;10<sup>6</sup>/L (see
section 4.2).</p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=NO-NYN>*</span><span lang=NO-NYN style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp; DRV&#8209;RAMs:
V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetics of darunavir
800&nbsp;mg co&#8209;administered with cobicistat 150&nbsp;mg in paediatric
patients have been studied in 7&nbsp;adolescents aged&nbsp;12 to less than
18&nbsp;years, weighing at least 40&nbsp;kg in Study GS&#8209;US&#8209;216&#8209;0128.
The geometric mean adolescent exposure (AUC<sub>tau</sub>) was similar for
darunavir and increased 19% for cobicistat compared to exposures achieved in adults
who received darunavir 800&nbsp;mg co&#8209;administered with cobicistat
150&nbsp;mg in Study GS&#8209;US&#8209;216&#8209;0130. The difference observed
for cobicistat was not considered clinically relevant.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=606
 style='width:454.5pt;margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=133 valign=top style='width:99.9pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=177 valign=top style='width:132.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Adults in Study GS&#8209;US&#8209;216&#8209;0130,
  week&nbsp;24</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(Reference)<sup>a</sup></span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Mean (%CV)</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>GLSM</span></b></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Adolescents in Study GS&#8209;US&#8209;216&#8209;0128,
  day&nbsp;10</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(Test)<sup>b</sup></span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Mean (%CV)</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>GLSM</span></b></p>
  </td>
  <td width=120 valign=top style='width:1.25in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>GLSM Ratio</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(90% CI)</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(Test/Reference)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=133 valign=top style='width:99.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>N</span></p>
  </td>
  <td width=177 valign=top style='width:132.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>60<sup>c</sup></span></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>7</span></p>
  </td>
  <td width=120 valign=top style='width:1.25in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=133 valign=top style='width:99.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>DRV PK
  Parameter</span></b></p>
  </td>
  <td width=177 valign=top style='width:132.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=120 valign=top style='width:1.25in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=133 valign=top style='width:99.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>AUC<sub>tau</sub> (h.ng/mL)<sup>d</sup></span></p>
  </td>
  <td width=177 valign=top style='width:132.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>81,646 (32.2)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>77,534</span></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>80,877 (29.5)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>77,217</span></p>
  </td>
  <td width=120 valign=top style='width:1.25in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1.00
  (0.79&#8209;1.26)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=133 valign=top style='width:99.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>max</sub> (ng/mL)</span></p>
  </td>
  <td width=177 valign=top style='width:132.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>7,663 (25.1)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>7,422</span></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>7,506 (21.7)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>7,319</span></p>
  </td>
  <td width=120 valign=top style='width:1.25in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.99
  (0.83&#8209;1.17)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=133 valign=top style='width:99.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>tau</sub> (ng/mL)<sup>d</sup></span></p>
  </td>
  <td width=177 valign=top style='width:132.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1,311 (74.0)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>947</span></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1,087 (91.6)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>676</span></p>
  </td>
  <td width=120 valign=top style='width:1.25in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.71
  (0.34&#8209;1.48)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=133 valign=top style='width:99.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>COBI PK
  Parameter</span></b></p>
  </td>
  <td width=177 valign=top style='width:132.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=120 valign=top style='width:1.25in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=133 valign=top style='width:99.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>AUC<sub>tau</sub> (h.ng/mL)<sup>d</sup></span></p>
  </td>
  <td width=177 valign=top style='width:132.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>7,596 (48.1)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>7,022</span></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>8,741 (34.9)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>8,330</span></p>
  </td>
  <td width=120 valign=top style='width:1.25in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1.19
  (0.95&#8209;1.48)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=133 valign=top style='width:99.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>max</sub> (ng/mL)</span></p>
  </td>
  <td width=177 valign=top style='width:132.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>991 (33.4)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>945</span></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1,116 (20.0)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1,095</span></p>
  </td>
  <td width=120 valign=top style='width:1.25in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1.16
  (1.00&#8209;1.35)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=133 valign=top style='width:99.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>tau</sub> (ng/mL)<sup>d</sup></span></p>
  </td>
  <td width=177 valign=top style='width:132.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>32.8 (289.4)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>17.2<sup>e</sup></span></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>28.3 (157.2)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>22.0<sup>e</sup></span></p>
  </td>
  <td width=120 valign=top style='width:1.25in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1.28
  (0.51&#8209;3.22)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=606 colspan=4 valign=top style='width:454.5pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;24
  intensive PK data from subjects who received DRV 800&nbsp;mg + COBI
  150&nbsp;mg.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Day&nbsp;10
  intensive PK data from subjects who received DRV 800&nbsp;mg + COBI
  150&nbsp;mg.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>c</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; N=59
  for AUC<sub>tau</sub> and C<sub>tau</sub>.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>d</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Concentration
  at predose (0&nbsp;hours) was used as surrogate for concentration at
  24&nbsp;hours for the purposes of estimating AUC<sub>tau</sub> and C<sub>tau </sub>in
  Study GS-US-216-0128.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>e</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; N=57
  and N=5 for GLSM of C<sub>tau</sub> in Study GS-US-216-0130 and Study
  GS-US-216-0128, respectively.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=NO-NYN>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Population pharmacokinetic analysis in HIV
infected patients showed that darunavir pharmacokinetics are not considerably
different in the age range (18 to 75&nbsp;years) evaluated in HIV infected
patients (n=12, age&nbsp;&#8805;&nbsp;65) (see section 4.4). However, only limited
data were available in patients above the age of 65&nbsp;year.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Gender</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Population pharmacokinetic analysis showed
a slightly higher darunavir exposure (16.8%) in HIV infected females compared
to males. This difference is not clinically relevant.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Results from a mass balance study with <sup>14</sup>C&#8209;darunavir
with ritonavir showed that approximately 7.7% of the administered dose of
darunavir is excreted in the urine unchanged.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Although darunavir has not been studied in
patients with renal impairment, population pharmacokinetic analysis showed that
the pharmacokinetics of darunavir were not significantly affected in HIV
infected patients with moderate renal impairment (CrCl between 30&#8209;60&nbsp;ml/min,
n=20) (see sections 4.2 and 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Hepatic
impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir is primarily metabolised and
eliminated by the liver. In a multiple dose study with PREZISTA co&#8209;administered
with ritonavir (600/100&nbsp;mg) twice daily, it was demonstrated that the
total plasma concentrations of darunavir in subjects with mild (Child&#8209;Pugh
Class&nbsp;A, n=8) and moderate (Child&#8209;Pugh Class&nbsp;B, n=8) hepatic
impairment were comparable with those in healthy subjects. However, unbound
darunavir concentrations were approximately 55% (Child&#8209;Pugh Class&nbsp;A)
and 100% (Child&#8209;Pugh Class&nbsp;B) higher, respectively. The clinical
relevance of this increase is unknown therefore, PREZISTA should be used with
caution. The effect of severe hepatic impairment on the pharmacokinetics of
darunavir has not been studied (see sections 4.2, 4.3 and 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Pregnancy
and postpartum</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The exposure to total darunavir and
ritonavir after intake of darunavir/ritonavir 600/100&nbsp;mg twice daily and
darunavir/ritonavir 800/100&nbsp;mg once daily as part of an antiretroviral
regimen was generally lower during pregnancy compared with postpartum. </span>However,
for unbound (i.e. active) darunavir, the pharmacokinetic parameters were less
reduced during pregnancy compared to postpartum, due to an increase in the
unbound fraction of darunavir during pregnancy compared to postpartum<span
lang=EN-GB>.</span></p>

<p class=MsoNormal>&nbsp;</p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=610 colspan=4 valign=top style='width:457.75pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Pharmacokinetic results of total darunavir after
  administration of </span></b><b><span lang=EN-GB>darunavir/ritonavir at
  600/100&nbsp;mg twice daily as part of an antiretroviral regimen, during the
  second trimester of pregnancy, the third trimester of pregnancy and
  postpartum</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=153 valign=top style='width:114.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pharmacokinetics
  of total darunavir</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>(mean &plusmn; SD)</span></p>
  </td>
  <td width=153 valign=top style='width:114.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Second trimester of pregnancy</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(n=12)<sup>a</sup></span></b></p>
  </td>
  <td width=153 valign=top style='width:114.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Third trimester of pregnancy</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(n=12)</span></b></p>
  </td>
  <td width=153 valign=top style='width:114.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Postpartum (6&#8209;12&nbsp;weeks)</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(n=12)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=153 style='width:114.4pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>max</sub>, ng/ml</span></p>
  </td>
  <td width=153 style='width:114.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>4,668
  &plusmn; 1,097</span></p>
  </td>
  <td width=153 style='width:114.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>5,328
  &plusmn; 1,631</span></p>
  </td>
  <td width=153 style='width:114.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>6,659
  &plusmn; 2,364</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=153 valign=bottom style='width:114.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>AUC<sub>12h</sub>, ng.h/ml</span></p>
  </td>
  <td width=153 valign=bottom style='width:114.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>39,370
  &plusmn; 9,597</span></p>
  </td>
  <td width=153 valign=bottom style='width:114.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>45,880
  &plusmn; 17,360</span></p>
  </td>
  <td width=153 valign=bottom style='width:114.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>56,890
  &plusmn; 26,340</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=153 style='width:114.4pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>min</sub>, ng/ml</span></p>
  </td>
  <td width=153 style='width:114.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1,922
  &plusmn; 825</span></p>
  </td>
  <td width=153 valign=bottom style='width:114.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2,661
  &plusmn; 1,269</span></p>
  </td>
  <td width=153 style='width:114.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2,851
  &plusmn; 2,216</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=610 colspan=4 valign=top style='width:457.75pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB>&nbsp;&nbsp;&nbsp; </span><span
  lang=EN-GB style='font-size:9.0pt'>n=11 for AUC<sub>12h</sub></span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal>&nbsp;</p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=4 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Pharmacokinetic results of total darunavir after
  administration of darunavir/ritonavir at 800/100&nbsp;mg once daily as part
  of an antiretroviral regimen, during the second trimester of pregnancy, the third
  trimester of pregnancy and postpartum</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=151 valign=top style='width:113.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pharmacokinetics
  of total darunavir</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>(mean &plusmn; SD)</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>Second trimester of pregnancy</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>(n=17)</span></b></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>Third Trimester of pregnancy</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>(n=15)</span></b></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>Postpartum (6&#8209;12&nbsp;weeks)</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>(n=16)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=151 style='width:113.4pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>max</sub>, ng/ml</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>4,964
  &plusmn; 1,505</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>5,132
  &plusmn; 1,198</span></p>
  </td>
  <td width=151 valign=bottom style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>7,310
  &plusmn; 1,704</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=151 valign=bottom style='width:113.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>AUC<sub>24h</sub>, ng.h/ml</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>62,289
  &plusmn; 16,234</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>61,112
  &plusmn; 13,790</span></p>
  </td>
  <td width=151 valign=bottom style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>92,116
  &plusmn; 29,241</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=151 style='width:113.4pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>min</sub>, ng/ml</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1,248
  &plusmn; 542</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1,075
  &plusmn; 594</span></p>
  </td>
  <td width=151 valign=bottom style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1,473
  &plusmn; 1,141</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>In women receiving darunavir/ritonavir
600/100&nbsp;mg twice daily during the second trimester of pregnancy, mean
intra&#8209;individual values for total darunavir C<sub>max</sub>, AUC<sub>12h</sub>
and C<sub>min</sub> were 28%, 26% and 26% lower, respectively, as compared with
postpartum; during the third trimester of pregnancy, total darunavir C<sub>max</sub>,
AUC<sub>12h</sub> and C<sub>min</sub> values were 18%, 16% lower and 2% higher,
respectively, as compared with postpartum.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In women receiving darunavir/ritonavir
800/100&nbsp;mg once daily during the second trimester of pregnancy, mean intra&#8209;individual
values for total darunavir C<sub>max</sub>, AUC<sub>24h</sub> and C<sub>min</sub>
were 33%, 31% and 30% lower, respectively, as compared with postpartum; during
the third trimester of pregnancy, total darunavir C<sub>max</sub>, AUC<sub>24h</sub>
and C<sub>min</sub> values were 29%, 32% and 50% lower, respectively, as
compared with postpartum.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Treatment with darunavir/cobicistat
800/150&nbsp;mg once daily during pregnancy results in low darunavir exposure.
In women receiving darunavir/cobicistat during the second trimester of
pregnancy, mean intra-individual values for total darunavir C<sub>max</sub>,
AUC<sub>24h</sub> and C<sub>min</sub> were 49%, 56% and 92% lower,
respectively, as compared with postpartum; during the third trimester of
pregnancy, total darunavir C<sub>max</sub>, AUC<sub>24h</sub> and C<sub>min</sub>
values were 37%, 50% and 89% lower, respectively, as compared with postpartum.
The unbound fraction was also substantially reduced, including around 90%
reductions of C<sub>min</sub> levels. The main cause of these low exposures is
a marked reduction in cobicistat exposure as a consequence of
pregnancy-associated enzyme induction (see below).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=638 colspan=4 valign=top style='width:6.65in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Pharmacokinetic results of total darunavir after
  administration of darunavir/cobicistat 800/150&nbsp;mg once daily as part of
  an antiretroviral regimen, during the second trimester of pregnancy,
  the&nbsp;third trimester of pregnancy, and postpartum</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=160 valign=top style='width:119.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pharmacokinetics
  of total darunavir</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(mean
  &plusmn; SD)</span></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Second trimester of&nbsp;pregnancy</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(n=7)</span></b></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Third trimester of&nbsp;pregnancy</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(n=6)</span></b></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Postpartum (6&#8209;12&nbsp;weeks)</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(n=6)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=160 valign=top style='width:119.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>max</sub>, ng/mL</span></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>4,340
  &plusmn; 1,616</span></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>4,910
  &plusmn; 970</span></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>7,918
  &plusmn; 2,199</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=160 valign=top style='width:119.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>AUC<sub>24h</sub>, ng.h/mL</span></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>47,293
  &plusmn; 19,058</span></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>47,991
  &plusmn; 9,879</span></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>99,613
  &plusmn; 34,862</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=160 valign=top style='width:119.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>min</sub>, ng/mL</span></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>168
  &plusmn; 149</span></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>184
  &plusmn; 99</span></p>
  </td>
  <td width=160 valign=top style='width:119.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1,538
  &plusmn; 1,344</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The exposure to cobicistat was lower during
pregnancy, potentially leading to suboptimal boosting of darunavir. During the
second trimester of pregnancy, cobicistat C<sub>max</sub>, AUC<sub>24h</sub>,
and C<sub>min</sub> were 50%, 63%, and 83% lower, respectively, as compared
with postpartum. During the third trimester of pregnancy, cobicistat C<sub>max</sub>,
AUC<sub>24h</sub>, and C<sub>min</sub>, were 27%, 49%, and 83% lower,
respectively, as compared with postpartum.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical
safety data</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Animal toxicology studies have been
conducted at exposures up to clinical exposure levels with darunavir alone, in
mice, rats and dogs and in combination with ritonavir in rats and dogs.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In repeated&#8209;dose toxicology studies
in mice, rats and dogs, there were only limited effects of treatment with
darunavir. In rodents the target organs identified were the haematopoietic
system, the blood coagulation system, liver and thyroid. A variable but limited
decrease in red blood cell&#8209;related parameters was observed, together with
increases in activated partial thromboplastin time.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Changes were observed in liver (hepatocyte
hypertrophy, vacuolation, increased liver enzymes) and thyroid (follicular
hypertrophy). In the rat, the combination of darunavir with ritonavir lead to a
small increase in effect on RBC parameters, liver and thyroid and increased
incidence of islet fibrosis in the pancreas (in male rats only) compared to
treatment with darunavir alone. In the dog, no major toxicity findings or
target organs were identified up to exposures equivalent to clinical exposure
at the recommended dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In a study conducted in rats, the number of
corpora lutea and implantations were decreased in the presence of maternal
toxicity. Otherwise, there were no effects on mating or fertility with
darunavir treatment up to 1,000&nbsp;mg/kg/day and exposure levels below (AUC&#8209;0.5&nbsp;fold)
of that in human at the clinically recommended dose. Up to same dose levels,
there was no teratogenicity with darunavir in rats and rabbits when treated
alone nor in mice when treated in combination with ritonavir. The exposure
levels were lower than those with the recommended clinical dose in humans. In a
pre&#8209; and postnatal development assessment in rats, darunavir with and
without ritonavir, caused a transient reduction in body weight gain of the
offspring pre&#8209;weaning and there was a slight delay in the opening of eyes
and ears. Darunavir in combination with ritonavir caused a reduction in the
number of pups that exhibited the startle response on day 15 of lactation and a
reduced pup survival during lactation. These effects may be secondary to pup
exposure to the active substance via the milk and/or maternal toxicity. No post
weaning functions were affected with darunavir alone or in combination with
ritonavir. In juvenile rats receiving darunavir up to days 23&#8209;26,
increased mortality was observed with convulsions in some animals. Exposure in
plasma, liver and brain was considerably higher than in adult rats after
comparable doses in mg/kg between days 5 and 11 of age. After day 23 of life,
the exposure was comparable to that in adult rats. The increased exposure was
likely at least partly due to immaturity of the drug&#8209;metabolising enzymes
in juvenile animals. No treatment related mortalities were noted in juvenile
rats dosed at 1,000&nbsp;mg/kg darunavir (single dose) on day 26 of age or at
500&nbsp;mg/kg (repeated dose) from day 23 to 50 of age, and the exposures and
toxicity profile were comparable to those observed in adult rats.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Due to uncertainties regarding the rate of
development of the human blood brain barrier and liver enzymes, PREZISTA with
low dose ritonavir should not be used in paediatric patients below 3&nbsp;years
of age.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir was evaluated for carcinogenic
potential by oral gavage administration to mice and rats up to 104&nbsp;weeks.
Daily doses of 150, 450 and 1,000&nbsp;mg/kg were administered to mice and
doses of 50, 150 and 500&nbsp;mg/kg were administered to rats. Dose&#8209;related
increases in the incidences of hepatocellular adenomas and carcinomas were
observed in males and females of both species. Thyroid follicular cell adenomas
were noted in male rats. Administration of darunavir did not cause a statistically
significant increase in the incidence of any other benign or malignant neoplasm
in mice or rats. The observed hepatocellular and thyroid tumours in rodents are
considered to be of limited relevance to humans. Repeated administration of
darunavir to rats caused hepatic microsomal enzyme induction and increased
thyroid hormone elimination, which predispose rats, but not humans, to thyroid
neoplasms. At the highest tested doses, the systemic exposures (based on AUC)
to darunavir were between 0.4&#8209; and 0.7&#8209;fold (mice) and 0.7&#8209;
and 1&#8209;fold (rats), relative to those observed in humans at the
recommended therapeutic doses.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>After
2&nbsp;years administration of darunavir at exposures at or below the human
exposure, kidney changes were observed in mice (nephrosis) and rats (chronic
progressive nephropathy).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Darunavir was not mutagenic or genotoxic in
a battery of <i>in vitro</i> and <i>in vivo</i> assays including bacterial
reverse mutation (Ames), chromosomal aberration in human lymphocytes and <i>in
vivo</i> micronucleus test in mice.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp;&nbsp; List
of excipients</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA
400&nbsp;mg film&#8209;coated tablets</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Tablet
core</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Microcrystalline cellulose</span></p>

<p class=MsoNormal><span lang=EN-GB>Colloidal anhydrous silica</span></p>

<p class=MsoNormal><span lang=EN-GB>Crospovidone</span></p>

<p class=MsoNormal><span lang=EN-GB>Magnesium stearate</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Tablet
film&#8209;coat</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Poly(vinyl alcohol) &#8211; partially
hydrolysed</span></p>

<p class=MsoNormal><span lang=EN-GB>Macrogol 3350</span></p>

<p class=MsoNormal><span lang=EN-GB>Titanium dioxide (E171)</span></p>

<p class=MsoNormal><span lang=EN-GB>Talc</span></p>

<p class=MsoNormal><span lang=EN-GB>Sunset yellow FCF (E110)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA 800&nbsp;mg
film&#8209;coated tablets</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Tablet
core</span></u></p>

<p class=MsoNormal><span lang=IT>Microcrystalline cellulose</span></p>

<p class=MsoNormal><span lang=IT>Colloidal anhydrous silica</span></p>

<p class=MsoNormal><span lang=IT>Crospovidone</span></p>

<p class=MsoNormal><span lang=EN-GB>Magnesium stearate</span></p>

<p class=MsoNormal><span lang=EN-GB>Hypromellose</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Tablet
film&#8209;coat</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Poly(vinyl alcohol) &#8211; partially
hydrolysed</span></p>

<p class=MsoNormal><span lang=EN-GB>Macrogol 3350</span></p>

<p class=MsoNormal><span lang=IT>Titanium dioxide (E171)</span></p>

<p class=MsoNormal><span lang=IT>Talc</span></p>

<p class=MsoNormal><span lang=IT>Iron oxide red (E172)</span></p>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=IT>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf
life</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>3&nbsp;years</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for storage</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product does not require any
special storage conditions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature
and contents of container</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA 400&nbsp;mg
film&#8209;coated tablets</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Opaque, white, high density polyethylene
(HDPE) plastic, 160&nbsp;ml bottle containing 60&nbsp;tablets, fitted with
polypropylene (PP) child resistant closure.</span></p>

<p class=MsoNormal><span lang=EN-GB>Pack size of one bottle.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA 800&nbsp;mg
film&#8209;coated tablets</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Opaque, white, high density polyethylene
(HDPE) plastic, 75&nbsp;ml bottle containing 30&nbsp;tablets, fitted with
polypropylene (PP) child resistant closure.</span></p>

<p class=MsoNormal><span lang=EN-GB>Pack size of one bottle or three bottles
per carton.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for disposal</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Janssen&#8209;Cilag&nbsp;International&nbsp;NV</span></p>

<p class=MsoNormal><span lang=EN-GB>Turnhoutseweg&nbsp;30</span></p>

<p class=MsoNormal><span lang=EN-GB>B&#8209;2340&nbsp;Beerse</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA 400&nbsp;mg
film&#8209;coated tablets</span></u></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/380/003</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA 800&nbsp;mg
film&#8209;coated tablets</span></u></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/380/007 - <span style='background:
silver'>30&nbsp;film&#8209;coated tablets</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>EU/1/06/380/008 -
90&nbsp;film&#8209;coated tablets (3&nbsp;x&nbsp;30)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of first authorisation: 12 February
2007</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of latest renewal: 19 September 2013</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this medicinal product
is available on the website of the European Medicines Agency </span><span
lang=EN-GB style='color:blue'><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></span><span
lang=EN-GB>.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
II</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURERS RESPONSIBLE FOR BATCH
RELEASE</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR RESTRICTIONS
REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER CONDITIONS AND REQUIREMENTS
OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR RESTRICTIONS WITH
REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURERS
RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Name and
address of the manufacturer responsible for batch release</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>PREZISTA
  oral suspension</span></u></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Janssen
  Pharmaceutica NV</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Turnhoutseweg
  30</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>B-2340
  Beerse</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Belgium</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=NL>PREZISTA
  tablets</span></u></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL>Janssen-Cilag
  SpA</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL>Via C.
  Janssen</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT>Borgo San
  Michele</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT>04100 Latina</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT>Italy</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The printed package leaflet of the
medicinal product must state the name and address of the manufacturer
responsible for the release of the concerned batch.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Medicinal product subject to restricted
medical prescription (see Annex I: Summary of Product Characteristics, section
4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER CONDITIONS
AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic safety update reports (PSURs)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The requirements for submission of PSURs
for this medicinal product are set out in the list of Union reference dates
(EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any
subsequent updates published on the European medicines web&#8209;portal.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk management plan (RMP)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The marketing authorisation holder (MAH) shall
perform the required pharmacovigilance activities and interventions detailed in
the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any
agreed subsequent updates of the RMP.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>An updated
RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
III</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>LABELLING
AND PACKAGE LEAFLET</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>A.
LABELLING</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON FOR ORAL SUSPENSION</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=IT>PREZISTA 100&nbsp;mg/ml oral suspension</span></p>

<p class=MsoNormal><span lang=IT>darunavir</span></p>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each ml of suspension contains 100&nbsp;mg
darunavir (as ethanolate).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Contains sodium methyl parahydroxybenzoate
(E219).</span></p>

<p class=MsoNormal><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral suspension</span></p>

<p class=MsoNormal><span lang=EN-GB>200&nbsp;ml bottle</span></p>

<p class=MsoNormal><span lang=EN-GB>Pack includes a 6&nbsp;ml dosing pipette
with 0.2&nbsp;ml gradations.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal><span lang=EN-GB>Shake bottle vigorously before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not store above 30&deg;C.</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not refrigerate or freeze. Avoid
exposure to excessive heat.</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in the original container.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>11.&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=NL>Janssen&#8209;Cilag&nbsp;International&nbsp;NV</span></p>

<p class=MsoNormal><span lang=NL>Turnhoutseweg&nbsp;30</span></p>

<p class=MsoNormal><span lang=NL>B&#8209;2340&nbsp;Beerse</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/380/006</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>prezista 100&nbsp;mg/ml</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>BOTTLE LABEL FOR ORAL SUSPENSION</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=IT>PREZISTA 100&nbsp;mg/ml oral suspension</span></p>

<p class=MsoNormal><span lang=IT>darunavir</span></p>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each ml of suspension contains 100&nbsp;mg
darunavir (as ethanolate).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Contains sodium methyl parahydroxybenzoate
(E219).</span></p>

<p class=MsoNormal><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral suspension</span></p>

<p class=MsoNormal><span lang=EN-GB>200&nbsp;ml</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal><span lang=EN-GB>Shake bottle vigorously before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not store above 30&deg;C.</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not refrigerate or freeze. Avoid
exposure to excessive heat.</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in the original container.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>11.&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=NL>Janssen&#8209;Cilag&nbsp;International&nbsp;NV</span></p>

<p class=MsoNormal><span lang=NL>Turnhoutseweg&nbsp;30</span></p>

<p class=MsoNormal><span lang=NL>B&#8209;2340&nbsp;Beerse</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/380/006</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE
PACKAGING</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON / BOTTLE LABEL</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA 75&nbsp;mg film&#8209;coated
tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>darunavir</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film&#8209;coated tablet contains
75&nbsp;mg darunavir (as ethanolate).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>480&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>11.&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=NL>Janssen&#8209;Cilag&nbsp;International&nbsp;NV</span></p>

<p class=MsoNormal><span lang=NL>Turnhoutseweg&nbsp;30</span></p>

<p class=MsoNormal><span lang=NL>B&#8209;2340&nbsp;Beerse</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/380/005</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>prezista 75&nbsp;mg <i><span
style='background:silver'>(this is only applicable to the outer pack)</span></i></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON / BOTTLE LABEL</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA 150&nbsp;mg film&#8209;coated
tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>darunavir</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film&#8209;coated tablet contains
150&nbsp;mg darunavir (as ethanolate).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>240&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>11.&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=NL>Janssen&#8209;Cilag&nbsp;International&nbsp;NV</span></p>

<p class=MsoNormal><span lang=NL>Turnhoutseweg&nbsp;30</span></p>

<p class=MsoNormal><span lang=NL>B&#8209;2340&nbsp;Beerse</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/380/004</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>prezista 150&nbsp;mg <i><span
style='background:silver'>(this is only applicable to the outer pack)</span></i></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE
PACKAGING</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON / BOTTLE LABEL</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA 400&nbsp;mg film&#8209;coated
tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>darunavir</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film&#8209;coated tablet contains
400&nbsp;mg darunavir (as ethanolate).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Also contains sunset yellow FCF (E110).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>60&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=NL>Janssen&#8209;Cilag&nbsp;International&nbsp;NV</span></p>

<p class=MsoNormal><span lang=NL>Turnhoutseweg&nbsp;30</span></p>

<p class=MsoNormal><span lang=NL>B&#8209;2340&nbsp;Beerse</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/380/003</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>prezista 400&nbsp;mg <i><span
style='background:silver'>(this is only applicable to the outer pack)</span></i></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE
PACKAGING</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON / BOTTLE LABEL</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA 600&nbsp;mg film&#8209;coated
tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>darunavir</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film&#8209;coated tablet contains
600&nbsp;mg darunavir (as ethanolate).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Also contains sunset yellow FCF (E110).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>60&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=NL>Janssen&#8209;Cilag&nbsp;International&nbsp;NV</span></p>

<p class=MsoNormal><span lang=NL>Turnhoutseweg&nbsp;30</span></p>

<p class=MsoNormal><span lang=NL>B&#8209;2340&nbsp;Beerse</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/380/002</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>prezista 600&nbsp;mg <i><span
style='background:silver'>(this is only applicable to the outer pack)</span></i></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE
PACKAGING</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON / BOTTLE LABEL</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA 800&nbsp;mg film&#8209;coated
tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>darunavir</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film&#8209;coated tablet contains
800&nbsp;mg darunavir (as ethanolate).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>30&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>90&nbsp;film&#8209;coated
tablets (3&nbsp;bottles containing 30&nbsp;tablets each)</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>The bottles are
not to be distributed individually.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=NL>Janssen&#8209;Cilag&nbsp;International&nbsp;NV</span></p>

<p class=MsoNormal><span lang=NL>Turnhoutseweg&nbsp;30</span></p>

<p class=MsoNormal><span lang=NL>B&#8209;2340&nbsp;Beerse</span></p>

<p class=MsoNormal><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/380/007 - <span style='background:
silver'>30&nbsp;film&#8209;coated tablets</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>EU/1/06/380/008 -
90&nbsp;film&#8209;coated tablets (3&nbsp;x&nbsp;30)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>prezista 800&nbsp;mg <i><span
style='background:silver'>(this is only applicable to the outer pack)</span></i></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>B.
PACKAGE LEAFLET</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Package
leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=IT>PREZISTA
100&nbsp;mg/ml oral suspension</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=IT>darunavir</span></p>

<p class=MsoNormal><b><span lang=IT>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Read all
of this leaflet carefully before you start taking this medicine because it
contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your doctor,
pharmacist or nurse. This includes any possible side effects not listed in this
leaflet. See section 4.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What is in
this leaflet</span></b></p>

<p class=MsoNormal><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
PREZISTA is and what it is used for</span></p>

<p class=MsoNormal><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take PREZISTA</span></p>

<p class=MsoNormal><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to take PREZISTA</span></p>

<p class=MsoNormal><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=MsoNormal><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store PREZISTA</span></p>

<p class=MsoNormal><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
PREZISTA is and what it is used for</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What is </span></b><b><span
lang=EN-GB>PREZISTA?</span></b></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA contains the active substance
darunavir. PREZISTA is an antiretroviral medicine used in the treatment of
Human Immunodeficiency Virus (HIV) infection. It belongs to a group of
medicines called protease inhibitors. PREZISTA works by reducing the amount of
HIV in your body. This will improve your immune system and reduces the risk of
developing illnesses linked to HIV infection.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What it
is used for?</span></b></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is used to treat HIV infected
adults as well as HIV infected children of 3&nbsp;years of age and above, and
at least 15&nbsp;kilogram body weight (see <b>How to take PREZISTA)</b>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA must be taken in combination with
a low dose of cobicistat or ritonavir and other anti&#8209;HIV medicines. Your
doctor will discuss with you which combination of medicines is best for you.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take PREZISTA</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not
take PREZISTA</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are <b>allergic</b> to darunavir or any
of the other ingredients of this medicine (listed in section 6) or to cobicistat
or ritonavir.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have <b>severe liver problems</b>. Ask
your doctor if you are unsure about the severity of your liver disease. Some
additional tests might be necessary.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not
combine PREZISTA with any of the following medicines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you are taking any of these, ask your
doctor about switching to another medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Medicine</span></b></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Purpose of the medicine</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Avanafil</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat erectile dysfunction </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Astemizole </span></i><span
  lang=EN-GB>or</span><i><span lang=EN-GB> terfenadine</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat allergy symptoms</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Triazolam </span></i><span lang=EN-GB>and
  </span><i><span lang=EN-GB>oral </span></i><span lang=EN-GB>(taken by mouth)</span><i><span
  lang=EN-GB> midazolam</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to help you sleep and/or relieve anxiety</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Cisapride</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat some stomach conditions</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Colchicine </span></i><span
  lang=EN-GB>(if you have kidney and/or liver problems)</span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat gout</span> or familial
  Mediterranean fever</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=PT>Lurasidone, pimozide, quetiapine </span></i><span
  lang=PT>or</span><i><span lang=PT> sertindole</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat psychiatric conditions</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Ergot alkaloids</span></i><span
  lang=EN-GB> like <i>ergotamine</i>, <i>dihydroergotamine</i>, <i>ergometrine</i>
  and <i>methylergonovine</i></span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat migraine headaches</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Amiodarone, bepridil, dronedarone, ivabradine,
  quinidine, ranolazine </span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat certain heart disorders e.g.
  abnormal heart beat</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Lovastatin</span></i><span lang=EN-GB>,<i>
  simvastatin and lomitapide</i></span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to lower cholesterol levels</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Rifampicin</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat some infections such as
  tuberculosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>The combination product<i>
  lopinavir/ritonavir</i></span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>this anti&#8209;HIV medicine belongs to
  the same class as PREZISTA</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Elbasvir/grazoprevir</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat hepatitis C infection</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Alfuzosin</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat enlarged prostate</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Sildenafil</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat high blood pressure in the
  pulmonary circulation</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Dabigatran</span></i><span lang=EN-GB>,
  <i>ticagrelor</i></span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to help stop the clumping of platelets in
  the treatment of patients with a history of a heart attack</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Naloxegol</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat opioid induced constipation</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Dapoxetine</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat premature ejaculation</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Domperidone</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat nausea and vomiting</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not combine PREZISTA with products that
contain St&nbsp;John&#8217;s&nbsp;wort <i>(Hypericum perforatum)</i>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Warnings
and precautions</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Talk to your doctor, pharmacist or nurse
before taking PREZISTA.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is not a cure for HIV infection.
You can still pass on HIV when taking this medicine, although the risk is
lowered by effective antiretroviral therapy. Discuss with your physician the
precautions needed to avoid infecting other people.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>People taking PREZISTA may still develop
infections or other illnesses associated with HIV infection. You must keep in
regular contact with your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>People taking PREZISTA may develop a skin
rash. Infrequently a rash may become severe or potentially life&#8209;threatening.
Please contact your doctor whenever you develop a rash.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients taking PREZISTA and raltegravir
(for HIV infection), rashes (generally mild or moderate) may occur more
frequently than in patients taking either medicine separately.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Tell your
doctor about your situation BEFORE and DURING your treatment</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Make sure that you check the following
points and tell your doctor if any of these apply to you.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you have had <b>problems
with your liver</b> before, including hepatitis B or C infection. Your doctor
may evaluate how severe your liver disease is before deciding if you can take
PREZISTA.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you have <b>diabetes</b>.
PREZISTA might increase sugar levels in the blood.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor immediately if you notice any <b>symptoms
of infection </b>(for example enlarged lymph nodes and fever). In some patients
with advanced HIV infection and a history of opportunistic infection, signs and
symptoms of inflammation from previous infections may occur soon after anti&#8209;HIV
treatment is started. It is believed that these symptoms are due to an
improvement in the body&#8217;s immune response, enabling the body to fight
infections that may have been present with no obvious symptoms.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In addition to the opportunistic infections, autoimmune
disorders (a condition that occurs when the immune system attacks healthy body
tissue) may also occur after you start taking medicines for the treatment of
your HIV infection. Autoimmune disorders may occur many months after the start
of treatment. If you notice any symptoms of infection or other symptoms such as
muscle weakness, weakness beginning in the hands and feet and moving up towards
the trunk of the body, palpitations, tremor or hyperactivity, please inform
your doctor immediately to seek necessary treatment.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you have <b>haemophilia</b>.
PREZISTA might increase the risk of bleeding.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you are <b>allergic to</b> <b>sulphonamides
</b>(e.g. used to treat certain infections).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you notice any </span><b><span
lang=EN-GB>musculoskeletal problems</span></b><span lang=EN-GB>. Some patients
taking combination antiretroviral therapy may develop a bone disease called
osteonecrosis (death of bone tissue caused by loss of blood supply to the
bone). The length of combination antiretroviral therapy, corticosteroid use,
alcohol consumption, severe immunosuppression, higher body mass index, among
others, may be some of the many risk factors for developing this disease. Signs
of osteonecrosis are joint stiffness, aches and pains (especially of the hip,
knee and shoulder) and difficulty in movement. If you notice any of these
symptoms please inform your doctor.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Elderly</span></b></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA has only been used in limited
numbers of patients 65&nbsp;years or older. If you belong to this age group,
please discuss with your doctor if you can use PREZISTA.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>Children</span></b></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is not for use in children younger
than 3&nbsp;years of age or weighing less than 15&nbsp;kilograms.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Other
medicines and PREZISTA</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor or pharmacist if you are
taking or have recently taken any other medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There are some medicines that <b>you must
not combine</b> with PREZISTA. These are mentioned above under the heading
&#8216;Do not combine PREZISTA with any of the following medicines:&#8217;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In most cases, PREZISTA can be combined
with anti&#8209;HIV medicines belonging to another class [e.g. NRTIs (nucleoside
reverse transcriptase inhibitors), NNRTIs (non&#8209;nucleoside reverse
transcriptase inhibitors), CCR5 antagonists and FIs (fusion inhibitors)].
PREZISTA with cobicistat or ritonavir has not been tested with all PIs
(protease inhibitors) and must not be used with other HIV PIs. In some cases
dosage of other medicines might need to be changed. Therefore always tell your
doctor if you take other anti&#8209;HIV medicines and follow your
doctor&#8217;s instruction carefully on which medicines can be combined.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The effects
of PREZISTA might be reduced if you take any of the following products. Tell
your doctor if you take:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Phenobarbital, phenytoin</span></i><span
lang=EN-GB> (to prevent seizures)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Dexamethasone</span></i><span lang=EN-GB>
(corticosteroid)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Efavirenz </span></i><span lang=EN-GB>(HIV
infection)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Rifapentine, rifabutin </span></i><span
lang=EN-GB>(medicines to treat some infections such as tuberculosis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Saquinavir</span></i><span lang=EN-GB> (HIV
infection).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The effects
of other medicines might be influenced if you take PREZISTA. Tell your doctor
if you take:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Amlodipine, diltiazem, disopyramide, carvedilol,
felodipine, flecainide, lidocaine, metoprolol, mexiletine, nifedipine,
nicardipine</span></i><span lang=EN-GB>, <i>propafenone</i>, <i>timolol,
verapamil</i> (for heart disease) as the therapeutic effect or side effects of
these medicines may be increased.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>A</span></i><i><span lang=EN-GB>pixaban, edoxaban,
rivaroxaban, warfarin, clopidogrel</span></i><span lang=EN-GB> (to reduce
clotting of the blood) as their therapeutic effect or side effects may be
altered; your doctor may have to check your blood.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><a name="_Hlk497686805"><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Oestrogen&#8209;based hormonal contraceptives
and hormonal replacement therapy. PREZISTA might reduce its effectiveness. When
used for birth control,</span></a><span lang=EN-GB> alternative methods of non&#8209;hormonal
contraception are recommended</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Ethinylestradiol/drospirenone</span></i><span
lang=EN-GB>. PREZISTA might increase the risk for elevated potassium levels by
drospirenone.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Atorvastatin, pravastatin, rosuvastatin</span></i><span
lang=EN-GB> (to lower cholesterol levels). The risk of muscle damage might be
increased. Your doctor will evaluate which cholesterol lowering regimen is best
for your specific situation.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Clarithromycin</span></i><span lang=EN-GB>
(antibiotic)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Ciclosporin, </span></i><i><span lang=EN-GB>everolimus,
tacrolimus, sirolimus</span></i><span lang=EN-GB> (</span><span lang=EN-GB>for
dampening down </span><span lang=EN-GB>your immune system) as the therapeutic
effect or side effects of these medicines might be increased. Your doctor might
want to do some additional tests.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i>Corticosteroids including betamethasone, budesonide,
fluticasone, mometasone, prednisone, triamcinolone</i><span lang=EN-GB>. These
medicines are used to treat allergies, asthma, inflammatory bowel diseases,
inflammatory conditions of the eyes, joints and muscles and other inflammatory
conditions. If alternatives cannot be used, its use should only take place
after medical evaluation and under close monitoring by your doctor for
corticosteroid side effects.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Buprenorphine/naloxone</span></i><span
lang=EN-GB> (medicines to treat opioid dependence)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Salmeterol</span></i><span lang=EN-GB>
(medicine to treat asthma)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Artemether/l</span></i><i><span lang=EN-GB>umefantrine</span></i><span
lang=EN-GB> (a combination medicine to treat malaria)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Dasatinib, everolimus, irinotecan, nilotinib,
vinblastine, vincristine </span></i><span lang=EN-GB>(to treat cancer)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Sildenafil, tadalafil, vardenafil </span></i><span
lang=EN-GB>(for erectile dysfunction or to treat a heart and lung disorder
called pulmonary arterial hypertension)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Glecaprevir/pibrentasvir</span><span
lang=EN-GB> </span></i><span lang=EN-GB>(to treat hepatitis C infection)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Fentanyl, oxycodone, tramadol</span></i><span
lang=EN-GB> (to treat pain)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><a
name="_Hlk525849805"><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Fesoterodine</span></i></a><span lang=EN-GB>,
<i>solifenacin</i> (to treat urologic disorders)</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The dosage of other medicines might need to
be changed since either their own or PREZISTA&#8217;s therapeutic effect or
side effects may be influenced when combined.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tell your
doctor if you take:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Alfentanil</span></i><span lang=EN-GB>
(injectable </span><span lang=EN-GB>strong and short&#8209;acting painkiller
that is used for surgical procedures)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Digoxin</span></i><span lang=EN-GB> (to treat
certain heart disorders)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Clarithromycin</span></i><span lang=EN-GB>
(antibiotic)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Itraconazole, isavuconazole, fluconazole, posaconazole,
clotrimazole</span></i><span lang=EN-GB> (to treat fungal infections).
Voriconazole should only be taken after medical evaluation.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Rifabutin</span></i><span lang=EN-GB>
(against bacterial infections)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Sildenafil, vardenafil, tadalafil</span></i><span
lang=EN-GB> (for erectile dysfunction or high blood pressure in the pulmonary
circulation)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Amitriptyline, desipramine, imipramine,
nortriptyline, paroxetine, sertraline, trazodone</span></i><span lang=EN-GB>
(to treat depression and anxiety)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Maraviroc </span></i><span lang=EN-GB>(to
treat HIV infection)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Methadone </span></i><span lang=EN-GB>(to
treat opiate dependence)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Carbamazepine, clonazepam</span></i><span
lang=EN-GB> (to prevent seizures or to treat certain types of nerve pain)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Colchicine </span></i><span lang=EN-GB>(to
treat gout</span> or familial Mediterranean fever<span lang=EN-GB>)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Bosentan</span></i><span lang=EN-GB> (to
treat high blood pressure in the pulmonary circulation)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Buspirone, clorazepate, diazepam, estazolam,
flurazepam, midazolam when used as injection, zolpidem</span></i><span
lang=EN-GB> (sedative agents)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Perphenazine,</span><span lang=EN-GB> risperidone,
thioridazine</span></i><span lang=EN-GB> (to treat psychiatric conditions)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=NO-BOK>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=NO-BOK>Metformin</span></i><span lang=NO-BOK> (to
treat type&nbsp;2&nbsp;diabetes).</span></p>

<p class=MsoNormal><span lang=NO-BOK>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This is <b>not</b> a complete list of
medicines. Tell your healthcare provider about <b><i>all </i></b>medicines that
you are taking.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>PREZISTA
with food and drink</span></b></p>

<p class=MsoNormal><span lang=EN-GB>See section&nbsp;3 &#8216;How to take
PREZISTA.&#8217;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pregnancy
and breast&#8209;feeding</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor immediately if you are
pregnant, planning to become pregnant or if you are breast&#8209;feeding.
Pregnant or breast&#8209;feeding mothers should not take PREZISTA with ritonavir
unless specifically directed by the doctor. </span><u><span lang=EN-AU>Pregnant
or breast&#8209;feeding mothers should not take PREZISTA with cobicistat.</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>It is recommended that HIV infected women
must not breast&#8209;feed their infants because of both the possibility of
your baby becoming infected with HIV through your breast milk and because of
the unknown effects of the medicine on your baby.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Do not operate machines or drive if you
feel dizzy after taking PREZISTA.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>PREZISTA
oral suspension contains sodium methyl parahydroxybenzoate</span></b><span
lang=EN-GB>. This ingredient may cause allergic reactions (sometimes delayed).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>PREZISTA
contains sodium</span></b></p>

<p class=MsoNormal><span lang=EN-GB>This medicine contains less than
1&nbsp;mmol sodium (23&nbsp;mg) per ml, that is to say essentially
&#8216;sodium&#8209;free&#8217;.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to take PREZISTA</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Always use this medicine exactly as
described in this leaflet or as your doctor, pharmacist or nurse has told you. Check
with your doctor, pharmacist or nurse if you are not sure.</span></p>

<p class=MsoNormal><span lang=EN-GB>Even if you feel better, do not stop taking
PREZISTA and cobicistat or ritonavir without talking to your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After therapy has been initiated, the dose or
dosage form must not be changed or therapy must not be stopped without
instruction of the doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Dose for children of 3&nbsp;years of age and above, weighing at
least 15&nbsp;kilograms who have not taken antiretroviral medicines before</span><span
lang=EN-GB> (your child&#8217;s doctor will determine this)</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The doctor will work out the right once
daily dose based on the weight and age of the child (see table below). This
dose must not exceed the recommended adult dose, which is 800&nbsp;milligram
PREZISTA together with 150&nbsp;milligram cobicistat or 100&nbsp;milligram
ritonavir once a day.</span></p>

<p class=MsoNormal><span lang=EN-GB>The doctor will inform you on how much
PREZISTA oral suspension and how much cobicistat (tablet) or ritonavir
(capsules, tablets or solution) the child must take.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=631
 style='width:472.95pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Weight</span></b></p>
  </td>
  <td width=165 valign=top style='width:123.9pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>One PREZISTA dose is</span></b></p>
  </td>
  <td width=156 valign=top style='width:117.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>One ritonavir<sup>a</sup> dose is</span></b></p>
  </td>
  <td width=151 valign=top style='width:113.15pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>One cobicistat dose is</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 15 and 30&nbsp;kilograms</span></p>
  </td>
  <td width=165 valign=top style='width:123.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>600&nbsp;milligram (6&nbsp;milliliter)</span></p>
  </td>
  <td width=156 valign=top style='width:117.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>100&nbsp;milligram (1.2&nbsp;milliliter)</span></p>
  </td>
  <td width=151 valign=top style='width:113.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Do not take</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 30 and 40&nbsp;kilograms</span></p>
  </td>
  <td width=165 valign=top style='width:123.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>675&nbsp;milligram (6.8&nbsp;milliliter)</span></p>
  </td>
  <td width=156 valign=top style='width:117.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>100&nbsp;milligram (1.2&nbsp;milliliter)</span></p>
  </td>
  <td width=151 valign=top style='width:113.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Do not take</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=158 valign=top style='width:1.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>more than 40&nbsp;kilograms</span></p>
  </td>
  <td width=165 valign=top style='width:123.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>800&nbsp;milligram (8&nbsp;milliliter)</span></p>
  </td>
  <td width=156 valign=top style='width:117.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>100&nbsp;milligram (1.2&nbsp;milliliter)</span></p>
  </td>
  <td width=151 valign=top style='width:113.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>150&nbsp;milligram<sup>b</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=480 colspan=3 valign=top style='width:359.8pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=IT>a</span></sup><span lang=IT>&nbsp;&nbsp;&nbsp; </span><span lang=IT
  style='font-size:9.0pt'>ritonavir oral solution: 80&nbsp;milligram per
  milliliter</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=IT>b</span></sup><span lang=IT>&nbsp;&nbsp;&nbsp; </span><span lang=IT
  style='font-size:9.0pt'>the child must be 12&nbsp;years old or older</span></p>
  </td>
  <td width=151 valign=top style='width:113.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=IT>&nbsp;</span></sup></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-autospace:none'><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The child must
take PREZISTA every day and always in combination with 150&nbsp;milligram
cobicistat or 100&nbsp;milligram of ritonavir and with food. PREZISTA cannot
work properly without cobicistat or ritonavir and food. The child must eat a
meal or a snack within 30&nbsp;minutes prior to taking PREZISTA and either
cobicistat or ritonavir. The type of food is not important.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Your
child&#8217;s doctor will determine if your child should take PREZISTA with
either cobicistat or ritonavir.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Dose for children of 3&nbsp;years of age and above, weighing at
least 15&nbsp;kilograms who </span><span lang=EN-GB>have taken antiretroviral
medicines before (your child&#8217;s doctor will determine this)</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The doctor will work out the right dose
based on the weight and age of the child (see table below). The doctor will
determine if once daily dosing or twice daily dosing is appropriate for the
child. This dose must not exceed the recommended adult dose, which is
600&nbsp;milligram PREZISTA together with 100&nbsp;milligram ritonavir two
times per day or 800&nbsp;milligram PREZISTA together with 150&nbsp;milligram cobicistat
or 100&nbsp;milligram ritonavir once a day.</span></p>

<p class=MsoNormal><span lang=EN-GB>The doctor will inform you on how much
PREZISTA oral suspension and how much cobicistat (tablet) or ritonavir (capsules,
tablets or solution) the child must take.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Twice
  daily dosing</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=197 valign=top style='width:147.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Weight</span></b></p>
  </td>
  <td width=204 valign=top style='width:152.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>One PREZISTA dose is</span></b></p>
  </td>
  <td width=204 valign=top style='width:153.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>One ritonavir<sup>a</sup> dose is</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=197 valign=top style='width:147.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>between 15
  and 30&nbsp;kilograms</span></p>
  </td>
  <td width=204 valign=top style='width:152.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>380&nbsp;milligram
  (3.8&nbsp;milliliter)</span></p>
  </td>
  <td width=204 valign=top style='width:153.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>50&nbsp;milligram
  (0.6&nbsp;milliliter)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=197 valign=top style='width:147.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 30 and 40&nbsp;kilograms</span></p>
  </td>
  <td width=204 valign=top style='width:152.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>460&nbsp;milligram (4.6&nbsp;milliliter)</span></p>
  </td>
  <td width=204 valign=top style='width:153.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>60&nbsp;milligram (0.8&nbsp;milliliter)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=197 valign=top style='width:147.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>more than 40&nbsp;kilograms</span></p>
  </td>
  <td width=204 valign=top style='width:152.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>600&nbsp;milligram (6&nbsp;milliliter)</span></p>
  </td>
  <td width=204 valign=top style='width:153.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>100&nbsp;milligram (1.2&nbsp;milliliter)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:none;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=IT>a</span></sup><span lang=IT>&nbsp;&nbsp;&nbsp; </span><span lang=IT
  style='font-size:9.0pt'>ritonavir oral solution: 80&nbsp;milligram per
  milliliter</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=631
 style='width:472.95pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=631 colspan=4 valign=top style='width:472.95pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Once daily
  dosing</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=161 valign=top style='width:120.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Weight</span></b></p>
  </td>
  <td width=163 valign=top style='width:122.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>One PREZISTA dose is</span></b></p>
  </td>
  <td width=157 valign=top style='width:117.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>One ritonavir<sup>a</sup> dose is</span></b></p>
  </td>
  <td width=150 valign=top style='width:112.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>One cobicistat dose is</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=161 valign=top style='width:120.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 15 and 30&nbsp;kilograms</span></p>
  </td>
  <td width=163 valign=top style='width:122.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>600&nbsp;milligram (6&nbsp;milliliter)</span></p>
  </td>
  <td width=157 valign=top style='width:117.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>100&nbsp;milligram (1.2&nbsp;milliliter)</span></p>
  </td>
  <td width=150 valign=top style='width:112.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Do not take</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=161 valign=top style='width:120.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 30 and 40&nbsp;kilograms</span></p>
  </td>
  <td width=163 valign=top style='width:122.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>675&nbsp;milligram (6.8&nbsp;milliliter)</span></p>
  </td>
  <td width=157 valign=top style='width:117.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>100&nbsp;milligram (1.2&nbsp;milliliter)</span></p>
  </td>
  <td width=150 valign=top style='width:112.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Do not take</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=161 valign=top style='width:120.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>more than 40&nbsp;kilograms</span></p>
  </td>
  <td width=163 valign=top style='width:122.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>800&nbsp;milligram (8&nbsp;milliliter)</span></p>
  </td>
  <td width=157 valign=top style='width:117.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>100&nbsp;milligram (1.2&nbsp;milliliter)</span></p>
  </td>
  <td width=150 valign=top style='width:112.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>150&nbsp;milligram<sup>b</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=480 colspan=3 valign=top style='width:360.25pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=IT>a</span></sup><span lang=IT>&nbsp;&nbsp;&nbsp; </span><span lang=IT
  style='font-size:9.0pt'>ritonavir oral solution: 80&nbsp;milligram per
  milliliter</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=IT>b</span></sup><span lang=IT>&nbsp;&nbsp;&nbsp; </span><span lang=IT
  style='font-size:9.0pt'>the child must be 12&nbsp;years old or older</span></p>
  </td>
  <td width=150 valign=top style='width:112.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=IT>&nbsp;</span></sup></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>Instructions
for children</span></i></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The child must take PREZISTA always together
with cobicistat or ritonavir. PREZISTA cannot work properly without cobicistat
or ritonavir.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The child must take the appropriate doses of
PREZISTA and ritonavir two times per day or once a day or PREZISTA and
cobicistat once a day. If prescribed PREZISTA twice daily the child must take one
dose in the morning, and one dose in the evening. Your child&#8217;s doctor will
determine the appropriate dosing regimen for your child.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The child must take PREZISTA with food. PREZISTA
cannot work properly without food. The type of food is not important.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Dose for
adults who have not taken antiretroviral medicines before (your doctor will
determine this)</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The usual dose
of PREZISTA is 800&nbsp;milligram once daily.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>You must take
PREZISTA every day and always in combination with 150&nbsp;milligram of
cobicistat or 100&nbsp;milligram of ritonavir and with food. PREZISTA cannot
work properly without cobicistat or ritonavir and food. You must eat a meal or
a snack within 30&nbsp;minutes prior to taking your PREZISTA and cobicistat or
ritonavir. The type of food is not important. Even if you feel better, do not
stop taking PREZISTA and cobicistat or ritonavir without talking to your
doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Dose for
adults who have taken antiretroviral medicines before (your doctor will
determine this)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The dose is
either:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>600&nbsp;milligram PREZISTA together with
100&nbsp;milligram ritonavir twice daily.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>OR</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>800&nbsp;milligram PREZISTA together with 150&nbsp;milligram
cobicistat or 100&nbsp;milligram ritonavir once daily.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Please discuss with your doctor which dose
is right for you.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><i><span lang=EN-GB>Instructions for adults</span></i></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take PREZISTA always together with cobicistat or
ritonavir. PREZISTA cannot work properly without cobicistat or ritonavir.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take PREZISTA with food. PREZISTA cannot work
properly without food. The type of food is not important.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><i><span lang=EN-GB>Instructions for use</span></i></b></p>

<p class=MsoNormal><span lang=EN-GB>Use the dosing pipette supplied with the
pack to measure your dose accurately:</span></p>

<p class=MsoNormal><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shake the
bottle well before each use.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Open the bottle of PREZISTA
oral suspension by pushing downward on the cap and twisting it counter&#8209;clockwise.</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=215 valign=top style='width:161.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB><img border=0 width=191 height=174
  src="Prezista%20PI%20E_files/image001.jpg"></span></p>
  </td>
  <td width=404 valign=top style='width:303.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insert the supplied oral
  dosing pipette all the way into the bottle.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pull the plunger until the
top of the barrel meets the line that matches the dose prescribed by your
healthcare provider.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take the dose of PREZISTA.
Place the tip of the oral dosing pipette in the mouth. Press on the plunger of
the pipette towards the mouth, then swallow.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Close the bottle with the cap
after use, and store PREZISTA oral suspension as directed in section 5 below.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the plunger from the
barrel of the pipette, rinse both with water and allow to air dry after each
use.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Put the oral dosing pipette
back together after air drying and store with the PREZISTA bottle.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use the dosing pipette for any other
medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
take more PREZISTA than you should</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Contact your doctor, pharmacist or nurse
immediately.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
forget to take PREZISTA</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you take PREZISTA two times a day and if
you notice <b>within 6&nbsp;hours</b>, you must take the oral suspension
immediately. Always take with ritonavir and food. If you notice <b>after
6&nbsp;hours</b>, then skip the intake and take the next doses as usual. Do not
take a double dose to make up for a forgotten dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you take PREZISTA once a day and if you
notice within <b>12&nbsp;hours</b>, you must take the oral suspension
immediately. Always take with cobicistat or ritonavir and food. If you notice <b>after
12&nbsp;hours</b>, then skip the intake and take the next doses as usual. Do
not take a double dose to make up for a forgotten dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
vomit after taking PREZISTA and cobicistat or ritonavir</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you vomit <b>within&nbsp;4 hours</b> of
taking the medicine, another dose of PREZISTA and cobicistat or ritonavir
should be taken with food as soon as possible. If you vomit <b>more than 4&nbsp;hours</b>
after taking the medicine, then you do not need to take another dose of
PREZISTA and cobicistat or ritonavir until the next regularly scheduled time.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Contact your doctor <b>if you are uncertain</b>
about what to do if you miss a dose or vomit.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not
stop taking PREZISTA without talking to your doctor first</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Anti-HIV medicines may make you feel better.
Even when you feel better, do not stop taking PREZISTA. Talk to your doctor
first.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you have any further questions on the
use of this medicine, ask your doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>During HIV therapy there may be an increase
in weight and in levels of blood lipids and glucose. This is partly linked to
restored health and life style, and in the case of blood lipids sometimes to
the HIV medicines themselves. Your doctor will test for these changes.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Like all medicines, this medicine can cause
side effects, although not everybody gets them.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Tell your
doctor if you develop any of the following side effects</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Liver problems
that may occasionally be severe have been reported. Your doctor should do blood
tests before you start PREZISTA. If you have chronic hepatitis&nbsp;B or C
infection, your doctor should check your blood tests more often because you
have an increased chance of developing liver problems. Talk to your doctor
about the signs and symptoms of liver problems. These may include yellowing of
your skin or whites of your eyes, dark (tea coloured) urine, pale coloured
stools (bowel movements), nausea, vomiting, loss of appetite, or pain, aching,
or </span><span lang=EN-GB>pain and discomfort</span><span lang=EN-GB> on your
right side below your ribs.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Skin rash (more
often when used in combination with raltegravir), itching. The rash is usually
mild to moderate. A skin rash might also be a symptom of a rare severe
situation. It is important to talk to your doctor if you develop a rash. Your
doctor will advise you how to deal with your symptoms or whether PREZISTA must
be stopped.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Other severe
side effects were diabetes (common) and inflammation of the pancreas (uncommon).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very common
side effects (may affect more than 1 in 10&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Common side
effects (may affect up to 1 in 10&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vomiting, nausea, abdominal pain or distension,
dyspepsia, flatulence</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>headache<i>,</i> tiredness, dizziness,
drowsiness, numbness, tingling or pain in hands or feet, loss of strength,
difficulty falling asleep.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Uncommon
side effects (may affect up to 1 in 100&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>chest pain, changes in electrocardiogram, rapid
heart beating</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased or abnormal skin sensibility, pins and
needles, attention disturbance, loss of memory, problems with your balance</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty breathing, cough, nosebleed, throat
irritation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the stomach or mouth, heartburn,
retching, dry mouth, discomfort of the abdomen, constipation, belching</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>kidney failure, kidney stones, difficult
discharge of urine, frequent or excessive passage of urine, sometimes at night</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>urticaria, severe swelling of the skin and other
tissues (most often the lips or the eyes), eczema, excessive sweating, night
sweats, hair loss, acne, scaly skin, colouration of nails</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle pain, muscle cramps or weakness, pain in
extremity, osteoporosis</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>slowing down of the thyroid gland function. This
can be seen in a blood test.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high blood pressure, flushing</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>red or dry eyes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fever, swelling of lower limbs due to fluids,
malaise, irritability, pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>symptoms of infection, herpes simplex</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>erectile dysfunction, enlargement of breasts</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sleeping problems, sleepiness, depression,
anxiety, abnormal dreams, decrease in sexual drive</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Rare side
effects (may affect up to 1 in 1,000&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a reaction called DRESS [severe rash, which may
be accompanied by fever, fatigue, swelling of the face or lymph glands,
increase of eosinophils (type of white blood cells), effects on liver, kidney
or lung]</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>heart attack, slow heart beating, palpitations</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>visual disturbance</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>chills, feeling abnormal</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a feeling of confusion or disorientation,
altered mood, restlessness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fainting,</span><span lang=EN-GB> epileptic
fits, changes or loss of taste</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>mouth sores, vomiting blood, inflammation of the
lips, dry lips, coated tongue</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>running nose</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin lesions, dry skin</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>stiffness of muscles or joints, joint pain with
or without inflammation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>changes in some values of your blood cells or
chemistry. These can be seen in the results of blood and/or urine tests. Your
doctor will explain these to you. Examples are: increase in some white blood
cells.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Some side
effects are typical for anti&#8209;HIV medicines in the same family as
PREZISTA. These are:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle pain, tenderness or weakness. On rare occasions,
these muscle disorders have been serious.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Reporting
of side effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you get any side effects, talk to your
doctor, pharmacist or nurse. This includes any possible side effects not listed
in this leaflet. You can also report side effects directly via <span
style='background:silver'>the national reporting system listed in </span></span><span
lang=EN-GB style='background:silver'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix&nbsp;V</a></span><span
lang=EN-GB>. By reporting side effects you can help provide more information on
the safety of this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store PREZISTA</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep this medicine out of the sight and reach
of children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use this medicine after the expiry
date which is stated on the carton and on the bottle after EXP. The expiry date
refers to the last day of that month.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not store above 30&deg;C.</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not refrigerate or freeze. Avoid
exposure to excessive heat.</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in the original container.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away any medicines
you no longer use. These measures will help protect the environment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
PREZISTA contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is darunavir. Each
milliliter contains 100&nbsp;milligram of darunavir (as ethanolate).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are hydroxypropyl cellulose,
microcrystalline cellulose and carmellose sodium, citric acid monohydrate,
sucralose, strawberry cream flavour, masking flavour, sodium methyl
parahydroxybenzoate (E219), hydrochloric acid (for pH adjustment), purified
water.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
PREZISTA looks like and contents of the pack</span></b></p>

<p class=MsoNormal><span lang=EN-GB>White to off&#8209;white opaque oral suspension.
Provided in a 200&nbsp;ml amber glass bottle with polypropylene child resistant
closure and a 6&nbsp;ml low density polyethylene (LDPE) oral dosing pipette
with 0.2&nbsp;ml gradations. The bottle neck is filled with a low density
polyethylene (LDPE) insert that accommodates the dosing pipette. Do not use the
oral dosing pipette for any other medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is also available as 75&nbsp;milligram,
150&nbsp;milligram, 400&nbsp;milligram, 600&nbsp;milligram and 800&nbsp;milligram
film&#8209;coated tablets.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Janssen&#8209;Cilag International NV, Turnhoutseweg
30, 2340 Beerse, Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal><span lang=NL>Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340
Beerse, Belgium</span></p>

<p class=MsoNormal><span lang=NL>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>For any
information about this medicine, please contact the local representative of the
Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag NV</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel/T&eacute;l: +32 14 64 94 11</span></p>
  <p class=MsoNormal><span lang=NL-BE>janssen@jacbe.jnj.com</span></p>
  <p class=MsoNormal><span lang=NL-BE>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UAB &quot;JOHNSON &amp; JOHNSON&quot;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +370 5 278 68 88</span></p>
  <p class=MsoNormal><span lang=EN-GB>lt@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>&#8222;&#1044;&#1078;&#1086;&#1085;&#1089;&#1098;&#1085;
  &amp; &#1044;&#1078;&#1086;&#1085;&#1089;&#1098;&#1085;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;&#8221;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&#1058;&#1077;&#1083;.: +359 2 489 94 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>jjsafety@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag NV</span></p>
  <p class=MsoNormal><span lang=NL-BE>T&eacute;l/Tel: +32 14 64 94 11</span></p>
  <p class=MsoNormal><span lang=EN-GB>janssen@jacbe.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>&#268;esk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag s.r.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +420 227 012 227</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Kft.</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel.: +36 1 884 2858</span></p>
  <p class=MsoNormal><span lang=NL-BE>janssenhu@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=NL-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Danmark</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag A/S</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tlf: +45 4594 8282</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacdk@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>AM MANGION LTD</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +356 2397 6000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag GmbH</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel: +49 2137 955 955</span></p>
  <p class=MsoNormal><span lang=EN-GB>jancil@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Nederland</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 76 711 1111</span></p>
  <p class=MsoNormal><span lang=EN-GB>janssen@jacnl.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Eesti</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UAB &quot;JOHNSON &amp; JOHNSON&quot;
  Eesti filiaal</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +372 617 7410</span></p>
  <p class=MsoNormal><span lang=EN-GB>ee@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen-Cilag AS</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +47 24 12 65 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacno@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen-Cilag
  &#934;&#945;&#961;&#956;&#945;&#954;&#949;&#965;&#964;&#953;&#954;&#942;
  &#913;.&#917;.&#914;.&#917;.</span></p>
  <p class=MsoNormal><span lang=EN-GB>T&#951;&#955;: +30 210 80 90 000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Pharma GmbH</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel: +43 1 610 300</span></p>
  <p class=MsoNormal><span lang=NL-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag, S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +34 91 722 81 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>contacto@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Polska</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Polska Sp. z o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel.: +48 22 237 60 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>France</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>Janssen-Cilag</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>T&eacute;l:
  0 800 25 50 75 / +33 1 55 00 40 03</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>medisource@its.jnj.com</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=NL-BE>Portugal</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>Janssen-Cilag
  Farmac&ecirc;utica, Lda.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +351
  214 368 600</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Johnson
  &amp; Johnson S.E. d.o.o.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +385
  1 6610 700</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>jjsafety@JNJCR.JNJ.com</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Johnson
  &amp; Johnson Rom<b>&acirc;</b>nia SRL</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +40
  21 207 1800</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen Sciences Ireland UC</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +353 1 800 709 122</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Johnson &amp; Johnson d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +386 1 401 18 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen_safety_slo@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>&Iacute;sland</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>Janssen-Cilag
  AB</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>c/o Vistor
  hf.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>S&iacute;mi:
  +354 535 7000</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>janssen@vistor.is</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Johnson
  &amp; Johnson, s.r.o.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +421
  232 408 400</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Italia</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag SpA</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel: 800.688.777 / +39 02 2510 1</span></p>
  <p class=MsoNormal><span lang=EN-GB><a href="mailto:janssenita@its.jnj.com"><span
  style='color:windowtext;text-decoration:none'>janssenita@its.jnj.com</span></a></span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Oy</span></p>
  <p class=MsoNormal><span lang=NL-BE>Puh/Tel: +358 207 531 300</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacfi@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>&#914;&#945;&#961;&#957;&#940;&#946;&#945;&#962;
  &#935;&#945;&#964;&#950;&#951;&#960;&#945;&#957;&#945;&#947;&#942;&#962;
  &#923;&#964;&#948;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&#932;&#951;&#955;: +357 22 207 700</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Sverige</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag AB</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tfn: +46 8 626 50 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacse@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UAB &quot;JOHNSON &amp; JOHNSON&quot;
  fili&#257;le Latvij&#257;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +371 678 93561</span></p>
  <p class=MsoNormal><span lang=EN-GB>lv@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen-Cilag Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +44 1 494 567 444</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>This
leaflet was last revised in </span></b><span lang=EN-GB>{MM/YYYY}.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this medicine is
available on the European Medicines Agency web site:<a href=""></a> </span><span
lang=EN-GB style='color:blue'><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></span><span
lang=EN-GB>.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Package
leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>PREZISTA
75&nbsp;mg film&#8209;coated tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>darunavir</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Read all
of this leaflet carefully before you start taking this medicine because it
contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness are
the same as yours.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your
doctor, pharmacist or nurse. This includes any possible side effects not listed
in this leaflet. See section 4.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What is
in this leaflet</span></b></p>

<p class=MsoNormal><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
PREZISTA is and what it is used for</span></p>

<p class=MsoNormal><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take PREZISTA</span></p>

<p class=MsoNormal><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to take PREZISTA</span></p>

<p class=MsoNormal><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=MsoNormal><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store PREZISTA</span></p>

<p class=MsoNormal><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
PREZISTA is and what it is used for</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What is
PREZISTA?</span></b></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA contains the active substance
darunavir. PREZISTA is an antiretroviral medicine used in the treatment of
Human Immunodeficiency Virus (HIV) infection. It belongs to a group of
medicines called protease inhibitors. PREZISTA works by reducing the amount of
HIV in your body. This will improve your immune system and reduces the risk of
developing illnesses linked to HIV infection.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What it
is used for?</span></b></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is used to treat adults and
children of 3&nbsp;years of age and above, and at least 15&nbsp;kilogram body
weight who are infected by HIV and who have already used other antiretroviral
medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA must be taken in combination with
a low dose of ritonavir and other anti&#8209;HIV medicines. Your doctor will
discuss with you which combination of medicines is best for you.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take PREZISTA</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not
take PREZISTA</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are <b>allergic</b> to darunavir or any
of the other ingredients of this medicine (listed in section 6) or to
ritonavir.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have <b>severe liver problems</b>. Ask
your doctor if you are unsure about the severity of your liver disease. Some
additional tests might be necessary.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not
combine PREZISTA with any of the following medicines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you are taking any of these, ask your
doctor about switching to another medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Medicine</span></b></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Purpose of the medicine</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Avanafil</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat erectile dysfunction </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Astemizole </span></i><span
  lang=EN-GB>or</span><i><span lang=EN-GB> terfenadine</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat allergy symptoms</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Triazolam </span></i><span lang=EN-GB>and
  </span><i><span lang=EN-GB>oral </span></i><span lang=EN-GB>(taken by mouth)</span><i><span
  lang=EN-GB> midazolam</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to help you sleep and/or relieve anxiety</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Cisapride</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat some stomach conditions</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Colchicine </span></i><span
  lang=EN-GB>(if you have kidney and/or liver problems)</span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat gout</span> or familial
  Mediterranean fever</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=PT>Lurasidone, pimozide, quetiapine </span></i><span
  lang=PT>or</span><i><span lang=PT> sertindole</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat psychiatric conditions</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Ergot alkaloids</span></i><span
  lang=EN-GB> like <i>ergotamine</i>, <i>dihydroergotamine</i>, <i>ergometrine</i>
  and <i>methylergonovine</i></span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat migraine headaches</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Amiodarone, bepridil, dronedarone, ivabradine,
  quinidine, ranolazine </span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat certain heart disorders e.g.
  abnormal heart beat</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Lovastatin, simvastatin and lomitapide</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to lower cholesterol levels</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Rifampicin</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat some infections such as
  tuberculosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>The combination product<i>
  lopinavir/ritonavir</i></span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>this anti&#8209;HIV medicine belongs to
  the same class as PREZISTA</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Elbasvir/grazoprevir</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat hepatitis C infection</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Alfuzosin</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat enlarged prostate</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Sildenafil</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat high blood pressure in the
  pulmonary circulation</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Dabigatran</span></i><span lang=EN-GB>,
  <i>ticagrelor</i></span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to help stop the clumping of platelets in
  the treatment of patients with a history of a heart attack</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Naloxegol</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat opioid induced constipation</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Dapoxetine</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat premature ejaculation</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Domperidone</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat nausea and vomiting</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not combine PREZISTA with products that
contain<i> </i>St&nbsp;John&#8217;s&nbsp;wort<i> (Hypericum perforatum)</i>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Warnings
and precautions</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Talk to your doctor, pharmacist or nurse
before taking PREZISTA.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is not a cure for HIV infection.
You can still pass on HIV when taking this medicine, although the risk is
lowered by effective antiretroviral therapy. Discuss with your physician the
precautions needed to avoid infecting other people.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>People taking PREZISTA may still develop
infections or other illnesses associated with HIV infection. You must keep in
regular contact with your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>People taking PREZISTA may develop a skin
rash. Infrequently a rash may become severe or potentially life&#8209;threatening.
Please contact your doctor whenever you develop a rash.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients taking PREZISTA and raltegravir
(for HIV infection), rashes (generally mild or moderate) may occur more
frequently than in patients taking either medicine separately.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Tell your
doctor about your situation BEFORE and DURING your treatment</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Make sure that you check the following
points and tell your doctor if any of these apply to you.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you have had <b>problems
with your liver</b> before, including hepatitis B or C infection. Your doctor
may evaluate how severe your liver disease is before deciding if you can take
PREZISTA.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you have <b>diabetes</b>.
PREZISTA might increase sugar levels in the blood.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor immediately if you notice any <b>symptoms
of infection </b>(for example enlarged lymph nodes and fever). In some patients
with advanced HIV infection and a history of opportunistic infection, signs and
symptoms of inflammation from previous infections may occur soon after anti&#8209;HIV
treatment is started. It is believed that these symptoms are due to an
improvement in the body&#8217;s immune response, enabling the body to fight
infections that may have been present with no obvious symptoms.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In addition to the opportunistic infections,
autoimmune disorders (a condition that occurs when the immune system attacks
healthy body tissue) may also occur after you start taking medicines for the
treatment of your HIV infection. Autoimmune disorders may occur many months
after the start of treatment. If you notice any symptoms of infection or other
symptoms such as muscle weakness, weakness beginning in the hands and feet and
moving up towards the trunk of the body, palpitations, tremor or hyperactivity,
please inform your doctor immediately to seek necessary treatment.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you have <b>haemophilia</b>.
PREZISTA might increase the risk of bleeding.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you are <b>allergic to</b> <b>sulphonamides
</b>(e.g. used to treat certain infections).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you notice any </span><b><span
lang=EN-GB>musculoskeletal problems</span></b><span lang=EN-GB>. Some patients
taking combination antiretroviral therapy may develop a bone disease called
osteonecrosis (death of bone tissue caused by loss of blood supply to the
bone). The length of combination antiretroviral therapy, corticosteroid use,
alcohol consumption, severe immunosuppression, higher body mass index, among
others, may be some of the many risk factors for developing this disease. Signs
of osteonecrosis are joint stiffness, aches and pains (especially of the hip,
knee and shoulder) and difficulty in movement. If you notice any of these
symptoms please inform your doctor.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>Elderly</span></b></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA has only been used in limited
numbers of patients 65&nbsp;years or older. If you belong to this age group,
please discuss with your doctor if you can use PREZISTA.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>Children</span></b></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is not for use in children younger
than 3&nbsp;years of age or weighing less than 15&nbsp;kilograms.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Other
medicines and PREZISTA</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor or pharmacist if you are
taking or have recently taken any other medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There are some medicines that <b>you must
not combine</b> with PREZISTA. These are mentioned above under the heading
&#8216;Do not combine PREZISTA with any of the following medicines:&#8217;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In most cases, PREZISTA can be combined
with anti&#8209;HIV medicines belonging to another class [e.g. NRTIs
(nucleoside reverse transcriptase inhibitors), NNRTIs (non&#8209;nucleoside
reverse transcriptase inhibitors), CCR5 antagonists and FIs (fusion
inhibitors)]. PREZISTA with ritonavir has not been tested with all PIs
(protease inhibitors) and must not be used with other HIV PIs. In some cases
dosage of other medicines might need to be changed. Therefore always tell your
doctor if you take other anti&#8209;HIV medicines and follow your
doctor&#8217;s instruction carefully on which medicines can be combined.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The effects
of PREZISTA might be reduced if you take any of the following products. Tell
your doctor if you take:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Phenobarbital, phenytoin</span></i><span
lang=EN-GB> (to prevent seizures)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Dexamethasone</span></i><span lang=EN-GB>
(corticosteroid)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Efavirenz </span></i><span lang=EN-GB>(HIV
infection)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Rifapentine, rifabutin </span></i><span
lang=EN-GB>(medicines to treat some infections such as tuberculosis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Saquinavir</span></i><span lang=EN-GB> (HIV
infection).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The effects
of other medicines might be influenced if you take PREZISTA. Tell your doctor
if you take:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Amlodipine, diltiazem, disopyramide, carvedilol,
felodipine, flecainide, lidocaine, metoprolol, mexiletine, nifedipine,
nicardipine</span></i><span lang=EN-GB>, <i>propafenone</i>, <i>timolol,
verapamil</i> (for heart disease) as the therapeutic effect or side effects of
these medicines may be increased.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>A</span></i><i><span lang=EN-GB>pixaban, edoxaban,
rivaroxaban, warfarin, clopidogrel</span></i><span lang=EN-GB> (to reduce
clotting of the blood) as their therapeutic effect or side effects may be
altered; your doctor may have to check your blood.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Oestrogen&#8209;based hormonal contraceptives
and hormonal replacement therapy. PREZISTA might reduce its effectiveness. When
used for birth control,</span><span lang=EN-GB> alternative methods of non&#8209;hormonal
contraception are recommended</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Ethinylestradiol/drospirenone</span></i><span
lang=EN-GB>. PREZISTA might increase the risk for elevated potassium levels by
drospirenone.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Atorvastatin, pravastatin, rosuvastatin</span></i><span
lang=EN-GB> (to lower cholesterol levels). The risk of muscle damage might be
increased. Your doctor will evaluate which cholesterol lowering regimen is best
for your specific situation.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Clarithromycin</span></i><span lang=EN-GB>
(antibiotic)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Ciclosporin, </span></i><i><span lang=EN-GB>everolimus,
tacrolimus, sirolimus</span></i><span lang=EN-GB> (</span><span lang=EN-GB>for
dampening down </span><span lang=EN-GB>your immune system) as the therapeutic
effect or side effects of these medicines might be increased. Your doctor might
want to do some additional tests.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i>Corticosteroids including betamethasone, budesonide,
fluticasone, mometasone, prednisone, triamcinolone</i><span lang=EN-GB>. These
medicines are used to treat allergies, asthma, inflammatory bowel diseases,
inflammatory conditions of the eyes, joints and muscles and other inflammatory
conditions. If alternatives cannot be used, its use should only take place
after medical evaluation and under close monitoring by your doctor for
corticosteroid side effects.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Buprenorphine/naloxone</span></i><span
lang=EN-GB> (medicines to treat opioid dependence)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Salmeterol</span></i><span lang=EN-GB>
(medicine to treat asthma)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Artemether/l</span></i><i><span lang=EN-GB>umefantrine</span></i><span
lang=EN-GB> (a combination medicine to treat malaria)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Dasatinib, everolimus, irinotecan, nilotinib,
vinblastine, vincristine </span></i><span lang=EN-GB>(to treat cancer)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Sildenafil, tadalafil, vardenafil </span></i><span
lang=EN-GB>(for erectile dysfunction or to treat a heart and lung disorder
called pulmonary arterial hypertension)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Glecaprevir/pibrentasvir</span><span
lang=EN-GB> </span></i><span lang=EN-GB>(to treat hepatitis C infection)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Fentanyl, oxycodone, tramadol</span></i><span
lang=EN-GB> (to treat pain)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Fesoterodine</span></i><span lang=EN-GB>, <i>solifenacin</i>
(to treat urologic disorders).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The dosage of other medicines might need to
be changed since either their own or PREZISTA&#8217;s therapeutic effect or
side effects may be influenced when combined.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tell your
doctor if you take:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Alfentanil</span></i><span lang=EN-GB>
(injectable </span><span lang=EN-GB>strong and short&#8209;acting painkiller
that is used for surgical procedures)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Digoxin</span></i><span lang=EN-GB> (to treat
certain heart disorders)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Clarithromycin</span></i><span lang=EN-GB>
(antibiotic)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Itraconazole, isavuconazole, fluconazole, posaconazole,
clotrimazole</span></i><span lang=EN-GB> (to treat fungal infections).
Voriconazole should only be taken after medical evaluation.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Rifabutin</span></i><span lang=EN-GB>
(against bacterial infections)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Sildenafil, vardenafil, tadalafil</span></i><span
lang=EN-GB> (for erectile dysfunction or high blood pressure in the pulmonary
circulation)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Amitriptyline, desipramine, imipramine,
nortriptyline, paroxetine, sertraline, trazodone</span></i><span lang=EN-GB>
(to treat depression and anxiety)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Maraviroc </span></i><span lang=EN-GB>(to
treat HIV infection)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Methadone </span></i><span lang=EN-GB>(to
treat opiate dependence)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Carbamazepine, clonazepam</span></i><span
lang=EN-GB> (to prevent seizures or to treat certain types of nerve pain)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Colchicine </span></i><span lang=EN-GB>(to
treat gout</span> or familial Mediterranean fever<span lang=EN-GB>)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Bosentan</span></i><span lang=EN-GB> (to
treat high blood pressure in the pulmonary circulation)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Buspirone, clorazepate, diazepam, estazolam,
flurazepam, midazolam when used as injection, zolpidem</span></i><span
lang=EN-GB> (sedative agents)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Perphenazine,</span><span lang=EN-GB> risperidone,
thioridazine</span></i><span lang=EN-GB> (to treat psychiatric conditions).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This is <b>not</b> a complete list of
medicines. Tell your healthcare provider about <b><i>all </i></b>medicines that
you are taking.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>PREZISTA
with food and drink</span></b></p>

<p class=MsoNormal><span lang=EN-GB>See section&nbsp;3 &#8216;How to take
PREZISTA.&#8217;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pregnancy
and breast&#8209;feeding</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor immediately if you are
pregnant, planning to become pregnant or if you are breast&#8209;feeding.
Pregnant or breast&#8209;feeding mothers should not take PREZISTA with
ritonavir unless specifically directed by the doctor.</span><span lang=EN-GB> </span><u><span
lang=EN-AU>Pregnant or breast&#8209;feeding mothers should not take PREZISTA
with cobicistat.</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>It is recommended that HIV infected women
must not breast&#8209;feed their infants because of both the possibility of
your baby becoming infected with HIV through your breast milk and because of
the unknown effects of the medicine on your baby.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Do not operate machines or drive if you
feel dizzy after taking PREZISTA.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>PREZISTA
contains sodium</span></b></p>

<p class=MsoNormal><span lang=EN-GB>This medicine contains less than
1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is to say essentially
&#8216;sodium&#8209;free&#8217;.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to take PREZISTA</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Always use this medicine exactly as
described in this leaflet or as your doctor, pharmacist or nurse has told you.
Check with your doctor, pharmacist or nurse if you are not sure.</span></p>

<p class=MsoNormal><span lang=EN-GB>Even if you feel better, do not stop taking
PREZISTA and ritonavir without talking to your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After therapy has been initiated, the dose
or dosage form must not be changed or therapy must not be stopped without
instruction of the doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Dose for
children of 3&nbsp;years of age and above, weighing at least 15&nbsp;kilograms </span></b><b><span
lang=EN-GB>who have not taken antiretroviral medicines before</span><span
lang=EN-GB> (your child&#8217;s doctor will determine this)</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The doctor will work out the right once
daily dose based on the weight of the child (see table below). This dose must
not exceed the recommended adult dose, which is 800&nbsp;milligram PREZISTA
together with 100&nbsp;milligram ritonavir once a day.</span></p>

<p class=MsoNormal><span lang=EN-GB>The doctor will inform you on how much
PREZISTA tablets and how much ritonavir (capsules, tablets or solution) the
child must take.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=205 valign=top style='width:154.0pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Weight</span></b></p>
  </td>
  <td width=205 valign=top style='width:154.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>One PREZISTA dose is</span></b></p>
  </td>
  <td width=205 valign=top style='width:154.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>One ritonavir<sup>a</sup> dose is</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=205 valign=top style='width:154.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 15 and 30&nbsp;kilograms</span></p>
  </td>
  <td width=205 valign=top style='width:154.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>600&nbsp;milligram</span></p>
  </td>
  <td width=205 valign=top style='width:154.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100&nbsp;milligram</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=205 valign=top style='width:154.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 30 and 40&nbsp;kilograms</span></p>
  </td>
  <td width=205 valign=top style='width:154.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>675&nbsp;milligram</span></p>
  </td>
  <td width=205 valign=top style='width:154.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100&nbsp;milligram</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=205 valign=top style='width:154.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>more than 40&nbsp;kilograms</span></p>
  </td>
  <td width=205 valign=top style='width:154.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>800&nbsp;milligram</span></p>
  </td>
  <td width=205 valign=top style='width:154.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100&nbsp;milligram</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=616 colspan=3 valign=top style='width:462.1pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=IT>a</span></sup><span lang=IT>&nbsp;&nbsp;&nbsp; </span><span lang=IT
  style='font-size:9.0pt'>ritonavir oral solution: 80&nbsp;milligram per
  milliliter</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Dose for children of 3&nbsp;years of age and above, weighing at
least 15&nbsp;kilograms who have taken antiretroviral medicines before (your child&#8217;s
doctor will determine this)</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The doctor will work out the right dose
based on the weight of the child (see table below). The doctor will determine
if once daily dosing or twice daily dosing is appropriate for the child. This
dose must not exceed the recommended adult dose, which is 600&nbsp;milligram
PREZISTA together with 100&nbsp;milligram ritonavir two times per day or
800&nbsp;milligram PREZISTA together with 100&nbsp;milligram ritonavir once a
day.</span></p>

<p class=MsoNormal><span lang=EN-GB>The doctor will inform you on how many
PREZISTA tablets and how much ritonavir (capsules, tablets or solution) the
child must take. Tablets of other strengths are available and your doctor may
have prescribed a certain combination of tablets to construct the appropriate
dosing regimen.</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA oral suspension is also available.
Your doctor will determine whether PREZISTA tablets or oral suspension is right
for the child.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=2 valign=top style='width:6.3in;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Twice
  daily dosing</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=200 valign=top style='width:149.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Weight</span></b></p>
  </td>
  <td width=405 valign=top style='width:303.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>One dose is</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=200 style='width:149.65pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 15 and 30&nbsp;kilograms</span></p>
  </td>
  <td width=405 style='width:303.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>375&nbsp;milligram PREZISTA +
  50&nbsp;milligram ritonavir twice a day</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=200 style='width:149.65pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 30 and 40&nbsp;kilograms</span></p>
  </td>
  <td width=405 style='width:303.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>450&nbsp;milligram PREZISTA +
  60&nbsp;milligram ritonavir twice a day</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=200 style='width:149.65pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>more than 40&nbsp;kilograms*</span></p>
  </td>
  <td width=405 style='width:303.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>600&nbsp;milligram PREZISTA +
  100&nbsp;milligram ritonavir twice a day</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=2 style='width:6.3in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
  lang=EN-GB>*&nbsp;&nbsp; </span><span lang=EN-GB style='font-size:9.0pt'>For
  children aged 12 or more and weighing at least 40</span><span lang=EN-GB>&nbsp;</span><span
  lang=EN-GB style='font-size:9.0pt'>kilograms, your child&#8217;s doctor will
  determine if PREZISTA 800&nbsp;milligram once daily dosing may be used. This
  cannot </span><span lang=EN-GB style='font-size:9.0pt'>be administered with
  these 75&nbsp;milligram tablets. Other strengths of PREZISTA are available.</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Once daily
  dosing</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Weight</span></b></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>One PREZISTA dose is</span></b></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>One ritonavir<sup>a</sup> dose is</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 15 and 30&nbsp;kilograms</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>600&nbsp;milligram</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100&nbsp;milligram</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 30 and 40&nbsp;kilograms</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>675&nbsp;milligram</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100&nbsp;milligram</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>more than 40&nbsp;kilograms</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>800&nbsp;milligram</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100&nbsp;milligram</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:none;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=IT>a</span></sup><span lang=IT>&nbsp;&nbsp;&nbsp; </span><span lang=IT
  style='font-size:9.0pt'>ritonavir oral solution: 80&nbsp;milligram per
  milliliter</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>Instructions
for children</span></i></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The child must take PREZISTA always together
with ritonavir. PREZISTA cannot work properly without ritonavir.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The child must take the appropriate doses of
PREZISTA and ritonavir two times per day or once a day. If prescribed PREZISTA
twice daily the child must take one dose in the morning, and one dose in the
evening. Your child&#8217;s doctor will determine the appropriate dosing
regimen for your child.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The child must take PREZISTA with food. PREZISTA
cannot work properly without food. The type of food is not important.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The child must swallow the tablets with a drink
such as water or milk.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Dose for
adults who have not taken antiretroviral medicines before (your doctor will
determine this)</span></b></p>

<p class=MsoNormal><span lang=EN-GB>You will require a different dose of
PREZISTA which cannot be administered with these 75&nbsp;milligram tablets.
Other strengths of PREZISTA are available.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Dose for
adults who have taken antiretroviral medicines before (your doctor will
determine this)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The dose is
either:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>600&nbsp;milligram PREZISTA together with
100&nbsp;milligram ritonavir twice daily.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>OR</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>800&nbsp;milligram PREZISTA </span><span
lang=EN-GB>(2&nbsp;tablets containing 400&nbsp;milligram of PREZISTA or
1&nbsp;tablet containing 800&nbsp;milligram of PREZISTA) </span><span
lang=EN-GB>together with 100&nbsp;milligram ritonavir once daily. PREZISTA 400&nbsp;milligram
and 800&nbsp;milligram tablets are only to be used to construct the once daily
800&nbsp;milligram regimen.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Please discuss with your doctor which dose
is right for you.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>Instructions
for adults</span></i></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take PREZISTA always together with ritonavir.
PREZISTA cannot work properly without ritonavir.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In the morning, take 600&nbsp;milligram PREZISTA
together with 100&nbsp;milligram ritonavir.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In the evening, take 600&nbsp;milligram PREZISTA
together with 100&nbsp;milligram ritonavir.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take PREZISTA with food. PREZISTA cannot work
properly without food. The type of food is not important.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Swallow the tablets with a drink such as water
or milk.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>PREZISTA 75&nbsp;milligram and 150&nbsp;milligram
tablets and 100&nbsp;milligram per milliliter oral suspension have been
developed for use in children, but can also be used in adults in some cases.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Removing
the child resistant cap</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=121 valign=top style='width:90.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB><img border=0 width=86 height=90
  src="Prezista%20PI%20E_files/image002.jpg"></span></p>
  </td>
  <td width=499 valign=top style='width:373.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>The plastic bottle comes with a child
  resistant cap and must be opened as follows:</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Push the plastic screw
  cap down while turning it counter clockwise.</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the unscrewed
  cap.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
take more PREZISTA than you should</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Contact your doctor, pharmacist or nurse
immediately.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
forget to take PREZISTA</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you notice <b>within 6&nbsp;hours</b>,
you must take the tablets immediately. Always take with ritonavir and food. If
you notice <b>after 6&nbsp;hours</b>, then skip the intake and take the next
doses as usual. Do not take a double dose to make up for a forgotten dose.</span></p>

<p class=MsoNormal><a name="_Hlk43730919"><span lang=EN-GB>&nbsp;</span></a></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="_Hlk34828940"><b><span
lang=EN-GB>If you vomit after taking PREZISTA and ritonavir</span></b></a></p>

<p class=MsoNormal><span lang=EN-GB>If you vomit <b>within 4&nbsp;hours</b> of
taking the medicine, another dose of PREZISTA and ritonavir should be taken
with food as soon as possible. If you vomit <b>more than 4&nbsp;hours</b> after
taking the medicine, then you do not need to take another dose of PREZISTA and
ritonavir until the next regularly scheduled time.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Contact your doctor <b>if you are uncertain</b>
about what to do if you miss a dose or vomit.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not
stop taking PREZISTA without talking to your doctor first</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Anti-HIV medicines may make you feel better.
Even when you feel better, do not stop taking PREZISTA. Talk to your doctor
first.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you have any further questions on the
use of this medicine, ask your doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>During HIV therapy there may be an increase
in weight and in levels of blood lipids and glucose. This is partly linked to
restored health and life style, and in the case of blood lipids sometimes to
the HIV medicines themselves. Your doctor will test for these changes.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Like all medicines, this medicine can cause
side effects, although not everybody gets them.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Tell your
doctor if you develop any of the following side effects</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Liver problems
that may occasionally be severe have been reported. Your doctor should do blood
tests before you start PREZISTA. If you have chronic hepatitis&nbsp;B or C
infection, your doctor should check your blood tests more often because you
have an increased chance of developing liver problems. Talk to your doctor
about the signs and symptoms of liver problems. These may include yellowing of
your skin or whites of your eyes, dark (tea coloured) urine, pale coloured
stools (bowel movements), nausea, vomiting, loss of appetite, or pain, aching,
or </span><span lang=EN-GB>pain and discomfort</span><span lang=EN-GB> on your
right side below your ribs.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Skin rash (more
often when used in combination with raltegravir), itching. The rash is usually
mild to moderate. A skin rash might also be a symptom of a rare severe
situation. It is therefore important to talk to your doctor if you develop a
rash. Your doctor will advise you how to deal with your symptoms or whether
PREZISTA must be stopped.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Other severe
side effects were diabetes (common) and inflammation of the pancreas (uncommon).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very common
side effects (may affect more than 1 in 10&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Common side
effects (may affect up to 1 in 10&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vomiting, nausea, abdominal pain or distension,
dyspepsia, flatulence</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>headache<i>,</i> tiredness, dizziness,
drowsiness, numbness, tingling or pain in hands or feet, loss of strength,
difficulty falling asleep.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Uncommon
side effects (may affect up to 1 in 100&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>chest pain, changes in electrocardiogram, rapid
heart beating</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased or abnormal skin sensibility, pins and
needles, attention disturbance, loss of memory, problems with your balance</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty breathing, cough, nosebleed, throat
irritation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the stomach or mouth, heartburn,
retching, dry mouth, discomfort of the abdomen, constipation, belching</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>kidney failure, kidney stones, difficult
discharge of urine, frequent or excessive passage of urine, sometimes at night</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>urticaria, severe swelling of the skin and other
tissues (most often the lips or the eyes), eczema, excessive sweating, night
sweats, hair loss, acne, scaly skin, colouration of nails</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle pain, muscle cramps or weakness, pain in
extremity, osteoporosis</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>slowing down of the thyroid gland function. This
can be seen in a blood test.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high blood pressure, flushing</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>red or dry eyes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fever, swelling of lower limbs due to fluids, malaise,
irritability, pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>symptoms of infection, herpes simplex</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>erectile dysfunction, enlargement of breasts</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sleeping problems, sleepiness, depression,
anxiety, abnormal dreams, decrease in sexual drive</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Rare side
effects (may affect up to 1 in 1,000&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a reaction called DRESS [severe rash, which may
be accompanied by fever, fatigue, swelling of the face or lymph glands,
increase of eosinophils (type of white blood cells), effects on liver, kidney
or lung]</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>heart attack, slow heart beating, palpitations</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>visual disturbance</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>chills, feeling abnormal</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a feeling of confusion or disorientation,
altered mood, restlessness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fainting,</span><span lang=EN-GB> epileptic
fits, changes or loss of taste</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>mouth sores, vomiting blood, inflammation of the
lips, dry lips, coated tongue</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>running nose</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin lesions, dry skin</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>stiffness of muscles or joints, joint pain with
or without inflammation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>changes in some values of your blood cells or
chemistry. These can be seen in the results of blood and/or urine tests. Your
doctor will explain these to you. Examples are: increase in some white blood
cells.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Some side
effects are typical for anti&#8209;HIV medicines in the same family as
PREZISTA. These are:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle pain, tenderness or weakness. On rare
occasions, these muscle disorders have been serious.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Reporting
of side effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you get any side effects, talk to your
doctor, pharmacist or nurse. This includes any possible side effects not listed
in this leaflet. You can also report side effects directly via <span
style='background:silver'>the national reporting system listed in </span></span><span
lang=EN-GB style='background:silver'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix&nbsp;V</a></span><span
lang=EN-GB>. By reporting side effects you can help provide more information on
the safety of this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store PREZISTA</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep this medicine out of the sight and reach
of children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use this medicine after the expiry
date which is stated on the carton and on the bottle after EXP. The expiry date
refers to the last day of that month.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA does not require any special
storage conditions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away any
medicines you no longer use. These measures will help protect the environment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
PREZISTA contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is darunavir. Each tablet
contains 75&nbsp;milligram of darunavir (as ethanolate).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are microcrystalline
cellulose, colloidal anhydrous silica, crospovidone, magnesium stearate. The
film&#8209;coating contains poly(vinyl alcohol) &#8209; partially hydrolysed,
macrogol 3350, titanium dioxide (E171), talc.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
PREZISTA looks like and contents of the pack</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Film&#8209;coated, white, caplet shaped
tablet, mentioning TMC on one side, 75 on the other side. 480&nbsp;tablets in a
plastic bottle.</span></p>

<p class=MsoNormal><a name="OLE_LINK16"></a><a name="OLE_LINK14"><span
lang=EN-GB>PREZISTA is also available as 150&nbsp;milligram, 400&nbsp;milligram,
600&nbsp;milligram and 800&nbsp;milligram film&#8209;coated tablets</span></a><span
lang=EN-GB> and 100&nbsp;milligram per milliliter oral suspension.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Janssen&#8209;Cilag International NV,
Turnhoutseweg 30, 2340 Beerse, Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal><span lang=NL>Janssen&#8209;Cilag SpA, Via C. Janssen, Borgo
San Michele, 04100 Latina, Italy</span></p>

<p class=MsoNormal><span lang=NL>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>For any
information about this medicine, please contact the local representative of the
Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag NV</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel/T&eacute;l: +32 14 64 94 11</span></p>
  <p class=MsoNormal><span lang=NL-BE>janssen@jacbe.jnj.com</span></p>
  <p class=MsoNormal><span lang=NL-BE>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UAB &quot;JOHNSON &amp; JOHNSON&quot;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +370 5 278 68 88</span></p>
  <p class=MsoNormal><span lang=EN-GB>lt@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>&#8222;&#1044;&#1078;&#1086;&#1085;&#1089;&#1098;&#1085;
  &amp; &#1044;&#1078;&#1086;&#1085;&#1089;&#1098;&#1085;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;&#8221;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&#1058;&#1077;&#1083;.: +359 2 489 94 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>jjsafety@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag NV</span></p>
  <p class=MsoNormal><span lang=NL-BE>T&eacute;l/Tel: +32 14 64 94 11</span></p>
  <p class=MsoNormal><span lang=EN-GB>janssen@jacbe.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>&#268;esk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag s.r.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +420 227 012 227</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Kft.</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel.: +36 1 884 2858</span></p>
  <p class=MsoNormal><span lang=NL-BE>janssenhu@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=NL-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Danmark</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag A/S</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tlf: +45 4594 8282</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacdk@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>AM MANGION LTD</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +356 2397 6000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag GmbH</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel: +49 2137 955 955</span></p>
  <p class=MsoNormal><span lang=EN-GB>jancil@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Nederland</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 76 711 1111</span></p>
  <p class=MsoNormal><span lang=EN-GB>janssen@jacnl.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Eesti</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UAB &quot;JOHNSON &amp; JOHNSON&quot;
  Eesti filiaal</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +372 617 7410</span></p>
  <p class=MsoNormal><span lang=EN-GB>ee@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen-Cilag AS</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +47 24 12 65 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacno@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen-Cilag
  &#934;&#945;&#961;&#956;&#945;&#954;&#949;&#965;&#964;&#953;&#954;&#942;
  &#913;.&#917;.&#914;.&#917;.</span></p>
  <p class=MsoNormal><span lang=EN-GB>T&#951;&#955;: +30 210 80 90 000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Pharma GmbH</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel: +43 1 610 300</span></p>
  <p class=MsoNormal><span lang=NL-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag, S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +34 91 722 81 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>contacto@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Polska</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Polska Sp. z o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel.: +48 22 237 60 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>France</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>Janssen-Cilag</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>T&eacute;l:
  0 800 25 50 75 / +33 1 55 00 40 03</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>medisource@its.jnj.com</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=NL-BE>Portugal</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>Janssen-Cilag
  Farmac&ecirc;utica, Lda.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +351
  214 368 600</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Johnson
  &amp; Johnson S.E. d.o.o.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +385
  1 6610 700</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>jjsafety@JNJCR.JNJ.com</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Johnson
  &amp; Johnson Rom<b>&acirc;</b>nia SRL</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +40
  21 207 1800</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen Sciences Ireland UC</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +353 1 800 709 122</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Johnson &amp; Johnson d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +386 1 401 18 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen_safety_slo@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>&Iacute;sland</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>Janssen-Cilag
  AB</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>c/o Vistor
  hf.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>S&iacute;mi:
  +354 535 7000</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>janssen@vistor.is</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Johnson
  &amp; Johnson, s.r.o.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +421
  232 408 400</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Italia</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag SpA</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel: 800.688.777 / +39 02 2510 1</span></p>
  <p class=MsoNormal><span lang=EN-GB><a href="mailto:janssenita@its.jnj.com"><span
  style='color:windowtext;text-decoration:none'>janssenita@its.jnj.com</span></a></span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Oy</span></p>
  <p class=MsoNormal><span lang=NL-BE>Puh/Tel: +358 207 531 300</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacfi@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>&#914;&#945;&#961;&#957;&#940;&#946;&#945;&#962;
  &#935;&#945;&#964;&#950;&#951;&#960;&#945;&#957;&#945;&#947;&#942;&#962;
  &#923;&#964;&#948;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&#932;&#951;&#955;: +357 22 207 700</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Sverige</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag AB</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tfn: +46 8 626 50 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacse@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UAB &quot;JOHNSON &amp; JOHNSON&quot;
  fili&#257;le Latvij&#257;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +371 678 93561</span></p>
  <p class=MsoNormal><span lang=EN-GB>lv@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen-Cilag Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +44 1 494 567 444</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>This
leaflet was last revised in </span></b><span lang=EN-GB>{MM/YYYY}.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="OLE_LINK6"><span lang=EN-GB>Detailed information on
this medicine is available on the European Medicines Agency web site:</span></a><a
href=""></a><span lang=EN-GB> </span><a href="http://www.ema.europa.eu/"><span
lang=EN-GB>http://www.ema.europa.eu</span></a><span lang=EN-GB>.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Package
leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>PREZISTA
150&nbsp;mg film&#8209;coated tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>darunavir</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Read all
of this leaflet carefully before you start taking this medicine because it contains
important information for you.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your
doctor, pharmacist or nurse. This includes any possible side effects not listed
in this leaflet. See section 4.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What is
in this leaflet</span></b></p>

<p class=MsoNormal><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
PREZISTA is and what it is used for</span></p>

<p class=MsoNormal><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take PREZISTA</span></p>

<p class=MsoNormal><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to take PREZISTA</span></p>

<p class=MsoNormal><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=MsoNormal><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store PREZISTA</span></p>

<p class=MsoNormal><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
PREZISTA is and what it is used for</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What is
PREZISTA?</span></b></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA contains the active substance
darunavir. PREZISTA is an antiretroviral medicine used in the treatment of
Human Immunodeficiency Virus (HIV) infection. It belongs to a group of
medicines called protease inhibitors. PREZISTA works by reducing the amount of
HIV in your body. This will improve your immune system and reduces the risk of
developing illnesses linked to HIV infection.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What it
is used for?</span></b></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is used to treat adults and
children of 3&nbsp;years of age and above, and at least 15&nbsp;kilogram body
weight who are infected by HIV and who have already used other antiretroviral
medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA must be taken in combination with
a low dose of ritonavir and other anti&#8209;HIV medicines. Your doctor will
discuss with you which combination of medicines is best for you.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take PREZISTA</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not
take PREZISTA</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are <b>allergic</b> to darunavir or any
of the other ingredients of this medicine (listed in section 6) or to
ritonavir.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have <b>severe liver problems</b>. Ask
your doctor if you are unsure about the severity of your liver disease. Some
additional tests might be necessary.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not
combine PREZISTA with any of the following medicines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you are taking any of these, ask your
doctor about switching to another medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Medicine</span></b></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Purpose of the medicine</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Avanafil</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat erectile dysfunction </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Astemizole </span></i><span
  lang=EN-GB>or</span><i><span lang=EN-GB> terfenadine</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat allergy symptoms</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Triazolam </span></i><span lang=EN-GB>and
  </span><i><span lang=EN-GB>oral </span></i><span lang=EN-GB>(taken by mouth)</span><i><span
  lang=EN-GB> midazolam</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to help you sleep and/or relieve anxiety</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Cisapride</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat some stomach conditions</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Colchicine </span></i><span
  lang=EN-GB>(if you have kidney and/or liver problems)</span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat gout</span> or familial
  Mediterranean fever</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=PT>Lurasidone, pimozide, quetiapine </span></i><span
  lang=PT>or</span><i><span lang=PT> sertindole</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat psychiatric conditions</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Ergot alkaloids</span></i><span
  lang=EN-GB> like <i>ergotamine</i>, <i>dihydroergotamine</i>, <i>ergometrine</i>
  and <i>methylergonovine</i></span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat migraine headaches</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Amiodarone, bepridil, dronedarone, ivabradine,
  quinidine, ranolazine </span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat certain heart disorders e.g.
  abnormal heart beat</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Lovastatin, simvastatin and lomitapide</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to lower cholesterol levels</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Rifampicin</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat some infections such as
  tuberculosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>The combination product<i>
  lopinavir/ritonavir</i></span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>this anti&#8209;HIV medicine belongs to
  the same class as PREZISTA</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Elbasvir/grazoprevir</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat hepatitis C infection</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Alfuzosin</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat enlarged prostate</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Sildenafil</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat high blood pressure in the
  pulmonary circulation</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Dabigatran</span></i><span lang=EN-GB>,
  <i>ticagrelor</i></span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to help stop the clumping of platelets in
  the treatment of patients with a history of a heart attack</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Naloxegol</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat opioid induced constipation</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Dapoxetine</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat premature ejaculation</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Domperidone</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat nausea and vomiting</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not combine PREZISTA with products that
contain St&nbsp;John&#8217;s&nbsp;wort<i> (Hypericum perforatum)</i>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Warnings
and precautions</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Talk to your doctor, pharmacist or nurse
before taking PREZISTA.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is not a cure for HIV infection.
You can still pass on HIV when taking this medicine, although the risk is
lowered by effective antiretroviral therapy. Discuss with your physician the
precautions needed to avoid infecting other people.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>People taking PREZISTA may still develop
infections or other illnesses associated with HIV infection. You must keep in
regular contact with your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>People taking PREZISTA may develop a skin
rash. Infrequently a rash may become severe or potentially life&#8209;threatening.
Please contact your doctor whenever you develop a rash.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients taking PREZISTA and raltegravir
(for HIV infection), rashes (generally mild or moderate) may occur more
frequently than in patients taking either medicine separately.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Tell your
doctor about your situation BEFORE and DURING your treatment</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Make sure that you check the following
points and tell your doctor if any of these apply to you.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you have had <b>problems
with your liver</b> before, including hepatitis B or C infection. Your doctor
may evaluate how severe your liver disease is before deciding if you can take
PREZISTA.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you have <b>diabetes</b>.
PREZISTA might increase sugar levels in the blood.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor immediately if you notice any <b>symptoms
of infection </b>(for example enlarged lymph nodes and fever). In some patients
with advanced HIV infection and a history of opportunistic infection, signs and
symptoms of inflammation from previous infections may occur soon after anti&#8209;HIV
treatment is started. It is believed that these symptoms are due to an
improvement in the body&#8217;s immune response, enabling the body to fight
infections that may have been present with no obvious symptoms.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In addition to the opportunistic infections,
autoimmune disorders (a condition that occurs when the immune system attacks
healthy body tissue) may also occur after you start taking medicines for the
treatment of your HIV infection. Autoimmune disorders may occur many months
after the start of treatment. If you notice any symptoms of infection or other
symptoms such as muscle weakness, weakness beginning in the hands and feet and
moving up towards the trunk of the body, palpitations, tremor or hyperactivity,
please inform your doctor immediately to seek necessary treatment.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you have <b>haemophilia</b>.
PREZISTA might increase the risk of bleeding.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you are <b>allergic to</b> <b>sulphonamides
</b>(e.g. used to treat certain infections).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you notice any </span><b><span
lang=EN-GB>musculoskeletal problems</span></b><span lang=EN-GB>. Some patients
taking combination antiretroviral therapy may develop a bone disease called
osteonecrosis (death of bone tissue caused by loss of blood supply to the
bone). The length of combination antiretroviral therapy, corticosteroid use,
alcohol consumption, severe immunosuppression, higher body mass index, among
others, may be some of the many risk factors for developing this disease. Signs
of osteonecrosis are joint stiffness, aches and pains (especially of the hip,
knee and shoulder) and difficulty in movement. If you notice any of these symptoms
please inform your doctor.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>Elderly</span></b></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA has only been used in limited
numbers of patients 65&nbsp;years or older. If you belong to this age group,
please discuss with your doctor if you can use PREZISTA.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>Children</span></b></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is not for use in children younger
than 3&nbsp;years of age or weighing less than 15&nbsp;kilograms.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Other
medicines and PREZISTA</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor or pharmacist if you are
taking or have recently taken any other medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There are some medicines that <b>you must
not combine</b> with PREZISTA. These are mentioned above under the heading
&#8216;Do not combine PREZISTA with any of the following medicines:&#8217;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In most cases, PREZISTA can be combined
with anti&#8209;HIV medicines belonging to another class [e.g. NRTIs
(nucleoside reverse transcriptase inhibitors), NNRTIs (non&#8209;nucleoside
reverse transcriptase inhibitors), CCR5 antagonists and FIs (fusion
inhibitors)]. PREZISTA with ritonavir has not been tested with all PIs
(protease inhibitors) and must not be used with other HIV PIs. In some cases
dosage of other medicines might need to be changed. Therefore always tell your
doctor if you take other anti&#8209;HIV medicines and follow your
doctor&#8217;s instruction carefully on which medicines can be combined.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The effects
of PREZISTA might be reduced if you take any of the following products. Tell
your doctor if you take:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Phenobarbital, phenytoin</span></i><span
lang=EN-GB> (to prevent seizures)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Dexamethasone</span></i><span lang=EN-GB>
(corticosteroid)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Efavirenz </span></i><span lang=EN-GB>(HIV
infection)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Rifapentine, rifabutin </span></i><span
lang=EN-GB>(medicines to treat some infections such as tuberculosis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Saquinavir</span></i><span lang=EN-GB> (HIV
infection).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The effects
of other medicines might be influenced if you take PREZISTA. Tell your doctor
if you take:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Amlodipine, diltiazem, disopyramide, carvedilol,
felodipine, flecainide, lidocaine, metoprolol, mexiletine, nifedipine,
nicardipine</span></i><span lang=EN-GB>, <i>propafenone</i>, <i>timolol,
verapamil</i> (for heart disease) as the therapeutic effect or side effects of
these medicines may be increased.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>A</span></i><i><span lang=EN-GB>pixaban, edoxaban,
rivaroxaban, warfarin, clopidogrel</span></i><span lang=EN-GB> (to reduce
clotting of the blood) as their therapeutic effect or side effects may be
altered; your doctor may have to check your blood.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Oestrogen&#8209;based hormonal contraceptives
and hormonal replacement therapy. PREZISTA might reduce its effectiveness. When
used for birth control,</span><span lang=EN-GB> alternative methods of non&#8209;hormonal
contraception are recommended</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Ethinylestradiol/drospirenone</span></i><span
lang=EN-GB>. PREZISTA might increase the risk for elevated potassium levels by
drospirenone.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Atorvastatin, pravastatin, rosuvastatin</span></i><span
lang=EN-GB> (to lower cholesterol levels). The risk of muscle damage might be
increased. Your doctor will evaluate which cholesterol lowering regimen is best
for your specific situation.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Clarithromycin</span></i><span lang=EN-GB>
(antibiotic)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Ciclosporin, </span></i><i><span lang=EN-GB>everolimus,
tacrolimus, sirolimus</span></i><span lang=EN-GB> (</span><span lang=EN-GB>for
dampening down </span><span lang=EN-GB>your immune system) as the therapeutic
effect or side effects of these medicines might be increased. Your doctor might
want to do some additional tests.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i>Corticosteroids including betamethasone, budesonide,
fluticasone, mometasone, prednisone, triamcinolone</i><span lang=EN-GB>. These
medicines are used to treat allergies, asthma, inflammatory bowel diseases, inflammatory
conditions of the eyes, joints and muscles and other inflammatory conditions.
If alternatives cannot be used, its use should only take place after medical
evaluation and under close monitoring by your doctor for corticosteroid side
effects.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Buprenorphine/naloxone</span></i><span
lang=EN-GB> (medicines to treat opioid dependence)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Salmeterol</span></i><span lang=EN-GB>
(medicine to treat asthma)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Artemether/l</span></i><i><span lang=EN-GB>umefantrine</span></i><span
lang=EN-GB> (a combination medicine to treat malaria)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Dasatinib, everolimus, irinotecan, nilotinib,
vinblastine, vincristine </span></i><span lang=EN-GB>(to treat cancer)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Sildenafil, tadalafil, vardenafil </span></i><span
lang=EN-GB>(for erectile dysfunction or to treat a heart and lung disorder
called pulmonary arterial hypertension)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Glecaprevir/pibrentasvir</span><span
lang=EN-GB> </span></i><span lang=EN-GB>(to treat hepatitis C infection)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Fentanyl, oxycodone, tramadol</span></i><span
lang=EN-GB> (to treat pain)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><a
name="_Hlk2967977"><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Fesoterodine</span></i></a><span lang=EN-GB>,
<i>solifenacin</i> (to treat urologic disorders).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The dosage of other medicines might need to
be changed since either their own or PREZISTA&#8217;s therapeutic effect or
side effects may be influenced when combined.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tell your
doctor if you take:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Alfentanil</span></i><span lang=EN-GB>
(injectable </span><span lang=EN-GB>strong and short&#8209;acting painkiller
that is used for surgical procedures)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Digoxin</span></i><span lang=EN-GB> (to treat
certain heart disorders)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Clarithromycin</span></i><span lang=EN-GB>
(antibiotic)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Itraconazole, isavuconazole, fluconazole, posaconazole,
clotrimazole</span></i><span lang=EN-GB> (to treat fungal infections).
Voriconazole should only be taken after medical evaluation.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Rifabutin</span></i><span lang=EN-GB>
(against bacterial infections)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Sildenafil, vardenafil, tadalafil</span></i><span
lang=EN-GB> (for erectile dysfunction or high blood pressure in the pulmonary
circulation)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Amitriptyline, desipramine, imipramine,
nortriptyline, paroxetine, sertraline, trazodone</span></i><span lang=EN-GB>
(to treat depression and anxiety)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Maraviroc </span></i><span lang=EN-GB>(to
treat HIV infection)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Methadone </span></i><span lang=EN-GB>(to
treat opiate dependence)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Carbamazepine, clonazepam</span></i><span
lang=EN-GB> (to prevent seizures or to treat certain types of nerve pain)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Colchicine </span></i><span lang=EN-GB>(to
treat gout </span>or familial Mediterranean fever<span lang=EN-GB>)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Bosentan</span></i><span lang=EN-GB> (to
treat high blood pressure in the pulmonary circulation)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Buspirone, clorazepate, diazepam, estazolam,
flurazepam, midazolam when used as injection, zolpidem</span></i><span
lang=EN-GB> (sedative agents)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Perphenazine,</span><span lang=EN-GB> risperidone,
thioridazine</span></i><span lang=EN-GB> (to treat psychiatric conditions).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This is <b>not</b> a complete list of
medicines. Tell your healthcare provider about <b><i>all </i></b>medicines that
you are taking.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>PREZISTA
with food and drink</span></b></p>

<p class=MsoNormal><span lang=EN-GB>See section&nbsp;3 &#8216;How to take
PREZISTA.&#8217;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pregnancy
and breast&#8209;feeding</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor immediately if you are
pregnant, planning to become pregnant or if you are breast&#8209;feeding.
Pregnant or breast&#8209;feeding mothers should not take PREZISTA with
ritonavir unless specifically directed by the doctor. </span><u><span
lang=EN-AU>Pregnant or breast&#8209;feeding mothers should not take PREZISTA
with cobicistat.</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>It is recommended that HIV infected women
must not breast&#8209;feed their infants because of both the possibility of
your baby becoming infected with HIV through your breast milk and because of
the unknown effects of the medicine on your baby.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Do not operate machines or drive if you
feel dizzy after taking PREZISTA.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>PREZISTA
contains sodium</span></b></p>

<p class=MsoNormal><span lang=EN-GB>This medicine contains less than
1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is to say essentially
&#8216;sodium&#8209;free&#8217;.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to take PREZISTA</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Always use this medicine exactly as
described in this leaflet or as your doctor, pharmacist or nurse has told you.
Check with your doctor, pharmacist or nurse if you are not sure.</span></p>

<p class=MsoNormal><span lang=EN-GB>Even if you feel better, do not stop taking
PREZISTA and ritonavir without talking to your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After therapy has been initiated, the dose or
dosage form must not be changed or therapy must not be stopped without
instruction of the doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Dose for
children of 3&nbsp;years of age and above, weighing at least 15&nbsp;kilograms who
</span></b><b><span lang=EN-GB>have not taken antiretroviral medicines before</span><span
lang=EN-GB> (your child&#8217;s doctor will determine this)</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The doctor will work out the right once
daily dose based on the weight of the child (see table below). This dose must
not exceed the recommended adult dose, which is 800&nbsp;milligram PREZISTA
together with 100&nbsp;milligram ritonavir once a day.</span></p>

<p class=MsoNormal><span lang=EN-GB>The doctor will inform you on how much
PREZISTA tablets and how much ritonavir (capsules, tablets or solution) the
child must take.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Weight</span></b></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>One PREZISTA dose is</span></b></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>One ritonavir<sup>a</sup> dose is</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 15 and 30&nbsp;kilograms</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>600&nbsp;milligram</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100&nbsp;milligram</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 30 and 40&nbsp;kilograms</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>675&nbsp;milligram</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100&nbsp;milligram</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>more than 40&nbsp;kilograms</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>800&nbsp;milligram</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100&nbsp;milligram</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:none;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=IT>a</span></sup><span lang=IT>&nbsp;&nbsp;&nbsp; </span><span lang=IT
  style='font-size:9.0pt'>ritonavir oral solution: 80&nbsp;milligram per
  milliliter</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Dose for
children of 3&nbsp;years of age and above, weighing at least 15&nbsp;kilograms
who have taken antiretroviral medicines before (your child&#8217;s doctor will
determine this)</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The doctor will work out the right dose
based on the weight of the child (see table below). The doctor will determine
if once daily dosing or twice daily dosing is appropriate for the child. This
dose must not exceed the recommended adult dose, which is 600&nbsp;milligram
PREZISTA together with 100&nbsp;milligram ritonavir two times per day or 800&nbsp;milligram
PREZISTA together with 100&nbsp;milligram ritonavir once a day.</span></p>

<p class=MsoNormal><span lang=EN-GB>The doctor will inform you on how many
PREZISTA tablets and how much ritonavir (capsules, tablets or solution) the
child must take. Tablets of other strengths are available and your doctor may
have prescribed a certain combination of tablets to construct the appropriate
dosing regimen.</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA oral suspension is also available.
Your doctor will determine whether PREZISTA tablets or oral suspension is right
for the child.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=2 valign=top style='width:6.3in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Twice
  daily dosing</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:151.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Weight</span></b></p>
  </td>
  <td width=403 valign=top style='width:301.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>One dose is</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 style='width:151.7pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 15 and 30&nbsp;kilograms</span></p>
  </td>
  <td width=403 style='width:301.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>375&nbsp;milligram PREZISTA +
  50&nbsp;milligram ritonavir twice a day</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 style='width:151.7pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 30 and 40&nbsp;kilograms</span></p>
  </td>
  <td width=403 style='width:301.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>450&nbsp;milligram PREZISTA +
  60&nbsp;milligram ritonavir twice a day</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 style='width:151.7pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>more than 40&nbsp;kilograms*</span></p>
  </td>
  <td width=403 style='width:301.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>600&nbsp;milligram PREZISTA +
  100&nbsp;milligram ritonavir twice a day</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=2 style='width:6.3in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
  lang=EN-GB>*&nbsp;&nbsp; </span><span lang=EN-GB style='font-size:9.0pt'>For
  children aged 12 or more and weighing at least 40&nbsp;kilograms, your
  child&#8217;s doctor will determine if PREZISTA 800&nbsp;milligram once daily
  dosing may be used. This cannot </span><span lang=EN-GB style='font-size:
  9.0pt'>be administered with these 150&nbsp;milligram tablets. Other strengths
  of PREZISTA are available.</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Once daily
  dosing</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Weight</span></b></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>One PREZISTA dose is</span></b></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>One ritonavir<sup>a</sup> dose is</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 15 and 30&nbsp;kilograms</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>600&nbsp;milligram</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100&nbsp;milligram</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 30 and 40&nbsp;kilograms</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>675&nbsp;milligram</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100&nbsp;milligram</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>more than 40&nbsp;kilograms</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>800&nbsp;milligram</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100&nbsp;milligram</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:none;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=IT>a</span></sup><span lang=IT>&nbsp;&nbsp;&nbsp; </span><span lang=IT
  style='font-size:9.0pt'>ritonavir oral solution: 80&nbsp;milligram per
  milliliter</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>Instructions
for children</span></i></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The child must take PREZISTA always together
with ritonavir. PREZISTA cannot work properly without ritonavir.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The child must take the appropriate doses of
PREZISTA and ritonavir two times per day or once a day. If prescribed PREZISTA
twice daily the child must take one dose in the morning, and one dose in the
evening. Your child&#8217;s doctor will determine the appropriate dosing
regimen for your child.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The child must take PREZISTA with food. PREZISTA
cannot work properly without food. The type of food is not important.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The child must swallow the tablets with a drink
such as water or milk.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Dose for
adults who have not taken antiretroviral medicines before (your doctor will
determine this)</span></b></p>

<p class=MsoNormal><span lang=EN-GB>You will require a different dose of
PREZISTA which cannot be administered with these 150&nbsp;milligram tablets.
Other strengths of PREZISTA are available.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Dose for
adults who have taken antiretroviral medicines before (your doctor will
determine this)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The dose is
either:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>600&nbsp;milligram PREZISTA together with
100&nbsp;milligram ritonavir twice daily.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>OR</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>800&nbsp;milligram PREZISTA </span><span
lang=EN-GB>(2&nbsp;tablets containing 400&nbsp;milligram of PREZISTA or
1&nbsp;tablet containing 800&nbsp;milligram of PREZISTA) </span><span
lang=EN-GB>together with 100&nbsp;milligram ritonavir once daily. PREZISTA 400&nbsp;milligram
and 800&nbsp;milligram tablets are only to be used to construct the once daily
800&nbsp;milligram regimen.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Please discuss with your doctor which dose
is right for you.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>Instructions
for adults</span></i></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take PREZISTA always together with ritonavir.
PREZISTA cannot work properly without ritonavir.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In the morning, take 600&nbsp;milligram PREZISTA
together with 100&nbsp;milligram ritonavir.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In the evening, take 600&nbsp;milligram PREZISTA
together with 100&nbsp;milligram ritonavir.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take PREZISTA with food. PREZISTA cannot work
properly without food. The type of food is not important.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Swallow the tablets with a drink such as water
or milk.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>PREZISTA 75&nbsp;milligram and 150&nbsp;milligram
tablets and 100&nbsp;milligram per milliliter oral suspension have been developed
for use in children, but can also be used in adults in some cases.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Removing
the child resistant cap</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=121 valign=top style='width:90.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB><img border=0 width=86 height=90
  src="Prezista%20PI%20E_files/image003.jpg"></span></p>
  </td>
  <td width=499 valign=top style='width:373.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>The plastic bottle comes with a child
  resistant cap and must be opened as follows:</span></p>
  <p class=MsoNormal><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Push
  the plastic screw cap down while turning it counter clockwise.</span></p>
  <p class=MsoNormal><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove
  the unscrewed cap.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
take more PREZISTA than you should</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Contact your doctor, pharmacist or nurse
immediately.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
forget to take PREZISTA</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you notice <b>within 6&nbsp;hours</b>,
you must take the tablets immediately. Always take with ritonavir and food. If
you notice <b>after 6&nbsp;hours</b>, then skip the intake and take the next
doses as usual. Do not take a double dose to make up for a forgotten dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
vomit after taking PREZISTA and ritonavir</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you vomit <b>within 4&nbsp;hours</b> of
taking the medicine, another dose of PREZISTA and ritonavir should be taken
with food as soon as possible. If you vomit <b>more than 4&nbsp;hours</b> after
taking the medicine, then you do not need to take another dose of PREZISTA and
ritonavir until the next regularly scheduled time.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Contact your doctor <b>if you are uncertain</b>
about what to do if you miss a dose or vomit.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not
stop taking PREZISTA without talking to your doctor first</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Anti-HIV medicines may make you feel better.
Even when you feel better, do not stop taking PREZISTA. Talk to your doctor
first.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you have any further questions on the
use of this medicine, ask your doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>During HIV therapy there may be an increase
in weight and in levels of blood lipids and glucose. This is partly linked to
restored health and life style, and in the case of blood lipids sometimes to
the HIV medicines themselves. Your doctor will test for these changes.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Like all medicines, this medicine can cause
side effects, although not everybody gets them.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Tell your
doctor if you develop any of the following side effects</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Liver problems
that may occasionally be severe have been reported. Your doctor should do blood
tests before you start PREZISTA. If you have chronic hepatitis&nbsp;B or C
infection, your doctor should check your blood tests more often because you
have an increased chance of developing liver problems. Talk to your doctor
about the signs and symptoms of liver problems. These may include yellowing of
your skin or whites of your eyes, dark (tea coloured) urine, pale coloured
stools (bowel movements), nausea, vomiting, loss of appetite, or pain, aching,
or pain and discomfort on your right side below your ribs.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Skin rash (more
often when used in combination with raltegravir), itching. The rash is usually
mild to moderate. A skin rash might also be a symptom of a rare severe
situation. It is therefore important to talk to your doctor if you develop a
rash. Your doctor will advise you how to deal with your symptoms or whether
PREZISTA must be stopped.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Other severe
side effects were diabetes (common) and inflammation of the pancreas (uncommon).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very common
side effects (may affect more than 1 in 10&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Common side
effects (may affect up to 1 in 10&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vomiting, nausea, abdominal pain or distension,
dyspepsia, flatulence</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>headache<i>,</i> tiredness, dizziness,
drowsiness, numbness, tingling or pain in hands or feet, loss of strength,
difficulty falling asleep.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Uncommon
side effects (may affect up to 1 in 100&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>chest pain, changes in electrocardiogram, rapid
heart beating</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased or abnormal skin sensibility, pins and
needles, attention disturbance, loss of memory, problems with your balance</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty breathing, cough, nosebleed, throat
irritation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the stomach or mouth, heartburn,
retching, dry mouth, discomfort of the abdomen, constipation, belching</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>kidney failure, kidney stones, difficult
discharge of urine, frequent or excessive passage of urine, sometimes at night</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>urticaria, severe swelling of the skin and other
tissues (most often the lips or the eyes), eczema, excessive sweating, night
sweats, hair loss, acne, scaly skin, colouration of nails</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle pain, muscle cramps or weakness, pain in
extremity, osteoporosis</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>slowing down of the thyroid gland function. This
can be seen in a blood test.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high blood pressure, flushing</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>red or dry eyes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fever, swelling of lower limbs due to fluids,
malaise, irritability, pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>symptoms of infection, herpes simplex</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>erectile dysfunction, enlargement of breasts</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sleeping problems, sleepiness, depression,
anxiety, abnormal dreams, decrease in sexual drive</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Rare side
effects (may affect up to 1 in 1,000&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a reaction called DRESS [severe rash, which may
be accompanied by fever, fatigue, swelling of the face or lymph glands,
increase of eosinophils (type of white blood cells), effects on liver, kidney
or lung]</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>heart attack, slow heart beating, palpitations</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>visual disturbance</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>chills, feeling abnormal</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a feeling of confusion or disorientation,
altered mood, restlessness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fainting,</span><span lang=EN-GB> epileptic
fits, changes or loss of taste</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>mouth sores, vomiting blood, inflammation of the
lips, dry lips, coated tongue</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>running nose</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin lesions, dry skin</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>stiffness of muscles or joints, joint pain with
or without inflammation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>changes in some values of your blood cells or
chemistry. These can be seen in the results of blood and/or urine tests. Your
doctor will explain these to you. Examples are: increase in some white blood
cells.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Some side
effects are typical for anti&#8209;HIV medicines in the same family as
PREZISTA. These are:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle pain, tenderness or weakness. On rare
occasions, these muscle disorders have been serious.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Reporting
of side effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you get any side effects, talk to your
doctor, pharmacist or nurse. This includes any possible side effects not listed
in this leaflet. You can also report side effects directly via <span
style='background:silver'>the national reporting system listed in </span></span><span
lang=EN-GB style='background:silver'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix&nbsp;V</a></span><span
lang=EN-GB>. By reporting side effects you can help provide more information on
the safety of this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store PREZISTA</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep this medicine out of the sight and
reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use this medicine after the expiry
date which is stated on the carton and on the bottle after EXP. The expiry date
refers to the last day of that month.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA does not require any special
storage conditions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away any
medicines you no longer use. These measures will help protect the environment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
PREZISTA contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is darunavir. Each tablet
contains 150&nbsp;milligram of darunavir (as ethanolate).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are microcrystalline
cellulose, colloidal anhydrous silica, crospovidone, magnesium stearate. The
film&#8209;coating contains poly(vinyl alcohol) &#8209; partially hydrolysed,
macrogol 3350, titanium dioxide (E171), talc.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
PREZISTA looks like and contents of the pack</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Film&#8209;coated, white, oval shaped
tablet, mentioning TMC on one side, 150 on the other side. 240&nbsp;tablets in
a plastic bottle.</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is also available as 75&nbsp;milligram,
400&nbsp;milligram, 600&nbsp;milligram and 800&nbsp;milligram film&#8209;coated
tablets and 100&nbsp;milligram per milliliter oral suspension.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Janssen&#8209;Cilag International NV,
Turnhoutseweg 30, 2340 Beerse, Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal><span lang=NL>Janssen&#8209;Cilag SpA, Via C. Janssen, Borgo
San Michele, 04100 Latina, Italy</span></p>

<p class=MsoNormal><span lang=NL>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>For any
information about this medicine, please contact the local representative of the
Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag NV</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel/T&eacute;l: +32 14 64 94 11</span></p>
  <p class=MsoNormal><span lang=NL-BE>janssen@jacbe.jnj.com</span></p>
  <p class=MsoNormal><span lang=NL-BE>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UAB &quot;JOHNSON &amp; JOHNSON&quot;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +370 5 278 68 88</span></p>
  <p class=MsoNormal><span lang=EN-GB>lt@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>&#8222;&#1044;&#1078;&#1086;&#1085;&#1089;&#1098;&#1085;
  &amp; &#1044;&#1078;&#1086;&#1085;&#1089;&#1098;&#1085;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;&#8221;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&#1058;&#1077;&#1083;.: +359 2 489 94 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>jjsafety@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag NV</span></p>
  <p class=MsoNormal><span lang=NL-BE>T&eacute;l/Tel: +32 14 64 94 11</span></p>
  <p class=MsoNormal><span lang=EN-GB>janssen@jacbe.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>&#268;esk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag s.r.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +420 227 012 227</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Kft.</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel.: +36 1 884 2858</span></p>
  <p class=MsoNormal><span lang=NL-BE>janssenhu@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=NL-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Danmark</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag A/S</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tlf: +45 4594 8282</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacdk@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>AM MANGION LTD</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +356 2397 6000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag GmbH</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel: +49 2137 955 955</span></p>
  <p class=MsoNormal><span lang=EN-GB>jancil@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Nederland</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 76 711 1111</span></p>
  <p class=MsoNormal><span lang=EN-GB>janssen@jacnl.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Eesti</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UAB &quot;JOHNSON &amp; JOHNSON&quot;
  Eesti filiaal</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +372 617 7410</span></p>
  <p class=MsoNormal><span lang=EN-GB>ee@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen-Cilag AS</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +47 24 12 65 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacno@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen-Cilag
  &#934;&#945;&#961;&#956;&#945;&#954;&#949;&#965;&#964;&#953;&#954;&#942;
  &#913;.&#917;.&#914;.&#917;.</span></p>
  <p class=MsoNormal><span lang=EN-GB>T&#951;&#955;: +30 210 80 90 000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Pharma GmbH</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel: +43 1 610 300</span></p>
  <p class=MsoNormal><span lang=NL-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag, S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +34 91 722 81 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>contacto@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Polska</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Polska Sp. z o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel.: +48 22 237 60 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>France</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>Janssen-Cilag</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>T&eacute;l:
  0 800 25 50 75 / +33 1 55 00 40 03</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>medisource@its.jnj.com</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=NL-BE>Portugal</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>Janssen-Cilag
  Farmac&ecirc;utica, Lda.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +351
  214 368 600</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Johnson
  &amp; Johnson S.E. d.o.o.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +385
  1 6610 700</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>jjsafety@JNJCR.JNJ.com</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Johnson
  &amp; Johnson Rom<b>&acirc;</b>nia SRL</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +40
  21 207 1800</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen Sciences Ireland UC</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +353 1 800 709 122</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Johnson &amp; Johnson d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +386 1 401 18 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen_safety_slo@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>&Iacute;sland</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>Janssen-Cilag
  AB</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>c/o Vistor
  hf.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>S&iacute;mi:
  +354 535 7000</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>janssen@vistor.is</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Johnson
  &amp; Johnson, s.r.o.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +421
  232 408 400</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Italia</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag SpA</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel: 800.688.777 / +39 02 2510 1</span></p>
  <p class=MsoNormal><span lang=EN-GB><a href="mailto:janssenita@its.jnj.com"><span
  style='color:windowtext;text-decoration:none'>janssenita@its.jnj.com</span></a></span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Oy</span></p>
  <p class=MsoNormal><span lang=NL-BE>Puh/Tel: +358 207 531 300</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacfi@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>&#914;&#945;&#961;&#957;&#940;&#946;&#945;&#962;
  &#935;&#945;&#964;&#950;&#951;&#960;&#945;&#957;&#945;&#947;&#942;&#962;
  &#923;&#964;&#948;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&#932;&#951;&#955;: +357 22 207 700</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Sverige</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag AB</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tfn: +46 8 626 50 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacse@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UAB &quot;JOHNSON &amp; JOHNSON&quot;
  fili&#257;le Latvij&#257;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +371 678 93561</span></p>
  <p class=MsoNormal><span lang=EN-GB>lv@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen-Cilag Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +44 1 494 567 444</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>This
leaflet was last revised in </span></b><span lang=EN-GB>{MM/YYYY}.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this medicine is
available on the European Medicines Agency web site:<a href=""></a> </span><span
lang=EN-GB style='color:blue'><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></span><span
lang=EN-GB>.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Package
leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>PREZISTA
400&nbsp;mg film&#8209;coated tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>darunavir</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Read all
of this leaflet carefully before you start taking this medicine because it
contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your doctor,
pharmacist or nurse.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your
doctor, pharmacist or nurse. This includes any possible side effects not listed
in this leaflet. See section 4.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What is
in this leaflet</span></b></p>

<p class=MsoNormal><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
PREZISTA is and what it is used for</span></p>

<p class=MsoNormal><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take PREZISTA</span></p>

<p class=MsoNormal><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to take PREZISTA</span></p>

<p class=MsoNormal><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=MsoNormal><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store PREZISTA</span></p>

<p class=MsoNormal><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
PREZISTA is and what it is used for</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What is
PREZISTA?</span></b></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA contains the active substance
darunavir. PREZISTA is an antiretroviral medicine used in the treatment of
Human Immunodeficiency Virus (HIV) infection. It belongs to a group of
medicines called protease inhibitors. PREZISTA works by reducing the amount of
HIV in your body. This will improve your immune system and reduces the risk of
developing illnesses linked to HIV infection.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What it
is used for?</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The PREZISTA 400&nbsp;milligram tablet is
used to treat adults and children (3&nbsp;years of age and above, at least
40&nbsp;kilograms body weight) who are infected by HIV and</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>who have not used antiretroviral medicines
before.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in certain patients who have used antiretroviral
medicines before (your doctor will determine this).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA must be taken in combination with
a low dose of cobicistat or ritonavir and other anti&#8209;HIV medicines. Your
doctor will discuss with you which combination of medicines is best for you.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take PREZISTA</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not
take PREZISTA</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are <b>allergic</b> to darunavir or any
of the other ingredients of this medicine (listed in section 6) or to
cobicistat or ritonavir.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have <b>severe liver problems</b>. Ask
your doctor if you are unsure about the severity of your liver disease. Some
additional tests might be necessary.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not
combine PREZISTA with any of the following medicines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you are taking any of these, ask your
doctor about switching to another medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Medicine</span></b></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Purpose of the medicine</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Avanafil</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>to treat
  erectile dysfunction </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Astemizole
  </span></i><span lang=EN-GB>or</span><i><span lang=EN-GB> terfenadine</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>to treat
  allergy symptoms</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Triazolam </span></i><span lang=EN-GB>and
  </span><i><span lang=EN-GB>oral </span></i><span lang=EN-GB>(taken by mouth)</span><i><span
  lang=EN-GB> midazolam</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to help you sleep and/or relieve anxiety</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Cisapride</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat some stomach conditions</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Colchicine </span></i><span
  lang=EN-GB>(if you have kidney and/or liver problems)</span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat gout</span> or familial
  Mediterranean fever</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=PT>Lurasidone, pimozide, quetiapine </span></i><span
  lang=PT>or</span><i><span lang=PT> sertindole</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat psychiatric conditions</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Ergot alkaloids</span></i><span
  lang=EN-GB> like <i>ergotamine</i>, <i>dihydroergotamine</i>, <i>ergometrine</i>
  and <i>methylergonovine</i></span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat migraine headaches</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Amiodarone, bepridil, dronedarone, ivabradine,
  quinidine, ranolazine </span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat certain heart disorders e.g.
  abnormal heart beat</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Lovastatin</span></i><span lang=EN-GB>,<i>
  simvastatin and lomitapide</i></span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to lower cholesterol levels</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Rifampicin</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat some infections such as
  tuberculosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>The combination product<i>
  lopinavir/ritonavir</i></span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>this anti&#8209;HIV medicine belongs to
  the same class as PREZISTA</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Elbasvir/grazoprevir</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat hepatitis C infection</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Alfuzosin</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat enlarged prostate</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Sildenafil</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat high blood pressure in the
  pulmonary circulation</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Dabigatran</span></i><span lang=EN-GB>,
  <i>ticagrelor</i></span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to help stop the clumping of platelets in
  the treatment of patients with a history of a heart attack</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Naloxegol</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat opioid induced constipation</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Dapoxetine</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat premature ejaculation</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Domperidone</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat nausea and vomiting</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not combine PREZISTA with products that
contain St&nbsp;John&#8217;s&nbsp;wort<i> (Hypericum perforatum)</i>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Warnings
and precautions</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Talk to your doctor, pharmacist or nurse
before taking PREZISTA.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is not a cure for HIV infection.
You can still pass on HIV when taking this medicine, although the risk is
lowered by effective antiretroviral therapy. Discuss with your physician the
precautions needed to avoid infecting other people.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>People taking PREZISTA may still develop
infections or other illnesses associated with HIV infection. You must keep in
regular contact with your doctor.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>People taking PREZISTA may develop a skin
rash. Infrequently a rash may become severe or potentially life&#8209;threatening.
Please contact your doctor whenever you develop a rash.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients taking PREZISTA and raltegravir
(for HIV infection), rashes (generally mild or moderate) may occur more
frequently than in patients taking either medicine separately.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Tell your
doctor about your situation BEFORE and DURING your treatment</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Make sure that you check the following
points and tell your doctor if any of these apply to you.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you have had <b>problems
with your liver</b> before, including hepatitis B or C infection. Your doctor
may evaluate how severe your liver disease is before deciding if you can take
PREZISTA.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you have <b>diabetes</b>.
PREZISTA might increase sugar levels in the blood.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor immediately if you notice any <b>symptoms
of infection </b>(for example enlarged lymph nodes and fever). In some patients
with advanced HIV infection and a history of opportunistic infection, signs and
symptoms of inflammation from previous infections may occur soon after anti&#8209;HIV
treatment is started. It is believed that these symptoms are due to an
improvement in the body&#8217;s immune response, enabling the body to fight
infections that may have been present with no obvious symptoms.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In addition to the opportunistic infections,
autoimmune disorders (a condition that occurs when the immune system attacks
healthy body tissue) may also occur after you start taking medicines for the
treatment of your HIV infection. Autoimmune disorders may occur many months
after the start of treatment. If you notice any symptoms of infection or other
symptoms such as muscle weakness, weakness beginning in the hands and feet and
moving up towards the trunk of the body, palpitations, tremor or hyperactivity,
please inform your doctor immediately to seek necessary treatment.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you have <b>haemophilia</b>.
PREZISTA might increase the risk of bleeding.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you are <b>allergic to</b> <b>sulphonamides
</b>(e.g. used to treat certain infections).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you notice any </span><b><span
lang=EN-GB>musculoskeletal problems</span></b><span lang=EN-GB>. Some patients
taking combination antiretroviral therapy may develop a bone disease called
osteonecrosis (death of bone tissue caused by loss of blood supply to the
bone). The length of combination antiretroviral therapy, corticosteroid use,
alcohol consumption, severe immunosuppression, higher body mass index, among
others, may be some of the many risk factors for developing this disease. Signs
of osteonecrosis are joint stiffness, aches and pains (especially of the hip,
knee and shoulder) and difficulty in movement. If you notice any of these
symptoms please inform your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>Elderly</span></b></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA has only been used in limited
numbers of patients 65&nbsp;years or older. If you belong to this age group,
please discuss with your doctor if you can use PREZISTA.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Children
and adolescents</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The PREZISTA 400&nbsp;milligram
tablet is not for use in children younger than 3&nbsp;years of age or weighing
less than 40&nbsp;kilograms.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Other
medicines and PREZISTA</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor or pharmacist if you are
taking or have recently taken any other medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There are some medicines that <b>you must
not combine</b> with PREZISTA. These are mentioned above under the heading
&#8216;Do not combine PREZISTA with any of the following medicines:&#8217;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In most cases, PREZISTA can be combined
with anti&#8209;HIV medicines belonging to another class [e.g. NRTIs
(nucleoside reverse transcriptase inhibitors), NNRTIs (non&#8209;nucleoside
reverse transcriptase inhibitors), CCR5 antagonists and FIs (fusion
inhibitors)]. PREZISTA with cobicistat or ritonavir has not been tested with
all PIs (protease inhibitors) and must not be used with other HIV PIs. In some
cases dosage of other medicines might need to be changed. Therefore always tell
your doctor if you take other anti&#8209;HIV medicines and follow your
doctor&#8217;s instruction carefully on which medicines can be combined.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The effects
of PREZISTA might be reduced if you take any of the following products. Tell
your doctor if you take:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Phenobarbital, phenytoin</span></i><span
lang=EN-GB> (to prevent seizures)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Dexamethasone</span></i><span lang=EN-GB>
(corticosteroid)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Efavirenz </span></i><span lang=EN-GB>(HIV
infection)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Rifapentine, rifabutin </span></i><span
lang=EN-GB>(medicines to treat some infections such as tuberculosis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Saquinavir</span></i><span lang=EN-GB> (HIV
infection).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The effects
of other medicines might be influenced if you take PREZISTA. Tell your doctor
if you take:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Amlodipine, diltiazem, disopyramide, carvedilol,
felodipine, flecainide, lidocaine, metoprolol, mexiletine, nifedipine,
nicardipine</span></i><span lang=EN-GB>, <i>propafenone</i>, <i>timolol,
verapamil</i> (for heart disease) as the therapeutic effect or side effects of
these medicines may be increased.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>A</span></i><i><span lang=EN-GB>pixaban, edoxaban,
rivaroxaban, warfarin, clopidogrel</span></i><span lang=EN-GB> (to reduce clotting
of the blood) as their therapeutic effect or side effects may be altered; your
doctor may have to check your blood.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Oestrogen&#8209;based hormonal contraceptives
and hormonal replacement therapy. PREZISTA might reduce its effectiveness. When
used for birth control,</span><span lang=EN-GB> alternative methods of non&#8209;hormonal
contraception are recommended</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Ethinylestradiol/drospirenone</span></i><span
lang=EN-GB>. PREZISTA might increase the risk for elevated potassium levels by
drospirenone.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Atorvastatin, pravastatin, rosuvastatin</span></i><span
lang=EN-GB> (to lower cholesterol levels). The risk of muscle damage might be
increased. Your doctor will evaluate which cholesterol lowering regimen is best
for your specific situation.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Clarithromycin</span></i><span lang=EN-GB>
(antibiotic)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Ciclosporin, </span></i><i><span lang=EN-GB>everolimus,
tacrolimus, sirolimus</span></i><span lang=EN-GB> (</span><span lang=EN-GB>for
dampening down</span><span lang=EN-GB> your immune system) as the therapeutic
effect or side effects of these medicines might be increased. Your doctor might
want to do some additional tests.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i>Corticosteroids including betamethasone, budesonide,
fluticasone, mometasone, prednisone, triamcinolone</i><span lang=EN-GB>. These
medicines are used to treat allergies, asthma, inflammatory bowel diseases,
inflammatory conditions of the eyes, joints and muscles and other inflammatory
conditions. If alternatives cannot be used, its use should only take place
after medical evaluation and under close monitoring by your doctor for
corticosteroid side effects.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Buprenorphine/naloxone</span></i><span
lang=EN-GB> (medicines to treat opioid dependence)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Salmeterol</span></i><span lang=EN-GB>
(medicine to treat asthma)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Artemether/l</span></i><i><span lang=EN-GB>umefantrine</span></i><span
lang=EN-GB> (a combination medicine to treat malaria)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Dasatinib, everolimus, irinotecan, nilotinib,
vinblastine, vincristine </span></i><span lang=EN-GB>(to treat cancer)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Sildenafil, tadalafil, vardenafil </span></i><span
lang=EN-GB>(for erectile dysfunction or to treat a heart and lung disorder
called pulmonary arterial hypertension)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Glecaprevir/pibrentasvir</span><span
lang=EN-GB> </span></i><span lang=EN-GB>(to treat hepatitis C infection)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Fentanyl, oxycodone, tramadol</span></i><span
lang=EN-GB> (to treat pain)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Fesoterodine</span></i><span lang=EN-GB>, <i>solifenacin</i>
(to treat urologic disorders).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The dosage of other medicines might need to
be changed since either their own or PREZISTA&#8217;s therapeutic effect or
side effects may be influenced when combined.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tell your
doctor if you take:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Alfentanil</span></i><span lang=EN-GB>
(injectable </span><span lang=EN-GB>strong and short&#8209;acting painkiller
that is used for surgical procedures)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Digoxin</span></i><span lang=EN-GB> (to treat
certain heart disorders)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Clarithromycin</span></i><span lang=EN-GB>
(antibiotic)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Itraconazole, isavuconazole, fluconazole, posaconazole,
clotrimazole</span></i><span lang=EN-GB> (to treat fungal infections).
Voriconazole should only be taken after medical evaluation.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Rifabutin</span></i><span lang=EN-GB>
(against bacterial infections)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Sildenafil, vardenafil, tadalafil</span></i><span
lang=EN-GB> (for erectile dysfunction or high blood pressure in the pulmonary circulation)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Amitriptyline, desipramine, imipramine,
nortriptyline, paroxetine, sertraline, trazodone</span></i><span lang=EN-GB>
(to treat depression and anxiety)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Maraviroc </span></i><span lang=EN-GB>(to
treat HIV infection)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Methadone </span></i><span lang=EN-GB>(to
treat opiate dependence)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Carbamazepine, clonazepam</span></i><span
lang=EN-GB> (to prevent seizures or to treat certain types of nerve pain)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Colchicine </span></i><span lang=EN-GB>(to
treat gout</span> or familial Mediterranean fever<span lang=EN-GB>)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Bosentan</span></i><span lang=EN-GB> (to
treat high blood pressure in the pulmonary circulation)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Buspirone, clorazepate, diazepam, estazolam,
flurazepam, midazolam <a name="_Hlk498525337">when used as injection</a>, zolpidem</span></i><span
lang=EN-GB> (sedative agents)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Perphenazine</span><span lang=EN-GB>, risperidone,
thioridazine</span></i><span lang=EN-GB> (to treat psychiatric conditions)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=NO-BOK>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=NO-BOK>Metformin</span></i><span lang=NO-BOK> (to
treat type&nbsp;2&nbsp;diabetes).</span></p>

<p class=MsoNormal><span lang=NO-BOK>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This is <b>not</b> a complete list of
medicines. Tell your healthcare provider about <b><i>all </i></b>medicines that
you are taking.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>PREZISTA
with food and drink</span></b></p>

<p class=MsoNormal><span lang=EN-GB>See section&nbsp;3 &#8216;How to take
PREZISTA.&#8217;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pregnancy
and breast&#8209;feeding</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor immediately if you are
pregnant, planning to become pregnant or if you are breast&#8209;feeding.
Pregnant or breast&#8209;feeding mothers should not take PREZISTA with
ritonavir unless specifically directed by the doctor. </span><u><span
lang=EN-AU>Pregnant or breast&#8209;feeding mothers should not take PREZISTA
with cobicistat.</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>It is recommended that HIV infected women
must not breast&#8209;feed their infants because of both the possibility of
your baby becoming infected with HIV through your breast milk and because of
the unknown effects of the medicine on your baby.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Do not operate machines or drive if you
feel dizzy after taking PREZISTA.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>PREZISTA tablets contain sunset yellow
FCF (E110) </span></b><span lang=EN-GB>which may cause allergic reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>PREZISTA
contains sodium</span></b></p>

<p class=MsoNormal><span lang=EN-GB>This medicine contains less than
1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is to say essentially
&#8216;sodium&#8209;free&#8217;.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to take PREZISTA</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Always use this medicine exactly as
described in this leaflet or as your doctor, pharmacist or nurse has told you.
Check with your doctor, pharmacist or nurse if you are not sure.</span></p>

<p class=MsoNormal><span lang=EN-GB>Even if you feel better, do not stop taking
PREZISTA and cobicistat or ritonavir without talking to your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After therapy has been initiated, the dose or
dosage form must not be changed or therapy must not be stopped without
instruction of the doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA 400&nbsp;milligram tablets are
only to be used to construct the once daily 800&nbsp;milligram regimen.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Dose for
adults who have not taken antiretroviral medicines before (your doctor will
determine this)</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The usual dose
of PREZISTA is 800&nbsp;milligram (2&nbsp;tablets containing 400&nbsp;milligram
of PREZISTA or 1&nbsp;tablet containing 800&nbsp;milligram of PREZISTA) once
daily.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>You must take
PREZISTA every day and always in combination with 150&nbsp;milligram of
cobicistat or 100&nbsp;milligram of ritonavir and with food. PREZISTA cannot
work properly without cobicistat or ritonavir and food. You must eat a meal or
a snack within 30&nbsp;minutes prior to taking your PREZISTA and cobicistat or ritonavir.
The type of food is not important. Even if you feel better, do not stop taking
PREZISTA and cobicistat or ritonavir without talking to your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Instructions
for adults</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take two 400&nbsp;milligram tablets at the same
time, once a day, every day.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take PREZISTA always together with 150&nbsp;milligram
of cobicistat or 100&nbsp;milligram of ritonavir.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take PREZISTA with food.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Swallow the tablets with a drink such as water
or milk.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take your other HIV medicines used in
combination with PREZISTA and cobicistat or ritonavir as recommended by your
doctor.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>PREZISTA 100&nbsp;milligram per milliliter oral
suspension has been developed for use in children, but can also be used in
adults in some cases.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Dose for adults who have taken antiretroviral medicines before (your
doctor will determine this)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>The dose is either:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>800&nbsp;milligram PREZISTA (2&nbsp;tablets
containing 400&nbsp;milligram of PREZISTA or 1&nbsp;tablet containing
800&nbsp;milligram of PREZISTA) together with 150&nbsp;milligram cobicistat or 100&nbsp;milligram
ritonavir once daily.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-autospace:none'><span
lang=EN-GB>OR</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>600&nbsp;milligram PREZISTA together with
100&nbsp;milligram ritonavir twice daily.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Please discuss
with your doctor which dose is right for you.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Dose for children 3&nbsp;years of age and above <a
name="_Hlk43731110">with ritonavir, and 12&nbsp;years of age and above with
cobicistat</a>, weighing more than 40&nbsp;kilograms who have not taken
antiretroviral medicines before (your child&#8217;s doctor will determine this)</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The usual dose of PREZISTA is 800&nbsp;milligram
(2&nbsp;tablets containing 400&nbsp;milligram of PREZISTA or 1&nbsp;tablet containing
800&nbsp;milligram of PREZISTA) together with 100&nbsp;milligram ritonavir <a
name="_Hlk43731155">or 150&nbsp;milligram of cobicistat</a> once daily.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Dose for children 3&nbsp;years of age and above with ritonavir, and
12&nbsp;years of age and above with cobicistat, weighing more than 40&nbsp;kilograms
who have taken antiretroviral medicines before (your child&#8217;s doctor will
determine this)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>The dose is either:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>800&nbsp;milligram PREZISTA (2&nbsp;tablets
containing 400&nbsp;milligram of PREZISTA or 1&nbsp;tablet containing
800&nbsp;milligram of PREZISTA) together with 100&nbsp;milligram ritonavir </span><span
lang=EN-GB>or 150&nbsp;milligram of cobicistat </span><span lang=EN-GB>once
daily.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-autospace:none'><span
lang=EN-GB>OR</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>600&nbsp;milligram PREZISTA together with
100&nbsp;milligram ritonavir twice daily.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Please discuss
with your doctor which dose is right for you.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><i><span
lang=EN-GB>Instructions for children 3&nbsp;years of age and above with ritonavir,
and 12&nbsp;years of age and above with cobicistat, weighing more than
40&nbsp;kilograms</span></i></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take 800&nbsp;milligram PREZISTA (</span><span
lang=EN-GB>2&nbsp;tablets containing 400&nbsp;milligram of PREZISTA or
1&nbsp;tablet containing 800&nbsp;milligram of PREZISTA</span><span lang=EN-GB>)
at the same time, once a day, every day.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take PREZISTA always together with
100&nbsp;milligram of ritonavir or 150&nbsp;milligram of cobicistat.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take PREZISTA with food.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Swallow the tablets with a drink such as water
or milk.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take your other HIV medicines used in
combination with PREZISTA and ritonavir or cobicistat as recommended by your
doctor.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Removing
the child resistant cap</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=121 valign=top style='width:90.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB><img border=0 width=86 height=90
  src="Prezista%20PI%20E_files/image002.jpg"></span></p>
  </td>
  <td width=499 valign=top style='width:373.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>The plastic bottle comes with a child
  resistant cap and must be opened as follows:</span></p>
  <p class=MsoNormal><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Push
  the plastic screw cap down while turning it counter clockwise.</span></p>
  <p class=MsoNormal><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove
  the unscrewed cap.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
take more PREZISTA than you should</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Contact your doctor, pharmacist or nurse
immediately.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
forget to take PREZISTA</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you notice <b>within 12&nbsp;hours</b>,
you must take the tablets immediately. Always take with cobicistat or ritonavir
and food. If you notice <b>after 12&nbsp;hours</b>, then skip the intake and
take the next doses as usual. Do not take a double dose to make up for a
forgotten dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="_Hlk31138892"><b><span
lang=EN-GB>If you vomit after taking PREZISTA and cobicistat or ritonavir</span></b></a></p>

<p class=MsoNormal><span lang=EN-GB>If you vomit <b>within 4&nbsp;hours</b> of
taking the medicine, another dose of PREZISTA and cobicistat or ritonavir
should be taken with food as soon as possible. If you vomit <b>more than 4&nbsp;hours</b>
after taking the medicine, then you do not need to take another dose of
PREZISTA and cobicistat or ritonavir until the next regularly scheduled time.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Contact your doctor <b>if you are uncertain</b>
about what to do if you miss a dose or vomit.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not
stop taking PREZISTA without talking to your doctor first</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Anti-HIV medicines may make you feel better.
Even when you feel better, do not stop taking PREZISTA. Talk to your doctor
first.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you have any further questions on the
use of this medicine, ask your doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>During HIV therapy there may be an increase
in weight and in levels of blood lipids and glucose. This is partly linked to
restored health and life style, and in the case of blood lipids sometimes to
the HIV medicines themselves. Your doctor will test for these changes.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Like all medicines, this medicine can cause
side effects, although not everybody gets them.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Tell your
doctor if you develop any of the following side effects</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Liver problems
that may occasionally be severe have been reported. Your doctor should do blood
tests before you start PREZISTA. If you have chronic hepatitis&nbsp;B or C
infection, your doctor should check your blood tests more often because you
have an increased chance of developing liver problems. Talk to your doctor
about the signs and symptoms of liver problems. These may include yellowing of
your skin or whites of your eyes, dark (tea coloured) urine, pale coloured
stools (bowel movements), nausea, vomiting, loss of appetite, or pain, aching,
or pain and discomfort on your right side below your ribs.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Skin rash (more
often when used in combination with raltegravir), itching. The rash is usually
mild to moderate. A skin rash might also be a symptom of a rare severe
situation. It is important to talk to your doctor if you develop a rash. Your
doctor will advise you how to deal with your symptoms or whether PREZISTA must
be stopped.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Other severe
side effects were diabetes (common) and inflammation of the pancreas (uncommon).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very common
side effects (may affect more than 1 in 10&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Common side
effects (may affect up to 1 in 10&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vomiting, nausea, abdominal pain or distension,
dyspepsia, flatulence</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>headache<i>,</i> tiredness, dizziness,
drowsiness, numbness, tingling or pain in hands or feet, loss of strength,
difficulty falling asleep.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Uncommon
side effects (may affect up to 1 in 100&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>chest pain, changes in electrocardiogram, rapid
heart beating</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased or abnormal skin sensibility, pins and
needles, attention disturbance, loss of memory, problems with your balance</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty breathing, cough, nosebleed, throat
irritation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the stomach or mouth, heartburn,
retching, dry mouth, discomfort of the abdomen, constipation, belching</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>kidney failure, kidney stones, difficult
discharge of urine, frequent or excessive passage of urine, sometimes at night</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>urticaria, severe swelling of the skin and other
tissues (most often the lips or the eyes), eczema, excessive sweating, night
sweats, hair loss, acne, scaly skin, colouration of nails</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle pain, muscle cramps or weakness, pain in
extremity, osteoporosis</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>slowing down of the thyroid gland function. This
can be seen in a blood test.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high blood pressure, flushing</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>red or dry eyes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fever, swelling of lower limbs due to fluids,
malaise, irritability, pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>symptoms of infection, herpes simplex</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>erectile dysfunction, enlargement of breasts</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sleeping problems, sleepiness, depression,
anxiety, abnormal dreams, decrease in sexual drive</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Rare side
effects (may affect up to 1 in 1,000&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a reaction called DRESS [severe rash, which may
be accompanied by fever, fatigue, swelling of the face or lymph glands,
increase of eosinophils (type of white blood cells), effects on liver, kidney
or lung]</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>heart attack, slow heart beating, palpitations</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>visual disturbance</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>chills, feeling abnormal</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a feeling of confusion or disorientation,
altered mood, restlessness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fainting,</span><span lang=EN-GB> epileptic
fits, changes or loss of taste</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>mouth sores, vomiting blood, inflammation of the
lips, dry lips, coated tongue</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>running nose</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin lesions, dry skin</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>stiffness of muscles or joints, joint pain with
or without inflammation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>changes in some values of your blood cells or
chemistry. These can be seen in the results of blood and/or urine tests. Your
doctor will explain these to you. Examples are: increase in some white blood
cells.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Some side
effects are typical for anti&#8209;HIV medicines in the same family as
PREZISTA. These are:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle pain, tenderness or weakness. On rare
occasions, these muscle disorders have been serious.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Reporting
of side effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you get any side effects, talk to your
doctor, pharmacist or nurse. This includes any possible side effects not listed
in this leaflet. You can also report side effects directly via <span
style='background:silver'>the national reporting system listed in </span></span><span
lang=EN-GB style='background:silver'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix&nbsp;V</a></span><span
lang=EN-GB>. By reporting side effects you can help provide more information on
the safety of this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store PREZISTA</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep this medicine out of the sight and
reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use this medicine after the expiry
date which is stated on the carton and on the bottle after EXP. The expiry date
refers to the last day of that month.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA does not require any special
storage conditions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away any
medicines you no longer use. These measures will help protect the environment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
PREZISTA contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is darunavir. Each tablet
contains 400&nbsp;milligram of darunavir (as ethanolate).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are microcrystalline
cellulose, colloidal anhydrous silica, crospovidone, magnesium stearate. The
film&#8209;coating contains poly(vinyl alcohol) &#8209; partially hydrolysed,
macrogol 3350, titanium dioxide (E171), talc, sunset yellow FCF (E110).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
PREZISTA looks like and contents of the pack</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Film&#8209;coated, light orange, oval
shaped tablet, mentioning TMC on one side, 400MG on the other side.
60&nbsp;tablets in a plastic bottle.</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is also available as 75&nbsp;milligram,
150&nbsp;milligram, 600&nbsp;milligram and 800&nbsp;milligram film&#8209;coated
tablets and 100&nbsp;milligram per milliliter oral suspension.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Janssen&#8209;Cilag International NV,
Turnhoutseweg 30, 2340 Beerse, Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal><span lang=NL>Janssen&#8209;Cilag SpA, Via C. Janssen, Borgo
San Michele, 04100 Latina, Italy</span></p>

<p class=MsoNormal><span lang=NL>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>For any
information about this medicine, please contact the local representative of the
Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag NV</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel/T&eacute;l: +32 14 64 94 11</span></p>
  <p class=MsoNormal><span lang=NL-BE>janssen@jacbe.jnj.com</span></p>
  <p class=MsoNormal><span lang=NL-BE>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UAB &quot;JOHNSON &amp; JOHNSON&quot;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +370 5 278 68 88</span></p>
  <p class=MsoNormal><span lang=EN-GB>lt@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>&#8222;&#1044;&#1078;&#1086;&#1085;&#1089;&#1098;&#1085;
  &amp; &#1044;&#1078;&#1086;&#1085;&#1089;&#1098;&#1085;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;&#8221;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&#1058;&#1077;&#1083;.: +359 2 489 94 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>jjsafety@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag NV</span></p>
  <p class=MsoNormal><span lang=NL-BE>T&eacute;l/Tel: +32 14 64 94 11</span></p>
  <p class=MsoNormal><span lang=EN-GB>janssen@jacbe.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>&#268;esk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag s.r.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +420 227 012 227</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Kft.</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel.: +36 1 884 2858</span></p>
  <p class=MsoNormal><span lang=NL-BE>janssenhu@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=NL-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Danmark</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag A/S</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tlf: +45 4594 8282</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacdk@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>AM MANGION LTD</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +356 2397 6000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag GmbH</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel: +49 2137 955 955</span></p>
  <p class=MsoNormal><span lang=EN-GB>jancil@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Nederland</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 76 711 1111</span></p>
  <p class=MsoNormal><span lang=EN-GB>janssen@jacnl.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Eesti</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UAB &quot;JOHNSON &amp; JOHNSON&quot;
  Eesti filiaal</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +372 617 7410</span></p>
  <p class=MsoNormal><span lang=EN-GB>ee@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen-Cilag AS</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +47 24 12 65 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacno@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen-Cilag
  &#934;&#945;&#961;&#956;&#945;&#954;&#949;&#965;&#964;&#953;&#954;&#942;
  &#913;.&#917;.&#914;.&#917;.</span></p>
  <p class=MsoNormal><span lang=EN-GB>T&#951;&#955;: +30 210 80 90 000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Pharma GmbH</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel: +43 1 610 300</span></p>
  <p class=MsoNormal><span lang=NL-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag, S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +34 91 722 81 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>contacto@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Polska</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Polska Sp. z o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel.: +48 22 237 60 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>France</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>Janssen-Cilag</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>T&eacute;l:
  0 800 25 50 75 / +33 1 55 00 40 03</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>medisource@its.jnj.com</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=NL-BE>Portugal</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>Janssen-Cilag
  Farmac&ecirc;utica, Lda.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +351
  214 368 600</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Johnson
  &amp; Johnson S.E. d.o.o.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +385
  1 6610 700</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>jjsafety@JNJCR.JNJ.com</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Johnson
  &amp; Johnson Rom<b>&acirc;</b>nia SRL</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +40
  21 207 1800</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen Sciences Ireland UC</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +353 1 800 709 122</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Johnson &amp; Johnson d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +386 1 401 18 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen_safety_slo@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>&Iacute;sland</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>Janssen-Cilag
  AB</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>c/o Vistor
  hf.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>S&iacute;mi:
  +354 535 7000</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>janssen@vistor.is</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Johnson
  &amp; Johnson, s.r.o.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +421
  232 408 400</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Italia</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag SpA</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel: 800.688.777 / +39 02 2510 1</span></p>
  <p class=MsoNormal><span lang=EN-GB><a href="mailto:janssenita@its.jnj.com"><span
  style='color:windowtext;text-decoration:none'>janssenita@its.jnj.com</span></a></span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Oy</span></p>
  <p class=MsoNormal><span lang=NL-BE>Puh/Tel: +358 207 531 300</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacfi@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>&#914;&#945;&#961;&#957;&#940;&#946;&#945;&#962;
  &#935;&#945;&#964;&#950;&#951;&#960;&#945;&#957;&#945;&#947;&#942;&#962;
  &#923;&#964;&#948;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&#932;&#951;&#955;: +357 22 207 700</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Sverige</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag AB</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tfn: +46 8 626 50 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacse@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UAB &quot;JOHNSON &amp; JOHNSON&quot;
  fili&#257;le Latvij&#257;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +371 678 93561</span></p>
  <p class=MsoNormal><span lang=EN-GB>lv@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen-Cilag Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +44 1 494 567 444</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>This
leaflet was last revised in </span></b><span lang=EN-GB>{MM/YYYY}.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this medicine is
available on the European Medicines Agency web site:<a href=""></a> </span><span
lang=EN-GB style='color:blue'><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></span><span
lang=EN-GB>.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Package
leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>PREZISTA
600&nbsp;mg film&#8209;coated tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>darunavir</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Read all
of this leaflet carefully before you start taking this medicine because it
contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your
doctor, pharmacist or nurse. This includes any possible side effects not listed
in this leaflet. See section 4.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What is
in this leaflet</span></b></p>

<p class=MsoNormal><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
PREZISTA is and what it is used for</span></p>

<p class=MsoNormal><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take PREZISTA</span></p>

<p class=MsoNormal><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to take PREZISTA</span></p>

<p class=MsoNormal><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=MsoNormal><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store PREZISTA</span></p>

<p class=MsoNormal><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
PREZISTA is and what it is used for</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What is
PREZISTA?</span></b></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA contains the active substance
darunavir. PREZISTA is an antiretroviral medicine used in the treatment of
Human Immunodeficiency Virus (HIV) infection. It belongs to a group of
medicines called protease inhibitors. PREZISTA works by reducing the amount of
HIV in your body. This will improve your immune system and reduces the risk of
developing illnesses linked to HIV infection.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What it
is used for?</span></b></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is used to treat adults and
children of 3&nbsp;years of age and above, and at least 15&nbsp;kilogram body
weight who are infected by HIV and who have already used other antiretroviral
medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA must be taken in combination with
a low dose of ritonavir and other anti&#8209;HIV medicines. Your doctor will
discuss with you which combination of medicines is best for you.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take PREZISTA</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not
take PREZISTA</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are <b>allergic</b> to darunavir or any
of the other ingredients of this medicine (listed in section 6) or to
ritonavir.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have <b>severe liver problems</b>. Ask
your doctor if you are unsure about the severity of your liver disease. Some
additional tests might be necessary.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not
combine PREZISTA with any of the following medicines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you are taking any of these, ask your
doctor about switching to another medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Medicine</span></b></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Purpose of the medicine</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Avanafil</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat erectile dysfunction </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Astemizole </span></i><span
  lang=EN-GB>or</span><i><span lang=EN-GB> terfenadine</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat allergy symptoms</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Triazolam </span></i><span lang=EN-GB>and
  </span><i><span lang=EN-GB>oral </span></i><span lang=EN-GB>(taken by mouth)</span><i><span
  lang=EN-GB> midazolam</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to help you sleep and/or relieve anxiety</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Cisapride</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat some stomach conditions</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Colchicine </span></i><span
  lang=EN-GB>(if you have kidney and/or liver problems)</span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat gout</span> or familial Mediterranean
  fever</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=PT>Lurasidone, pimozide, quetiapine </span></i><span
  lang=PT>or</span><i><span lang=PT> sertindole</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat psychiatric conditions</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Ergot alkaloids</span></i><span
  lang=EN-GB> like <i>ergotamine</i>, <i>dihydroergotamine</i>, <i>ergometrine</i>
  and <i>methylergonovine</i></span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat migraine headaches</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Amiodarone, bepridil, dronedarone, ivabradine,
  quinidine, ranolazine</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat certain heart disorders e.g.
  abnormal heart beat</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Lovastatin</span></i><span lang=EN-GB>,<i>
  simvastatin and lomitapide</i></span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to lower cholesterol levels</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Rifampicin</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat some infections such as
  tuberculosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>The combination product<i>
  lopinavir/ritonavir</i></span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>this anti&#8209;HIV medicine belongs to
  the same class as PREZISTA</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Elbasvir/grazoprevir</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat hepatitis C infection</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Alfuzosin</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat enlarged prostate</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Sildenafil</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat high blood pressure in the
  pulmonary circulation</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Dabigatran</span></i><span lang=EN-GB>,
  <i>ticagrelor</i></span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to help stop the clumping of platelets in
  the treatment of patients with a history of a heart attack</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Naloxegol</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat opioid induced constipation</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Dapoxetine</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat premature ejaculation</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Domperidone</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat nausea and vomiting</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not combine PREZISTA with products that
contain St&nbsp;John&#8217;s&nbsp;wort <i>(Hypericum perforatum)</i>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Warnings
and precautions</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Talk to your doctor, pharmacist or nurse
before taking PREZISTA.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is not a cure for HIV infection.
You can still pass on HIV when taking this medicine, although the risk is
lowered by effective antiretroviral therapy. Discuss with your physician the
precautions needed to avoid infecting other people.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>People taking PREZISTA may still develop
infections or other illnesses associated with HIV infection. You must keep in
regular contact with your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>People taking PREZISTA may develop a skin
rash. Infrequently a rash may become severe or potentially life&#8209;threatening.
Please contact your doctor whenever you develop a rash.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients taking PREZISTA and raltegravir
(for HIV infection), rashes (generally mild or moderate) may occur more
frequently than in patients taking either medicine separately.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Tell your
doctor about your situation BEFORE and DURING your treatment</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Make sure that you check the following
points and tell your doctor if any of these apply to you.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you have had <b>problems
with your liver</b> before, including hepatitis B or C infection. Your doctor
may evaluate how severe your liver disease is before deciding if you can take
PREZISTA.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you have <b>diabetes</b>.
PREZISTA might increase sugar levels in the blood.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor immediately if you notice any <b>symptoms
of infection </b>(for example enlarged lymph nodes and fever). In some patients
with advanced HIV infection and a history of opportunistic infection, signs and
symptoms of inflammation from previous infections may occur soon after anti&#8209;HIV
treatment is started. It is believed that these symptoms are due to an
improvement in the body&#8217;s immune response, enabling the body to fight
infections that may have been present with no obvious symptoms.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In addition to the opportunistic infections,
autoimmune disorders (a condition that occurs when the immune system attacks
healthy body tissue) may also occur after you start taking medicines for the
treatment of your HIV infection. Autoimmune disorders may occur many months
after the start of treatment. If you notice any symptoms of infection or other
symptoms such as muscle weakness, weakness beginning in the hands and feet and
moving up towards the trunk of the body, palpitations, tremor or hyperactivity,
please inform your doctor immediately to seek necessary treatment.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you have <b>haemophilia</b>.
PREZISTA might increase the risk of bleeding.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you are <b>allergic to</b> <b>sulphonamides
</b>(e.g. used to treat certain infections).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you notice any </span><b><span
lang=EN-GB>musculoskeletal problems</span></b><span lang=EN-GB>. Some patients
taking combination antiretroviral therapy may develop a bone disease called
osteonecrosis (death of bone tissue caused by loss of blood supply to the
bone). The length of combination antiretroviral therapy, corticosteroid use,
alcohol consumption, severe immunosuppression, higher body mass index, among
others, may be some of the many risk factors for developing this disease. Signs
of osteonecrosis are joint stiffness, aches and pains (especially of the hip,
knee and shoulder) and difficulty in movement. If you notice any of these
symptoms please inform your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>Elderly</span></b></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA has only been used in limited
numbers of patients 65&nbsp;years or older. If you belong to this age group,
please discuss with your doctor if you can use PREZISTA.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>Children</span></b></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is not for use in children younger
than 3&nbsp;years of age or weighing less than 15&nbsp;kilograms.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Other
medicines and PREZISTA</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor or pharmacist if you are
taking or have recently taken any other medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There are some medicines that <b>you must
not combine</b> with PREZISTA. These are mentioned above under the heading
&#8216;Do not combine PREZISTA with any of the following medicines:&#8217;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In most cases, PREZISTA can be combined
with anti&#8209;HIV medicines belonging to another class [e.g. NRTIs
(nucleoside reverse transcriptase inhibitors), NNRTIs (non&#8209;nucleoside
reverse transcriptase inhibitors), CCR5 antagonists and FIs (fusion
inhibitors)]. PREZISTA with ritonavir has not been tested with all PIs
(protease inhibitors) and must not be used with other HIV PIs. In some cases
dosage of other medicines might need to be changed. Therefore always tell your
doctor if you take other anti&#8209;HIV medicines and follow your
doctor&#8217;s instruction carefully on which medicines can be combined.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The effects
of PREZISTA might be reduced if you take any of the following products. Tell
your doctor if you take:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Phenobarbital, phenytoin</span></i><span
lang=EN-GB> (to prevent seizures)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Dexamethasone</span></i><span lang=EN-GB>
(corticosteroid)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Efavirenz </span></i><span lang=EN-GB>(HIV
infection)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Rifapentine, rifabutin </span></i><span
lang=EN-GB>(medicines to treat some infections such as tuberculosis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Saquinavir</span></i><span lang=EN-GB> (HIV
infection).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The effects
of other medicines might be influenced if you take PREZISTA. Tell your doctor
if you take:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Amlodipine, diltiazem, disopyramide, carvedilol,
felodipine, flecainide, lidocaine, metoprolol, mexiletine, nifedipine,
nicardipine</span></i><span lang=EN-GB>, <i>propafenone</i>, <i>timolol,
verapamil</i> (for heart disease) as the therapeutic effect or side effects of
these medicines may be increased.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>A</span></i><i><span lang=EN-GB>pixaban, edoxaban,
rivaroxaban, warfarin, clopidogrel</span></i><span lang=EN-GB> (to reduce
clotting of the blood) as their therapeutic effect or side effects may be
altered; your doctor may have to check your blood.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Oestrogen&#8209;based hormonal contraceptives
and hormonal replacement therapy. PREZISTA might reduce its effectiveness. When
used for birth control,</span><span lang=EN-GB> alternative methods of non&#8209;hormonal
contraception are recommended</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Ethinylestradiol/drospirenone</span></i><span
lang=EN-GB>. PREZISTA might increase the risk for elevated potassium levels by
drospirenone.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Atorvastatin, pravastatin, rosuvastatin</span></i><span
lang=EN-GB> (to lower cholesterol levels). The risk of muscle damage might be
increased. Your doctor will evaluate which cholesterol lowering regimen is best
for your specific situation.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Clarithromycin</span></i><span lang=EN-GB>
(antibiotic)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Ciclosporin, </span></i><i><span lang=EN-GB>everolimus,
tacrolimus, sirolimus</span></i><span lang=EN-GB> (</span><a
name="_Hlk498525924"><span lang=EN-GB>for dampening down</span></a><span
lang=EN-GB> your immune system) as the therapeutic effect or side effects of
these medicines might be increased. Your doctor might want to do some
additional tests.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i>Corticosteroids including betamethasone, budesonide,
fluticasone, mometasone, prednisone, triamcinolone</i><span lang=EN-GB>. These
medicines are used to treat allergies, asthma, inflammatory bowel diseases,
inflammatory conditions of the eyes, joints and muscles and other inflammatory
conditions. If alternatives cannot be used, its use should only take place
after medical evaluation and under close monitoring by your doctor for
corticosteroid side effects.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Buprenorphine/naloxone</span></i><span
lang=EN-GB> (medicines to treat opioid dependence)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Salmeterol</span></i><span lang=EN-GB>
(medicine to treat asthma)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Artemether/l</span></i><i><span lang=EN-GB>umefantrine</span></i><span
lang=EN-GB> (a combination medicine to treat malaria)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Dasatinib, everolimus, irinotecan, nilotinib,
vinblastine, vincristine </span></i><span lang=EN-GB>(to treat cancer)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Sildenafil, tadalafil, vardenafil </span></i><span
lang=EN-GB>(for erectile dysfunction or to treat a heart and lung disorder
called pulmonary arterial hypertension)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Glecaprevir/pibrentasvir</span><span
lang=EN-GB> </span></i><span lang=EN-GB>(to treat hepatitis C infection)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Fentanyl, oxycodone, tramadol</span></i><span
lang=EN-GB> (to treat pain)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Fesoterodine</span></i><span lang=EN-GB>, <i>solifenacin</i>
(to treat urologic disorders).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The dosage of other medicines might need to
be changed since either their own or PREZISTA&#8217;s therapeutic effect or
side effects may be influenced when combined.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tell your
doctor if you take:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Alfentanil</span></i><span lang=EN-GB>
(injectable </span><span lang=EN-GB>strong and short&#8209;acting painkiller
that is used for surgical procedures)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Digoxin</span></i><span lang=EN-GB> (to treat
certain heart disorders)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Clarithromycin</span></i><span lang=EN-GB>
(antibiotic)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Itraconazole, isavuconazole, fluconazole, posaconazole,
clotrimazole</span></i><span lang=EN-GB> (to treat fungal infections).
Voriconazole should only be taken after medical evaluation.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Rifabutin</span></i><span lang=EN-GB>
(against bacterial infections)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Sildenafil, vardenafil, tadalafil</span></i><span
lang=EN-GB> (for erectile dysfunction or high blood pressure in the pulmonary
circulation)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Amitriptyline, desipramine, imipramine,
nortriptyline, paroxetine, sertraline, trazodone</span></i><span lang=EN-GB>
(to treat depression and anxiety)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Maraviroc </span></i><span lang=EN-GB>(to
treat HIV infection)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Methadone </span></i><span lang=EN-GB>(to
treat opiate dependence)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Carbamazepine, clonazepam</span></i><span
lang=EN-GB> (to prevent seizures or to treat certain types of nerve pain)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Colchicine </span></i><span lang=EN-GB>(to
treat gout </span>or familial Mediterranean fever<span lang=EN-GB>)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Bosentan</span></i><span lang=EN-GB> (to
treat high blood pressure in the pulmonary circulation)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Buspirone, clorazepate, diazepam, estazolam,
flurazepam, midazolam when used as injection, zolpidem</span></i><span
lang=EN-GB> (sedative agents)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Perphenazine,</span><span lang=EN-GB> risperidone,
thioridazine</span></i><span lang=EN-GB> (to treat psychiatric conditions).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This is <b>not</b> a complete list of
medicines. Tell your healthcare provider about <b><i>all </i></b>medicines that
you are taking.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>PREZISTA
with food and drink</span></b></p>

<p class=MsoNormal><span lang=EN-GB>See section&nbsp;3 &#8216;How to take
PREZISTA.&#8217;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pregnancy
and breast&#8209;feeding</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor immediately if you are
pregnant, planning to become pregnant or if you are breast&#8209;feeding.
Pregnant or breast&#8209;feeding mothers should not take PREZISTA with
ritonavir unless specifically directed by the doctor. </span><u><span
lang=EN-AU>Pregnant or breast&#8209;feeding mothers should not take PREZISTA
with cobicistat.</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>It is recommended that HIV infected women
must not breast&#8209;feed their infants because of both the possibility of
your baby becoming infected with HIV through your breast milk and because of
the unknown effects of the medicine on your baby.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Do not operate machines or drive if you
feel dizzy after taking PREZISTA.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>PREZISTA tablets contain sunset yellow
FCF (E110)</span></b><span lang=EN-GB> which may cause allergic reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>PREZISTA
contains sodium</span></b></p>

<p class=MsoNormal><span lang=EN-GB>This medicine contains less than
1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is to say essentially
&#8216;sodium&#8209;free&#8217;.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to take PREZISTA</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Always use this medicine exactly as
described in this leaflet or as your doctor, pharmacist or nurse has told you.
Check with your doctor, pharmacist or nurse if you are not sure.</span></p>

<p class=MsoNormal><span lang=EN-GB>Even if you feel better, do not stop taking
PREZISTA and ritonavir without talking to your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After therapy has been initiated, the dose or
dosage form must not be changed or therapy must not be stopped without
instruction of the doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Dose for
adults who have not taken antiretroviral medicines before (your doctor will
determine this)</span></b></p>

<p class=MsoNormal><span lang=EN-GB>You will require a different dose of
PREZISTA which cannot be administered with these 600&nbsp;milligram tablets.
Other strengths of PREZISTA are available.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Dose for
adults who have taken antiretroviral medicines before (your doctor will
determine this)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The dose is
either:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>600&nbsp;milligram PREZISTA together with
100&nbsp;milligram ritonavir twice daily.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>OR</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>800&nbsp;milligram PREZISTA </span><span
lang=EN-GB>(2&nbsp;tablets containing 400&nbsp;milligram of PREZISTA</span><span
lang=EN-GB> or 1&nbsp;tablet containing 800&nbsp;milligram of PREZISTA</span><span
lang=EN-GB>) </span><span lang=EN-GB>together with 100&nbsp;milligram ritonavir
once daily. PREZISTA 400&nbsp;milligram and 800&nbsp;milligram tablets are only
to be used to construct the once daily 800&nbsp;milligram regimen.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Please discuss with your doctor which dose
is right for you.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>Instructions
for adults</span></i></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take PREZISTA always together with ritonavir.
PREZISTA cannot work properly without ritonavir.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In the morning, take one 600&nbsp;milligram
PREZISTA tablet together with 100&nbsp;milligram ritonavir.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In the evening, take one 600&nbsp;milligram
PREZISTA tablet together with 100&nbsp;milligram ritonavir.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take PREZISTA with food. PREZISTA cannot work
properly without food. The type of food is not important.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Swallow the tablets with a drink such as water
or milk.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>PREZISTA 75&nbsp;milligram and 150&nbsp;milligram
tablets and 100&nbsp;milligram per milliliter oral suspension have been
developed for use in children, but can also be used in adults in some cases.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Dose for
children of 3&nbsp;years of age and above, weighing at least 15&nbsp;kilograms
who </span></b><b><span lang=EN-GB>have not taken antiretroviral medicines
before </span><span lang=EN-GB>(your child&#8217;s doctor will determine this)</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The doctor will work out the right once
daily dose based on the weight of the child (see table below). This dose must
not exceed the recommended adult dose, which is 800&nbsp;milligram PREZISTA
together with 100&nbsp;milligram ritonavir once a day.</span></p>

<p class=MsoNormal><span lang=EN-GB>The doctor will inform you on how much
PREZISTA tablets and how much ritonavir (capsules, tablets or solution) the
child must take.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Weight</span></b></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>One PREZISTA dose is</span></b></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>One ritonavir<sup>a</sup> dose is</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 15 and 30&nbsp;kilograms</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>600&nbsp;milligram</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100&nbsp;milligram</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 30 and 40&nbsp;kilograms</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>675&nbsp;milligram</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100&nbsp;milligram</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>more than 40&nbsp;kilograms</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>800&nbsp;milligram</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100&nbsp;milligram</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:none;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=IT>a</span></sup><span lang=IT>&nbsp;&nbsp;&nbsp; </span><span lang=IT
  style='font-size:9.0pt'>ritonavir oral solution: 80&nbsp;milligram per
  milliliter</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Dose for children of 3&nbsp;years of age and above, weighing at
least 15&nbsp;kilograms</span></b><b><span lang=EN-GB> who have taken
antiretroviral medicines before (your child&#8217;s doctor will determine this)</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The doctor will work out the right dose
based on the weight of the child (see table below). The doctor will determine
if once daily dosing or twice daily dosing is appropriate for the child. This
dose must not exceed the recommended adult dose, which is 600&nbsp;milligram
PREZISTA together with 100&nbsp;milligram of ritonavir two times per day or
800&nbsp;milligram PREZISTA together with 100&nbsp;milligram ritonavir once a
day. The doctor will inform you on how many PREZISTA tablets and how much
ritonavir (capsules, tablets or solution) the child must take. Tablets of lower
strengths are available to construct the appropriate dosing regimen. PREZISTA
oral suspension is also available. Your doctor will determine whether PREZISTA
tablets or oral suspension is right for the child.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=2 valign=top style='width:6.3in;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Twice
  daily dosing</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=204 valign=top style='width:153.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Weight</span></b></p>
  </td>
  <td width=400 valign=top style='width:300.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>One dose is</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=204 style='width:153.25pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 15 and 30&nbsp;kilograms</span></p>
  </td>
  <td width=400 style='width:300.35pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>375&nbsp;milligram PREZISTA +
  50&nbsp;milligram ritonavir twice a day</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=204 style='width:153.25pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 30 and 40&nbsp;kilograms</span></p>
  </td>
  <td width=400 style='width:300.35pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>450&nbsp;milligram PREZISTA +
  60&nbsp;milligram ritonavir twice a day</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=204 style='width:153.25pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>more than 40&nbsp;kilograms*</span></p>
  </td>
  <td width=400 style='width:300.35pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>600&nbsp;milligram PREZISTA +
  100&nbsp;milligram ritonavir twice a day</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=2 style='width:6.3in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
  lang=EN-GB>*&nbsp;&nbsp; </span><span lang=EN-GB style='font-size:9.0pt'>For
  children aged 12 or more and weighing at least 40&nbsp;kilograms, your
  child&#8217;s doctor will determine if PREZISTA 800&nbsp;milligram once daily
  dosing may be used. This cannot </span><span lang=EN-GB style='font-size:
  9.0pt'>be administered with these 600&nbsp;milligram tablets. Other strengths
  of PREZISTA are available.</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Once daily
  dosing</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Weight</span></b></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>One PREZISTA dose is</span></b></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>One ritonavir<sup>a</sup> dose is</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 15 and 30&nbsp;kilograms</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>600&nbsp;milligram</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100&nbsp;milligram</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>between 30 and 40&nbsp;kilograms</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>675&nbsp;milligram</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100&nbsp;milligram</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:2.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>more than 40&nbsp;kilograms</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>800&nbsp;milligram</span></p>
  </td>
  <td width=202 valign=top style='width:2.1in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100&nbsp;milligram</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:none;border-left:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=IT>a</span></sup><span lang=IT>&nbsp;&nbsp;&nbsp; </span><span lang=IT
  style='font-size:9.0pt'>ritonavir oral solution: 80&nbsp;milligram per
  milliliter</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>Instructions
for children</span></i></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The child must take PREZISTA always together
with ritonavir. PREZISTA cannot work properly without ritonavir.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The child must take the appropriate doses of
PREZISTA and ritonavir two times per day or once a day. If prescribed PREZISTA
twice daily the child must take one dose in the morning, and one dose in the
evening. Your child&#8217;s doctor will determine the appropriate dosing
regimen for your child.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The child must take PREZISTA with food. PREZISTA
cannot work properly without food. The type of food is not important.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The child must swallow the tablets with a drink
such as water or milk.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>PREZISTA 75&nbsp;milligram and 150&nbsp;milligram
tablets and 100&nbsp;milligram per milliliter oral suspension have been
developed for use in children weighing less than 40&nbsp;kilograms, but can
also be used in some cases.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Removing
the child resistant cap</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=121 valign=top style='width:90.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB><img border=0 width=86 height=90
  src="Prezista%20PI%20E_files/image002.jpg"></span></p>
  </td>
  <td width=499 valign=top style='width:373.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>The plastic bottle comes with a child
  resistant cap and must be opened as follows:</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Push the plastic screw
  cap down while turning it counter clockwise.</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
  lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the unscrewed
  cap.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
take more PREZISTA than you should</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Contact your doctor, pharmacist or nurse
immediately.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
forget to take PREZISTA</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you notice <b>within 6&nbsp;hours</b>,
you must take your missed dose immediately. Always take with ritonavir and
food. If you notice <b>after 6&nbsp;hours</b>, then skip the intake and take
the next doses as usual. Do not take a double dose to make up for a forgotten
dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
vomit after taking PREZISTA and ritonavir</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you vomit <b>within 4&nbsp;hours</b> of
taking the medicine, another dose of PREZISTA and ritonavir should be taken
with food as soon as possible. If you vomit <b>more than 4&nbsp;hours</b> after
taking the medicine, then you do not need to take another dose of PREZISTA and
ritonavir until the next regularly scheduled time.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Contact your doctor <b>if you are uncertain</b>
about what to do if you miss a dose or vomit.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not
stop taking PREZISTA without talking to your doctor first</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Anti-HIV medicine may make you feel better.
Even when you feel better, do not stop taking PREZISTA. Talk to your doctor
first.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you have any further questions on the
use of this medicine, ask your doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>During HIV therapy there may be an increase
in weight and in levels of blood lipids and glucose. This is partly linked to
restored health and life style, and in the case of blood lipids sometimes to
the HIV medicines themselves. Your doctor will test for these changes.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Like all medicines, this medicine can cause
side effects, although not everybody gets them.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Tell your
doctor if you develop any of the following side effects</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Liver problems
that may occasionally be severe have been reported. Your doctor should do blood
tests before you start PREZISTA. If you have chronic hepatitis&nbsp;B or C
infection, your doctor should check your blood tests more often because you
have an increased chance of developing liver problems. Talk to your doctor
about the signs and symptoms of liver problems. These may include yellowing of
your skin or whites of your eyes, dark (tea coloured) urine, pale coloured
stools (bowel movements), nausea, vomiting, loss of appetite, or pain, aching,
or pain and discomfort on your right side below your ribs.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Skin rash (more
often when used in combination with raltegravir), itching. The rash is usually
mild to moderate. A skin rash might also be a symptom of a rare severe
situation. It is therefore important to talk to your doctor if you develop a
rash. Your doctor will advise you how to deal with your symptoms or whether
PREZISTA must be stopped.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Other severe
side effects were diabetes (common) and inflammation of the pancreas (uncommon).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very common
side effects (may affect more than 1 in 10&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Common side
effects (may affect up to 1 in 10&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vomiting, nausea, abdominal pain or distension,
dyspepsia, flatulence</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>headache<i>,</i> tiredness, dizziness,
drowsiness, numbness, tingling or pain in hands or feet, loss of strength,
difficulty falling asleep.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Uncommon
side effects (may affect up to 1 in 100&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>chest pain, changes in electrocardiogram, rapid
heart beating</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased or abnormal skin sensibility, pins and
needles, attention disturbance, loss of memory, problems with your balance</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty breathing, cough, nosebleed, throat
irritation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the stomach or mouth, heartburn,
retching, dry mouth, discomfort of the abdomen, constipation, belching</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>kidney failure, kidney stones, difficult
discharge of urine, frequent or excessive passage of urine, sometimes at night</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>urticaria, severe swelling of the skin and other
tissues (most often the lips or the eyes), eczema, excessive sweating, night
sweats, hair loss, acne, scaly skin, colouration of nails</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle pain, muscle cramps or weakness, pain in
extremity, osteoporosis</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>slowing down of the thyroid gland function. This
can be seen in a blood test.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high blood pressure, flushing</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>red or dry eyes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fever, swelling of lower limbs due to fluids,
malaise, irritability, pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>symptoms of infection, herpes simplex</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>erectile dysfunction, enlargement of breasts</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sleeping problems, sleepiness, depression,
anxiety, abnormal dreams, decrease in sexual drive</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Rare side
effects (may affect up to 1 in 1,000&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a reaction called DRESS [severe rash, which may
be accompanied by fever, fatigue, swelling of the face or lymph glands,
increase of eosinophils (type of white blood cells), effects on liver, kidney
or lung]</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>heart attack, slow heart beating, palpitations</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>visual disturbance</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>chills, feeling abnormal</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a feeling of confusion or disorientation,
altered mood, restlessness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fainting,</span><span lang=EN-GB> epileptic
fits, changes or loss of taste</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>mouth sores, vomiting blood, inflammation of the
lips, dry lips, coated tongue</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>running nose</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin lesions, dry skin</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>stiffness of muscles or joints, joint pain with
or without inflammation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>changes in some values of your blood cells or
chemistry. These can be seen in the results of blood and/or urine tests. Your
doctor will explain these to you. Examples are: increase in some white blood
cells.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Some side
effects are typical for anti&#8209;HIV medicines in the same family as
PREZISTA. These are:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle pain, tenderness or weakness. On rare
occasions, these muscle disorders have been serious.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Reporting
of side effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you get any side effects, talk to your
doctor, pharmacist or nurse. This includes any possible side effects not listed
in this leaflet. You can also report side effects directly via <span
style='background:silver'>the national reporting system listed in </span></span><span
lang=EN-GB style='background:silver'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix&nbsp;V</a></span><span
lang=EN-GB>. By reporting side effects you can help provide more information on
the safety of this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store PREZISTA</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep this medicine out of the sight and
reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use this medicine after the expiry
date which is stated on the carton and on the bottle after EXP. The expiry date
refers to the last day of that month.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA does not require any special
storage conditions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away any
medicines you no longer use. These measures will help protect the environment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
PREZISTA contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><a
name="_Hlk3219623"><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is darunavir. Each tablet
contains 600&nbsp;milligram of darunavir (as ethanolate).</span></a></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are microcrystalline
cellulose, colloidal anhydrous silica, crospovidone, magnesium stearate. The
film&#8209;coating contains poly(vinyl alcohol) &#8209; partially hydrolysed,
macrogol 3350, titanium dioxide (E171), talc, sunset yellow FCF (E110).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
PREZISTA looks like and contents of the pack</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Film&#8209;coated, orange, oval shaped
tablet, mentioning TMC on one side, 600MG on the other side. 60&nbsp;tablets in
a plastic bottle.</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is also available as 75&nbsp;milligram,
150&nbsp;milligram, 400&nbsp;milligram and 800&nbsp;milligram film&#8209;coated
tablets and 100&nbsp;milligram per milliliter oral suspension.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Janssen&#8209;Cilag International NV,
Turnhoutseweg 30, 2340 Beerse, Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal><span lang=NL>Janssen&#8209;Cilag SpA, Via C. Janssen, Borgo
San Michele, 04100 Latina, Italy</span></p>

<p class=MsoNormal><span lang=NL>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>For any
information about this medicine, please contact the local representative of the
Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag NV</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel/T&eacute;l: +32 14 64 94 11</span></p>
  <p class=MsoNormal><span lang=NL-BE>janssen@jacbe.jnj.com</span></p>
  <p class=MsoNormal><span lang=NL-BE>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UAB &quot;JOHNSON &amp; JOHNSON&quot;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +370 5 278 68 88</span></p>
  <p class=MsoNormal><span lang=EN-GB>lt@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>&#8222;&#1044;&#1078;&#1086;&#1085;&#1089;&#1098;&#1085;
  &amp; &#1044;&#1078;&#1086;&#1085;&#1089;&#1098;&#1085;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;&#8221;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&#1058;&#1077;&#1083;.: +359 2 489 94 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>jjsafety@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag NV</span></p>
  <p class=MsoNormal><span lang=NL-BE>T&eacute;l/Tel: +32 14 64 94 11</span></p>
  <p class=MsoNormal><span lang=EN-GB>janssen@jacbe.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>&#268;esk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag s.r.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +420 227 012 227</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Kft.</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel.: +36 1 884 2858</span></p>
  <p class=MsoNormal><span lang=NL-BE>janssenhu@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=NL-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Danmark</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag A/S</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tlf: +45 4594 8282</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacdk@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>AM MANGION LTD</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +356 2397 6000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag GmbH</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel: +49 2137 955 955</span></p>
  <p class=MsoNormal><span lang=EN-GB>jancil@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Nederland</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 76 711 1111</span></p>
  <p class=MsoNormal><span lang=EN-GB>janssen@jacnl.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Eesti</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UAB &quot;JOHNSON &amp; JOHNSON&quot;
  Eesti filiaal</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +372 617 7410</span></p>
  <p class=MsoNormal><span lang=EN-GB>ee@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen-Cilag AS</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +47 24 12 65 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacno@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen-Cilag
  &#934;&#945;&#961;&#956;&#945;&#954;&#949;&#965;&#964;&#953;&#954;&#942;
  &#913;.&#917;.&#914;.&#917;.</span></p>
  <p class=MsoNormal><span lang=EN-GB>T&#951;&#955;: +30 210 80 90 000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Pharma GmbH</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel: +43 1 610 300</span></p>
  <p class=MsoNormal><span lang=NL-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag, S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +34 91 722 81 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>contacto@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Polska</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Polska Sp. z o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel.: +48 22 237 60 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>France</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>Janssen-Cilag</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>T&eacute;l:
  0 800 25 50 75 / +33 1 55 00 40 03</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>medisource@its.jnj.com</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=NL-BE>Portugal</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>Janssen-Cilag
  Farmac&ecirc;utica, Lda.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +351
  214 368 600</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Johnson
  &amp; Johnson S.E. d.o.o.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +385
  1 6610 700</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>jjsafety@JNJCR.JNJ.com</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Johnson
  &amp; Johnson Rom<b>&acirc;</b>nia SRL</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +40
  21 207 1800</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen Sciences Ireland UC</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +353 1 800 709 122</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Johnson &amp; Johnson d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +386 1 401 18 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen_safety_slo@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>&Iacute;sland</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>Janssen-Cilag
  AB</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>c/o Vistor
  hf.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>S&iacute;mi:
  +354 535 7000</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>janssen@vistor.is</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Johnson
  &amp; Johnson, s.r.o.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +421
  232 408 400</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Italia</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag SpA</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel: 800.688.777 / +39 02 2510 1</span></p>
  <p class=MsoNormal><span lang=EN-GB><a href="mailto:janssenita@its.jnj.com"><span
  style='color:windowtext;text-decoration:none'>janssenita@its.jnj.com</span></a></span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Oy</span></p>
  <p class=MsoNormal><span lang=NL-BE>Puh/Tel: +358 207 531 300</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacfi@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>&#914;&#945;&#961;&#957;&#940;&#946;&#945;&#962;
  &#935;&#945;&#964;&#950;&#951;&#960;&#945;&#957;&#945;&#947;&#942;&#962;
  &#923;&#964;&#948;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&#932;&#951;&#955;: +357 22 207 700</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Sverige</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag AB</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tfn: +46 8 626 50 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacse@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:234.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UAB &quot;JOHNSON &amp; JOHNSON&quot;
  fili&#257;le Latvij&#257;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +371 678 93561</span></p>
  <p class=MsoNormal><span lang=EN-GB>lv@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=307 valign=top style='width:230.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen-Cilag Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +44 1 494 567 444</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>This
leaflet was last revised in </span></b><span lang=EN-GB>{MM/YYYY}.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this medicine is available
on the European Medicines Agency web site:<a href=""></a> </span><span
lang=EN-GB style='color:blue'><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></span><span
lang=EN-GB>.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Package
leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>PREZISTA
800&nbsp;mg film&#8209;coated tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>darunavir</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Read all
of this leaflet carefully before you start taking this medicine because it
contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your
doctor, pharmacist or nurse. This includes any possible side effects not listed
in this leaflet. See section 4.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What is
in this leaflet</span></b></p>

<p class=MsoNormal><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
PREZISTA is and what it is used for</span></p>

<p class=MsoNormal><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take PREZISTA</span></p>

<p class=MsoNormal><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to take PREZISTA</span></p>

<p class=MsoNormal><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=MsoNormal><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store PREZISTA</span></p>

<p class=MsoNormal><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
PREZISTA is and what it is used for</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What is
PREZISTA?</span></b></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA contains the active substance
darunavir. PREZISTA is an antiretroviral medicine used in the treatment of
Human Immunodeficiency Virus (HIV) infection. It belongs to a group of
medicines called protease inhibitors. PREZISTA works by reducing the amount of
HIV in your body. This will improve your immune system and reduces the risk of
developing illnesses linked to HIV infection.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What it
is used for?</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The PREZISTA 800&nbsp;milligram tablet is
used to treat adults and children (3&nbsp;years of age and above, at least
40&nbsp;kilograms body weight) who are infected by HIV and</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>who have not used antiretroviral medicines
before.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in certain patients who have used antiretroviral
medicines before (your doctor will determine this).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA must be taken in combination with
a low dose of cobicistat or ritonavir and other anti&#8209;HIV medicines. Your
doctor will discuss with you which combination of medicines is best for you.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take PREZISTA</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not
take PREZISTA</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are <b>allergic</b> to darunavir or any
of the other ingredients of this medicine (listed in section 6) or to cobicistat
or ritonavir.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have <b>severe liver problems</b>. Ask
your doctor if you are unsure about the severity of your liver disease. Some
additional tests might be necessary.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not
combine PREZISTA with any of the following medicines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you are taking any of these, ask your
doctor about switching to another medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Medicine</span></b></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Purpose of the medicine</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Avanafil</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>to treat
  erectile dysfunction </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Astemizole
  </span></i><span lang=EN-GB>or</span><i><span lang=EN-GB> terfenadine</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>to treat
  allergy symptoms</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Triazolam
  </span></i><span lang=EN-GB>and </span><i><span lang=EN-GB>oral </span></i><span
  lang=EN-GB>(taken by mouth)</span><i><span lang=EN-GB> midazolam</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>to help
  you sleep and/or relieve anxiety</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Cisapride</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat some stomach conditions</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Colchicine </span></i><span
  lang=EN-GB>(if you have kidney and/or liver problems)</span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat gout</span> or familial
  Mediterranean fever</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=PT>Lurasidone, pimozide, quetiapine </span></i><span
  lang=PT>or</span><i><span lang=PT> sertindole</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat psychiatric conditions</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Ergot alkaloids</span></i><span
  lang=EN-GB> like <i>ergotamine</i>, <i>dihydroergotamine</i>, <i>ergometrine</i>
  and <i>methylergonovine</i></span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat migraine headaches</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Amiodarone, bepridil, dronedarone, ivabradine
  quinidine, ranolazine </span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat certain heart disorders e.g.
  abnormal heart beat</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Lovastatin</span></i><span lang=EN-GB>,<i>
  simvastatin and lomitapide</i></span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to lower cholesterol levels</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Rifampicin</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat some infections such as
  tuberculosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>The combination product<i>
  lopinavir/ritonavir</i></span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>this anti&#8209;HIV medicine belongs to
  the same class as PREZISTA</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Elbasvir/grazoprevir</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat hepatitis C infection</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Alfuzosin</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat enlarged prostate</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Sildenafil</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat high blood pressure in the
  pulmonary circulation</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Dabigatran</span></i><span lang=EN-GB>,
  <i>ticagrelor</i></span></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to help stop the clumping of platelets in
  the treatment of patients with a history of a heart attack</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Naloxegol</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat opioid induced constipation</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Dapoxetine</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat premature ejaculation</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=303 valign=top style='width:227.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i><span lang=EN-GB>Domperidone</span></i></p>
  </td>
  <td width=302 valign=top style='width:226.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>to treat nausea and vomiting</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not combine PREZISTA with products that
contain St&nbsp;John&#8217;s&nbsp;wort<i> (Hypericum perforatum)</i>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Warnings
and precautions</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Talk to your doctor, pharmacist or nurse
before taking PREZISTA.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is not a cure for HIV infection.
You can still pass on HIV when taking this medicine, although the risk is
lowered by effective antiretroviral therapy. Discuss with your physician the
precautions needed to avoid infecting other people.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>People taking PREZISTA may still develop
infections or other illnesses associated with HIV infection. You must keep in
regular contact with your doctor.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>People taking PREZISTA may develop a skin
rash. Infrequently a rash may become severe or potentially life&#8209;threatening.
Please contact your doctor whenever you develop a rash.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients taking PREZISTA and raltegravir
(for HIV infection), rashes (generally mild or moderate) may occur more
frequently than in patients taking either medicine separately.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Tell your
doctor about your situation BEFORE and DURING your treatment</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Make sure that you check the following
points and tell your doctor if any of these apply to you.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you have had <b>problems
with your liver</b> before, including hepatitis B or C infection. Your doctor
may evaluate how severe your liver disease is before deciding if you can take
PREZISTA.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you have <b>diabetes</b>.
PREZISTA might increase sugar levels in the blood.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor immediately if you notice any <b>symptoms
of infection </b>(for example enlarged lymph nodes and fever). In some patients
with advanced HIV infection and a history of opportunistic infection, signs and
symptoms of inflammation from previous infections may occur soon after anti&#8209;HIV
treatment is started. It is believed that these symptoms are due to an
improvement in the body&#8217;s immune response, enabling the body to fight
infections that may have been present with no obvious symptoms.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In addition to the opportunistic infections,
autoimmune disorders (a condition that occurs when the immune system attacks
healthy body tissue) may also occur after you start taking medicines for the
treatment of your HIV infection. Autoimmune disorders may occur many months
after the start of treatment. If you notice any symptoms of infection or other
symptoms such as muscle weakness, weakness beginning in the hands and feet and
moving up towards the trunk of the body, palpitations, tremor or hyperactivity,
please inform your doctor immediately to seek necessary treatment.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you have <b>haemophilia</b>.
PREZISTA might increase the risk of bleeding.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you are <b>allergic to</b> <b>sulphonamides
</b>(e.g. used to treat certain infections).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you notice any </span><b><span
lang=EN-GB>musculoskeletal problems</span></b><span lang=EN-GB>. Some patients
taking combination antiretroviral therapy may develop a bone disease called osteonecrosis
(death of bone tissue caused by loss of blood supply to the bone). The length
of combination antiretroviral therapy, corticosteroid use, alcohol consumption,
severe immunosuppression, higher body mass index, among others, may be some of
the many risk factors for developing this disease. Signs of osteonecrosis are
joint stiffness, aches and pains (especially of the hip, knee and shoulder) and
difficulty in movement. If you notice any of these symptoms please inform your
doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>Elderly</span></b></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA has only been used in limited
numbers of patients 65&nbsp;years or older. If you belong to this age group,
please discuss with your doctor if you can use PREZISTA.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Children
and adolescents</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The PREZISTA
800&nbsp;milligram tablet is not for use in children younger than 3&nbsp;years
of age or weighing less than 40&nbsp;kilograms.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Other
medicines and PREZISTA</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor or pharmacist if you are
taking or have recently taken any other medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There are some medicines that <b>you must
not combine</b> with PREZISTA. These are mentioned above under the heading
&#8216;Do not combine PREZISTA with any of the following medicines:&#8217;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In most cases, PREZISTA can be combined
with anti&#8209;HIV medicines belonging to another class [e.g. NRTIs
(nucleoside reverse transcriptase inhibitors), NNRTIs (non&#8209;nucleoside
reverse transcriptase inhibitors), CCR5 antagonists and FIs (fusion
inhibitors)]. PREZISTA with cobicistat or ritonavir has not been tested with
all PIs (protease inhibitors) and must not be used with other HIV PIs. In some
cases dosage of other medicines might need to be changed. Therefore always tell
your doctor if you take other anti&#8209;HIV medicines and follow your
doctor&#8217;s instruction carefully on which medicines can be combined.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The effects
of PREZISTA might be reduced if you take any of the following products. Tell
your doctor if you take:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Phenobarbital, phenytoin</span></i><span
lang=EN-GB> (to prevent seizures)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Dexamethasone</span></i><span lang=EN-GB>
(corticosteroid)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Efavirenz </span></i><span lang=EN-GB>(HIV
infection)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Rifapentine, rifabutin </span></i><span
lang=EN-GB>(medicines to treat some infections such as tuberculosis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Saquinavir</span></i><span lang=EN-GB> (HIV
infection).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The effects
of other medicines might be influenced if you take PREZISTA. Tell your doctor
if you take:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Amlodipine, diltiazem, disopyramide, carvedilol,
felodipine, flecainide, lidocaine, metoprolol, mexiletine, nifedipine,
nicardipine</span></i><span lang=EN-GB>, <i>propafenone</i>, <i>timolol,
verapamil</i> (for heart disease) as the therapeutic effect or side effects of
these medicines may be increased.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>A</span></i><i><span lang=EN-GB>pixaban, edoxaban,
rivaroxaban, warfarin, clopidogrel</span></i><span lang=EN-GB> (to reduce
clotting of the blood) as their therapeutic effect or side effects may be
altered; your doctor may have to check your blood.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Oestrogen&#8209;based hormonal contraceptives
and hormonal replacement therapy. PREZISTA might reduce its effectiveness. When
used for birth control,</span><span lang=EN-GB> alternative methods of non&#8209;hormonal
contraception are recommended</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Ethinylestradiol/drospirenone</span></i><span
lang=EN-GB>. PREZISTA might increase the risk for elevated potassium levels by
drospirenone.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Atorvastatin, pravastatin, rosuvastatin</span></i><span
lang=EN-GB> (to lower cholesterol levels). The risk of muscle damage might be
increased. Your doctor will evaluate which cholesterol lowering regimen is best
for your specific situation.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Clarithromycin</span></i><span lang=EN-GB>
(antibiotic)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Ciclosporin, </span></i><i><span lang=EN-GB>everolimus,
tacrolimus, sirolimus</span></i><span lang=EN-GB> (</span><span lang=EN-GB>for
dampening down</span><span lang=EN-GB> your immune system) as the therapeutic
effect or side effects of these medicines might be increased. Your doctor might
want to do some additional tests.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i>Corticosteroids including betamethasone, budesonide,
fluticasone, mometasone, prednisone, triamcinolone</i><span lang=EN-GB>. These
medicines are used to treat allergies, asthma, inflammatory bowel diseases,
inflammatory conditions of the eyes, joints and muscles and other inflammatory
conditions. If alternatives cannot be used, its use should only take place
after medical evaluation and under close monitoring by your doctor for
corticosteroid side effects.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Buprenorphine/naloxone</span></i><span
lang=EN-GB> (medicines to treat opioid dependence)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Salmeterol</span></i><span lang=EN-GB>
(medicine to treat asthma)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Artemether/l</span></i><i><span lang=EN-GB>umefantrine</span></i><span
lang=EN-GB> (a combination medicine to treat malaria)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Dasatinib, everolimus, irinotecan, nilotinib,
vinblastine, vincristine </span></i><span lang=EN-GB>(to treat cancer)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Sildenafil, tadalafil, vardenafil </span></i><span
lang=EN-GB>(for erectile dysfunction or to treat a heart and lung disorder
called pulmonary arterial hypertension)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Glecaprevir/pibrentasvir</span><span
lang=EN-GB> </span></i><span lang=EN-GB>(to treat hepatitis C infection)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Fentanyl, oxycodone, tramadol</span></i><span
lang=EN-GB> (to treat pain)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Fesoterodine</span></i><span lang=EN-GB>, <i>solifenacin</i>
(to treat urologic disorders).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The dosage of other medicines might need to
be changed since either their own or PREZISTA&#8217;s therapeutic effect or
side effects may be influenced when combined.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tell your
doctor if you take:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Alfentanil</span></i><span lang=EN-GB>
(injectable </span><span lang=EN-GB>strong and short&#8209;acting painkiller
that is used for surgical procedures)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Digoxin</span></i><span lang=EN-GB> (to treat
certain heart disorders)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Clarithromycin</span></i><span lang=EN-GB>
(antibiotic)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Itraconazole, isavuconazole, fluconazole, posaconazole,
clotrimazole</span></i><span lang=EN-GB> (to treat fungal infections).
Voriconazole should only be taken after medical evaluation.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Rifabutin</span></i><span lang=EN-GB>
(against bacterial infections)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Sildenafil, vardenafil, tadalafil</span></i><span
lang=EN-GB> (for erectile dysfunction or high blood pressure in the pulmonary
circulation)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Amitriptyline, desipramine, imipramine,
nortriptyline, paroxetine, sertraline, trazodone</span></i><span lang=EN-GB>
(to treat depression and anxiety)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Maraviroc </span></i><span lang=EN-GB>(to
treat HIV infection)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Methadone </span></i><span lang=EN-GB>(to
treat opiate dependence)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Carbamazepine<a name="_Hlk498526576">,
clonazepam</a></span></i><span lang=EN-GB> (to prevent seizures or to treat
certain types of nerve pain)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Colchicine </span></i><span lang=EN-GB>(to
treat gout</span> or familial Mediterranean fever<span lang=EN-GB>)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Bosentan</span></i><span lang=EN-GB> (to
treat high blood pressure in the pulmonary circulation)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Buspirone, clorazepate, diazepam, estazolam,
flurazepam, midazolam when used as injection, zolpidem</span></i><span
lang=EN-GB> (sedative agents)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Perphenazine</span><span lang=EN-GB>, risperidone,
thioridazine</span></i><span lang=EN-GB> (to treat psychiatric conditions)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=NO-BOK>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=NO-BOK>Metformin</span></i><span lang=NO-BOK> (to
treat type&nbsp;2&nbsp;diabetes).</span></p>

<p class=MsoNormal><span lang=NO-BOK>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This is <b>not</b> a complete list of
medicines. Tell your healthcare provider about <b><i>all </i></b>medicines that
you are taking.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>PREZISTA
with food and drink</span></b></p>

<p class=MsoNormal><span lang=EN-GB>See section&nbsp;3 &#8216;How to take
PREZISTA.&#8217;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pregnancy
and breast&#8209;feeding</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor immediately if you are
pregnant<a name="_Hlk510189683">, planning to become pregnant</a> or if you are
breast&#8209;feeding. Pregnant or breast&#8209;feeding mothers should not take
PREZISTA with ritonavir unless specifically directed by the doctor. </span><u><span
lang=EN-AU>Pregnant or breast&#8209;feeding mothers should not take PREZISTA
with cobicistat.</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>It is recommended that HIV infected women
must not breast&#8209;feed their infants because of both the possibility of
your baby becoming infected with HIV through your breast milk and because of
the unknown effects of the medicine on your baby.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Do not operate machines or drive if you
feel dizzy after taking PREZISTA.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>PREZISTA
contains sodium</span></b></p>

<p class=MsoNormal><span lang=EN-GB>This medicine contains less than
1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is to say essentially
&#8216;sodium&#8209;free&#8217;.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to take PREZISTA</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Always use this medicine exactly as
described in this leaflet or as your doctor, pharmacist or nurse has told you.
Check with your doctor, pharmacist or nurse if you are not sure.</span></p>

<p class=MsoNormal><span lang=EN-GB>Even if you feel better, do not stop taking
PREZISTA and cobicistat or ritonavir without talking to your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After therapy has been initiated, the dose
or dosage form must not be changed or therapy must not be stopped without
instruction of the doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA 800&nbsp;milligram tablets are
intended for once daily use only.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Dose for
adults who have not taken antiretroviral medicines before (your doctor will
determine this)</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The usual dose
of PREZISTA is 800&nbsp;milligram (2&nbsp;tablets containing 400&nbsp;milligram
of PREZISTA or 1&nbsp;tablet containing 800&nbsp;milligram of PREZISTA) once
daily.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>You must take
PREZISTA every day and always in combination with 150&nbsp;milligram of
cobicistat or 100&nbsp;milligram of ritonavir and with food. PREZISTA cannot
work properly without cobicistat or ritonavir and food. You must eat a meal or
a snack within 30&nbsp;minutes prior to taking your PREZISTA and cobicistat or ritonavir.
The type of food is not important. Even if you feel better, do not stop taking
PREZISTA and cobicistat or ritonavir without talking to your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Instructions
for adults</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take one 800&nbsp;milligram tablet at the same
time, once a day, every day.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take PREZISTA always together with 150&nbsp;milligram
of cobicistat or 100&nbsp;milligram of ritonavir.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take PREZISTA with food.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Swallow the tablet with a drink such as water or
milk.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take your other HIV medicines used in
combination with PREZISTA and cobicistat or ritonavir as recommended by your
doctor.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>PREZISTA 100&nbsp;milligram per milliliter oral
suspension has been developed for use in children, but can also be used in
adults in some cases.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Dose for adults who have taken antiretroviral medicines before (your
doctor will determine this)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>The dose is either:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>800&nbsp;milligram PREZISTA (2&nbsp;tablets
containing 400&nbsp;milligram of PREZISTA or 1&nbsp;tablet containing
800&nbsp;milligram of PREZISTA) together with 150&nbsp;milligram cobicistat or 100&nbsp;milligram
ritonavir once daily.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-autospace:none'><span
lang=EN-GB>OR</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>600&nbsp;milligram PREZISTA together with
100&nbsp;milligram ritonavir twice daily.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Please discuss
with your doctor which dose is right for you.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Dose for children 3&nbsp;years of age and above with ritonavir, and
12&nbsp;years of age and above with cobicistat, weighing more than 40&nbsp;kilograms
who have not taken antiretroviral medicines before (your child&#8217;s doctor
will determine this)</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The usual dose of PREZISTA is 800&nbsp;milligram
(2&nbsp;tablets containing 400&nbsp;milligram of PREZISTA or 1&nbsp;tablet
containing 800&nbsp;milligram of PREZISTA) together with 100&nbsp;milligram
ritonavir or 150&nbsp;milligram of cobicistat once daily.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Dose for children 3&nbsp;years of age and above with ritonavir, and
12&nbsp;years of age and above with cobicistat, weighing more than 40&nbsp;kilograms
who have taken antiretroviral medicines before (your child&#8217;s doctor will
determine this)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>The dose is either:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>800&nbsp;milligram PREZISTA (2&nbsp;tablets
containing 400&nbsp;milligram of PREZISTA or 1&nbsp;tablet containing
800&nbsp;milligram of PREZISTA) together with 100&nbsp;milligram ritonavir </span><span
lang=EN-GB>or 150&nbsp;milligram of cobicistat </span><span lang=EN-GB>once
daily.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-autospace:none'><span
lang=EN-GB>OR</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>600&nbsp;milligram PREZISTA together with
100&nbsp;milligram ritonavir twice daily.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Please discuss
with your doctor which dose is right for you.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><i><span
lang=EN-GB>Instructions for children 3&nbsp;years of age and above with
ritonavir, and 12&nbsp;years of age and above with cobicistat, weighing more
than 40&nbsp;kilograms</span></i></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take 800&nbsp;milligram PREZISTA (</span><span
lang=EN-GB>2&nbsp;tablets containing 400&nbsp;milligram of PREZISTA or
1&nbsp;tablet containing 800&nbsp;milligram of PREZISTA</span><span lang=EN-GB>)
at the same time, once a day, every day.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take PREZISTA always together with
100&nbsp;milligram of ritonavir or 150&nbsp;milligram of cobicistat.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take PREZISTA with food.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Swallow the tablets with a drink such as water
or milk.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take your other HIV medicines used in
combination with PREZISTA and ritonavir or cobicistat as recommended by your
doctor</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Removing
the child resistant cap</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=121 valign=top style='width:90.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB><img border=0 width=86 height=90
  id="Picture 1" src="Prezista%20PI%20E_files/image002.jpg" alt="Dop_15mm"></span></p>
  </td>
  <td width=499 valign=top style='width:373.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>The plastic bottle comes with a child
  resistant cap and must be opened as follows:</span></p>
  <p class=MsoNormal><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Push
  the plastic screw cap down while turning it counter clockwise.</span></p>
  <p class=MsoNormal><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove
  the unscrewed cap.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
take more PREZISTA than you should</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Contact your doctor, pharmacist or nurse
immediately.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
forget to take PREZISTA</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you notice <b>within 12&nbsp;hours</b>,
you must take the tablets immediately. Always take with cobicistat or ritonavir
and food. If you notice <b>after 12&nbsp;hours</b>, then skip the intake and
take the next doses as usual. Do not take a double dose to make up for a
forgotten dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
vomit after taking PREZISTA and cobicistat or ritonavir</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you vomit <b>within 4&nbsp;hours</b> of
taking the medicine, another dose of PREZISTA and cobicistat or ritonavir
should be taken with food as soon as possible. If you vomit <b>more than 4&nbsp;hours</b>
after taking the medicine, then you do not need to take another dose of
PREZISTA and cobicistat or ritonavir until the next regularly scheduled time.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Contact your doctor <b>if you are uncertain</b>
about what to do if you miss a dose or vomit.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not
stop taking PREZISTA without talking to your doctor first</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Anti-HIV medicines may make you feel better.
Even when you feel better, do not stop taking PREZISTA. Talk to your doctor
first.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you have any further questions on the
use of this medicine, ask your doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>During HIV therapy there may be an increase
in weight and in levels of blood lipids and glucose. This is partly linked to
restored health and life style, and in the case of blood lipids sometimes to
the HIV medicines themselves. Your doctor will test for these changes.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Like all medicines, this medicine can cause
side effects, although not everybody gets them.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Tell your
doctor if you develop any of the following side effects</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Liver problems
that may occasionally be severe have been reported. Your doctor should do blood
tests before you start PREZISTA. If you have chronic hepatitis&nbsp;B or C
infection, your doctor should check your blood tests more often because you
have an increased chance of developing liver problems. Talk to your doctor
about the signs and symptoms of liver problems. These may include yellowing of
your skin or whites of your eyes, dark (tea coloured) urine, pale coloured
stools (bowel movements), nausea, vomiting, loss of appetite, or pain, aching,
or pain and discomfort on your right side below your ribs.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Skin rash (more
often when used in combination with raltegravir), itching. The rash is usually
mild to moderate. A skin rash might also be a symptom of a rare severe
situation. It is therefore important to talk to your doctor if you develop a
rash. Your doctor will advise you how to deal with your symptoms or whether
PREZISTA must be stopped.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Other severe
side effects were diabetes (common) and inflammation of the pancreas (uncommon).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very common
side effects (may affect more than 1 in 10&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Common side
effects (may affect up to 1 in 10&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vomiting, nausea, abdominal pain or distension,
dyspepsia, flatulence</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>headache<i>,</i> tiredness, dizziness,
drowsiness, numbness, tingling or pain in hands or feet, loss of strength,
difficulty falling asleep.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Uncommon
side effects (may affect up to 1 in 100&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>chest pain, changes in electrocardiogram, rapid
heart beating</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased or abnormal skin sensibility, pins and
needles, attention disturbance, loss of memory, problems with your balance</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty breathing, cough, nosebleed, throat
irritation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the stomach or mouth, heartburn,
retching, dry mouth, discomfort of the abdomen, constipation, belching</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>kidney failure, kidney stones, difficult
discharge of urine, frequent or excessive passage of urine, sometimes at night</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>urticaria, severe swelling of the skin and other
tissues (most often the lips or the eyes), eczema, excessive sweating, night
sweats, hair loss, acne, scaly skin, colouration of nails</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle pain, muscle cramps or weakness, pain in
extremity, osteoporosis</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>slowing down of the thyroid gland function. This
can be seen in a blood test.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high blood pressure, flushing</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>red or dry eyes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fever, swelling of lower limbs due to fluids,
malaise, irritability, pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>symptoms of infection, herpes simplex</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>erectile dysfunction, enlargement of breasts</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sleeping problems, sleepiness, depression,
anxiety, abnormal dreams, decrease in sexual drive</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Rare side
effects (may affect up to 1 in 1,000&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a reaction called DRESS [severe rash, which may
be accompanied by fever, fatigue, swelling of the face or lymph glands,
increase of eosinophils (type of white blood cells), effects on liver, kidney
or lung]</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>heart attack, slow heart beating, palpitations</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>visual disturbance</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>chills, feeling abnormal</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a feeling of confusion or disorientation,
altered mood, restlessness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fainting,</span><span lang=EN-GB> epileptic
fits, changes or loss of taste</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>mouth sores, vomiting blood, inflammation of the
lips, dry lips, coated tongue</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>running nose</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin lesions, dry skin</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>stiffness of muscles or joints, joint pain with
or without inflammation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>changes in some values of your blood cells or
chemistry. These can be seen in the results of blood and/or urine tests. Your
doctor will explain these to you. Examples are: increase in some white blood
cells.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Some side
effects are typical for anti&#8209;HIV medicines in the same family as
PREZISTA. These are:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle pain, tenderness or weakness. On rare
occasions, these muscle disorders have been serious.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Reporting
of side effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you get any side effects, talk to your
doctor, pharmacist or nurse. This includes any possible side effects not listed
in this leaflet. You can also report side effects directly via <span
style='background:silver'>the national reporting system listed in </span></span><span
lang=EN-GB style='background:silver'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix&nbsp;V</a></span><span
lang=EN-GB>. By reporting side effects you can help provide more information on
the safety of this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store PREZISTA</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep this medicine out of the sight and
reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use this medicine after the expiry
date which is stated on the carton and on the bottle after EXP. The expiry date
refers to the last day of that month.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA does not require any special
storage conditions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away any
medicines you no longer use. These measures will help protect the environment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
PREZISTA contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is darunavir. Each tablet
contains 800&nbsp;milligram of darunavir (as ethanolate).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are microcrystalline
cellulose, colloidal anhydrous silica, crospovidone, magnesium stearate,
hypromellose. The film&#8209;coating contains poly(vinyl alcohol) &#8209;
partially hydrolysed, macrogol 3350, titanium dioxide (E171), talc, iron oxide
red (E172).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
PREZISTA looks like and contents of the pack</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Film&#8209;coated, dark red, oval shaped
tablet, mentioning T on one side, 800 on the other side. 30&nbsp;tablets in a
plastic bottle. The PREZISTA 800&nbsp;milligram tablets are available in packs
containing one bottle or three bottles per carton.</span></p>

<p class=MsoNormal><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PREZISTA is also available as 75&nbsp;milligram,
150&nbsp;milligram, 400&nbsp;milligram and 600&nbsp;milligram film&#8209;coated
tablets and 100&nbsp;milligram per milliliter oral suspension.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Janssen&#8209;Cilag International NV,
Turnhoutseweg 30, 2340 Beerse, Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal><span lang=NL>Janssen&#8209;Cilag SpA, Via C. Janssen, Borgo
San Michele, 04100 Latina, Italy</span></p>

<p class=MsoNormal><span lang=NL>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>For any
information about this medicine, please contact the local representative of the
Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag NV</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel/T&eacute;l: +32 14 64 94 11</span></p>
  <p class=MsoNormal><span lang=NL-BE>janssen@jacbe.jnj.com</span></p>
  <p class=MsoNormal><span lang=NL-BE>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UAB &quot;JOHNSON &amp; JOHNSON&quot;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +370 5 278 68 88</span></p>
  <p class=MsoNormal><span lang=EN-GB>lt@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>&#8222;&#1044;&#1078;&#1086;&#1085;&#1089;&#1098;&#1085;
  &amp; &#1044;&#1078;&#1086;&#1085;&#1089;&#1098;&#1085;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;&#8221;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&#1058;&#1077;&#1083;.: +359 2 489 94 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>jjsafety@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag NV</span></p>
  <p class=MsoNormal><span lang=NL-BE>T&eacute;l/Tel: +32 14 64 94 11</span></p>
  <p class=MsoNormal><span lang=EN-GB>janssen@jacbe.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>&#268;esk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag s.r.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +420 227 012 227</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><a name="_Hlk31295015"><b><span lang=NL-BE>Magyarorsz&aacute;g</span></b></a></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Kft.</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel.: +36 1 884 2858</span></p>
  <p class=MsoNormal><span lang=NL-BE>janssenhu@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=NL-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Danmark</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag A/S</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tlf: +45 4594 8282</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacdk@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>AM MANGION LTD</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +356 2397 6000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag GmbH</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel: +49 2137 955 955</span></p>
  <p class=MsoNormal><span lang=EN-GB>jancil@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Nederland</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 76 711 1111</span></p>
  <p class=MsoNormal><span lang=EN-GB>janssen@jacnl.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Eesti</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UAB &quot;JOHNSON &amp; JOHNSON&quot;
  Eesti filiaal</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +372 617 7410</span></p>
  <p class=MsoNormal><span lang=EN-GB>ee@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen-Cilag AS</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +47 24 12 65 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacno@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen-Cilag
  &#934;&#945;&#961;&#956;&#945;&#954;&#949;&#965;&#964;&#953;&#954;&#942;
  &#913;.&#917;.&#914;.&#917;.</span></p>
  <p class=MsoNormal><span lang=EN-GB>T&#951;&#955;: +30 210 80 90 000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Pharma GmbH</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel: +43 1 610 300</span></p>
  <p class=MsoNormal><span lang=NL-BE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag, S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +34 91 722 81 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>contacto@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Polska</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Polska Sp. z o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel.: +48 22 237 60 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>France</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>Janssen-Cilag</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>T&eacute;l:
  0 800 25 50 75 / +33 1 55 00 40 03</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>medisource@its.jnj.com</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=NL-BE>Portugal</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>Janssen-Cilag
  Farmac&ecirc;utica, Lda.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +351
  214 368 600</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Johnson
  &amp; Johnson S.E. d.o.o.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +385
  1 6610 700</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>jjsafety@JNJCR.JNJ.com</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Johnson
  &amp; Johnson Rom<b>&acirc;</b>nia SRL</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +40
  21 207 1800</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen Sciences Ireland UC</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +353 1 800 709 122</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Johnson &amp; Johnson d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +386 1 401 18 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen_safety_slo@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>&Iacute;sland</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>Janssen-Cilag
  AB</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=NL-BE>c/o Vistor
  hf.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>S&iacute;mi:
  +354 535 7000</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>janssen@vistor.is</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Johnson
  &amp; Johnson, s.r.o.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +421
  232 408 400</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Italia</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag SpA</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tel: 800.688.777 / +39 02 2510 1</span></p>
  <p class=MsoNormal><span lang=EN-GB><a href="mailto:janssenita@its.jnj.com"><span
  style='color:windowtext;text-decoration:none'>janssenita@its.jnj.com</span></a></span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag Oy</span></p>
  <p class=MsoNormal><span lang=NL-BE>Puh/Tel: +358 207 531 300</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacfi@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>&#914;&#945;&#961;&#957;&#940;&#946;&#945;&#962;
  &#935;&#945;&#964;&#950;&#951;&#960;&#945;&#957;&#945;&#947;&#942;&#962;
  &#923;&#964;&#948;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&#932;&#951;&#955;: +357 22 207 700</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL-BE>Sverige</span></b></p>
  <p class=MsoNormal><span lang=NL-BE>Janssen-Cilag AB</span></p>
  <p class=MsoNormal><span lang=NL-BE>Tfn: +46 8 626 50 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>jacse@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>UAB &quot;JOHNSON &amp; JOHNSON&quot;
  fili&#257;le Latvij&#257;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +371 678 93561</span></p>
  <p class=MsoNormal><span lang=EN-GB>lv@its.jnj.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=319 valign=top style='width:239.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Janssen-Cilag Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +44 1 494 567 444</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>This leaflet
was last revised in </span></b><span lang=EN-GB>{MM/YYYY}.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this medicine is
available on the European Medicines Agency web site:<a href=""></a> </span><span
lang=EN-GB style='color:blue'><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></span><span
lang=EN-GB>.</span></p>

</div>

</body>

</html>
